PageSourceSearch

https://oncotherm.com/clinical-publications/

html oncotherm.com collected 2026-09-28 10:18:02 UTC 412,183 bytes, 6,821 lines download raw bytes

1<!doctype html>
2<html dir="ltr" lang="en-GB" prefix="og: https://ogp.me/ns#">
3<head>
4	<meta charset="UTF-8">
5	<meta name="viewport" content="width=device-width, initial-scale=1">
6	<link rel="profile" href="https://gmpg.org/xfn/11">
7
8	<title>Clinical publications - Oncotherm Kft.</title>
9
10		<!-- All in One SEO 5.0.1.1 - aioseo.com -->
11	<meta name="robots" content="max-image-preview:large" />
12	<link rel="canonical" href="https://oncotherm.com/clinical-publications/" />
13	<meta name="generator" content="All in One SEO (AIOSEO) 5.0.1.1" />
14		<meta property="og:locale" content="en_GB" />
15		<meta property="og:site_name" content="Oncotherm Kft. -" />
16		<meta property="og:type" content="website" />
17		<meta property="og:title" content="Clinical publications - Oncotherm Kft." />
18		<meta property="og:url" content="https://oncotherm.com/clinical-publications/" />
19		<meta property="og:image" content="https://oncotherm.com/wp-content/uploads/2022/11/logo_ar-01.svg" />
20		<meta property="og:image:secure_url" content="https://oncotherm.com/wp-content/uploads/2022/11/logo_ar-01.svg" />
21		<meta property="og:image:width" content="220" />
22		<meta property="og:image:height" content="50" />
23		<meta name="twitter:card" content="summary_large_image" />
24		<meta name="twitter:title" content="Clinical publications - Oncotherm Kft." />
25		<meta name="twitter:image" content="https://oncotherm.com/wp-content/uploads/2022/11/logo_ar-01.svg" />
26		
26<script type="application/ld+json" class="aioseo-schema">
27			{"@context":"https:\/\/schema.org","@graph":[{"@type":"BreadcrumbList","@id":"https:\/\/oncotherm.com\/clinical-publications\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/oncotherm.com#listItem","position":1,"name":"Home","item":"https:\/\/oncotherm.com","nextItem":{"@type":"ListItem","@id":"https:\/\/oncotherm.com\/clinical-publications\/#listItem","name":"Archives for "}},{"@type":"ListItem","@id":"https:\/\/oncotherm.com\/clinical-publications\/#listItem","position":2,"name":"Archives for ","previousItem":{"@type":"ListItem","@id":"https:\/\/oncotherm.com#listItem","name":"Home"}}]},{"@type":"CollectionPage","@id":"https:\/\/oncotherm.com\/clinical-publications\/#collectionpage","url":"https:\/\/oncotherm.com\/clinical-publications\/","name":"Clinical publications - Oncotherm Kft.","inLanguage":"en-GB","isPartOf":{"@id":"https:\/\/oncotherm.com\/#website"},"breadcrumb":{"@id":"https:\/\/oncotherm.com\/clinical-publications\/#breadcrumblist"}},{"@type":"Organization","@id":"https:\/\/oncotherm.com\/#organization","name":"Oncotherm Kft.","url":"https:\/\/oncotherm.com\/","logo":{"@type":"ImageObject","url":"https:\/\/oncotherm.com\/wp-content\/uploads\/2022\/11\/logo_ar-01.svg","@id":"https:\/\/oncotherm.com\/clinical-publications\/#organizationLogo","width":220,"height":50},"image":{"@id":"https:\/\/oncotherm.com\/clinical-publications\/#organizationLogo"}},{"@type":"WebSite","@id":"https:\/\/oncotherm.com\/#website","url":"https:\/\/oncotherm.com\/","name":"Oncotherm Kft.","inLanguage":"en-GB","publisher":{"@id":"https:\/\/oncotherm.com\/#organization"}}]}
28		</script>
28
29		<!-- All in One SEO -->
30
31<link rel="alternate" href="https://oncotherm.com/hu/klinikai-publikaciok/" hreflang="hu" />
32<link rel="alternate" href="https://oncotherm.com/clinical-publications/" hreflang="en" />
33<link rel="alternate" href="https://oncotherm.com/de/klinische-publikationen/" hreflang="de" />
34<link rel='dns-prefetch' href='//maps.googleapis.com' />
35<link rel='dns-prefetch' href='//www.googletagmanager.com' />
36<style id="wp-img-auto-sizes-contain-inline-css">
37img:is([sizes=auto i],[sizes^="auto," i]){contain-intrinsic-size:3000px 1500px}
38/*# sourceURL=wp-img-auto-sizes-contain-inline-css */
39</style>
40
41<link rel='stylesheet' id='cf7apps-honeypot-frontend-css' href='https://oncotherm.com/wp-content/plugins/contact-form-7-honeypot/legacy-honeypot/includes/css/honeypot-frontend.css?ver=3.7.1' media='all' />
42<link rel='stylesheet' id='contact-form-7-css' href='https://oncotherm.com/wp-content/plugins/contact-form-7/includes/css/styles.css?ver=6.1.7' media='all' />
43<link rel='stylesheet' id='cookie-notice-front-css' href='https://oncotherm.com/wp-content/plugins/cookie-notice/css/front.min.css?ver=3.1.9' media='all' />
44<link rel='stylesheet' id='lbwps-styles-photoswipe5-main-css' href='https://oncotherm.com/wp-content/plugins/lightbox-photoswipe/assets/ps5/styles/main.css?ver=5.13.0' media='all' />
45<link rel='stylesheet' id='dashicons-css' href='https://oncotherm.com/wp-includes/css/dashicons.min.css?ver=9b4fda4fc00966c4c30efe23c40953c0' media='all' />
46<link rel='stylesheet' id='rmp-menu-styles-css' href='https://oncotherm.com/wp-content/uploads/rmp-menu/css/rmp-menu.css?ver=12.22.42' media='all' />
47<link rel='stylesheet' id='sow-icon-default-77a6afac270e-css' href='https://oncotherm.com/wp-content/uploads/siteorigin-widgets/sow-icon-default-77a6afac270e.css?ver=9b4fda4fc00966c4c30efe23c40953c0' media='all' />
48<link rel='stylesheet' id='sow-image-default-4e6925654b7a-css' href='https://oncotherm.com/wp-content/uploads/siteorigin-widgets/sow-image-default-4e6925654b7a.css?ver=9b4fda4fc00966c4c30efe23c40953c0' media='all' />
49<link rel='stylesheet' id='sow-image-default-8b5b6f678277-css' href='https://oncotherm.com/wp-content/uploads/siteorigin-widgets/sow-image-default-8b5b6f678277.css?ver=9b4fda4fc00966c4c30efe23c40953c0' media='all' />
50<link rel='stylesheet' id='sow-image-default-e4c2d9f6c920-css' href='https://oncotherm.com/wp-content/uploads/siteorigin-widgets/sow-image-default-e4c2d9f6c920.css?ver=9b4fda4fc00966c4c30efe23c40953c0' media='all' />
51<link rel='stylesheet' id='pojo-a11y-css' href='https://oncotherm.com/wp-content/plugins/pojo-accessibility/modules/legacy/assets/css/style.min.css?ver=1.0.0' media='all' />
52<link rel='stylesheet' id='oncotherm-style-css' href='https://oncotherm.com/wp-content/themes/oncotherm/style.css?ver=1.0.0' media='all' />
53<link rel='stylesheet' id='slick-css-css' href='https://oncotherm.com/wp-content/themes/oncotherm/css/slick.css?ver=9b4fda4fc00966c4c30efe23c40953c0' media='all' />
54<link rel='stylesheet' id='slick-theme-css-css' href='https://oncotherm.com/wp-content/themes/oncotherm/css/slick-theme.css?ver=9b4fda4fc00966c4c30efe23c40953c0' media='all' />
55<link rel='stylesheet' id='dflip-style-css' href='https://oncotherm.com/wp-content/plugins/3d-flipbook-dflip-lite/assets/css/dflip.min.css?ver=2.4.37' media='all' />
56<link rel='stylesheet' id='wpc-filter-everything-css' href='https://oncotherm.com/wp-content/plugins/filter-everything/assets/css/filter-everything.min.css?ver=1.9.6' media='all' />
57<link rel='stylesheet' id='wpc-filter-everything-custom-css' href='https://oncotherm.com/wp-content/uploads/cache/filter-everything/201e335fb0207fa2b238a2a4c4ed80c8.css?ver=9b4fda4fc00966c4c30efe23c40953c0' media='all' />
58<script id="jquery-core-js" src="https://oncotherm.com/wp-content/plugins/jquery-manager/assets/js/jquery-3.5.1.min.js"></script>
vendor: 1 bytes, line 58
58
59<script id="jquery-migrate-js" src="https://oncotherm.com/wp-content/plugins/jquery-manager/assets/js/jquery-migrate-3.3.0.min.js"></script>
vendor: 1 bytes, line 59
59
60<script id="cookie-notice-front-js-before">
61var cnArgs = {"ajaxUrl":"https:\/\/oncotherm.com\/wp-admin\/admin-ajax.php","nonce":"4735d4a978","hideEffect":"fade","position":"bottom","onScroll":false,"onScrollOffset":100,"onClick":false,"cookieName":"cookie_notice_accepted","cookieTime":2592000,"cookieTimeRejected":2592000,"globalCookie":false,"redirection":false,"cache":false,"revokeCookies":false,"revokeCookiesOpt":"automatic"};
62
63//# sourceURL=cookie-notice-front-js-before
64</script>
vendor: 1 bytes, line 64
64
65<script id="cookie-notice-front-js" src="https://oncotherm.com/wp-content/plugins/cookie-notice/js/front.min.js?ver=3.1.9"></script>
vendor: 1 bytes, line 65
65
66<script id="lbwps-options-js-extra">
67var lbwpsOptions = {"label_facebook":"Share on Facebook","label_twitter":"Tweet","label_pinterest":"Pin it","label_download":"Download image","label_copyurl":"Copy image URL","label_ui_close":"Close [Esc]","label_ui_zoom":"Zoom","label_ui_prev":"Previous [\u2190]","label_ui_next":"Next [\u2192]","label_ui_error":"The image cannot be loaded","label_ui_fullscreen":"Toggle fullscreen [F]","label_ui_download":"Download image","share_facebook":"1","share_twitter":"1","share_pinterest":"1","share_download":"1","share_direct":"0","share_copyurl":"0","close_on_drag":"1","history":"1","show_counter":"1","show_fullscreen":"1","show_download":"0","show_zoom":"1","show_caption":"1","loop":"1","pinchtoclose":"1","taptotoggle":"1","close_on_click":"1","fulldesktop":"0","use_alt":"0","usecaption":"1","desktop_slider":"1","share_custom_label":"","share_custom_link":"","wheelmode":"zoom","spacing":"12","idletime":"4000","hide_scrollbars":"1","caption_type":"overlay","bg_opacity":"100","padding_left":"0","padding_top":"0","padding_right":"0","padding_bottom":"0"};
68//# sourceURL=lbwps-options-js-extra
69</script>
vendor: 1 bytes, line 69
69
70<script id="slick-min-js-js" src="https://oncotherm.com/wp-content/themes/oncotherm/js/slick.min.js?ver=9b4fda4fc00966c4c30efe23c40953c0"></script>
vendor: 1 bytes, line 70
70
71<script id="custom-js-js" src="https://oncotherm.com/wp-content/themes/oncotherm/js/custom-js.js?ver=1.0.0"></script>
71
72
73<!-- Google tag (gtag.js) snippet added by Site Kit -->
74<!-- Google Analytics snippet added by Site Kit -->
vendor: 80 bytes, lines 74-75
74
75<script id="google_gtagjs-js" src="https://www.googletagmanager.com/gtag/js?id=
75GT-WVJGXK7
vendor: 18 bytes, line 75
75" async></script>
76<script id="google_gtagjs-js-after">
77window.dataLayer = window.dataLayer || [];function gtag(){dataLayer.push(arguments);}
78gtag("set","linker",{"domains":["oncotherm.com"]});
79gtag("js", new Date());
80gtag("set", "developer_id.dZTNiMT", true);
81gtag("config", "GT-WVJGXK7");
82//# sourceURL=google_gtagjs-js-after
83</script>
83
84<link rel="https://api.w.org/" href="https://oncotherm.com/wp-json/" /><meta name="generator" content="Site Kit by Google 1.186.0" /><style type="text/css">
85#pojo-a11y-toolbar .pojo-a11y-toolbar-toggle a{ background-color: #4054b2;	color: #ffffff;}
86#pojo-a11y-toolbar .pojo-a11y-toolbar-overlay, #pojo-a11y-toolbar .pojo-a11y-toolbar-overlay ul.pojo-a11y-toolbar-items.pojo-a11y-links{ border-color: #4054b2;}
87body.pojo-a11y-focusable a:focus{ outline-style: solid !important;	outline-width: 1px !important;	outline-color: #FF0000 !important;}
88#pojo-a11y-toolbar{ top: 90px !important;}
89#pojo-a11y-toolbar .pojo-a11y-toolbar-overlay{ background-color: #162c4d;}
90#pojo-a11y-toolbar .pojo-a11y-toolbar-overlay ul.pojo-a11y-toolbar-items li.pojo-a11y-toolbar-item a, #pojo-a11y-toolbar .pojo-a11y-toolbar-overlay p.pojo-a11y-toolbar-title{ color: #9e8053;}
91#pojo-a11y-toolbar .pojo-a11y-toolbar-overlay ul.pojo-a11y-toolbar-items li.pojo-a11y-toolbar-item a.active{ background-color: #162c4d;	color: #9e8053;}
92@media (max-width: 767px) { #pojo-a11y-toolbar { top: 80px !important; } }</style><style type="text/css" id="filter-everything-inline-css">.wpc-orderby-select{width:100%}.wpc-filters-open-button-container{display:none}.wpc-debug-message{padding:16px;font-size:14px;border:1px dashed #ccc;margin-bottom:20px}.wpc-debug-title{visibility:hidden}.wpc-button-inner,.wpc-chip-content{display:flex;align-items:center}.wpc-icon-html-wrapper{position:relative;margin-right:10px;top:2px}
92.wpc-icon-html-wrapper span{display:block;height:1px;width:18px;border-radius:3px;background:#2c2d33;margin-bottom:4px;position:relative}span.wpc-icon-line-1:after,span.wpc-icon-line-2:after,span.wpc-icon-line-3:after{content:"";display:block;width:3px;height:3px;border:1px solid #2c2d33;background-color:#fff;position:absolute;top:-2px;box-sizing:content-box}span.wpc-icon-line-3:after{border-radius:50%;left:2px}span.wpc-icon-line-1:after{border-radius:50%;left:5px}span.wpc-icon-line-2:after{border-radius:50%;left:12px}body .wpc-filters-open-button-container a.wpc-filters-open-widget,body .wpc-filters-open-button-container a.wpc-open-close-filters-button{display:inline-block;text-align:left;border:1px solid #2c2d33;border-radius:2px;line-height:1.5;padding:7px 12px;background-color:transparent;color:#2c2d33;box-sizing:border-box;text-decoration:none!important;font-weight:400;transition:none;position:relative}@media screen and (max-width:768px){.wpc_show_bottom_widget .wpc-filters-open-button-container,.wpc_show_open_close_button .wpc-filters-open-button-container{display:block}.wpc_show_bottom_widget .wpc-filters-open-button-container{margin-top:1em;margin-bottom:1em}}</style>
93<link rel="icon" href="https://oncotherm.com/wp-content/uploads/2022/11/cropped-favi-32x32.png" sizes="32x32" />
94<link rel="icon" href="https://oncotherm.com/wp-content/uploads/2022/11/cropped-favi-192x192.png" sizes="192x192" />
95<link rel="apple-touch-icon" href="https://oncotherm.com/wp-content/uploads/2022/11/cropped-favi-180x180.png" />
96<meta name="msapplication-TileImage" content="https://oncotherm.com/wp-content/uploads/2022/11/cropped-favi-270x270.png" />
97<link rel='stylesheet' id='sow-icon-default-543ad11e08c1-css' href='https://oncotherm.com/wp-content/uploads/siteorigin-widgets/sow-icon-default-543ad11e08c1.css?ver=9b4fda4fc00966c4c30efe23c40953c0' media='all' />
98<link rel='stylesheet' id='siteorigin-widget-icon-font-ionicons-css' href='https://oncotherm.com/wp-content/plugins/so-widgets-bundle/icons/ionicons/style.css?ver=9b4fda4fc00966c4c30efe23c40953c0' media='all' />
99<link rel='stylesheet' id='siteorigin-panels-front-css' href='https://oncotherm.com/wp-content/plugins/siteorigin-panels/css/front-flex.min.css?ver=2.36.0' media='all' />
100<link rel='stylesheet' id='siteorigin-widget-icon-font-materialicons-css' href='https://oncotherm.com/wp-content/plugins/so-widgets-bundle/icons/materialicons/style.css?ver=9b4fda4fc00966c4c30efe23c40953c0' media='all' />
101<link rel='stylesheet' id='sow-image-default-c67d20f9f743-css' href='https://oncotherm.com/wp-content/uploads/siteorigin-widgets/sow-image-default-c67d20f9f743.css?ver=9b4fda4fc00966c4c30efe23c40953c0' media='all' />
102<link rel='stylesheet' id='sow-social-media-buttons-flat-8f436be6ec16-css' href='https://oncotherm.com/wp-content/uploads/siteorigin-widgets/sow-social-media-buttons-flat-8f436be6ec16.css?ver=9b4fda4fc00966c4c30efe23c40953c0' media='all' />
103<link rel='stylesheet' id='siteorigin-widget-icon-font-fontawesome-css' href='https://oncotherm.com/wp-content/plugins/so-widgets-bundle/icons/fontawesome/style.css?ver=9b4fda4fc00966c4c30efe23c40953c0' media='all' />
104
105</head>
106
107<body class="archive post-type-archive post-type-archive-klinikai-publikaciok wp-custom-logo wp-theme-oncotherm cookies-not-set ally-default hfeed no-sidebar klinikai-publikaciok modulated-electrohyperthermia-in-locally-advanced-cervical-cancer-results-of-an-observational-study-of-95-patients language-en">
108			<button type="button"  aria-controls="rmp-container-2025" aria-label="Menu Trigger" id="rmp_menu_trigger-2025"  class="rmp_menu_trigger rmp-menu-trigger-boring">
109								<span class="rmp-trigger-box">
110									<span class="responsive-menu-pro-inner"></span>
111								</span>
112					</button>
113						<div id="rmp-container-2025" class="rmp-container rmp-container rmp-slide-left">
114							<div id="rmp-menu-additional-content-2025" class="rmp-menu-additional-content">
115					Add more content here...				</div>
116			<div id="rmp-menu-wrap-2025" class="rmp-menu-wrap"><ul id="rmp-menu-2025" class="rmp-menu" role="menubar" aria-label="Mobil main menu"><li id="rmp-menu-item-3233" class=" menu-item menu-item-type-post_type menu-item-object-page current-menu-ancestor current-menu-parent current_page_parent current_page_ancestor menu-item-has-children rmp-menu-item rmp-menu-item-current-ancestor rmp-menu-item-current-parent rmp-menu-item-has-children rmp-menu-top-level-item" role="none"><a  href="https://oncotherm.com/oncothermia/"  class="rmp-menu-item-link"  role="menuitem"  >Oncothermia<div class="rmp-menu-subarrow">+</div></a><ul aria-label="Oncothermia"
117            role="menu" data-depth="2"
118            class="rmp-submenu rmp-submenu-depth-1"><li id="rmp-menu-item-6147" class=" menu-item menu-item-type-post_type menu-item-object-page rmp-menu-item rmp-menu-sub-level-item" role="none"><a  href="https://oncotherm.com/oncothermia/"  class="rmp-menu-item-link"  role="menuitem"  >Oncothermia</a></li><li id="rmp-menu-item-3396" class=" menu-item menu-item-type-custom menu-item-object-custom current-menu-item rmp-menu-item rmp-menu-current-item rmp-menu-sub-level-item" role="none"><a  href="https://oncotherm.com/clinical-publications/"  class="rmp-menu-item-link"  role="menuitem"  >Clinical Publications</a></li><li id="rmp-menu-item-3240" class=" menu-item menu-item-type-post_type menu-item-object-page rmp-menu-item rmp-menu-sub-level-item" role="none"><a  href="https://oncotherm.com/collection-of-experimental-publications/"  class="rmp-menu-item-link"  role="menuitem"  >Experimental publications</a></li><li id="rmp-menu-item-3457" class=" menu-item menu-item-type-custom menu-item-object-custom rmp-menu-item rmp-menu-sub-level-item" role="none"><a  href="https://oncotherm.com/oncothermia-journal/"  class="rmp-menu-item-link"  role="menuitem"  >Oncothermia Journal</a></li></ul></li><li id="rmp-menu-item-3229" class=" menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children rmp-menu-item rmp-menu-item-has-children rmp-menu-top-level-item" role="none"><a  href="##"  class="rmp-menu-item-link"  role="menuitem"  >Partners<div class="rmp-menu-subarrow">+</div></a><ul aria-label="Partners"
119            role="menu" data-depth="2"
120            class="rmp-submenu rmp-submenu-depth-1"><li id="rmp-menu-item-4028" class=" menu-item menu-item-type-custom menu-item-object-custom rmp-menu-item rmp-menu-sub-level-item" role="none"><a  href="https://oncotherm.com/map/distributor-partnerships/"  class="rmp-menu-item-link"  role="menuitem"  >Distributors</a></li><li id="rmp-menu-item-4029" class=" menu-item menu-item-type-custom menu-item-object-custom rmp-menu-item rmp-menu-sub-level-item" role="none"><a  href="https://oncotherm.com/map/research-partnerships"  class="rmp-menu-item-link"  role="menuitem"  >Research Partnerships</a></li><li id="rmp-menu-item-4030" class=" menu-item menu-item-type-custom menu-item-object-custom rmp-menu-item rmp-menu-sub-level-item" role="none"><a  href="https://oncotherm.com/map/oncothermia-clinics/"  class="rmp-menu-item-link"  role="menuitem"  >Oncothermia Clinics</a></li><li id="rmp-menu-item-3245" class=" menu-item menu-item-type-post_type menu-item-object-page rmp-menu-item rmp-menu-sub-level-item" role="none"><a  href="https://oncotherm.com/faq-professional/"  class="rmp-menu-item-link"  role="menuitem"  >FAQ Professional</a></li><li id="rmp-menu-item-3246" class=" menu-item menu-item-type-post_type menu-item-object-page rmp-menu-item rmp-menu-sub-level-item" role="none"><a  href="https://oncotherm.com/faq-patient/"  class="rmp-menu-item-link"  role="menuitem"  >FAQ Patient</a></li><li id="rmp-menu-item-3247" class=" menu-item menu-item-type-post_type menu-item-object-page rmp-menu-item rmp-menu-sub-level-item" role="none"><a  href="https://oncotherm.com/faq-distributor/"  class="rmp-menu-item-link"  role="menuitem"  >FAQ Distributor</a></li></ul></li><li id="rmp-menu-item-3230" class=" menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children rmp-menu-item rmp-menu-item-has-children rmp-menu-top-level-item" role="none"><a  href="##"  class="rmp-menu-item-link"  role="menuitem"  >Products<div class="rmp-menu-subarrow">+</div></a><ul aria-label="Products"
121            role="menu" data-depth="2"
122            class="rmp-submenu rmp-submenu-depth-1"><li id="rmp-menu-item-4532" class=" menu-item menu-item-type-post_type menu-item-object-page rmp-menu-item rmp-menu-sub-level-item" role="none"><a  href="https://oncotherm.com/ehy-2030/"  class="rmp-menu-item-link"  role="menuitem"  >EHY-2030</a></li><li id="rmp-menu-item-4533" class=" menu-item menu-item-type-post_type menu-item-object-page rmp-menu-item rmp-menu-sub-level-item" role="none"><a  href="https://oncotherm.com/labehy/"  class="rmp-menu-item-link"  role="menuitem"  >LabEHY</a></li></ul></li><li id="rmp-menu-item-3458" class=" menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children rmp-menu-item rmp-menu-item-has-children rmp-menu-top-level-item" role="none"><a  href="##"  class="rmp-menu-item-link"  role="menuitem"  >News<div class="rmp-menu-subarrow">+</div></a><ul aria-label="News"
123            role="menu" data-depth="2"
124            class="rmp-submenu rmp-submenu-depth-1"><li id="rmp-menu-item-3459" class=" menu-item menu-item-type-taxonomy menu-item-object-category rmp-menu-item rmp-menu-sub-level-item" role="none"><a  href="https://oncotherm.com/news/"  class="rmp-menu-item-link"  role="menuitem"  >Latest news</a></li><li id="rmp-menu-item-3460" class=" menu-item menu-item-type-taxonomy menu-item-object-category rmp-menu-item rmp-menu-sub-level-item" role="none"><a  href="https://oncotherm.com/events/"  class="rmp-menu-item-link"  role="menuitem"  >Events</a></li><li id="rmp-menu-item-3461" class=" menu-item menu-item-type-taxonomy menu-item-object-category rmp-menu-item rmp-menu-sub-level-item" role="none"><a  href="https://oncotherm.com/corporate-social-responsibility/"  class="rmp-menu-item-link"  role="menuitem"  >Corporate Social Responsibility</a></li></ul></li><li id="rmp-menu-item-3272" class=" menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children rmp-menu-item rmp-menu-item-has-children rmp-menu-top-level-item" role="none"><a  href="https://oncotherm.com/about-us/"  class="rmp-menu-item-link"  role="menuitem"  >About Us<div class="rmp-menu-subarrow">+</div></a><ul aria-label="About Us"
125            role="menu" data-depth="2"
126            class="rmp-submenu rmp-submenu-depth-1"><li id="rmp-menu-item-4130" class=" menu-item menu-item-type-custom menu-item-object-custom rmp-menu-item rmp-menu-sub-level-item" role="none"><a  href="https://oncotherm.com/about-us/#oncothermteam"  class="rmp-menu-item-link"  role="menuitem"  >Oncotherm Team</a></li><li id="rmp-menu-item-4129" class=" menu-item menu-item-type-custom menu-item-object-custom rmp-menu-item rmp-menu-sub-level-item" role="none"><a  href="https://oncotherm.com/about-us/#timeline"  class="rmp-menu-item-link"  role="menuitem"  >Timeline of Oncotherm</a></li><li id="rmp-menu-item-4128" class=" menu-item menu-item-type-custom menu-item-object-custom rmp-menu-item rmp-menu-sub-level-item" role="none"><a  href="https://oncotherm.com/about-us/#tenders"  class="rmp-menu-item-link"  role="menuitem"  >Tenders</a></li><li id="rmp-menu-item-4126" class=" menu-item menu-item-type-post_type menu-item-object-page rmp-menu-item rmp-menu-sub-level-item" role="none"><a  href="https://oncotherm.com/certificates/"  class="rmp-menu-item-link"  role="menuitem"  >Certificates</a></li><li id="rmp-menu-item-4127" class=" menu-item menu-item-type-custom menu-item-object-custom rmp-menu-item rmp-menu-sub-level-item" role="none"><a  href="https://oncotherm.com/about-us/#contact"  class="rmp-menu-item-link"  role="menuitem"  >Contact</a></li></ul></li><li id="rmp-menu-item-3277" class=" menu-item menu-item-type-post_type menu-item-object-page rmp-menu-item rmp-menu-top-level-item" role="none"><a  href="https://oncotherm.com/career/"  class="rmp-menu-item-link"  role="menuitem"  >Career</a></li><li id="rmp-menu-item-3278" class="pll-parent-menu-item menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children rmp-menu-item rmp-menu-item-has-children rmp-menu-top-level-item" role="none"><a  href="#pll_switcher"  class="rmp-menu-item-link"  role="menuitem"  >EN<div class="rmp-menu-subarrow">+</div></a><ul aria-label="EN"
127            role="menu" data-depth="2"
128            class="rmp-submenu rmp-submenu-depth-1"><li id="rmp-menu-item-3278-hu" class="lang-item lang-item-3 lang-item-hu lang-item-first menu-item menu-item-type-custom menu-item-object-custom rmp-menu-item rmp-menu-sub-level-item" role="none"><a  href="https://oncotherm.com/hu/klinikai-publikaciok/"  class="rmp-menu-item-link"  role="menuitem"  lang="hu-HU"  hreflang="hu-HU"  >HU</a></li><li id="rmp-menu-item-3278-de" class="lang-item lang-item-617 lang-item-de menu-item menu-item-type-custom menu-item-object-custom rmp-menu-item rmp-menu-sub-level-item" role="none"><a  href="https://oncotherm.com/de/klinische-publikationen/"  class="rmp-menu-item-link"  role="menuitem"  lang="de-DE"  hreflang="de-DE"  >DE</a></li></ul></li></ul></div>			<div id="rmp-search-box-2025" class="rmp-search-box">
129					<form action="https://oncotherm.com/" class="rmp-search-form" role="search">
130						<input type="search" name="s" title="Search" placeholder="Search" class="rmp-search-box">
131					</form>
132				</div>
133						</div>
134			<div id="page" class="site">
135	<a class="skip-link screen-reader-text" href="#primary">Skip to content</a>
136	<div id="hirlevel-badge">
137	<section id="sow-image-5" class="widget widget_sow-image"><div
138			
139			class="so-widget-sow-image so-widget-sow-image-default-e4c2d9f6c920"
140			
141		>
142<div class="sow-image-container">
143			<a href="https://oncotherm.com/sign-up-for-newsletter/"
144					>
145			<img 
146	src="https://oncotherm.com/wp-content/uploads/2023/05/hirlevel-badge_en-01.svg" width="30" height="70" alt="" decoding="async" 		class="so-widget-image"/>
147			</a></div>
148
149</div></section>	</div>
150	<header id="masthead" class="site-header">
151		<div class="container flex space-between">
152		<div class="site-branding">
153			<a href="https://oncotherm.com/" class="custom-logo-link" rel="home"><img width="220" height="50" src="https://oncotherm.com/wp-content/uploads/2022/11/logo_ar-01.svg" class="custom-logo" alt="Oncotherm Kft." decoding="async" /></a>			
154		</div><!-- .site-branding -->
155		<div class="right-header flex ">
156		<nav id="site-navigation" class="main-navigation">
157			
158			<div class="menu-main-nav-en-container"><ul id="primary-menu" class="menu"><li id="menu-item-3233" class="menu-item menu-item-type-post_type menu-item-object-page current-menu-ancestor current-menu-parent current_page_parent current_page_ancestor menu-item-has-children menu-item-3233"><a href="https://oncotherm.com/oncothermia/">Oncothermia</a>
159<ul class="sub-menu">
160	<li id="menu-item-6147" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-6147"><a href="https://oncotherm.com/oncothermia/">Oncothermia</a></li>
161	<li id="menu-item-3396" class="menu-item menu-item-type-custom menu-item-object-custom current-menu-item menu-item-3396"><a href="https://oncotherm.com/clinical-publications/" aria-current="page">Clinical Publications</a></li>
162	<li id="menu-item-3240" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3240"><a href="https://oncotherm.com/collection-of-experimental-publications/">Experimental publications</a></li>
163	<li id="menu-item-3457" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-3457"><a href="https://oncotherm.com/oncothermia-journal/">Oncothermia Journal</a></li>
164</ul>
165</li>
166<li id="menu-item-3229" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-3229"><a href="##">Partners</a>
167<ul class="sub-menu">
168	<li id="menu-item-4028" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-4028"><a href="https://oncotherm.com/map/distributor-partnerships/">Distributors</a></li>
169	<li id="menu-item-4029" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-4029"><a href="https://oncotherm.com/map/research-partnerships">Research Partnerships</a></li>
170	<li id="menu-item-4030" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-4030"><a href="https://oncotherm.com/map/oncothermia-clinics/">Oncothermia Clinics</a></li>
171	<li id="menu-item-3245" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3245"><a href="https://oncotherm.com/faq-professional/">FAQ Professional</a></li>
172	<li id="menu-item-3246" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3246"><a href="https://oncotherm.com/faq-patient/">FAQ Patient</a></li>
173	<li id="menu-item-3247" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3247"><a href="https://oncotherm.com/faq-distributor/">FAQ Distributor</a></li>
174</ul>
175</li>
176<li id="menu-item-3230" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-3230"><a href="##">Products</a>
177<ul class="sub-menu">
178	<li id="menu-item-4532" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4532"><a href="https://oncotherm.com/ehy-2030/">EHY-2030</a></li>
179	<li id="menu-item-4533" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4533"><a href="https://oncotherm.com/labehy/">LabEHY</a></li>
180</ul>
181</li>
182<li id="menu-item-3458" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-3458"><a href="##">News</a>
183<ul class="sub-menu">
184	<li id="menu-item-3459" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-3459"><a href="https://oncotherm.com/news/">Latest news</a></li>
185	<li id="menu-item-3460" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-3460"><a href="https://oncotherm.com/events/">Events</a></li>
186	<li id="menu-item-3461" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-3461"><a href="https://oncotherm.com/corporate-social-responsibility/">Corporate Social Responsibility</a></li>
187</ul>
188</li>
189<li id="menu-item-3272" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-3272"><a href="https://oncotherm.com/about-us/">About Us</a>
190<ul class="sub-menu">
191	<li id="menu-item-4130" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-4130"><a href="https://oncotherm.com/about-us/#oncothermteam">Oncotherm Team</a></li>
192	<li id="menu-item-4129" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-4129"><a href="https://oncotherm.com/about-us/#timeline">Timeline of Oncotherm</a></li>
193	<li id="menu-item-4128" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-4128"><a href="https://oncotherm.com/about-us/#tenders">Tenders</a></li>
194	<li id="menu-item-4126" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4126"><a href="https://oncotherm.com/certificates/">Certificates</a></li>
195	<li id="menu-item-4127" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-4127"><a href="https://oncotherm.com/about-us/#contact">Contact</a></li>
196</ul>
197</li>
198<li id="menu-item-3277" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3277"><a href="https://oncotherm.com/career/">Career</a></li>
199<li id="menu-item-3278" class="pll-parent-menu-item menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-3278"><a href="#pll_switcher">EN</a>
200<ul class="sub-menu">
201	<li id="menu-item-3278-hu" class="lang-item lang-item-3 lang-item-hu lang-item-first menu-item menu-item-type-custom menu-item-object-custom menu-item-3278-hu"><a href="https://oncotherm.com/hu/klinikai-publikaciok/" lang="hu-HU" hreflang="hu-HU">HU</a></li>
202	<li id="menu-item-3278-de" class="lang-item lang-item-617 lang-item-de menu-item menu-item-type-custom menu-item-object-custom menu-item-3278-de"><a href="https://oncotherm.com/de/klinische-publikationen/" lang="de-DE" hreflang="de-DE">DE</a></li>
203</ul>
204</li>
205</ul></div>		</nav><!-- #site-navigation -->
206		<section id="siteorigin-panels-builder-3" class="widget widget_siteorigin-panels-builder"><div id="pl-w6489d1a75c44d"  class="panel-layout" ><div id="pg-w6489d1a75c44d-0"  class="panel-grid panel-no-style" ><div id="pgc-w6489d1a75c44d-0-0"  class="panel-grid-cell" ><div id="panel-w6489d1a75c44d-0-0-0" class="so-panel widget widget_sow-icon panel-first-child panel-last-child" data-index="0" ><div id="keres-ikon" class="panel-widget-style panel-widget-style-for-w6489d1a75c44d-0-0-0" ><div
207			
208			class="so-widget-sow-icon so-widget-sow-icon-default-543ad11e08c1"
209			
210		>
211<div class="sow-icon-container sow-icon">
212			<span class="sow-icon-ionicons" data-sow-icon="&#xf4a4;"
213		 
214		aria-hidden="true"></span>	</div>
215</div></div></div></div></div><div id="pg-w6489d1a75c44d-1"  class="panel-grid panel-has-style" ><div id="kereso" class="panel-row-style panel-row-style-for-w6489d1a75c44d-1" ><div id="pgc-w6489d1a75c44d-1-0"  class="panel-grid-cell" ><div id="panel-w6489d1a75c44d-1-0-0" class="so-panel widget widget_search panel-first-child panel-last-child" data-index="1" ><form role="search" method="get" class="search-form" action="https://oncotherm.com/">
216				<label>
217					<span class="screen-reader-text">Search for:</span>
218					<input type="search" class="search-field" placeholder="Search &hellip;" value="" name="s" />
219				</label>
220				<input type="submit" class="search-submit" value="Search" />
221			</form></div></div></div></div></div></section><section id="sow-icon-2" class="widget widget_sow-icon"><div
222			
223			class="so-widget-sow-icon so-widget-sow-icon-default-77a6afac270e"
224			
225		>
226<div class="sow-icon-container sow-icon">
227			<span class="sow-icon-materialicons sowm-regular" data-sow-icon="&#xe914"
228		 
229		aria-hidden="true"></span>	</div>
230</div></section>		</div>
231		</div>
232
233	</header><!-- #masthead -->
234	<div id="palyazat">
235			<section id="sow-image-6" class="widget widget_sow-image"><div
236			
237			class="so-widget-sow-image so-widget-sow-image-default-4e6925654b7a"
238			
239		>
240<div class="sow-image-container">
241			<a href="https://oncotherm.com/projects-financed-by-the-hungarian-ministry-of-finance/"
242					>
243			<img 
244	src="https://oncotherm.com/wp-content/uploads/2024/01/kedvezmenyezetti_infoblokk_fekvo_angol_rgb.jpg" width="300" height="88" sizes="(max-width: 300px) 100v
244w, 300px" alt="" decoding="async" 		class="so-widget-image"/>
245			</a></div>
246
247</div></section><section id="sow-image-12" class="widget widget_sow-image"><div
248			
249			class="so-widget-sow-image so-widget-sow-image-default-8b5b6f678277"
250			
251		>
252<div class="sow-image-container">
253			<a href="https://oncotherm.com/our-projects-implemented-with-co-financing-from-the-european-union/"
254					>
255			<img 
256	src="https://oncotherm.com/wp-content/uploads/2026/03/kedvezmenyezetti_infoblokk_fekvo_angol_rgb-300x88.png" width="230" height="67" srcset="https://oncotherm.com/wp-content/uploads/2026/03/kedvezmenyezetti_infoblokk_fekvo_angol_rgb-300x88.png 300w, https://oncotherm.com/wp-content/uploads/2026/03/kedvezmenyezetti_infoblokk_fekvo_angol_rgb.png 600w" sizes="(max-width: 230px) 100vw, 230px" alt="" decoding="async" 		class="so-widget-image"/>
257			</a></div>
258
259</div></section>		</div>
260	<!-- home-slider -->
261	<!-- home-slider  -->
262	<main id="primary" class="site-main ot-events">
263<div class="container kp-top">
264		
265				<section id="sow-editor-3" class="widget widget_sow-editor"><div
266			
267			class="so-widget-sow-editor so-widget-sow-editor-base"
268			
269		>
270<div class="siteorigin-widget-tinymce textwidget">
271	<h1 class="page-title" style="text-align: left; margin-bottom: 10px;">CLINICAL PUBLICATIONS</h1>
272<p>If you would like to read about experimental publications <span style="color: #9e8053;"><a style="color: #9e8053;" href="https://oncotherm.com/collection-of-experimental-publications/" target="_blank" rel="noopener">please click here</a></span></p>
273</div>
274</div></section><section id="wpc_filters_widget-9" class="widget widget_wpc_filters_widget"><div class="wpc-filters-main-wrap  wpc-filter-set-3389 wpc-horizontal-layout wpc-horizontal-cols-3" data-wpc-hide-empty="no" data-wpc-use-apply-button="" data-set="3389">
275<div class="wpc-filters-open-button-container wpc-open-button-3389 ">
276    <a class="wpc-open-close-filters-button wpc-show-counts-no" href="javascript:void(0);" data-wid="3389"><span class="wpc-button-inner">    <span class="wpc-icon-html-wrapper">
277    <span class="wpc-icon-line-1"></span>
278    <span class="wpc-icon-line-2"></span>
279    <span class="wpc-icon-line-3"></span>
280</span>
281    <span class="wpc-filters-button-text">Filters</span></span></a>
282</div><div class="wpc-spinner"></div><div class="wpc-filters-widget-content wpc-show-counts-no wpc-query-on-the-page"><div class="wpc-widget-close-container">
283                            <a class="wpc-widget-close-icon">
284                                <span class="wpc-icon-html-wrapper">
285                                <span class="wpc-icon-line-1"></span><span class="wpc-icon-line-2"></span><span class="wpc-icon-line-3"></span>
286                                </span>
287                            </a><span class="wpc-widget-popup-title">Filters</span></div><div class="wpc-filters-widget-containers-wrapper">
288<div class="wpc-filters-widget-top-container"><div class="wpc-widget-top-inside"><div class="wpc-inner-widget-chips-wrapper"><ul class="wpc-filter-chips-list wpc-filter-chips-3389-1 wpc-filter-chips-3389 wpc-empty-chips-container" data-set="3389" data-setcount="3389-1">
289    </ul></div></div></div><div class="wpc-filters-scroll-container"><div class="wpc-filters-widget-wrapper">
290<div class="wpc-posts-found wpc-posts-found-hidden" data-found="">
291</div><div class="wpc-filters-section wpc-filters-section-3389s wpc-filter-layout-search-field" data-fid="3389s">
292            <div class="wpc-filter-header">
293        <div class="widget-title wpc-filter-title">SEARCH</div></div><form action="https://oncotherm.com/clinical-publications/" role="search" method="GET" class="wpc-filter-search-form"><div class="wpc-search-field-wrapper wpc-search-field-wrapper-3389s"><span class="wpc-search-icon"></span><label for="srch" class="screen-reader-text">Search</label><input type="text" class="wpc-search-field" placeholder="Author" value="" name="srch"><span class="wpc-search-clear-icon-wrapper"><a class="wpc-search-clear-icon" href="https://oncotherm.com/clinical-publications/" title="Clear search">&#215;</a></span>
294                </div></form></div><div class="wpc-filters-section wpc-filters-section-3394 wpc-filter-bizonyitas wpc-filter-post_meta wpc-filter-layout-dropdown wpc-counter-length-2 wpc-filter-terms-count-10 wpc-filter-visible-term-names" data-fid="3394" data-filter-e-name="bizonyitas">
295            <div class="wpc-filter-header">
296        <div class="widget-title wpc-filter-title">Evidence</div></div>    <div class="wpc-filter-content wpc-filter-bizonyitas">
297                    <select id="wpc-post_meta-bizonyitas-3394"
298                    aria-label="wpc-post_meta-bizonyitas-3394"
299                    class="wpc-filters-widget-select" style="width: 100%">
300                                        
301                        <option class="wpc-dropdown-default wpc-dropdown-default-bizonyitas" value="
3010" data-wpc-link="https://oncotherm.com/clinical-publications/" id="wpc-option-post_meta-bizonyitas-0" data-wpc-select-parent-text="" data-wpc-default-option-text="Evidence">Evidence</option>
302                                                    <option data-wpc-chip="Case report" class="wpc-term-item wpc-term-count-12 wpc-term-id-11" value="11"   data-wpc-link="https://oncotherm.com/clinical-publications/?_bizonyitas=case-report" id="wpc-option-post_meta-bizonyitas-11" data-wpc-e-name="bizonyitas" data-wpc-slug="case-report" data-term-id="11">
303                                Case report</option>
304                                                    <option data-wpc-chip="Clinical study" class="wpc-term-item wpc-term-count-4 wpc-term-id-60" value="60"   data-wpc-link="https://oncotherm.com/clinical-publications/?_bizonyitas=clinical-study" id="wpc-option-post_meta-bizonyitas-60" data-wpc-e-name="bizonyitas" data-wpc-slug="clinical-study" data-term-id="60">
305                                Clinical study</option>
306                                                    <option data-wpc-chip="Comparative study" class="wpc-term-item wpc-term-count-1 wpc-term-id-36" value="36"   data-wpc-link="https://oncotherm.com/clinical-publications/?_bizonyitas=comparative-study" id="wpc-option-post_meta-bizonyitas-36" data-wpc-e-name="bizonyitas" data-wpc-slug="comparative-study" data-term-id="36">
307                                Comparative study</option>
308                                                    <option data-wpc-chip="Open-label study" class="wpc-term-item wpc-term-count-3 wpc-term-id-53" value="53"   data-wpc-link="https://oncotherm.com/clinical-publications/?_bizonyitas=open-label-study" id="wpc-option-post_meta-bizonyitas-53" data-wpc-e-name="bizonyitas" data-wpc-slug="open-label-study" data-term-id="53">
309                                Open-label study</option>
310                                                    <option data-wpc-chip="Phase I" class="wpc-term-item wpc-term-count-6 wpc-term-id-15" value="15"   data-wpc-link="https://oncotherm.com/clinical-publications/?_bizonyitas=phase-i" id="wpc-option-post_meta-bizonyitas-15" data-wpc-e-name="bizonyitas" data-wpc-slug="phase-i" data-term-id="15">
311                                Phase I</option>
312                                                    <option data-wpc-chip="Phase I/II" class="wpc-term-item wpc-term-count-2 wpc-term-id-27" value="27"   data-wpc-link="https://oncotherm.com/clinical-publications/?_bizonyitas=phase-i-ii" id="wpc-option-post_meta-bizonyitas-27" data-wpc-e-name="bizonyitas" data-wpc-slug="phase-i-ii" data-term-id="27">
313                                Phase I/II</option>
314                                                    <option data-wpc-chip="Phase II" class="wpc-term-item wpc-term-count-6 wpc-term-id-38" value="38"   data-wpc-link="https://oncotherm.com/clinical-publications/?_bizonyitas=phase-ii" id="wpc-option-post_meta-bizonyitas-38" data-wpc-e-name="bizonyitas" data-wpc-slug="phase-ii" data-term-id="38">
315                                Phase II</option>
316                                                    <option data-wpc-chip="Phase III" class="wpc-term-item wpc-term-count-6 wpc-term-id-17" value="17"   data-wpc-link="https://oncotherm.com/clinical-publications/?_bizonyitas=phase-iii" id="wpc-option-post_meta-bizonyitas-17" data-wpc-e-name="bizonyitas" data-wpc-slug="phase-iii" data-term-id="17">
317                                Phase III</option>
318                                                    <option data-wpc-chip="Retrospective study" class="wpc-term-item wpc-term-count-7 wpc-term-id-33" value="33"   data-wpc-link="https://oncotherm.com/clinical-publications/?_bizonyitas=retrospective-study" id="wpc-option-post_meta-bizonyitas-33" data-wpc-e-name="bizonyitas" data-wpc-slug="retrospective-study" data-term-id="33">
319                                Retrospective study</option>
320                                                    <option data-wpc-chip="Review" class="wpc-term-item wpc-term-count-8 wpc-term-id-6" value="6"   data-wpc-link="https://oncotherm.com/clinical-publications/?_bizonyitas=review" id="wpc-option-post_meta-bizonyitas-6" data-wpc-e-name="bizonyitas" data-wpc-slug="review" data-term-id="6">
321                                Review</option>
322                        <!-- end foreach -->
323
324                            </select>
325                        </div>
326</div><div class="wpc-filters-section wpc-filters-section-3391 wpc-filter-terapia wpc-filter-post_meta wpc-filter-layout-dropdown wpc-counter-length-2 wpc-filter-terms-count-23 wpc-filter-visible-term-names" data-fid="3391" data-filter-e-name="terapia">
327            <div class="wpc-filter-header">
328        <div class="widget-title wpc-filter-title">Therapy</div></div>    <div class="wpc-filter-content wpc-filter-terapia">
329                    <select id="wpc-post_meta-terapia-3391"
330                    aria-label="wpc-post_meta-terapia-3391"
331                    class="wpc-filters-widget-select" style="width: 100%">
332                                        
333                        <option class="wpc-dropdown-default wpc-dropdown-default-terapia" value="
3330" data-wpc-link="https://oncotherm.com/clinical-publications/" id="wpc-option-post_meta-terapia-0" data-wpc-select-parent-text="" data-wpc-default-option-text="Therapy">Therapy</option>
334                                                    <option data-wpc-chip="Autophagy Inhibitor+mEHT" class="wpc-term-item wpc-term-count-1 wpc-term-id-31" value="31"   data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=autophagy-inhibitormeht" id="wpc-option-post_meta-terapia-31" data-wpc-e-name="terapia" data-wpc-slug="autophagy-inhibitormeht" data-term-id="31">
335                                Autophagy Inhibitor+mEHT</option>
336                                                    <option data-wpc-chip="CCRT + mEHT" class="wpc-term-item wpc-term-count-1 wpc-term-id-221" value="221"   data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=ccrt-meht" id="wpc-option-post_meta-terapia-221" data-wpc-e-name="terapia" data-wpc-slug="ccrt-meht" data-term-id="221">
337                                CCRT + mEHT</option>
338                                                    <option data-wpc-chip="Chemotherapy, Hyperthermia, Phytotherapy" class="wpc-term-item wpc-term-count-1 wpc-term-id-41" value="41"   data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=chemotherapy-hyperthermia-phytotherapy" id="wpc-option-post_meta-terapia-41" data-wpc-e-name="terapia" data-wpc-slug="chemotherapy-hyperthermia-phytotherapy" data-term-id="41">
339                                Chemotherapy, Hyperthermia, Phytotherapy</option>
340                                                    <option data-wpc-chip="Chemotherapy, Ketogenic Diet, Hyperthermia, Hyperbaric Oxygen Therapy" class="wpc-term-item wpc-term-count-1 wpc-term-id-16" value="16"   data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=chemotherapy-ketogenic-diet-hyperthermia-hyperbaric-oxygen-therapy" id="wpc-option-post_meta-terapia-16" data-wpc-e-name="terapia" data-wpc-slug="chemotherapy-ketogenic-diet-hyperthermia-hyperbaric-oxygen-therapy" data-term-id="16">
341                                Chemotherapy, Ketogenic Diet, Hyperthermia, Hyperbaric Oxygen Therapy</option>
342                                                    <option data-wpc-chip="Conventional treatment, Hyperthermia" class="wpc-term-item wpc-term-count-1 wpc-term-id-59" value="59"   data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=conventional-treatment-hyperthermia" id="wpc-option-post_meta-terapia-59" data-wpc-e-name="terapia" data-wpc-slug="conventional-treatment-hyperthermia" data-term-id="59">
343                                Conventional treatment, Hyperthermia</option>
344                                                    <option data-wpc-chip="CRT+mEHT" class="wpc-term-item wpc-term-count-2 wpc-term-id-4" value="4"   data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=crtmeht" id="wpc-option-post_meta-terapia-4" data-wpc-e-name="terapia" data-wpc-slug="crtmeht" data-term-id="4">
345                                CRT+mEHT</option>
346                                                    <option data-wpc-chip="CT+mEHT" class="wpc-term-item wpc-term-count-22 wpc-term-id-29" value="29"   data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=ctmeht" id="wpc-option-post_meta-terapia-29" data-wpc-e-name="terapia" data-wpc-slug="ctmeht" data-term-id="29">
347                                CT+mEHT</option>
348                                                    <option data-wpc-chip="CT+RT+mEHT" class="wpc-term-item wpc-term-count-11 wpc-term-id-11" value="11"   data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=ctrtmeht" id="wpc-option-post_meta-terapia-11" data-wpc-e-name="terapia" data-wpc-slug="ctrtmeht" data-term-id="11">
349                                CT+RT+mEHT</option>
350                                                    <option data-wpc-chip="CT+WBH" class="wpc-term-item wpc-term-count-2 wpc-term-id-97" value="97"   data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=ctwbh" id="wpc-option-post_meta-terapia-97" data-wpc-e-name="terapia" data-wpc-slug="ctwbh" data-term-id="97">
351                                CT+WBH</option>
352                                                    <option data-wpc-chip="ECT" class="wpc-term-item wpc-term-count-1 wpc-term-id-67" value="67"   data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=ect" id="wpc-option-post_meta-terapia-67" data-wpc-e-name="terapia" data-wpc-slug="ect" data-term-id="67">
353                                ECT</option>
354                                                    <option data-wpc-chip="IMT+mEHT" class="wpc-term-item wpc-term-count-3 wpc-term-id-33" value="33"   data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=imtmeht" id="wpc-option-post_meta-terapia-33" data-wpc-e-name="terapia" data-wpc-slug="imtmeht" data-term-id="33">
355                                IMT+mEHT</option>
356                                                    <option data-wpc-chip="Integrative Therapeutic Options" class="wpc-term-item wpc-term-count-1 wpc-term-id-28" value="28"   data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=integrative-therapeutic-options" id="wpc-option-post_meta-terapia-28" data-wpc-e-name="terapia" data-wpc-slug="integrative-therapeutic-options" data-term-id="28">
357                                Integrative Therapeutic Options</option>
358                                                    <option data-wpc-chip="IVC + mEHT + BSC" class="wpc-term-item wpc-term-count-1 wpc-term-id-18" value="18"   data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=ivc-meht-bsc" id="wpc-option-post_meta-terapia-18" data-wpc-e-name="terapia" data-wpc-slug="ivc-meht-bsc" data-term-id="18">
359                                IVC + mEHT + BSC</option>
360                                                    <option data-wpc-chip="MEHT" class="wpc-term-item wpc-term-count-25 wpc-term-id-5" value="5"   data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=meht" id="wpc-option-post_meta-terapia-5" data-wpc-e-name="terapia" data-wpc-slug="meht" data-term-id="5">
361                                MEHT</option>
362                                                    <option data-wpc-chip="MEHT + TTF" class="wpc-term-item wpc-term-count-1 wpc-term-id-3" value="3"   data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=meht-ttf" id="wpc-option-post_meta-terapia-3" data-wpc-e-name="terapia" data-wpc-slug="meht-ttf" data-term-id="3">
363                                MEHT + TTF</option>
364                                                    <option data-wpc-chip="MEHT+OV therapy+DC" class="wpc-term-item wpc-term-count-1 wpc-term-id-66" value="66"   data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=mehtov-therapydc" id="wpc-option-post_meta-terapia-66" data-wpc-e-name="terapia" data-wpc-slug="mehtov-therapydc" data-term-id="66">
365                                MEHT+OV therapy+DC</option>
366                                                    <option data-wpc-chip="MEHT+TCM" class="wpc-term-item wpc-term-count-2 wpc-term-id-37" value="37"   data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=mehttcm" id="wpc-option-post_meta-terapia-37" data-wpc-e-name="terapia" data-wpc-slug="mehttcm" data-term-id="37">
367                                MEHT+TCM</option>
368                                                    <option data-wpc-chip="MEHT+Vitamins" class="wpc-term-item wpc-term-count-1 wpc-term-id-72" value="72"   data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=mehtvitamins" id="wpc-option-post_meta-terapia-72" data-wpc-e-name="terapia" data-wpc-slug="mehtvitamins" data-term-id="72">
369                                MEHT+Vitamins</option>
370                                                    <option data-wpc-chip="PT + mEHT" class="wpc-term-item wpc-term-count-1 wpc-term-id-35" value="35"   data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=pt-meht" id="wpc-option-post_meta-terapia-35" data-wpc-e-name="terapia" data-wpc-slug="pt-meht" data-term-id="35">
371                                PT + mEHT</option>
372                                                    <option data-wpc-chip="RT+mEHT" class="wpc-term-item wpc-term-count-4 wpc-term-id-9" value="9"   data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=rtmeht" id="wpc-option-post_meta-terapia-9" data-wpc-e-name="terapia" data-wpc-slug="rtmeht" data-term-id="9">
373                                RT+mEHT</option>
374                                                    <option data-wpc-chip="SRG+CT+mEHT" class="wpc-term-item wpc-term-count-3 wpc-term-id-57" value="5
3747"   data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=srgctmeht" id="wpc-option-post_meta-terapia-57" data-wpc-e-name="terapia" data-wpc-slug="srgctmeht" data-term-id="57">
375                                SRG+CT+mEHT</option>
376                                                    <option data-wpc-chip="SRG+CT+RT+mEHT" class="wpc-term-item wpc-term-count-1 wpc-term-id-95" value="95"   data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=srgctrtmeht" id="wpc-option-post_meta-terapia-95" data-wpc-e-name="terapia" data-wpc-slug="srgctrtmeht" data-term-id="95">
377                                SRG+CT+RT+mEHT</option>
378                                                    <option data-wpc-chip="TSL+mEHT" class="wpc-term-item wpc-term-count-1 wpc-term-id-30" value="30"   data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=tslmeht" id="wpc-option-post_meta-terapia-30" data-wpc-e-name="terapia" data-wpc-slug="tslmeht" data-term-id="30">
379                                TSL+mEHT</option>
380                        <!-- end foreach -->
381
382                            </select>
383                        </div>
384</div><div class="wpc-filters-section wpc-filters-section-3395 wpc-filter-indikacio wpc-filter-post_meta wpc-filter-layout-dropdown wpc-counter-length-2 wpc-filter-terms-count-24 wpc-filter-visible-term-names" data-fid="3395" data-filter-e-name="indikacio">
385            <div class="wpc-filter-header">
386        <div class="widget-title wpc-filter-title">Indication</div></div>    <div class="wpc-filter-content wpc-filter-indikacio">
387                    <select id="wpc-post_meta-indikacio-3395"
388                    aria-label="wpc-post_meta-indikacio-3395"
389                    class="wpc-filters-widget-select" style="width: 100%">
390                                        
391                        <option class="wpc-dropdown-default wpc-dropdown-default-indikacio" value="0" data-wpc-link="https://oncotherm.com/clinical-publications/" id="wpc-option-post_meta-indikacio-0" data-wpc-select-parent-text="" data-wpc-default-option-text="Indication">Indication</option>
392                                                    <option data-wpc-chip="Bone" class="wpc-term-item wpc-term-count-2 wpc-term-id-79" value="79"   data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=bone" id="wpc-option-post_meta-indikacio-79" data-wpc-e-name="indikacio" data-wpc-slug="bone" data-term-id="79">
393                                Bone</option>
394                                                    <option data-wpc-chip="Breast Cancer" class="wpc-term-item wpc-term-count-3 wpc-term-id-5" value="5"   data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=breast-cancer" id="wpc-option-post_meta-indikacio-5" data-wpc-e-name="indikacio" data-wpc-slug="breast-cancer" data-term-id="5">
395                                Breast Cancer</option>
396                                                    <option data-wpc-chip="Cervical cancer" class="wpc-term-item wpc-term-count-4 wpc-term-id-17" value="17"   data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=cervical-cancer" id="wpc-option-post_meta-indikacio-17" data-wpc-e-name="indikacio" data-wpc-slug="cervical-cancer" data-term-id="17">
397                                Cervical cancer</option>
398                                                    <option data-wpc-chip="Gastric Cancer" class="wpc-term-item wpc-term-count-1 wpc-term-id-16" value="16"   data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=gastric-cancer" id="wpc-option-post_meta-indikacio-16" data-wpc-e-name="indikacio" data-wpc-slug="gastric-cancer" data-term-id="16">
399                                Gastric Cancer</option>
400                                                    <option data-wpc-chip="Gastrointestinal" class="wpc-term-item wpc-term-count-4 wpc-term-id-4" value="4"   data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=gastrointestinal" id="wpc-option-post_meta-indikacio-4" data-wpc-e-name="indikacio" data-wpc-slug="gastrointestinal" data-term-id="4">
401                                Gastrointestinal</option>
402                                                    <option data-wpc-chip="Glioblastoma" class="wpc-term-item wpc-term-count-2 wpc-term-id-3" value="3"   data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=glioblastoma" id="wpc-option-post_meta-indikacio-3" data-wpc-e-name="indikacio" data-wpc-slug="glioblastoma" data-term-id="3">
403                                Glioblastoma</option>
404                                                    <option data-wpc-chip="Gliomas" class="wpc-term-item wpc-term-count-1 wpc-term-id-39" value="39"   data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=gliomas" id="wpc-option-post_meta-indikacio-39" data-wpc-e-name="indikacio" data-wpc-slug="gliomas" data-term-id="39">
405                                Gliomas</option>
406                                                    <option data-wpc-chip="Gliomas (advanced)" class="wpc-term-item wpc-term-count-11 wpc-term-id-9" value="9"   data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=gliomas-advanced" id="wpc-option-post_meta-indikacio-9" data-wpc-e-name="indikacio" data-wpc-slug="gliomas-advanced" data-term-id="9">
407                                Gliomas (advanced)</option>
408                                                    <option data-wpc-chip="Gynecology" class="wpc-term-item wpc-term-count-13 wpc-term-id-7" value="7"   data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=gynecology" id="wpc-option-post_meta-indikacio-7" data-wpc-e-name="indikacio" data-wpc-slug="gynecology" data-term-id="7">
409                                Gynecology</option>
410                                                    <option data-wpc-chip="Hemangioma" class="wpc-term-item wpc-term-count-1 wpc-term-id-67" value="67"   data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=hemangioma" id="wpc-option-post_meta-indikacio-67" data-wpc-e-name="indikacio" data-wpc-slug="hemangioma" data-term-id="67">
411                                Hemangioma</option>
412                                                    <option data-wpc-chip="Immuno-oncology" class="wpc-term-item wpc-term-count-6 wpc-term-id-24" value="24"   data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=immuno-oncology" id="wpc-option-post_meta-indikacio-24" data-wpc-e-name="indikacio" data-wpc-slug="immuno-oncology" data-term-id="24">
413                                Immuno-oncology</option>
414                                                    <option data-wpc-chip="Liver" class="wpc-term-item wpc-term-count-2 wpc-term-id-88" value="88"   data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=liver" id="wpc-option-post_meta-indikacio-88" data-wpc-e-name="indikacio" data-wpc-slug="liver" data-term-id="88">
415                                Liver</option>
416                                                    <option data-wpc-chip="Lung" class="wpc-term-item wpc-term-count-7 wpc-term-id-20" value="20"   data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=lung" id="wpc-option-post_meta-indikacio-20" data-wpc-e-name="indikacio" data-wpc-slug="lung" data-term-id="20">
417                                Lung</option>
418                                                    <option data-wpc-chip="Lung cancer" class="wpc-term-item wpc-term-count-3 wpc-term-id-14" value="14"   data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=lung-cancer" id="wpc-option-post_meta-indikacio-14" data-wpc-e-name="indikacio" data-wpc-slug="lung-cancer" data-term-id="14">
419                                Lung cancer</option>
420                                                    <option data-wpc-chip="Lyme-disease" class="wpc-term-item wpc-term-count-1 wpc-term-id-72" value="72"   data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=lyme-disease" id="wpc-option-post_meta-indikacio-72" data-wpc-e-name="indikacio" data-wpc-slug="lyme-disease" data-term-id="72">
421                                Lyme-disease</option>
422                                                    <option data-wpc-chip="Melanoma" class="wpc-term-item wpc-term-count-1 wpc-term-id-94" value="94"   data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=melanoma" id="wpc-option-post_meta-indikacio-94" data-wpc-e-name="indikacio" data-wpc-slug="melanoma" data-term-id="94">
423                                Melanoma</option>
424                                                    <option data-wpc-chip="Multiple" class="wpc-term-item wpc-term-count-4 wpc-term-id-13" value="13"   data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=multiple" id="wpc-option-post_meta-indikacio-13" data-wpc-e-name="indikacio" data-wpc-slug="multiple" data-term-id="13">
425                                Multiple</option>
426                                                    <option data-wpc-chip="Non-oncology" class="wpc-term-item wpc-term-count-7 wpc-term-id-22" value="22"   data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=non-oncology" id="wpc-option-post_meta-indikacio-22" data-wpc-e-name="indikacio" data-wpc-slug="non-oncology" data-term-id="22">
427                                Non-oncology</option>
428                                                    <option data-wpc-chip="Pancreas" class="wpc-term-item wpc-term-count-8 wpc-term-id-25" value="25"   data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=pancreas" id="wpc-option-post_meta-indikacio-25" data-wpc-e-name="indikacio" data-wpc-slug="pancreas" data-term-id="25">
429                                Pancreas</option>
430                                                    <option data-wpc-chip="Prostate" class="wpc-term-item wpc-term-count-14 wpc-term-id-61" value="61"   data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=prostate" id="wpc-option-post_meta-indikacio-61" data-wpc-e-name="indikacio" data-wpc-slug="prostate" data-term-id="61">
431                                Prostate</option>
432                                                    <option data-wpc-chip="Rectal Cancer" class="wpc-term-item wpc-term-count-3 wpc-term-id-12" value="12"   data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=rectal-cancer" id="wpc-option-post_meta-indikacio-12" data-wpc-e-name="indikacio" data-wpc-slug="rectal-cancer" data-term-id="12">
433                                Rectal Cancer</option>
434                                                    <option data-wpc-chip="Sarcoma" class="wpc-term-item wpc-term-count-2 wpc-term-id-57" value="57"   data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=sarcoma" id="wpc-option-post_meta-indikacio-57" data-wpc-e-name="indikacio" data-wpc-slug="sarcoma" data-term-id="57">
435                                Sarcoma</option>
436                                                    <option data-wpc-chip="Temperature" class="wpc-term-item wpc-term-count-3 wpc-term-id-32" value="32"   data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=temperature" id="wpc-option-post_meta-indikacio-32" data-wpc-e-name="indikacio" data-wpc-slug="temperature" data-term-id="32">
437                                Temperature</option>
438                                                    <option data-wpc-chip="Toxicity" class="wpc-term-item wpc-term-count-1 wpc-term-id-104" value="104"   data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=toxicity" id="wpc-option-post_meta-indikacio-104" data-wpc-e-name="indikacio" data-wpc-slug="toxicity" data-term-id="104">
439                                Toxicity</option>
440                        <!-- end foreach -->
441
442                            </select>
443                        </div>
444</div><div class="wpc-filters-section wpc-filters-section-3389 wpc-filter-layout-submit-button wpc-pc-sticky-buttons">
445    <div class="wpc-sticky-buttons">
446        <a class="wpc-filters-submit-button" href="https://oncotherm.com/clinical-publications/" data-wpc-apply-url="https://oncotherm.com/clinical-publications/" data-wpc-apply-base-url="" data-apply-button-page="">
447            Filter<span class='wpc-pc-apply-button  wpc-hidden-term-count'>(110)</span></a>
448        <a class="wpc-filters-reset-button wpc-filters-reset-button-3389" href="https://oncotherm.com/clinical-publications/" data-wpc-apply-reset-url="https://oncotherm.com/clinical-publications/">Reset</a>
449    </div>
450</div>
451</div>
452</div>
453<div class="wpc-filters-widget-controls-container">
454                <div class="wpc-filters-widget-controls-wrapper"><div class="wpc-filters-widget-controls-item wpc-filters-widget-controls-one">
455    <a class="wpc-filters-apply-button wpc-posts-loaded" href="https://oncotherm.com/clinical-publications/">Show <span class="wpc-filters-found-posts-wrapper">(<span class="wpc-filters-found-posts" data-wpc-total-found-posts="110">110</span>)</span></a>
456</div>
457<div class="wpc-filters-widget-controls-item wpc-filters-widget-controls-two">
458    <a class="wpc-filters-close-button" href="https://oncotherm.com/clinical-publications/">Cancel    </a>
459</div>
460                </div><div class="wpc-filters-section wpc-filters-section-3389 wpc-filter-layout-submit-button wpc-pc-sticky-buttons">
461    <div class="wpc-sticky-buttons">
462        <a class="wpc-filters-submit-button" href="https://oncotherm.com/clinical-publications/" data-wpc-apply-url="https://oncotherm.com/clinical-publications/" data-wpc-apply-base-url="" data-apply-button-page="">
463            Filter<span class='wpc-pc-apply-button  wpc-hidden-term-count'>(110)</span></a>
464        <a class="wpc-filters-reset-button wpc-filters-reset-button-3389" href="https://oncotherm.com/clinical-publications/" data-wpc-apply-reset-url="https://oncotherm.com/clinical-publications/">Reset</a>
465    </div>
466</div>
467</div></div>
468</div>
469</div>
470</section></div>
471
472			<div class="accordion-list">			
473			
474<article id="post-3393" class="post-3393 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
475	
476	<header class="pub-entry-header">
477	<div class="container">
478		<h2>Modulated electrohyperthermia in locally advanced cervical cancer Results of an observational study of 95 patients</h2>
479	</div>
480	</header><!-- .entry-header -->
481
482
483<div class="entry-content kl-pub-content">
484	<div class="container">
485		<div class="acf-fields">
486	<div class="acf-row"><span class="publ-label">Indication:</span> Gynecology <hr/> <span class="publ-label">Evidence:</span>  </div>
487	<div class="publ-acf acf-row acf-flex">
488	<span class="publ-label">Author:&nbsp;</span>
489	<div class="szerzok">
490		
491		 
492		
493		<span class="sz-nev">Sun Young Lee</span>
494   
495		 
496		
497		<span class="sz-nev">Dong Hyun Lee</span>
498   
499		 
500		
501		<span class="sz-nev">Dong-Hyu Cho</span>
502   
503				</div>
504	
505	</div>
506	<div class="acf-row"><span class="publ-label">No. of patients:</span> 95 <hr/> <span class="publ-label">Therapy:</span>  CCRT + mEHT<hr/> <span class="publ-label">Year:</span>  2023</div>
507	</div><!-- .acf-fields -->
508	<p><strong>Abstract</strong><br />
509Abstract Most federation of gynecology and obstetrics stage II or higher locally advanced cervical cancer (LACC) patients are treated with concurrent chemoradiotherapy (CCRT); however, recurrence is high, and the prognosis is poor. In this observational retrospective study, data from LACC patients treated with CCRT alone or combined with modulated electrohyperthermia (mEHT) were collected from 2011 to 2018. Ninety-five LACC patients, including 53 (%) treated with CCRT alone and 42 (%) treated with CCRT + mEHT, were enrolled. The complete remission rate significantly increased with CCRT + mEHT compared with CCRT alone among LACC cases with lymph node metastasis (45% vs 71%, P = .0377). Additionally, at the last follow-up point, the no-evidence-of-disease rate significantly improved with CCRT + mEHT compared with CCRT (58% vs 82%, P = .0315). Disease-free survival increased in the CCRT + mEHT group with lymph node metastasis (P = .04). The addition of mEHT to CCRT led to a better therapeutic response in LACC with regional lymph node metastasis without severe complications.</p>
510<p><strong>Abbreviations</strong><br />
511AEs = adverse events, CCRT = concurrent chemoradiotherapy, CR = complete remission, DFS = disease-free survival, HIF-1a = hypoxia-inducible factor-1a, LACC = locally advanced cervical cancer, mEHT = modulated electrohyperthermia, NED = no-evidence-of-disease, OS = overall survival, RF = radio frequency, VEGF = vascular endothelial growth factor.</p>
512
513			<div id="teljes-cikk" class="btn">
514		<a href="https://journals.lww.com/md-journal/Fulltext/2023/01200/Modulated_electrohyperthermia_in_locally_advanced.1.aspx" target="_blank">
514 View abstract</a>
515	</div>
516	
517	</div>	<!-- .container -->
518</div><!-- .entry-content -->
519
520
521
522</article><!-- #post-3393 -->
523
524			
525<article id="post-3279" class="post-3279 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
526	
527	<header class="pub-entry-header">
528	<div class="container">
529		<h2>Meta-Analysis of Modulated Electro-Hyperthermia and Tumor Treating Fields in the Treatment of Glioblastomas</h2>
530	</div>
531	</header><!-- .entry-header -->
532
533
534<div class="entry-content kl-pub-content">
535	<div class="container">
536		<div class="acf-fields">
537	<div class="acf-row"><span class="publ-label">Indication:</span> Glioblastoma <hr/> <span class="publ-label">Evidence:</span>  </div>
538	<div class="publ-acf acf-row acf-flex">
539	<span class="publ-label">Author:&nbsp;</span>
540	<div class="szerzok">
541		
542		 
543		
544		<span class="sz-nev">Attila Marcell Szasz</span>
545   
546		 
547		
548		<span class="sz-nev">Elisabeth Estefanía</span>
549   
550		 
551		
552		<span class="sz-nev">Arrojo Alvarez</span>
553   
554		 
555		
556		<span class="sz-nev">Giammaria Fiorentini</span>
557   
558		 
559		
560		<span class="sz-nev">Magdolna Herold</span>
561   
562		 
563		
564		<span class="sz-nev">Zoltan Herold</span>
565   
566		 
567		
568		<span class="sz-nev">Donatella Sarti</span>
569   
570		 
571		
572		<span class="sz-nev">Magdolna Dank</span>
573   
574				</div>
575	
576	</div>
577	<div class="acf-row"><span class="publ-label">No. of patients:</span> 450 <hr/> <span class="publ-label">Therapy:</span>  mEHT + TTF<hr/> <span class="publ-label">Year:</span>  2022</div>
578	</div><!-- .acf-fields -->
579	<p class="text-align-justify"><span style="color: #9e8053;"><strong>Simple Summary</strong></span><br />
580Glioblastoma is a highly aggressive brain tumor, which has a very poor 5-year survival rate (&lt;5%). In the last decades, the concomitant use of two non-invasive, electromagnetic devices, modulated electro-hyperthermia (mEHT) and Tumor Treating Fields (TTF) has been introduced. Both mEHT and TTF have specific anti-tumor effects, which can help to achieve a more efficient<br />
581treatment of patients and a higher rate of therapeutic response. In this meta-analysis we investigated how patient survival rates change if either device is used. The significant difference in the 1-year survival rates between the treated (&gt;60%) and untreated groups (historical data: &lt;40%) confirms the observation that the use of both mEHT and TTF in the treatment of glioblastomas benefits patients. In addition, it is important to emphasize that most studies have proven that the mEHT or TTF-treated patients’ quality of life is much better than that of the untreated patients.</p>
582<p class="text-align-justify"><span style="color: #9e8053;"><strong>Abstract</strong></span><br />
583Background: Glioblastoma is one of the most difficult to treat and most aggressive brain tumors, having a poor survival rate. The use of non-invasive modulated electro-hyperthermia (mEHT) and Tumor Treating Fields (TTF) devices has been introduced in the last few decades, both of which having proven anti-tumor effects. Methods: A meta-analysis of randomized and observational studies about mEHT and TTF was conducted. Results: A total of seven and fourteen studies about mEHT and TTF were included, with a total number of 450 and 1309 cases, respectively. A 42% [95% confidence interval (95% CI): 25–59%] 1-year survival rate was found for mEHT, which was raised to 61% (95% CI: 32–89%) if only the studies conducted after 2008 were investigated. In the case of TTF, 1-year survival was 67% (95% CI: 53–81%). Subgroup analyses revealed that newly diagnosed patients might get extra benefits from the early introduction of the devices (mEHT all studies: 73% vs. 37%, p = 0.0021; mEHT studies after 2008: 73% vs. 54%, p = 0.4214; TTF studies: 83% vs. 52%, p = 0.0083), compared with recurrent glioblastoma. Conclusions: Our meta-analysis showed that both mEHT and TTF can improve glioblastoma survival, and the most benefit may be achieved in newly diagnosed cases.</p>
584<p class="text-align-justify"><span style="color: #9e8053;"><strong>Keywords:</strong> </span>astrocytoma; glioblastoma; modulated electro-hyperthermia; tumor treating fields</p>
585
586			<div id="teljes-cikk" class="btn">
587		<a href="https://doi.org/10.3390/cancers15030880" target="_blank">
587 View abstract</a>
588	</div>
589	
590	</div>	<!-- .container -->
591</div><!-- .entry-content -->
592
593
594
595</article><!-- #post-3279 -->
596
597			
598<article id="post-3280" class="post-3280 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
599	
600	<header class="pub-entry-header">
601	<div class="container">
602		<h2>The first experience of application of remote radiotherapy in combination with hyperthermia (oncothermia) in the treatment of patients with primary gliomas of the brain of a high degree of malignancy</h2>
603	</div>
604	</header><!-- .entry-header -->
605
606
607<div class="entry-content kl-pub-content">
608	<div class="container">
609		<div class="acf-fields">
610	<div class="acf-row"><span class="publ-label">Indication:</span> Gliomas (advanced) <hr/> <span class="publ-label">Evidence:</span>  </div>
611	<div class="publ-acf acf-row acf-flex">
612	<span class="publ-label">Author:&nbsp;</span>
613	<div class="szerzok">
614		
615		 
616		
617		<span class="sz-nev">Solodkiy VA.</span>
618   
619		 
620		
621		<span class="sz-nev">Panshin GA.</span>
622   
623		 
624		
625		<span class="sz-nev">Izmailov TR.</span>
626   
627		 
628		
629		<span class="sz-nev">Shevchenko TA.</span>
630   
631				</div>
632	
633	</div>
634	<div class="acf-row"><span class="publ-label">No. of patients:</span> 20 <hr/> <span class="publ-label">Therapy:</span>  RT+mEHT<hr/> <span class="publ-label">Year:</span>  2021</div>
635	</div><!-- .acf-fields -->
636	<div class="c-rich-text">
637<h2>Abstract</h2>
638<p>High-grade brain gliomas are characterized by a rapid clinical course and a 2-year survival rate of 8-12%. Despite the improvement of methods of surgery, radiotherapy (RT), and systemic drug therapy, it is still not possible to significantly increase the overall and relapse-free survival in patients withth is neuro-oncological pathology, and the combination of RT and CT with hyperthermic electrotherapy (oncothermy) (OT) looks like a promising method that helps to increase the effectiveness of special treatment. At the same time, oncothermia does not cause brain edema and does not worsen the quality of life of neuro-oncological patients. At the same time, a possible alternative to further progress in improving the results of treatment of primary brain gliomas (WHO Grade III-IV) is not only to optimize the radiotherapy program, but also to combine standard methods of radical treatment with hyperthermic electrotherapy. This article presents preliminary immediate results of treatment of 20 patients who received special treatment in the RSCRR with an assessment of the toxicity and safety of its implementation and with an assessment of the likely resumption of continued tumor growth 1.5 and 3 months after the end of treatment. In General, the data obtained indicate the safety of the developed method of special treatment of this category of neuro-oncological patients, which confirms the results obtained in 28.09.2019 patent for an invention. However, for final conclusions, further clinical studies are required on a larger group of patients with longer follow-up periods, followed by a thorough analysis of the results.</p>
639</div>
640<div class="field field--name-field-url field--type-link field--label-hidden field__item"><a href="https://voprosyonkologii.ru/index.php/journal/issue/view/45" target="_blank" rel="noopener">https://voprosyonkologii.ru/index.php/journal/issue/view/45</a></div>
641
642			<div id="teljes-cikk" class="btn">
643		<a href="https://voprosyonkologii.ru/index.php/journal/issue/view/45" target="_blank"> View abstract</a>
644	</div>
645	
646	</div>	<!-- .container -->
647</div><!-- .entry-content -->
648
649
650
651</article><!-- #post-3280 -->
652
653			
654<article id="post-3281" class="post-3281 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
655	
656	<header class="pub-entry-header">
657	<div class="container">
658		<h2>Modulated Electro-Hyperthermic (mEHT) Treatment in the Therapy of Inoperable Pancreatic Cancer Patients—A Single-Center Case-Control Study</h2>
659	</div>
660	</header><!-- .entry-header -->
661
662
663<div class="entry-content kl-pub-content">
664	<div class="container">
665		<div class="acf-fields">
666	<div class="acf-row"><span class="publ-label">Indication:</span> Gastrointestinal <hr/> <span class="publ-label">Evidence:</span>  </div>
667	<div class="publ-acf acf-row acf-flex">
668	<span class="publ-label">Author:&nbsp;</span>
669	<div class="szerzok">
670		
671		 
672		
673		<span class="sz-nev">Flora Greta Petenyi</span>
674   
675		 
676		
677		<span class="sz-nev">Tamas Garay</span>
678   
679		 
680		
681		<span class="sz-nev">Dorottya Muhl</span>
682   
683		 
684		
685		<span class="sz-nev">Blanka Izso</span>
686   
687		 
688		
689		<span class="sz-nev">Adam Karaszi</span>
690   
691		 
692		
693		<span class="sz-nev">Erika Borbenyi</span>
694   
695		 
696		
697		<span class="sz-nev">Magdolna Herold</span>
698   
699		 
700		
701		<span class="sz-nev">Zoltan Herold</span>
702   
703		 
704		
705		<span class="sz-nev">Attila Marcell Szasz</span>
706   
707		 
708		
709		<span class="sz-nev">Magdolna Dan</span>
710   
711				</div>
712	
713	</div>
714	<div class="acf-row"><span class="publ-label">No. of patients:</span> 78 <hr/> <span class="publ-label">Therapy:</span>  mEHT<hr/> <span class="publ-label">Year:</span>  2021</div>
715	</div><!-- .acf-fields -->
716	<p>Abstract: Our present oncological treatment arsenal has limited treatment options for pancreatic ductal adenocarcinoma (PDAC). Extended reviews have shown the benefits of hyperthermia for PDAC, supporting the perspectives with the improvements of the treatment possibilities. METHODS: A retrospective single-center case-control study was conducted with the inclusion of 78 inoperable PDAC patients. Age-, sex-, chemotherapy-, stage-, and ascites formation-matched patients were assigned to two equal groups based on the application of modulated electro-hyperthermia (mEHT). The EHY2030 mEHT device was used. RESULTS: A trend in favor of mEHT was found in overall survival (p = 0.1420). To further evaluate the potential beneficial effects of mEHT, the presence of distant metastasis or ascites in the patients’ oncological history was investigated. Of note, mEHT treatment had a favorable effect on patients’ overall survival in metastatic disease (p = 0.0154), while less abdominal fluid responded to the mEHT treatment in a more efficient way (p 0.0138). CONCLUSION: mEHT treatment was associated with improved overall survival in PDAC in our single-center retrospective case-control study. The outcome measures encourage us to design a randomized prospective clinical study to further confirm the efficiency of mEHT in this patien cohort.</p>
717
718			<div id="teljes-cikk" class="btn">
719		<a href="https://doi.org/10.3390/%20diseases9040081" target="_blank">
719 View abstract</a>
720	</div>
721	
722	</div>	<!-- .container -->
723</div><!-- .entry-content -->
724
725
726
727</article><!-- #post-3281 -->
728
729			
730<article id="post-3282" class="post-3282 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
731	
732	<header class="pub-entry-header">
733	<div class="container">
734		<h2>Modulated electro-hyperthermia in stage III and IV pancreatic cancer: Results of an observational study on 158 patients</h2>
735	</div>
736	</header><!-- .entry-header -->
737
738
739<div class="entry-content kl-pub-content">
740	<div class="container">
741		<div class="acf-fields">
742	<div class="acf-row"><span class="publ-label">Indication:</span> Gastrointestinal <hr/> <span class="publ-label">Evidence:</span>  </div>
743	<div class="publ-acf acf-row acf-flex">
744	<span class="publ-label">Author:&nbsp;</span>
745	<div class="szerzok">
746		
747		 
748		
749		<span class="sz-nev">Giammaria Fiorentini</span>
750   
751		 
752		
753		<span class="sz-nev">Donatella Sarti</span>
754   
755		 
756		
757		<span class="sz-nev">Girolamo Ranieri</span>
758   
759		 
760		
761		<span class="sz-nev">Cosmo Damiano Gadaleta</span>
762   
763		 
764		
765		<span class="sz-nev">Caterina Fiorentini</span>
766   
767		 
768		
769		<span class="sz-nev">Carlo Milandri</span>
770   
771		 
772		
773		<span class="sz-nev">Andrea Mambrini</span>
774   
775		 
776		
777		<span class="sz-nev">Stefano Guadagni</span>
778   
779				</div>
780	
781	</div>
782	<div class="acf-row"><span class="publ-label">No. of patients:</span> 158 <hr/> <span class="publ-label">Therapy:</span>  CRT+mEHT<hr/> <span class="publ-label">Year:</span>  2021</div>
783	</div><!-- .acf-fields -->
784	<p class="text-align-justify"><span style="color: #9e8053;">Abstract</span><br />
785BACKGROUND<br />
786An increasing number of studies report the beneficial effects of regional hyperthermia in association with chemotherapy (CHT) and radiotherapy for the treatment of pancreatic cancer; in particular, the use of modulated electrohyperthermia (mEHT) results in increased survival and tumor response.</p>
787<p class="text-align-justify"><span style="color: #9e8053;">AIM</span><br />
788To compare outcomes of CHT alone or in association with mEHT for the treatment of stage III and IV pancreatic cancer. METHODS<br />
789This was an observational retrospective study; data were collected for patients with stage III-IV pancreatic cancer that were treated with CHT alone or in combination with mEHT from 2003 to 2019. A total of 158 patients were included in the study out 270 patients screened in four Italian hospitals; 58 (37%) of these received CHT + mEHT and 100 (63%) CHT. CHT was mainly gemcitabine-based<br />
790regimens in both groups.</p>
791<p class="text-align-justify">
792<span style="color: #9e8053;">RESULTS</span><br />
793Overall (19.5 mo vs 11.02 mo, P &lt; 0.001) and progression-free (12 mo vs 3 mo, P &lt; 0.001) survival were better for the CHT + mEHT group compared to the CHT group. The association of mEHT resulted also in an improvement of tumor response with disease control rate 95% vs 58% (P &lt; 0.001) at 3 mo. Toxicity was comparable in the two study groups, and mEHT related adverse events were<br />
794limited in 8 patients presenting G1-2 skin burns.</p>
795<p class="text-align-justify"><span style="color: #9e8053;">CONCLUSION</span><br />
796The addition of mEHT to systemic CHT improved overall and progression-freesurvival and local tumor control with comparable toxicity.</p>
797
798	
799	</div>	<!-- .container -->
800</div><!-- .entry-content -->
801
802
803
804</article><!-- #post-3282 -->
805
806			
807<article id="post-3283" class="post-3283 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
808	
809	<header class="pub-entry-header">
810	<div class="container">
811		<h2>Clinical study of modulated electro‑hyperthermia for advanced metastatic breast cancer</h2>
812	</div>
813	</header><!-- .entry-header -->
814
815
816<div class="entry-content kl-pub-content">
817	<div class="container">
818		<div class="acf-fields">
819	<div class="acf-row"><span class="publ-label">Indication:</span> Breast Cancer <hr/> <span class="publ-label">Evidence:</span>  </div>
820	<div class="publ-acf acf-row acf-flex">
821	<span class="publ-label">Author:&nbsp;</span>
822	<div class="szerzok">
823		
824		 
825		
826		<span class="sz-nev">Takuya Nagata</span>
827   
828		 
829		
830		<span class="sz-nev">Masahiko Kanamori</span>
831   
832		 
833		
834		<span class="sz-nev">Shinichi Sekine</span>
835   
836		 
837		
838		<span class="sz-nev">Mie Arai</span>
839   
840		 
841		
842		<span class="sz-nev">Makoto Moriyama</span>
843   
844		 
845		
846		<span class="sz-nev">Tsutomu Fujii</span>
847   
848				</div>
849	
850	</div>
851	<div class="acf-row"><span class="publ-label">No. of patients:</span> 10 <hr/> <span class="publ-label">Therapy:</span>  mEHT<hr/> <span class="publ-label">Year:</span>  2021</div>
852	</div><!-- .acf-fields -->
853	<p><span style="color: #9e8053;"><strong>Abstract.</strong></span> Modulated electro‑hyperthermia (mEHT) is a new treatment modality developed to overcome the problems associated with traditional hyperthermia; mEHT uses a precise impedance‑matched system and modulated radiofrequency current flow to malignant tumors. It selects the malignant cells based on their biophysical differences, due to their high metabolic rate, individual (autonomic) behavior and membrane status. The aim of the present study was to report the outcomes of mEHT in the treatment of advanced breast cancer. mEHT was examined in 10 patients with advanced metastatic breast cancer and recurrent disease, who were considered incurable by standard therapy protocols. Of the 10 patients, partial response was achieved in 3, disease stability in 3, and progressive disease in 4; however, their quality of life was improved based on their subjective reports. No adverse effects were observed in any of the 10 patients. The present study demonstrated the feasibility of mEHT as a possible therapy for advanced breast cancer cases when standard therapies fail. Moreover, mEHT had no side effects and may be combined with various treatments for long‑term therapy.</p>
854
855	
856	</div>	<!-- .container -->
857</div><!-- .entry-content -->
858
859
860
861</article><!-- #post-3283 -->
862
863			
864<article id="post-3284" class="post-3284 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
865	
866	<header class="pub-entry-header">
867	<div class="container">
868		<h2>“Oncothermia” (Modulated electro-hyperthermia) ― Present status and future development</h2>
869	</div>
870	</header><!-- .entry-header -->
871
872
873<div class="entry-content kl-pub-content">
874	<div class="container">
875		<div class="acf-fields">
876	<div class="acf-row"><span class="publ-label">Indication:</span>  <hr/> <span class="publ-label">Evidence:</span>  Review</div>
877	<div class="publ-acf acf-row acf-flex">
878	<span class="publ-label">Author:&nbsp;</span>
879	<div class="szerzok">
880		
881		 
882		
883		<span class="sz-nev">Masahiko Kanamori</span>
884   
885		 
886		
887		<span class="sz-nev">Tsutomu Sato</span>
888   
889		 
890		
891		<span class="sz-nev">Tomoko Shima</span>
892   
893		 
894		
895		<span class="sz-nev">Jun-Ichi Saitoh</span>
896   
897		 
898		
899		<span class="sz-nev">
899 Gabor Andocs</span>
900   
901		 
902		
903		<span class="sz-nev">Takashi Kondo</span>
904   
905				</div>
906	
907	</div>
908	<div class="acf-row"><span class="publ-label">No. of patients:</span>  <hr/> <span class="publ-label">Therapy:</span>  mEHT<hr/> <span class="publ-label">Year:</span>  2021</div>
909	</div><!-- .acf-fields -->
910	<p>Modulated electro-hyperthermia (mEHT) ‒ trade name: Oncothermia ‒ is an emerging curative treatment method in oncological hyperthermia. Although mEHT is similar to other classic hyperthermia methods to utilize temperature rise in tumor, there are several features; i.e. use precise impedance-matched, capacitive-coupled 13.56 MHz radiofrequency (RF) with amplitude modulation, in order to keep the tumor temperature below the cytotoxic range (<42 °C) but induce continuous temperature gradient on the tumor cell membrane. This in homogenous, non-equilibrium heating on the cell membrane induces programmed cancer cell death (apoptosis). mEHT effectiveness has been also proven in clinical studies, and has fewer side effects due to low RF output. Therefore, not only thermal effects but also non-thermal (temperature independent) effects of mEHT are important for considering the biological and clinical significance. Basic, preclinical and clinical reports have been published after “Oncothermia: Principles and Practices” by Szasz A. et al. In this review article these outcomes will be summarized and discuss on the further possibilities and problems of mEHT.</p>
911
912	
913	</div>	<!-- .container -->
914</div><!-- .entry-content -->
915
916
917
918</article><!-- #post-3284 -->
919
920			
921<article id="post-3285" class="post-3285 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
922	
923	<header class="pub-entry-header">
924	<div class="container">
925		<h2>Modulated electro‑hyperthermia with weekly paclitaxel or cisplatin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: The KGOG 3030 trial</h2>
926	</div>
927	</header><!-- .entry-header -->
928
929
930<div class="entry-content kl-pub-content">
931	<div class="container">
932		<div class="acf-fields">
933	<div class="acf-row"><span class="publ-label">Indication:</span> Gynecology <hr/> <span class="publ-label">Evidence:</span>  </div>
934	<div class="publ-acf acf-row acf-flex">
935	<span class="publ-label">Author:&nbsp;</span>
936	<div class="szerzok">
937		
938		 
939		
940		<span class="sz-nev">Kidong Kim</span>
941   
942		 
943		
944		<span class="sz-nev">Jae‑Hoon Kim</span>
945   
946		 
947		
948		<span class="sz-nev">Seung Cheol Kim</span>
949   
950		 
951		
952		<span class="sz-nev">Yong Beom Kim</span>
953   
954		 
955		
956		<span class="sz-nev">Byung‑Ho Nam</span>
957   
958		 
959		
960		<span class="sz-nev">Jae Hong No</span>
961   
962		 
963		
964		<span class="sz-nev">Hanbyoul Cho</span>
965   
966		 
967		
968		<span class="sz-nev">Woong Ju</span>
969   
970		 
971		
972		<span class="sz-nev">Dong Hoon Suh</span>
973   
974		 
975		
976		<span class="sz-nev">Yun Hwan Kim</span>
977   
978				</div>
979	
980	</div>
981	<div class="acf-row"><span class="publ-label">No. of patients:</span> 12 <hr/> <span class="publ-label">Therapy:</span>  mEHT<hr/> <span class="publ-label">Year:</span>  2021</div>
982	</div><!-- .acf-fields -->
983	<p>The study (KGOG 3030) aimed to evaluate the safety of modulated electro‑hyperthermia (mEHT) therapy with weekly administration of paclitaxel or cisplatin in female patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. A total of 12 patients were randomized into the paclitaxel or cisplatin arm at a 1:1 ratio. Patients received weekly administration of paclitaxel (70 mg/m2) or cisplatin (40 mg/m2) intravenously on days 1, 8 and 15, and underwent mEHT therapy for 1 h on days 1, 4, 8, 11, 15, 18, 21 and 24 for each 4‑week cycle. The primary endpoint was the occurrence of dose‑limiting toxicity (DLT). The secondary endpoints were treatment‑emergent adverse events (TEAEs), objective response rate, carbohydrate antigen 125 (CA125) response rate, progression‑free survival (PFS) and overall survival (OS). In total, 16 patients were recruited, but four patients dropped out. None of the 12 remaining patients (6 each in the two arms) experienced DLT. Overall, 0 and 4 grade 3 TEAEs (anemia, nausea, neutrophil count decreased and platelet 
983count decreased) occurred in the paclitaxel and cisplatin arm, respectively. Furthermore, one confirmed partial response and two CA125 responses were observed in the cisplatin arm. The median PFS time in the paclitaxel and cisplatin arms was 3.0 months (range, 1.7‑4.6 months) and 6.8 months (range, 3.9‑11.8 months), respectively, while the median OS time was 11.5 months (range, 8.4‑28.8+ months) and not reached (range, 3.9‑38.5+ months), respectively. In conclusion, mEHT therapy with weekly paclitaxel or cisplatin appeared safe and warrants further investigation. The present trial was registered with www.clinicaltrials.gov on January 22, 2015 (trial registration no. NCT02344095).</p>
984
985	
986	</div>	<!-- .container -->
987</div><!-- .entry-content -->
988
989
990
991</article><!-- #post-3285 -->
992
993			
994<article id="post-3286" class="post-3286 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
995	
996	<header class="pub-entry-header">
997	<div class="container">
998		<h2>Marked local and distant response of heavily treated breast cancer with cardiac metastases treated by combined low dose radiotherapy, low dose immunotherapy and hyperthermia: a case report</h2>
999	</div>
1000	</header><!-- .entry-header -->
1001
1002
1003<div class="entry-content kl-pub-content">
1004	<div class="container">
1005		<div class="acf-fields">
1006	<div class="acf-row"><span class="publ-label">Indication:</span> Breast Cancer <hr/> <span class="publ-label">Evidence:</span>  Case report</div>
1007	<div class="publ-acf acf-row acf-flex">
1008	<span class="publ-label">Author:&nbsp;</span>
1009	<div class="szerzok">
1010		
1011		 
1012		
1013		<span class="sz-nev">Mau-Shin Chi</span>
1014   
1015		 
1016		
1017		<span class="sz-nev">Jen-Hong Wu</span>
1018   
1019		 
1020		
1021		<span class="sz-nev">Suzun Shaw</span>
1022   
1023		 
1024		
1025		<span class="sz-nev">Ching-Jung Wu</span>
1026   
1027		 
1028		
1029		<span class="sz-nev">Liang-Kuang Chen</span>
1030   
1031		 
1032		
1033		<span class="sz-nev">Ho-Chi Hsu</span>
1034   
1035		 
1036		
1037		<span class="sz-nev">Kwan-Hwa Chi</span>
1038   
1039				</div>
1040	
1041	</div>
1042	<div class="acf-row"><span class="publ-label">No. of patients:</span> 1 <hr/> <span class="publ-label">Therapy:</span>  CT+RT+mEHT<hr/> <span class="publ-label">Year:</span>  2021</div>
1043	</div><!-- .acf-fields -->
1044	<p>Abstract: Breast cancer (BC) with cardiac metastases (CMs) is often associated with poor prognosis due to late stage of diagnosis. Palliative radiotherapy (RT) for CMs is generally used for symptomatic treatment and to maintain normal cardiac function. Palliative RT with hyperthermia (HT) or immunotherapy have been reported to be effective in prolonging the overall survival and progression-free survival in metastatic patients. In this case report, we present a heavily pretreated 51-year-old lady of metastatic BC presented with recurrent right breast mass with progressive exertional dyspnea caused by symptomatic CM. She received combined palliative low-dose palliative RT [20 Gray (Gy) in 12 fractions], combined with low-dose chemotherapy, biweekly HT treatment course, and low-dose “double blockade” immunotherapy by ipilimumab (0.3 mg/kg) and nivolumab (0.5 mg/kg). The irradiated right chest tumors responded rapidly to treatment. Interestingly, unirradiated metastatic lesions outside the RT and HT treatment field also demonstrated a sustained abscopal response. She continued monthly low-dose immunotherapy in conjunction with HT after RT. The posttreatment cardiac echography disclosed considerably reduced pericardial effusions without cardiac wall motion abnormalities. She remained stable for more than 6 months with no notable treatment-related toxicities. The combination of low-dose RT, low-dose immunotherapy, and HT protocol appears to be a safe method with promising efficacy in metastatic BC patients.</p>
1045
1046			<div id="teljes-cikk" class="btn">
1047		<a href="https://dx.doi.org/10.21037/tro-21-16" target="_blank"> View abstract</a>
1048	</div>
1049	
1050	</div>	<!-- .container -->
1051</div><!-- .entry-content -->
1052
1053
1054
1055</article><!-- #post-3286 -->
1056
1057			
1058<article id="post-3287" class="post-3287 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
1059	
1060	<header class="pub-entry-header">
1061	<div class="container">
1062		<h2>Beneficial effects of modulated electro-hyperthermia during neoadjuvant treatment for locally advanced rectal cancer</h2>
1063	</div>
1064	</header><!-- .entry-header -->
1065
1066
1067<div class="entry-content kl-pub-content">
1068	<div class="container">
1069		<div class="acf-fields">
1070	<div class="acf-row"><span class="publ-label">Indication:</span> Rectal Cancer <hr/> <span class="publ-label">Evidence:</span>  </div>
1071	<div class="publ-acf acf-row acf-flex">
1072	<span class="publ-label">Author:&nbsp;</span>
1073	<div class="szerzok">
1074			</div>
1075	
1076	</div>
1077	<div class="acf-row"><span class="publ-label">No. of patients:</span> 120 <hr/> <span class="publ-label">Therapy:</span>  mEHT<hr/> <span class="publ-label">Year:</span>  2021</div>
1078	</div><!-- .acf-fields -->
1079	<p>Purpose: Modulated electro-hyperthermia (mEHT) may enhance the tumor response, although the effectiveness of combined neoadjuvant therapy remains unclear. Therefore, we investigated the role of mEHT with neoadjuvant therapy for locally advanced rectal cancer. Materials and methods: Clinical data were analyzed for 120 patients who received neoadjuvant treatment for locally advanced rectal cancer (T3/4 or Nþ, M0) from May 2012 to December 2017. Capecitabine or 5-fluorouracil was administered along with radiotherapy. Patients were categorized 
1079into mEHT group (62 patients) and non-mEHT group (58 patients) depending on whether mEHT was added. Surgery was performed 6–8 weeks after the end of radiotherapy. Results: The median age was 59 years (range, 33–83). The median radiation dose was significantly less for mEHT group (40 Gy) than for non-mEHT group (50.4 Gy). In mEHT group, 80.7% showed down-staging compared with 67.2% in non-mEHT group. For large tumors of more than 65 cm3 (mean), improved tumor regression was observed in 31.6% of mEHT group compared with 0% of non-mEHT group (p¼.024). The gastrointestinal toxicity rate of mEHT group was 64.5%, which was found to be statistically significantly less than 87.9% of non-mEHT group (p¼.010). The 2-year disease-free survival was 96% for mEHT group and 79% for non-mEHT group (p¼.054). Conclusion: The overall mEHT group had a comparable response and survival using less radiation dosing compared with standard care; the subgroup with large tumors showed improved efficacy for tumor regression after mEHT.</p>
1080
1081	
1082	</div>	<!-- .container -->
1083</div><!-- .entry-content -->
1084
1085
1086
1087</article><!-- #post-3287 -->
1088
1089			
1090<article id="post-3288" class="post-3288 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
1091	
1092	<header class="pub-entry-header">
1093	<div class="container">
1094		<h2>Evidence based tools to improve efficiency of currently administered oncotherapies for tumors of the hepatopancreatobiliary system</h2>
1095	</div>
1096	</header><!-- .entry-header -->
1097
1098
1099<div class="entry-content kl-pub-content">
1100	<div class="container">
1101		<div class="acf-fields">
1102	<div class="acf-row"><span class="publ-label">Indication:</span>  <hr/> <span class="publ-label">Evidence:</span>  </div>
1103	<div class="publ-acf acf-row acf-flex">
1104	<span class="publ-label">Author:&nbsp;</span>
1105	<div class="szerzok">
1106		
1107		 
1108		
1109		<span class="sz-nev">Herold Z.</span>
1110   
1111		 
1112		
1113		<span class="sz-nev">Szasz A.</span>
1114   
1115		 
1116		
1117		<span class="sz-nev">Dank M.</span>
1118   
1119				</div>
1120	
1121	</div>
1122	<div class="acf-row"><span class="publ-label">No. of patients:</span>  <hr/> <span class="publ-label">Therapy:</span>  <hr/> <span class="publ-label">Year:</span>  2021</div>
1123	</div><!-- .acf-fields -->
1124	<p>Hepatopancreatobiliary tumors are challenging to treat, and the advanced or metastatic forms have a very low 5-year survival rate. Several drug combinations have been tested, and new therapeutic approaches have been introduced in the last decades, including radiofrequency and heat based methods. Hyperthermia is the artificial heating of tumors by various biophysical methods that may possess immunostimulant, tumoricidal, and chemoradiotherapy sensitizer effects. Both whole-body and regional hyperthermia studies have been conducted since the 1980s after the introduction of deep-seated tumor hyperthermia techniques. Results of the effects of hyperthermia in hepatocellular and pancreatic cancer are known from several studies. Hyperthermia in biliary cancers is a less investigated area. High local and overall responses to treatment, increased progression-free and overall survival, and improved laboratory and quality-of-life results are associated with hyperthermia in all three tumor types. With the evolution of chemotherapeutic agents and the introduction of newer techniques, the combination of adjuvant hyperthermia with those therapies is advantageous and has not been associated with an increase in alarming adverse effects. However, despite the many positive effects of hyperthermia, its use is still only known at the experimental level, and its concomitant utilization in routine cancer treatment is not certain because of the lack of thorough clinical studies.</p>
1125<p>Herold Z., Szasz A.M., Dank M., Evidence based tools to improve efficiency of currently administered oncotherapies for tumors of the hepatopancreatobiliary system. <em>World J Gastrointest Oncol</em> 2021; 13(9): 1109-1120 [DOI: <a href="https://dx.doi.org/10.4251/wjgo.v13.i9.1109" target="_blank" rel="noopener">10.4251/wjgo.v13.i9.1109</a>]</p>
1126<p><a href="https://www.wjgnet.com/1948-5204/full/v13/i9/1109.htm" target="_blank" rel="noopener">Evidence based tools to improve efficiency of currently administered oncotherap…</a></p>
1127
1128			<div id="teljes-cikk" class="btn">
1129		<a href="https://www.wjgnet.com/1948-5204/full/v13/i9/1109.htm" target="_blank">
1129 View abstract</a>
1130	</div>
1131	
1132	</div>	<!-- .container -->
1133</div><!-- .entry-content -->
1134
1135
1136
1137</article><!-- #post-3288 -->
1138
1139			
1140<article id="post-3289" class="post-3289 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
1141	
1142	<header class="pub-entry-header">
1143	<div class="container">
1144		<h2>Suppression of Metastatic Melanoma Growth in Lung by Modulated Electro-Hyperthermia Monitored by a Minimally Invasive Heat Stress Testing Approach in Mice</h2>
1145	</div>
1146	</header><!-- .entry-header -->
1147
1148
1149<div class="entry-content kl-pub-content">
1150	<div class="container">
1151		<div class="acf-fields">
1152	<div class="acf-row"><span class="publ-label">Indication:</span> Lung cancer <hr/> <span class="publ-label">Evidence:</span>  </div>
1153	<div class="publ-acf acf-row acf-flex">
1154	<span class="publ-label">Author:&nbsp;</span>
1155	<div class="szerzok">
1156		
1157		 
1158		
1159		<span class="sz-nev">Mbuotidem Jeremiah Thomas</span>
1160   
1161		 
1162		
1163		<span class="sz-nev">Eniko Major</span>
1164   
1165		 
1166		
1167		<span class="sz-nev">Anett Benedek</span>
1168   
1169		 
1170		
1171		<span class="sz-nev">ldikó Horváth</span>
1172   
1173		 
1174		
1175		<span class="sz-nev">Domokos Máthé</span>
1176   
1177		 
1178		
1179		<span class="sz-nev">Ralf Bergmann</span>
1180   
1181		 
1182		
1183		<span class="sz-nev">Attila Marcell Szász</span>
1184   
1185		 
1186		
1187		<span class="sz-nev">Tibor Krenács</span>
1188   
1189		 
1190		
1191		<span class="sz-nev">Zoltán Benyó</span>
1192   
1193				</div>
1194	
1195	</div>
1196	<div class="acf-row"><span class="publ-label">No. of patients:</span>  <hr/> <span class="publ-label">Therapy:</span>  mEHT<hr/> <span class="publ-label">Year:</span>  2020</div>
1197	</div><!-- .acf-fields -->
1198	<p><strong>Simple Summary</strong><br />
1199The lung is the most frequent site of distant melanoma metastases. Metastases of melanoma in the lungs offer a very poor prognosis, with a 5-year survival rate of below 10%. Hyperthermic therapies including modulated electro-hyperthermia (mEHT) in clinical settings have been used to improve the efficacy of radiotherapy, chemotherapy, and immunotherapy of tumors. In this study, we focused primarily on the optimization of mEHT for targeted lung treatment of mice lungsburdenedwithB16F10melanomapulmonarymetastases,withaparticularfocusonelucidating the mechanism of action of mEHT on treated melanoma cells while investigating any potential treatment-relatedsideeffectsonnormallungtissue. mEHTshowedevidenceofsignificantanti-tumor effects as demonstrated by the reduced number of pulmonary metastatic nodules, DNA damage response, downregulation of Ki67 expression, higher immune cell infiltration, and upregulation of p21waf1 expression in mEHT-treated tumors.</p>
1200<p><strong>Abstract</strong><br />
1201Modulated electro-hyperthermia (mEHT) is a novel complementary therapy in oncology which is based on the higher conductivity and permittivity of cancerous tissues due to their enhanced glycolytic activity and ionic content compared to healthy normal tissues. We aimed to evaluate the potential of mEHT, inducing local hyperthermia, in the treatment of pulmonary metastatic melanoma. Our primary objective was the optimization of mEHT for targeted lung treatment as well as to identify the mechanism of its potential anti-tumor effect in the B16F10 mouse melanoma pulmonarymetastasesmodelwhileinvestigatingthepotentialtreatment-relatedsideeffectsofmEHT on normal lung tissue. Repeated treatment of tumor-bearing lungs with mEHT induced significant anti-tumor effects as demonstrated by the lower number of tumor nodules and the downregulation of Ki67 expression in treated tumor cells. mEHT treatment provoked significant DNA double-strand breaks indicated by the increased expression of phosphorylated H2AX protein in treated tumors, although treatment-induced elevation of cleaved/activated casp
1201ase-3 expression was insignificant, suggesting the minimal role of apoptosis in this process. The mEHT-related significant increase in p21waf1 positive tumor cells suggested that p21waf1-mediated cell cycle arrest plays an important role in the anti-tumor effect of mEHT on melanoma metastases. Significantly increased CD3+, CD8+ T-lymphocytes, and F4/80+CD11b+ macrophage density in the whole lung and tumor of treated animals emphasizes the mobilizing capability of mEHT on immune cells. In conclusion, mEHT can reduce the growth potential of melanoma, thus offering itself as a complementary therapeutic option to chemo- and/or radiotherapy.</p>
1202
1203			<div id="teljes-cikk" class="btn">
1204		<a href="https://www.scirp.org/journal/PaperInformation.aspx?PaperID=106089" target="_blank"> View abstract</a>
1205	</div>
1206	
1207	</div>	<!-- .container -->
1208</div><!-- .entry-content -->
1209
1210
1211
1212</article><!-- #post-3289 -->
1213
1214			
1215<article id="post-3290" class="post-3290 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
1216	
1217	<header class="pub-entry-header">
1218	<div class="container">
1219		<h2>A randomized phase II trial of best supportive care with or without hyperthermia and vitamin C for heavily pretreated, advanced, refractory non-small-cell lung cancer</h2>
1220	</div>
1221	</header><!-- .entry-header -->
1222
1223
1224<div class="entry-content kl-pub-content">
1225	<div class="container">
1226		<div class="acf-fields">
1227	<div class="acf-row"><span class="publ-label">Indication:</span> Lung cancer <hr/> <span class="publ-label">Evidence:</span>  Phase I.</div>
1228	<div class="publ-acf acf-row acf-flex">
1229	<span class="publ-label">Author:&nbsp;</span>
1230	<div class="szerzok">
1231		
1232		 
1233		
1234		<span class="sz-nev">Junwen Ou</span>
1235   
1236		 
1237		
1238		<span class="sz-nev">Xinyu Zhu</span>
1239   
1240		 
1241		
1242		<span class="sz-nev">Pengfei Chen</span>
1243   
1244		 
1245		
1246		<span class="sz-nev">Yanping Du</span>
1247   
1248		 
1249		
1250		<span class="sz-nev">Yimin Lu</span>
1251   
1252		 
1253		
1254		<span class="sz-nev">Xiufan Peng</span>
1255   
1256		 
1257		
1258		<span class="sz-nev">Shuang Bao</span>
1259   
1260		 
1261		
1262		<span class="sz-nev">Junhua Wang</span>
1263   
1264		 
1265		
1266		<span class="sz-nev">Xinting Zhang</span>
1267   
1268		 
1269		
1270		<span class="sz-nev">Tao Zhang</span>
1271   
1272		 
1273		
1274		<span class="sz-nev">Clifford L.K. Pang</span>
1275   
1276				</div>
1277	
1278	</div>
1279	<div class="acf-row"><span class="publ-label">No. of patients:</span> 97 <hr/> <span class="publ-label">Therapy:</span>  IVC + mEHT + BSC<hr/> <span class="publ-label">Year:</span>  2020</div>
1280	</div><!-- .acf-fields -->
1281	<p><strong>Abstract</strong></p>
1282<p id="sp0010">Our previous study indicated that intravenous vitamin C (IVC) treatment concurrent with modulated electrohyperthermia (mEHT) was safe and improved the quality of life (QoL) of non-small-cell lung cancer (NSCLC) patients. The aim of this trial was to further verify the efficacy of the above combination therapy in previously treated patients with refractory advanced (stage IIIb or IV) NSCLC. A total of 97 patients were randomized to receive IVC and mEHT plus best supportive care (BSC) (n = 49 in the active arm, receiving 1 g/kg * d IVC concurrently with mEHT, three times a week for 25 treatments in total) or BSC alone (n = 48 in the control arm). After a median follow-up of 24 months, progression-free survival (PFS) and overall survival (OS) were significantly prolonged by combination therapy compared to BSC alone (PFS: 3 months vs 1.85 months, P &lt; 0.05; OS: 9.4 months vs 5.6 months, P &lt; 0.05). QoL was significantly increased in the active arm despite the advanced stage of disease. The 3-month disease control rate after treatment was 42.9
1282% in the active arm and 16.7% in the control arm (P &lt; 0.05). Overall, IVC and mEHT may have the ability to improve the prognosis of patients with advanced NSCLC.</p>
1283
1284			<div id="teljes-cikk" class="btn">
1285		<a href="https://www.sciencedirect.com/science/article/pii/S2090123220300539?via%3Dihub=" target="_blank"> View abstract</a>
1286	</div>
1287	
1288	</div>	<!-- .container -->
1289</div><!-- .entry-content -->
1290
1291
1292
1293</article><!-- #post-3290 -->
1294
1295			
1296<article id="post-3291" class="post-3291 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
1297	
1298	<header class="pub-entry-header">
1299	<div class="container">
1300		<h2>Analysis of the effects of mEHT on the treatmentrelated toxicity and quality of life of HIV-positive cervical cancer patients</h2>
1301	</div>
1302	</header><!-- .entry-header -->
1303
1304
1305<div class="entry-content kl-pub-content">
1306	<div class="container">
1307		<div class="acf-fields">
1308	<div class="acf-row"><span class="publ-label">Indication:</span> Cervical cancer <hr/> <span class="publ-label">Evidence:</span>  Phase III</div>
1309	<div class="publ-acf acf-row acf-flex">
1310	<span class="publ-label">Author:&nbsp;</span>
1311	<div class="szerzok">
1312		
1313		 
1314		
1315		<span class="sz-nev">Carrie Anne Minnaar</span>
1316   
1317		 
1318		
1319		<span class="sz-nev">Jeffrey Allan Kotzen</span>
1320   
1321		 
1322		
1323		<span class="sz-nev">Thanushree Naidoo</span>
1324   
1325		 
1326		
1327		<span class="sz-nev">Mariza Tunmer</span>
1328   
1329		 
1330		
1331		<span class="sz-nev">Vinay Sharma</span>
1332   
1333		 
1334		
1335		<span class="sz-nev">Mboyo-Di-Tamba Vangu</span>
1336   
1337		 
1338		
1339		<span class="sz-nev">Ans Baeyens</span>
1340   
1341				</div>
1342	
1343	</div>
1344	<div class="acf-row"><span class="publ-label">No. of patients:</span>  <hr/> <span class="publ-label">Therapy:</span>  CRT+mEHT<hr/> <span class="publ-label">Year:</span>  2020</div>
1345	</div><!-- .acf-fields -->
1346	<div class="c-rich-text">
1347<p><strong>ABSTRACT</strong><br />
1348<strong>Introduction: </strong>HIV infection is associated with increased treatment-related toxicity and worse outcomes in locally advanced cervical cancer patients (LACC), especially in resource-constrained settings. Local control (LC) in a phase III randomized, controlled trial investigating modulated electro-hyperthermia (mEHT) on LACC patients in South Africa (ethics registration: M120477/M190295), was significantly higher in participants randomized to receive chemoradiotherapy (CRT) with mEHT compared to CRT alone (stratum: HIV status, accounting for age and stage). This analysis investigates whether mEHT adds to the toxicity profile of CRT in HIV-positive LACC participants.<br />
1349<strong>Methods: </strong>Inclusion criteria: signed informed consent; International Federation of Gynecology and Obstetrics stages IIB to IIIB squamous cell carcinoma of the cervix; HIV-positive patients: CD4 count &gt;200 cell/mL/on antiretroviral treatment for &gt;6 months; eligible for CRT with radical intent. Recruitment: January 2014 to November 2017 (ClinicalTrials.gov: NCT03332069). Acute toxicity (evaluated using CTCAE v4 criteria) and quality of life (according to EORTC forms) in 206 participants randomized for treatment were evaluated alongside the LC results to determine safety and efficacy in HIV-positive participants.<br />
1350<strong>Results: </strong>Compliance to mEHT treatment was high (97% completed 8 treatments) with no significant differences in CRT-related toxicity between treatment groups or between HIV-positive and -negative participants. Adverse events attributed to mEHT were minor, even in obese patients, and did not affect CRT compliance. Participants treated with mEHT reported improved fatigue, pain, emotional and cognitive functioning.<br />
1351<strong>Conclusion:</strong> mEHT did not cause unexpected CRT-related toxicities and is a safe treatment modality for HIV-positive patients, with minor limitations regarding body weight, even in a low-resource setting.</p>
1352</div>
1353
1354			<div id="teljes-cikk" class="btn">
1355		<a href="https://www.tandfonline.com/doi/full/10.1080/02656736.2020.1737253" target="_blank"> View abstract</a>
1356	</div>
1357	
1358	</div>	<!-- .container -->
1359</div><!-- .entry-content -->
1360
1361
1362
1363</article><!-- #post-3291 -->
1364
1365			
1366<article id="post-3292" class="post-3292 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
1367	
1368	<header class="pub-entry-header">
1369	<div class="container">
1370		<h2>Feasibility of Modulated Electro-Hyperthermia in Preoperative Treatment for Locally Advanced Rectal Cancer: Early Phase 2 Clinical Results</h2>
1371	</div>
1372	</header><!-- .entry-header -->
1373
1374
1375<div class="entry-content kl-pub-content">
1376	<div class="container">
1377		<div class="acf-fields">
1378	<div class="acf-row"><span class="publ-label">Indication:</span> Rectal Cancer <hr/> <span class="publ-label">Evidence:</span>  Phase I</div>
1379	<div class="publ-acf acf-row acf-flex">
1380	<span class="publ-label">Author:&nbsp;</span>
1381	<div class="szerzok">
1382		
1383		 
1384		
1385		<span class="sz-nev">S H You</span>
1386   
1387		 
1388		
1389		<span class="sz-nev"> S Kim</span>
1390   
1391				</div>
1392	
1393	</div>
1394	<div class="acf-row"><span class="publ-label">No. of patients:</span> 60 <hr/> <span class="publ-label">Therapy:</span>  mEHT<hr/> <span class="publ-label">Year:</span>  2020</div>
1395	</div><!-- .acf-fields -->
1396	<div id="region-content-top" class="c-region c-region--content-top">
1397<div class="c-region__inner">
1398<header class="c-page-title">
1399<div class="c-container">
1400<div class="c-container__content">
1401<div class="row column">
1402<div class="row">
1403<div class="column">
1404<div id="region-content" class="c-region c-region--content">
1405<div class="c-region__inner">
1406<div id="block-oncotherm-content" data-block-plugin-id="system_main_block">
1407<article class="c-publication c-publication-full" role="article" data-id="1851">
1408<div class="c-rich-text">
1409<p><span style="color: #9e8053;"><strong>Abstract:</strong></span> Despite advances in the multimodal approach for rectal cancer, treatment-related side effects remain an important issue. From this perspective, a prospective trial was performed to investigate the feasibility of modulated electro-hyperthermia (mEHT) as a concomitant boost to preoperative chemoradiation in locally advanced rectal cancer. Seventy-six patients with cT3-4 or cT2N+ rectal cancer were enrolled consecutively. Whole pelvic radiotherapy of 40 Gy was delivered with a 2-Gy daily fraction. mEHT with 13.56 MHz frequency was boosted on a twice-weekly schedule concurrently with intravenous 5-fluorouracil or oral capecitabine. Surgical resection was planned 6-8 weeks after radiotherapy. The primary endpoint was the non-inferior treatment response rate assessed by pathologic downstaging and tumor regression. The secondary endpoint was acceptable toxicity during the preoperative treatment period. Sixty patients completed the planned treatment schedule. T- and N-downstaging was demonstrated in 40 patients (66.7%) and 53 patients (88.3%), respectively. Pathologic complete response was noted in 15.0% (9 patients) and 76.7% (46 patients) for T-stage and N-stage, respectively. Total or near total tumor regression was observed in 20 patients (33.3%). Grade ≥3 toxicity occurred only in hematologic assessment; one case (1.7%) of leukopenia and one case (1.7%) of anemia. Sixteen patients (26.7%) developed thermal toxicity, which was mostly Grade 1 (15 patients, 93.8%). The relatively low dose of 40 Gy radiation showed comparable pathologic treatment outcomes and tolerable toxicity profiles with the addition of mEHT, which may potentially replace part of the radiation dose in neoadjuvant treatment for rectal cancer.</p>
1410</div>
1411</article>
1412</div>
1413</div>
1414</div>
1415</div>
1416</div>
1417</div>
1418</div>
1419</div>
1420</header>
1421</div>
1422</div>
1423
1424			<div id="teljes-cikk" class="btn">
1425		<a href="https://pubmed.ncbi.nlm.nih.gov/32039629/" target="_blank"> View abstract</a>
1426	</div>
1427	
1428	</div>	<!-- .container -->
1429</div><!-- .entry-content -->
1430
1431
1432
1433</article><!-- #post-3292 -->
1434
1435			
1436<article id="post-3293" class="post-3293 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
1437	
1438	<header class="pub-entry-header">
1439	<div class="container">
1440		<h2>Survival Outcomes of Metabolically Supported Chemotherapy Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy in Advanced Gastric Cancer</h2>
1441	</div>
1442	</header><!-- .entry-header -->
1443
1444
1445<div class="entry-content kl-pub-content">
1446	<div class="container">
1447		<div class="acf-fields">
1448	<div class="acf-row"><span class="publ-label">Indication:</span> Gastric Cancer <hr/> <span class="publ-label">Evidence:</span>  </div>
1449	<div class="publ-acf acf-row acf-flex">
1450	<span class="publ-label">Author:&nbsp;</span>
1451	<div class="szerzok">
1452		
1453		 
1454		
1455		<span class="sz-nev">MS Iyikesici</span>
1456   
1457				</div>
1458	
1459	</div>
1460	<div class="acf-row"><span class="publ-label">No. of patients:</span> 22 <hr/> <span class="publ-label">Therapy:</span>  Chemotherapy, Ketogenic Diet, Hyperthermia, Hyperbaric Oxygen Therapy<hr/> <span class="publ-label">Year:</span>  2020</div>
1461	</div><!-- .acf-fields -->
1462	<p><strong><span style="color: #9e8053;">Abstract:</span></strong></p>
1463<p>Background: Survival outcomes are still far from being satisfactory in patients with advanced gastric cancer, despite availability of novel chemotherapeutic regimens. Aim: This study evaluated the outcomes of patients with advanced gastric cancer who received chemotherapy along with additional treatment modalities targeting multiple tumor cell vulnerabilities. Materials and Methods: A total of 24 patients diagnosed with stage III–IV locally advanced or metastatic gastric aden
1463ocarcinoma that received metabolically supported chemotherapy (MSCT) combined with ketogenic diet, local hyperthermia, and hyperbaric oxygen therapy (HBOT) between April 2014 and October 2017 were included in this retrospective study. Survival outcomes were evaluated. Results: In 22 patients (88.0%), complete response was achieved. Mean duration of follow‑up was 23.9 ± 12.7 months. Mean overall survival was 39.5 months (95% confidence interval [CI]: 28.1–51.0) and mean progression free survival was 36.5 months (95% CI: 25.7–47.2). No problems were encountered due to fasting, hypoglycemia, ketogenic diet, hyperthermia or HBOT. Conclusions: The combination treatment used in this study (MSCT together with a ketogenic diet, hyperthermia and HBOT) appears to be promising in the treatment of advanced gastric cancer. Further research and comparative clinical trials are warranted to support and standardize this novel treatment protocol. Keywords: Advanced gastric cancer, hyperbaric oxygen therapy, hyperthermia, ketogenic diet, metabolically supported chemotherapy</p>
1464
1465	
1466	</div>	<!-- .container -->
1467</div><!-- .entry-content -->
1468
1469
1470
1471</article><!-- #post-3293 -->
1472
1473			
1474<article id="post-3294" class="post-3294 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
1475	
1476	<header class="pub-entry-header">
1477	<div class="container">
1478		<h2>Potentiation of the Abscopal Effect by Modulated Electro-Hyperthermia in Locally Advanced Cervical Cancer Patients</h2>
1479	</div>
1480	</header><!-- .entry-header -->
1481
1482
1483<div class="entry-content kl-pub-content">
1484	<div class="container">
1485		<div class="acf-fields">
1486	<div class="acf-row"><span class="publ-label">Indication:</span> Cervical cancer <hr/> <span class="publ-label">Evidence:</span>  Phase III</div>
1487	<div class="publ-acf acf-row acf-flex">
1488	<span class="publ-label">Author:&nbsp;</span>
1489	<div class="szerzok">
1490		
1491		 
1492		
1493		<span class="sz-nev">Carrie Anne Minnaar</span>
1494   
1495		 
1496		
1497		<span class="sz-nev">Jeffrey Allan Kotzen</span>
1498   
1499		 
1500		
1501		<span class="sz-nev">Olusegun Akinwale Ayeni</span>
1502   
1503		 
1504		
1505		<span class="sz-nev">Mboyo-Di-Tamba Vangu</span>
1506   
1507		 
1508		
1509		<span class="sz-nev">Ans Baeyens</span>
1510   
1511				</div>
1512	
1513	</div>
1514	<div class="acf-row"><span class="publ-label">No. of patients:</span> 108 <hr/> <span class="publ-label">Therapy:</span>  mEHT<hr/> <span class="publ-label">Year:</span>  2020</div>
1515	</div><!-- .acf-fields -->
1516	<p><strong><span style="color: #9e8053;">ABSTRACT</span><br />
1517Background:</strong> A Phase III randomized controlled trial investigating the addition of modulated electro-hyperthermia (mEHT) to chemoradiotherapy for locally advanced cervical cancer patients is being conducted in South Africa (Human Research Ethics Committee approval: M1704133; <a href="https://clincialtrials.gov/" target="_blank" rel="noopener noreferrer">ClincialTrials.gov</a> ID: NCT03332069). Two hundred and ten participants were randomized and 202 participants were eligible for six month local disease control evaluation. Screening <sup>18</sup>F-FDG PET/CT scans were conducted and repeated at six months post-treatment. Significant improvement in local control was reported in the mEHT group and complete metabolic resolution (CMR) of extra-pelvic disease was noted in some participants. We report on an analysis of the participants with CMR of disease inside and outside the radiation field.<br />
1518<strong>Method:</strong> Participants were included in this analysis if nodes outside the treatment field (FDG-uptake SUV&gt;2.5) were visualized on pre-treatment scans and if participants were evaluated by <sup>18</sup>F-FDG PET/CT scans at six months post-treatment.<br />
1519<strong>Results:</strong> One hundred and eight participants (mEHT: HIV-positive <i>n</i> = 25, HIV-negative <i>n</i> = 29; Control Group: HIV-positive <i>n</i> = 26, HIV-negative <i>n</i> = 28) were eligible for analysis. There was a higher CMR of all disease inside and outside the radiation field in the mEHT Group: <i>n</i> = 13 [24.1%] than the control group: <i>n</i> = 3 [5.6%] (Chi squared, Fisher&#8217;s exact: <i>p</i>
1519 = 0.013) with no significant difference in the extra-pelvic response to treatment between the HIV-positive and -negative participants of each group.<br />
1520<strong>Conclusion:</strong> The CMR of disease outside the radiation field at six months post-treatment provides evidence of an abscopal effect which was significantly associated with the addition of mEHT to treatment protocols. This finding is important as the combined synergistic use of radiotherapy with mEHT could broaden the scope of radiotherapy to include systemic disease.</p>
1521
1522			<div id="teljes-cikk" class="btn">
1523		<a href="https://www.frontiersin.org/articles/10.3389/fonc.2020.00376/full" target="_blank"> View abstract</a>
1524	</div>
1525	
1526	</div>	<!-- .container -->
1527</div><!-- .entry-content -->
1528
1529
1530
1531</article><!-- #post-3294 -->
1532
1533			
1534<article id="post-3295" class="post-3295 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
1535	
1536	<header class="pub-entry-header">
1537	<div class="container">
1538		<h2>Putative Abscopal Effect in Three Patients Treated by Combined Radiotherapy and Modulated Electrohyperthermia</h2>
1539	</div>
1540	</header><!-- .entry-header -->
1541
1542
1543<div class="entry-content kl-pub-content">
1544	<div class="container">
1545		<div class="acf-fields">
1546	<div class="acf-row"><span class="publ-label">Indication:</span> Multiple <hr/> <span class="publ-label">Evidence:</span>  </div>
1547	<div class="publ-acf acf-row acf-flex">
1548	<span class="publ-label">Author:&nbsp;</span>
1549	<div class="szerzok">
1550		
1551		 
1552		
1553		<span class="sz-nev">Mau-Shin Chi</span>
1554   
1555		 
1556		
1557		<span class="sz-nev">Minesh P. Mehta</span>
1558   
1559		 
1560		
1561		<span class="sz-nev">Kai-Lin Yang</span>
1562   
1563		 
1564		
1565		<span class="sz-nev">Hung-Chih Lai</span>
1566   
1567		 
1568		
1569		<span class="sz-nev">Ying-Chu Lin</span>
1570   
1571		 
1572		
1573		<span class="sz-nev">Hui-Ling Ko</span>
1574   
1575		 
1576		
1577		<span class="sz-nev">Yu-Shan Wang</span>
1578   
1579		 
1580		
1581		<span class="sz-nev">Kuang-Wen Liao</span>
1582   
1583		 
1584		
1585		<span class="sz-nev">Kwan-Hwa Chi</span>
1586   
1587				</div>
1588	
1589	</div>
1590	<div class="acf-row"><span class="publ-label">No. of patients:</span> 33 <hr/> <span class="publ-label">Therapy:</span>  RT+mEHT<hr/> <span class="publ-label">Year:</span>  2020</div>
1591	</div><!-- .acf-fields -->
1592	<p><strong>ABSTRACT<br />
1593Purpose: </strong>True abscopal responses from radiation therapy are extremely rare; the combination of immune checkpoint inhibitors with radiation therapy has led to more reports of the abscopal effect, but even in this setting, the genuine magnitude remains unknown and is still considered generally uncommon. We report the occurrence of what appears to be putative, durable abscopal tumor responses with associated auto-immune systemic reactions resulting from the combination of local radiotherapy (RT) and modulated electrohyperthermia (mEHT).</p>
1594<p><strong>Materials and Methods: </strong>Data from advanced cancer patients treated palliatively with RT and mEHT between January and December 2017 were collected as part of a post-marketing safety monitoring program of mEHT therapy. We specified a minimum RT dose of 30Gy and at least four mEHT treatments for reporting toxicities, which was the primary aim of the larger study.</p>
1595<p><strong>Results:</strong> Thirty-three patients treated with RT and mEHT, both applied to the same lesion, were included. The median RT dose was 45.5Gy in 20 fractions (fxs) and the median number of mEHT treatments was 12 (range, 4–20). Most patients had subsequent systemic therapy after one course of RT and mEHT. Three patients (9.1%) developed autoimmune toxicities. Case number 1 received RT and mEHT only; case number 2 had two cycles of concurrent low dose chemotherapy during RT; and case number 3 received concurrent immune checkpoint inhibitors. None of the three patients received any further systemic treatment due to obvious treatment-related autoimmune reactions which occurred rapidly after RT; one had autoimmune hepatitis, one had dermatitis herpetiformis and the third developed severe myasthenia gravis. Interestingly, what we surmise to be long-lasting abscopal responses outside the irradiated area, were noted in all three patients.</p>
1596<p><strong>Conclusion:</strong> RT combined with mEHT could putatively result in enhancing immune responsiveness. These preliminary observational findings lead to the generation of a hypothesis that this combination induces both an in-situ, tumor-specific immune reaction and an anti-self-autoimmune reaction, in at least a small proportion of patients, and of those who experience the auto-immune response, tumor response is a concomitant finding. Mechanisms underlying this phenomenon need to be investigated further.</p>
1597
1598			<div id="teljes-cikk" class="btn">
1599		<a href="https://www.frontiersin.org/articles/10.3389/fonc.2020.00254/full" target="_blank">
1599 View abstract</a>
1600	</div>
1601	
1602	</div>	<!-- .container -->
1603</div><!-- .entry-content -->
1604
1605
1606
1607</article><!-- #post-3295 -->
1608
1609			
1610<article id="post-3296" class="post-3296 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
1611	
1612	<header class="pub-entry-header">
1613	<div class="container">
1614		<h2>Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy</h2>
1615	</div>
1616	</header><!-- .entry-header -->
1617
1618
1619<div class="entry-content kl-pub-content">
1620	<div class="container">
1621		<div class="acf-fields">
1622	<div class="acf-row"><span class="publ-label">Indication:</span> Immuno-oncology <hr/> <span class="publ-label">Evidence:</span>  </div>
1623	<div class="publ-acf acf-row acf-flex">
1624	<span class="publ-label">Author:&nbsp;</span>
1625	<div class="szerzok">
1626		
1627		 
1628		
1629		<span class="sz-nev">Volker Schirrmacher</span>
1630   
1631		 
1632		
1633		<span class="sz-nev">Stefaan van Gool</span>
1634   
1635		 
1636		
1637		<span class="sz-nev">Wilfried Stuecker</span>
1638   
1639				</div>
1640	
1641	</div>
1642	<div class="acf-row"><span class="publ-label">No. of patients:</span>  <hr/> <span class="publ-label">Therapy:</span>  <hr/> <span class="publ-label">Year:</span>  2019</div>
1643	</div><!-- .acf-fields -->
1644	<p><strong>Abstract</strong><br />
1645Resistance to therapy is a major obstacle to cancer treatment. It may exist from the beginning, or it may develop during therapy. The review focusses on oncolytic Newcastle disease virus(NDV)asabiologicalagentwithpotentialtobreaktherapyresistance. Thisavianviruscombines, upon inoculation into non-permissive hosts such as human, 12 described anti-neoplastic effects with 11describedimmunestimulatoryproperties. FiftyyearsofclinicalapplicationofNDVgivewitnessto the high safety profile of this biological agent. In 2015, an important milestone was achieved, namely the successful production of NDV according to Good Manufacturing Practice (GMP). Based on this, IOZK in Cologne, Germany, obtained a GMP certificate for the production of a dendritic cell vaccine loadedwithtumorantigensfromalysateofpatient-derivedtumorcellstogetherwithimmunological dangersignalsfromNDVforintracutaneousapplication. Thisupdateincludessinglecasereportsand retrospective analyses from patients treated at IOZK. The review also presents future perspectives, including the concept of in situ vaccination and the combination of NDV or other oncolytic viruses with checkpoint inhibitors.<br />
1646Keywords: NDV; viral oncolysis; immunogenic cell death; type I interferon; dendritic cells; active-specific immunotherapy; bispecific antibodies; gene therapy; checkpoint inhibition; T cell costimulation; RIG-I; IFNAR</p>
1647
1648			<div id="teljes-cikk" class="btn">
1649		<a href="https://www.ncbi.nlm.nih.gov/pubmed/31480379" target="_blank"> View abstract</a>
1650	</div>
1651	
1652	</div>	<!-- .container -->
1653</div><!-- .entry-content -->
1654
1655
1656
1657</article><!-- #post-3296 -->
1658
1659			
1660<article id="post-3297" class="post-3297 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
1661	
1662	<header class="pub-entry-header">
1663	<div class="container">
1664		<h2>Long-Term Survival Outcomes of Metabolically Supported Chemotherapy with Gemcitabine-Based or FOLFIRINOX Regimen Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy in Metastatic Pancreatic Cancer</h2>
1665	</div>
1666	</header><!-- .entry-header -->
1667
1668
1669<div class="entry-content kl-pub-content">
1670	<div class="container">
1671		<div class="acf-fields">
1672	<div class="acf-row"><span class="publ-label">Indication:</span> Pancreas <hr/> <span class="publ-label">Evidence:</span>  </div>
1673	<div class="publ-acf acf-row acf-flex">
1674	<span class="publ-label">Author:&nbsp;</span>
1675	<div class="szerzok">
1676		
1677		 
1678		
1679		<span class="sz-nev">Mehmet Salih Iyikesici</span>
1680   
1681				</div>
1682	
1683	</div>
1684	<div class="acf-row"><span class="publ-label">No. of patients:</span> 25 <hr/> <span class="publ-label">Therapy:</span>  <hr/> <span class="publ-label">Year:</span>  2019</div>
1685	</div><!-- .acf-fields -->
1686	<p><strong>Abstract</strong></p>
1687<p>Background: Despite introduction of new chemotherapeutic agents, outcomes of patients with metastatic pancreatic cancer are still poor. Metabolically supported chemotherapy (MSCT) is a novel approach targeting dysregulated energy mechanism of the tumor cell.<br />
1688Objectives: This study aimed to examine the efficacy of metabolically supported administration of chemotherapy combined with ketogenic diet, hyperthermia, and hyperbaric oxygen therapy (HBOT) in patients with metastatic pancreatic cancer.<br />
1689Method: This retrospective observational study included 25 patients with metastatic pancreatic ductal carcinoma (stage IV) who received MSCT (either gemcitabine-based or FOLFIRINO
1689X regimen administered concomitantly with induced hypoglycemia) plus ketogenic diet, hyperthermia, and HBOT combination. Survival outcomes were evaluated.<br />
1690Results: During the mean follow-up duration of 25.4 ± 19.3 months, median overall survival and median progression-free survival were 15.8 months (95% CI, 10.5–21.1) and 12.9 months (95% CI, 11.2–14.6), respectively. Age and gender did not have any effect on overall survival (p &gt; 0.05 for all).<br />
1691Conclusions: MSCT administered together with ketogenic diet, hyperthermia, and HBOT appears to be a viable option with the potential to improve survival outcomes in patients diagnosed with metastatic pancreatic cancer. Further research, particularly with larger comparative clinical trials, is warranted.</p>
1692
1693			<div id="teljes-cikk" class="btn">
1694		<a href="https://www.ncbi.nlm.nih.gov/pubmed/31527373" target="_blank"> View abstract</a>
1695	</div>
1696	
1697	</div>	<!-- .container -->
1698</div><!-- .entry-content -->
1699
1700
1701
1702</article><!-- #post-3297 -->
1703
1704			
1705<article id="post-3298" class="post-3298 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
1706	
1707	<header class="pub-entry-header">
1708	<div class="container">
1709		<h2>Modulated Electro-Hyperthermia as Palliative Treatment for Pancreatic Cancer: A Retrospective Observational Study on 106 Patients</h2>
1710	</div>
1711	</header><!-- .entry-header -->
1712
1713
1714<div class="entry-content kl-pub-content">
1715	<div class="container">
1716		<div class="acf-fields">
1717	<div class="acf-row"><span class="publ-label">Indication:</span> Pancreas <hr/> <span class="publ-label">Evidence:</span>  Review</div>
1718	<div class="publ-acf acf-row acf-flex">
1719	<span class="publ-label">Author:&nbsp;</span>
1720	<div class="szerzok">
1721		
1722		 
1723		
1724		<span class="sz-nev">Giammaria Fiorentini</span>
1725   
1726		 
1727		
1728		<span class="sz-nev">Donatella Sarti</span>
1729   
1730		 
1731		
1732		<span class="sz-nev">Virginia Casadei</span>
1733   
1734		 
1735		
1736		<span class="sz-nev">Carlo Milandri</span>
1737   
1738		 
1739		
1740		<span class="sz-nev">Patrizia Dentico</span>
1741   
1742		 
1743		
1744		<span class="sz-nev">Andrea Mambrini</span>
1745   
1746		 
1747		
1748		<span class="sz-nev">Roberto Nani</span>
1749   
1750		 
1751		
1752		<span class="sz-nev">Caterina Fiorentini</span>
1753   
1754		 
1755		
1756		<span class="sz-nev">Stefano Guadagni</span>
1757   
1758				</div>
1759	
1760	</div>
1761	<div class="acf-row"><span class="publ-label">No. of patients:</span> 106 <hr/> <span class="publ-label">Therapy:</span>  CT+RT+mEHT<hr/> <span class="publ-label">Year:</span>  2019</div>
1762	</div><!-- .acf-fields -->
1763	<h3 class="text-align-justify"><strong>Abstract</strong></h3>
1764<p class="text-align-justify"><strong>Background</strong>: Pancreatic adenocarcinoma has a poor prognosis, resulting in a &lt;10% survival rate at 5 years. Modulated electro-hyperthermia (mEHT) has been increasingly used for pancreatic cancer palliative care and therapy. Objective: To monitor the efficacy and safety of mEHT for the treatment of advanced pancreatic cancer. <strong>Methods</strong>: We collected data retrospectively on 106 patients affected by stage III-IV pancreatic adenocarcinoma. They were divided into 2 groups: patients who did not receive mEHT (no-mEHT) and patients who were treated with mEHT. We performed mEHT applying a power of 60 to 150 W for 40 to 90 minutes. The mEHT treatment was associated with chemotherapy and/
1764or radiotherapy for 33 (84.6%) patients, whereas 6 (15.4%) patients received mEHT alone. The patients of the no-mEHT group received chemotherapy and/or radiotherapy in 55.2% of cases. <strong>Results</strong>: Median age of the sample was 65.3 years (range = 31-80 years). After 3 months of therapy, the mEHT group had partial response in 22/34 patients (64.7%), stable disease in 10/34 patients (29.4%), and progressive disease in 2/34 patients (8.3%). The no-mEHT group had partial response in 3/36 patients (8.3%), stable disease in 10/36 patients (27.8%), and progressive disease in 23/36 patients (34.3%). The median overall survival of the mEHT group was 18.0 months (range = 1.5-68.0 months) and 10.9 months (range = 0.4-55.4 months) for the non-mEHT group. <strong>Conclusions</strong>: mEHT may improve tumor response and survival of pancreatic cancer patients.</p>
1765
1766			<div id="teljes-cikk" class="btn">
1767		<a href="https://journals.sagepub.com/doi/10.1177/1534735419878505" target="_blank"> View abstract</a>
1768	</div>
1769	
1770	</div>	<!-- .container -->
1771</div><!-- .entry-content -->
1772
1773
1774
1775</article><!-- #post-3298 -->
1776
1777			
1778<article id="post-3299" class="post-3299 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
1779	
1780	<header class="pub-entry-header">
1781	<div class="container">
1782		<h2>Feasibility study of metabolically supported chemotherapy with weekly carboplatin/paclitaxel combined with ketogenic diet, hyperthermia and hyperbaric oxygen therapy in metastatic nonsmall cell lung cancer</h2>
1783	</div>
1784	</header><!-- .entry-header -->
1785
1786
1787<div class="entry-content kl-pub-content">
1788	<div class="container">
1789		<div class="acf-fields">
1790	<div class="acf-row"><span class="publ-label">Indication:</span> Lung <hr/> <span class="publ-label">Evidence:</span>  </div>
1791	<div class="publ-acf acf-row acf-flex">
1792	<span class="publ-label">Author:&nbsp;</span>
1793	<div class="szerzok">
1794		
1795		 
1796		
1797		<span class="sz-nev">Mehmet Salih Iyikesici</span>
1798   
1799				</div>
1800	
1801	</div>
1802	<div class="acf-row"><span class="publ-label">No. of patients:</span> 44 <hr/> <span class="publ-label">Therapy:</span>  <hr/> <span class="publ-label">Year:</span>  2019</div>
1803	</div><!-- .acf-fields -->
1804	<p><strong>ABSTRACT</strong><br />
1805Background: Previous evidence suggests that metabolically supported chemotherapy (MSCT), ketogenic diet, hyperthermia and hyperbaric oxygen therapy (HBOT) could all target vulnerabilities of cancer cells. This study aimed to evaluate the efficacy and the tolerability of this combination therapy in the treatment of stage IV non-small cell lung cancer (NSCLC).<br />
1806Methods: Forty-four NSCLC patients with distant metastasis that received MSCT (administration of chemotherapy regimen following induced hypoglycemia) plus ketogenic diet, hyperthermia and HBOT combination were included in this retrospective study. Survival and treatment response rates as well as toxicities were evaluated.<br />
1807Results: Overall response rate (ORR, complete response plus partial response) was 61.4%; whereas, 15.9% and 22.7% of patients had stable disease (SD) and progressive disease (PD), respectively. Mean overall survival (OS) and progression-free survival (PFS) was 42.9months (95% CI: 34.0–51.8) and 41.0months (95% CI: 31.1–50.9), respectively. A higher Eastern Cooperative Oncology Group (ECOG) performance status (ECOG 2) was associated with worse OS and PFS. Patients received chemotherapy cycles with acceptable toxicity and adverse events. No problems were encountered due to fasting, hypoglycemia, ketogenic diet, hyperthermia or hyperbaric oxygen therapy.<br />
1808Conclusions: Findings of this study suggest that MSCT combined with other modalities targeting multiple pathways and cellular vulnerabilities may bring about remarkable improvements in survival outcomes and treatment response rates in metastatic NSCLC, without additional safety concerns. Large comparative studies are warranted to draw robust conclusions.</p>
1809
1810			<div id="teljes-cikk" class="btn">
1811		<a href="https://www.tandfonline.com/doi/full/10.1080/02656736.2019.1589584" target="_blank"> View abstract</a>
1812	</div>
1813	
1814	</div>	<!-- .container -->
1815</div><!-- .entry-content -->
1816
1817
1818
1819</article><!-- #post-3299 -->
1820
1821			
1822<article id="post-3300" class="post-3300 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
1823	
1824	<header class="pub-entry-header">
1825	<div class="container">
1826		<h2>Defining Characteristics of Nodal Disease on PET/CT Scans in Patients W
1826ith HIV-Positive and-Negative Locally Advanced Cervical Cancer in South Africa</h2>
1827	</div>
1828	</header><!-- .entry-header -->
1829
1830
1831<div class="entry-content kl-pub-content">
1832	<div class="container">
1833		<div class="acf-fields">
1834	<div class="acf-row"><span class="publ-label">Indication:</span> Cervical cancer <hr/> <span class="publ-label">Evidence:</span>  </div>
1835	<div class="publ-acf acf-row acf-flex">
1836	<span class="publ-label">Author:&nbsp;</span>
1837	<div class="szerzok">
1838		
1839		 
1840		
1841		<span class="sz-nev">Carrie Anne Minaar</span>
1842   
1843		 
1844		
1845		<span class="sz-nev">Ans Baeyens</span>
1846   
1847		 
1848		
1849		<span class="sz-nev">Olusegun Akinwale Ayeni</span>
1850   
1851		 
1852		
1853		<span class="sz-nev">Jeffrey Allan Kotzen</span>
1854   
1855		 
1856		
1857		<span class="sz-nev">Mboyo-Di-Tamba Vangu</span>
1858   
1859				</div>
1860	
1861	</div>
1862	<div class="acf-row"><span class="publ-label">No. of patients:</span>  <hr/> <span class="publ-label">Therapy:</span>  <hr/> <span class="publ-label">Year:</span>  2019</div>
1863	</div><!-- .acf-fields -->
1864	<p><strong>Abstract </strong><br />
1865Literature reports increased FDG nodal uptake in HIV-positive patients. Our aim is to identify differences in presentation and characteristics of FDG-avid lymph nodes between HIV-positive and HIV-negative locally advanced cervical cancer (LACC) patients in our clinical setting. We evaluated 250 pre-treatment 18F-FDG PET/CT imaging studies from women screened for a phase III randomised controlled trial investigating modulated electro-hyperthermia as a radiosensitiser (Ethics approval: M120477). The number of nodes; size; maximum standardised uptake value (SUVmax); symmetry; and relationship between nodal size and SUVmax uptake, were assessed by region and by HIV status. In total, 1314 nodes with a SUVmax ≥ 2.5 were visualised. Of 128(51%) HIV-positive participants, 82% were on antiretroviral therapy (ART) and 10 had a CD4 count &lt;
1865200 cells/mL. Overall pattern of presentation and nodal characteristics were similar between HIV-positive and -negative groups and the uniformity in presentation of the nodes draining the cervix strongly suggests these nodes may be attributed to malignancy rather than HIV infection. Novel findings: HIV infection is associated with: &gt;four nodes visualised in the neck, symmetrical inguinal lymph nodes, increased rates of supraclavicular node visualisation; FDG-avid axillary nodes were more common, but not exclusive, in HIV-positive participants. 18F-FDG PET/CT is a reliable staging method for LACC in HIV-positive patients who are not in acute stages of HIV infection, have a CD4 count &gt;200 cells/mL, and/or are on ART and there is a potential risk of underestimating metastatic spread by attributing increased nodal metabolic activity to HIV infection in these patients.</p>
1866
1867			<div id="teljes-cikk" class="btn">
1868		<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935993/" target="_blank"> View abstract</a>
1869	</div>
1870	
1871	</div>	<!-- .container -->
1872</div><!-- .entry-content -->
1873
1874
1875
1876</article>
1876<!-- #post-3300 -->
1877
1878			
1879<article id="post-3301" class="post-3301 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
1880	
1881	<header class="pub-entry-header">
1882	<div class="container">
1883		<h2>Fluctuations hypothesize the new explanation of meridians in living systems</h2>
1884	</div>
1885	</header><!-- .entry-header -->
1886
1887
1888<div class="entry-content kl-pub-content">
1889	<div class="container">
1890		<div class="acf-fields">
1891	<div class="acf-row"><span class="publ-label">Indication:</span> Non-oncology <hr/> <span class="publ-label">Evidence:</span>  </div>
1892	<div class="publ-acf acf-row acf-flex">
1893	<span class="publ-label">Author:&nbsp;</span>
1894	<div class="szerzok">
1895		
1896		 
1897		
1898		<span class="sz-nev">Szigeti Gy</span>
1899   
1900		 
1901		
1902		<span class="sz-nev">Szasz A</span>
1903   
1904				</div>
1905	
1906	</div>
1907	<div class="acf-row"><span class="publ-label">No. of patients:</span>  <hr/> <span class="publ-label">Therapy:</span>  <hr/> <span class="publ-label">Year:</span>  2019</div>
1908	</div><!-- .acf-fields -->
1909	<h3 class="text-align-justify"><strong>Abstract </strong></h3>
1910<p class="text-align-justify">Biosystems are complex. Their physiology is well-controlled with various negative feedback signals and processes, it describes by opposite interfering effects which are characterized in the Eastern philosophy by Yin-Yang (Y-Y) pairs. Y-Y pairs could be described by the promoter-suppressor pairs in a wide range of physiologic signals creating the homeostasis of the complex system. This type of control appears as fluctuations from the average (mean) value of the signal. The mean carries an ineluctable fluctuation (called pink-noise or 1/f noise). All signals in homeostasis have equal entropy (SE = 1.8), which is the character of the complex equilibrium. The various controlling opposite signals (Y-Y) have different time-scales which change by aging. The processes with smaller time-scale are degraded by aging, but the pink-noise ensures that the deviations of the signals of the healthy homeostatic system remain constant. Meridians are connected to the general transport systems that combined the material and the information transport with the considerable transport networks, like blood, lymph, nerve, cell-junctions, mesenchymal “ground substance” cytoskeletons. The meridians in this meaning only virtual line averaged from multiple realized paths to connect two acupuncture points by the material, energy and information transport processes. The meridian network is designed by various coupling points (acupoints), which could be perturbed by actuating stimulus. Our objective is to describe the meridian system from complexity point of view.</p>
1911
1912			<div id="teljes-cikk" class="btn">
1913		<a href="https://www.scirp.org/journal/PaperInformation.aspx?PaperID=89697" target="_blank"> View abstract</a>
1914	</div>
1915	
1916	</div>	<!-- .container -->
1917</div><!-- .entry-content -->
1918
1919
1920
1921</article>
1921<!-- #post-3301 -->
1922
1923			
1924<article id="post-3302" class="post-3302 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
1925	
1926	<header class="pub-entry-header">
1927	<div class="container">
1928		<h2>Thermal and Nonthermal Effects of Radiofrequency on Living State and Applications as an Adjuvant with Radiation Therapy</h2>
1929	</div>
1930	</header><!-- .entry-header -->
1931
1932
1933<div class="entry-content kl-pub-content">
1934	<div class="container">
1935		<div class="acf-fields">
1936	<div class="acf-row"><span class="publ-label">Indication:</span> Non-oncology <hr/> <span class="publ-label">Evidence:</span>  Review</div>
1937	<div class="publ-acf acf-row acf-flex">
1938	<span class="publ-label">Author:&nbsp;</span>
1939	<div class="szerzok">
1940		
1941		 
1942		
1943		<span class="sz-nev">Andras Szasz</span>
1944   
1945				</div>
1946	
1947	</div>
1948	<div class="acf-row"><span class="publ-label">No. of patients:</span>  <hr/> <span class="publ-label">Therapy:</span>  <hr/> <span class="publ-label">Year:</span>  2019</div>
1949	</div><!-- .acf-fields -->
1950	<div class="c-rich-text">
1951<p class="text-align-justify"><strong>Abstract</strong></p>
1952<p class="text-align-justify">One of the most frequently applied bioelectromagnetic effects is the deep heating of living species with electromotive force energy. Despite its long history, hyperthermia is a rarely applied oncotherapy because of controversial results and complicated control. The challenge in clinical studies of oncological hyperthermia is the disharmony of the local response and local control with overall survival. Both whole‑body (complete isothermia for the body) and local (isothermia for the chosen target) heating show excellent local effects; however, this is not followed with the expected elongation of survival time. A possible solution could be nonisothermal heating to the heterogeneity of the malignancy itself. The distinguishing parameters to select the target are the electromagnetic properties of the malignant tissue together with the physiological differences between malignant cells and their healthy counterparts. Selection could allow for cellular targeting, generating<br />
1953natural reactions, such as programmed cell death (apoptosis) followed by immunogenic cell death involving extended immune reactions. This complex method is a new kind of hyperthermia, named modulated electrohyperthermia (tradename oncothermia). The selective, nonequilibrium energy absorption is well synergized with modern radiation therapies, presenting a solution of an active and controllable tumor‑specific immune reaction and subsequent abscopal effects.</p>
1954</div>
1955<div class="field field--name-field-url field--type-link field--label-hidden field__item"></div>
1956
1957			<div id="teljes-cikk" class="btn">
1958		<a href="http://www.journalrcr.org/article.asp?issn=2588-9273%3Byear%3D2019%3Bvolume%3D10%3Bissue%3D1%3Bspage%3D1%3Bepage%3D17%3Baulast%3DSzasz" target="_blank"> View abstract</a>
1959	</div>
1960	
1961	</div>	<!-- .container -->
1962</div><!-- .entry-content -->
1963
1964
1965
1966</article>
1966<!-- #post-3302 -->
1967
1968			
1969<article id="post-3303" class="post-3303 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
1970	
1971	<header class="pub-entry-header">
1972	<div class="container">
1973		<h2>Phase I/II clinical trial of modulated electro-hyperthermia treatment in patients with relapsed, refractory or progressive heavily treated ovarian cancer</h2>
1974	</div>
1975	</header><!-- .entry-header -->
1976
1977
1978<div class="entry-content kl-pub-content">
1979	<div class="container">
1980		<div class="acf-fields">
1981	<div class="acf-row"><span class="publ-label">Indication:</span> Gynecology <hr/> <span class="publ-label">Evidence:</span>  Phase I/II</div>
1982	<div class="publ-acf acf-row acf-flex">
1983	<span class="publ-label">Author:&nbsp;</span>
1984	<div class="szerzok">
1985		
1986		 
1987		
1988		<span class="sz-nev">Heon Jong Yoo</span>
1989   
1990		 
1991		
1992		<span class="sz-nev">Myong Cheol Lim</span>
1993   
1994		 
1995		
1996		<span class="sz-nev">Sang-Soo Seo</span>
1997   
1998		 
1999		
2000		<span class="sz-nev">Sokbom Kang</span>
2001   
2002		 
2003		
2004		<span class="sz-nev">Jungnam Joo</span>
2005   
2006		 
2007		
2008		<span class="sz-nev">Sang-Yoon Park</span>
2009   
2010				</div>
2011	
2012	</div>
2013	<div class="acf-row"><span class="publ-label">No. of patients:</span> 19 <hr/> <span class="publ-label">Therapy:</span>  mEHT<hr/> <span class="publ-label">Year:</span>  2019</div>
2014	</div><!-- .acf-fields -->
2015	<h3 class="text-align-justify">Abstract</h3>
2016<p class="text-align-justify"><strong>Objective:</strong> To determine the maximal tolerated dose (MTD) of modulated electro-hyperthermia (mEHT) treatment and to reveal whether mEHT treatment is feasible and effective as second-line therapy in recurrent and progressive ovarian cancer.</p>
2017<p class="text-align-justify"><strong>Methods:</strong> Patients were treated with mEHT with dose escalation during the first cycle (two sessions each week for three weeks) to determine the MTD. Additional cycles were carried out with the determined dose. Dose limiting toxicity (DLT) was defined grade ≥ 2: skin burns and inability to endure the hyperthermic state of the study. The Fact-O quality of life scale was used to assess health-related well-being.</p>
2018<p class="text-align-justify"><strong>Results:</strong> Nineteen patients with recurrent and progressive ovarian cancer were enrolled. In the first cycle of mEHT treatment, no patient developed DLT with applied power up to 110 W, 130 W, and 150 W/day; the 150W was the maximal applied power. Stable disease was observed in only one patient (12.5%). With median progression of 4.0 months (range, 2–17 months), 18 patients (95%) demonstrated disease progression. With median overall survival of 8.0 months (range, 2–32 months), 18 patients (95%) had died. Physical well-being scores were significantly decreased over the study period, although social, emotional, and functional well-being scores did not significantly change.</p>
2019<p class="text-align-justify"><strong>Conclusions:</strong> The mEHT treatment was feasible in patients with recurrent or progressive ovarian cancer without any complication and optimal dose of mEHT treatment was up to 150W for 1 hour/ day.</p>
2020
2021			<div id="teljes-cikk" class="btn">
2022		<a href="https://academic.oup.com/jjco/advance-article-abstract/doi/10.1093/jjco/hyz071/5487439?redirectedFrom=fulltext" target="_blank"> View abstract</a>
2023	</div>
2024	
2025	</div>	<!-- .container -->
2026</div><!-- .entry-content -->
2027
2028
2029
2030</article>
2030<!-- #post-3303 -->
2031
2032			
2033<article id="post-3304" class="post-3304 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
2034	
2035	<header class="pub-entry-header">
2036	<div class="container">
2037		<h2>Integrative Therapeutic Options for Treating Stage Four Breast Cancer</h2>
2038	</div>
2039	</header><!-- .entry-header -->
2040
2041
2042<div class="entry-content kl-pub-content">
2043	<div class="container">
2044		<div class="acf-fields">
2045	<div class="acf-row"><span class="publ-label">Indication:</span> Breast Cancer <hr/> <span class="publ-label">Evidence:</span>  </div>
2046	<div class="publ-acf acf-row acf-flex">
2047	<span class="publ-label">Author:&nbsp;</span>
2048	<div class="szerzok">
2049		
2050		 
2051		
2052		<span class="sz-nev">Magda Havas</span>
2053   
2054				</div>
2055	
2056	</div>
2057	<div class="acf-row"><span class="publ-label">No. of patients:</span>  <hr/> <span class="publ-label">Therapy:</span>  Integrative Therapeutic Options<hr/> <span class="publ-label">Year:</span>  2019</div>
2058	</div><!-- .acf-fields -->
2059	<p><strong>Abstract</strong><br />
2060Traditional Western medicine treats breast cancer – the most commonly occurring cancer in women with some combination of surgery, chemotherapy and/
2060or radiation therapy. Few doctors’ council their patients to use complementary modalities and some forbid their use. However, complementary therapies in the form of agents or activities that minimize exposure to toxins, detoxify the body, strengthen the immune system, increase cellular energy, promote circulation, reduce inflammation, alleviate pain and create a hostile internal environment for the growth of cancerous cells without damage to normal healthy cells have been shown to enhance survival and reduce morbidity of cancer patients. Some of these complementary modalities are presented here as options for both oncologists and patients to consider.</p>
2061
2062			<div id="teljes-cikk" class="btn">
2063		<a href="http://www.clinicsinoncology.com/pdfs_folder/cio-v4-id1607.pdf" target="_blank"> View abstract</a>
2064	</div>
2065	
2066	</div>	<!-- .container -->
2067</div><!-- .entry-content -->
2068
2069
2070
2071</article><!-- #post-3304 -->
2072
2073			
2074<article id="post-3305" class="post-3305 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
2075	
2076	<header class="pub-entry-header">
2077	<div class="container">
2078		<h2>The effect of modulated electro-hyperthermia on local disease control in HIV-positive and -negative cervical cancer women in South Africa: Early results from a phase III randomised controlled trial</h2>
2079	</div>
2080	</header><!-- .entry-header -->
2081
2082
2083<div class="entry-content kl-pub-content">
2084	<div class="container">
2085		<div class="acf-fields">
2086	<div class="acf-row"><span class="publ-label">Indication:</span> Cervical cancer <hr/> <span class="publ-label">Evidence:</span>  Phase III</div>
2087	<div class="publ-acf acf-row acf-flex">
2088	<span class="publ-label">Author:&nbsp;</span>
2089	<div class="szerzok">
2090		
2091		 
2092		
2093		<span class="sz-nev">Carrie Anne Minnaar</span>
2094   
2095		 
2096		
2097		<span class="sz-nev">Jeffrey Allan Kotzen</span>
2098   
2099		 
2100		
2101		<span class="sz-nev">Olusegun Akinwale Ayeni</span>
2102   
2103		 
2104		
2105		<span class="sz-nev">Thanushree Naidoo</span>
2106   
2107		 
2108		
2109		<span class="sz-nev">Mariza Tunmer</span>
2110   
2111		 
2112		
2113		<span class="sz-nev">Vinay Sharma</span>
2114   
2115		 
2116		
2117		<span class="sz-nev">Mboyo-Di-Tamba Vangu</span>
2118   
2119		 
2120		
2121		<span class="sz-nev">Ans Baeyens</span>
2122   
2123				</div>
2124	
2125	</div>
2126	<div class="acf-row"><span class="publ-label">No. of patients:</span> 271 <hr/> <span class="publ-label">Therapy:</span>  CT+mEHT<hr/> <span class="publ-label">Year:</span>  2019</div>
2127	</div><!-- .acf-fields -->
2128	<p class="text-align-justify"><strong>Background</strong><br />
2129The global burden of cervical cancer remains high with the highest morbidity and mortality rates reported in developing countries. Hyperthermia as a chemo- and radiosensitiser has shown to improve treatment outcomes. This is an analysis of the local control results at six months post-treatment of patients enrolled in an ongoing study investigating the effects of the addition of modulated electro-hyperthermia (mEHT) to chemoradiotherapy for the treatment of HIV-positive and -negative cervical cancer patients in a low-resource setting.</p>
2130<p class="text-align-justify">
2131<strong>Methods</strong><br />
2132This ongoing Phase III randomised controlled trial, conducted at a state hospital in Johannesburg, South Africa, was registered with the appropriate ethics committee. After signing an informed consent, participants with FIGO stages IIB to IIIB squamous cell carcinoma of the cervix were randomised to receive chemoradiotherapy with/without mEHT using a secure online random-sampling tool (stratum: HIV status) accounting for age and stage. Reporting physicians were blind to treatment allocation. HIV-positive participants on antiretroviral treatment, or with a CD4 count &gt;200cell/μL were included. mEHT was administered 2/weekly immediately before external beam radiation. The primary end point is local disease control (LDC) and secondary endpoints are toxicity; quality of life analysis; and two year survival. We report on six month LDC, including nodes visualised in the radiation field on 18FFDG PET/CT (censored for six month survival), and six month local disease free survival (LDFS) (based on intention to treat). Trial status: Recruitment closed (ClinicalTr
2132ials.gov: NCT03332069).</p>
2133<p class="text-align-justify"><strong>Results</strong><br />
2134271 participants were recruited between January 2014 and November 2017, of which 210 were randomised for trial and 202 were available for analysis at six months post-treatment (mEHT: n = 101; Control: n = 101). Six month LDFS was higher in the mEHT Group (n = 39[38.6%]), than in the Control Group (n = 20[19.8%]); p = 0.003). LDC was also higher in the mEHT Group (n = 40[45.5%]) than the Control Group (n = 20[24.1%]); (p = 0.003).</p>
2135<p class="text-align-justify"><strong>Conclusion</strong><br />
2136Our results show that mEHT is effective as a chemo-radiosensitiser for cervical cancer, even in high risk a patients and resource-constrained settings.</p>
2137
2138			<div id="teljes-cikk" class="btn">
2139		<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584021/" target="_blank"> View abstract</a>
2140	</div>
2141	
2142	</div>	<!-- .container -->
2143</div><!-- .entry-content -->
2144
2145
2146
2147</article><!-- #post-3305 -->
2148
2149			
2150<article id="post-3306" class="post-3306 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
2151	
2152	<header class="pub-entry-header">
2153	<div class="container">
2154		<h2>Nanoparticles and nanothermia for malignant brain tumors, a suggestion of treatment for further investigations</h2>
2155	</div>
2156	</header><!-- .entry-header -->
2157
2158
2159<div class="entry-content kl-pub-content">
2160	<div class="container">
2161		<div class="acf-fields">
2162	<div class="acf-row"><span class="publ-label">Indication:</span> Gliomas (advanced) <hr/> <span class="publ-label">Evidence:</span>  </div>
2163	<div class="publ-acf acf-row acf-flex">
2164	<span class="publ-label">Author:&nbsp;</span>
2165	<div class="szerzok">
2166		
2167		 
2168		
2169		<span class="sz-nev">Prieto C</span>
2170   
2171		 
2172		
2173		<span class="sz-nev">Linares I</span>
2174   
2175				</div>
2176	
2177	</div>
2178	<div class="acf-row"><span class="publ-label">No. of patients:</span>  <hr/> <span class="publ-label">Therapy:</span>  TSL+mEHT<hr/> <span class="publ-label">Year:</span>  2018</div>
2179	</div><!-- .acf-fields -->
2180	<h3>Abstract</h3>
2181<p>The current treatment for brain tumors, such as glioblastoma multiforme (GBM), has not been developed enough yet in order to fully heal them. The main causes are the lack of specificity of the treatments, the difficulty of passage of drugs through the blood-brain barrier, heterogeneity and tumor aggressiveness, and widespread dissemination in the brain. The application of nanoparticles (Nps) have been a breakthrough for both diagnostic imaging and targeted therapies. There have been numerous studies with different types of Nps in brain tumors, but we have focused on thermosensitive liposomes, which are characterized by releasing the chemotherapeutic agent included within its lipophilic membranes through heat. Furthermore, increasing the temperature in brain tumors through hyperthermia has been proven therapeutically beneficial. Nanothermia or modulated-electro-hyperthermia (MEHT) is an improved technique that allows to create hot spots in nanorange at the membrane rafts, specifically in tumor cells, theoretically increasing the selectivity of the damage. In scie
2181ntific records, experiments that combine both techniques (thermosensitive liposomes and nanothermia) have never been conducted. We propose a hypothesis for further research.</p>
2182<h4>KEYWORDS:</h4>
2183<p>GBM; Liposomes; MEHT; Nanoparticles; Termosensitive</p>
2184
2185			<div id="teljes-cikk" class="btn">
2186		<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Nanoparticles%20and%20nanothermia%20for%20malignant%20brain%20tumors%2C%20a%20suggestion%20of%20treatment%20for%20further%20investigations%2C%20Reports%20of%20Practical%20Oncology%20and%20Radiotherapy" target="_blank"> View abstract</a>
2187	</div>
2188	
2189	</div>	<!-- .container -->
2190</div><!-- .entry-content -->
2191
2192
2193
2194</article><!-- #post-3306 -->
2195
2196			
2197<article id="post-3307" class="post-3307 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
2198	
2199	<header class="pub-entry-header">
2200	<div class="container">
2201		<h2>Combined treatment with modulated electro-hyperthermia and an autophagy inhibitor effectively inhibit ovarian and cervical cancer growth</h2>
2202	</div>
2203	</header><!-- .entry-header -->
2204
2205
2206<div class="entry-content kl-pub-content">
2207	<div class="container">
2208		<div class="acf-fields">
2209	<div class="acf-row"><span class="publ-label">Indication:</span> Gynecology <hr/> <span class="publ-label">Evidence:</span>  </div>
2210	<div class="publ-acf acf-row acf-flex">
2211	<span class="publ-label">Author:&nbsp;</span>
2212	<div class="szerzok">
2213		
2214		 
2215		
2216		<span class="sz-nev">Wookyeom Yang</span>
2217   
2218		 
2219		
2220		<span class="sz-nev">Gwan Hee Han</span>
2221   
2222		 
2223		
2224		<span class="sz-nev">Ha-Yeon Shin</span>
2225   
2226		 
2227		
2228		<span class="sz-nev">Eun-Ju Lee</span>
2229   
2230		 
2231		
2232		<span class="sz-nev">Hanbyoul Cho</span>
2233   
2234		 
2235		
2236		<span class="sz-nev">Doo Byung Chay &amp; Jae-Hoon Kim</span>
2237   
2238				</div>
2239	
2240	</div>
2241	<div class="acf-row"><span class="publ-label">No. of patients:</span>  <hr/> <span class="publ-label">Therapy:</span>  Autophagy Inhibitor+mEHT<hr/> <span class="publ-label">Year:</span>  2018</div>
2242	</div><!-- .acf-fields -->
2243	<h3 id="abstract">Abstract</h3>
2244<p>Purpose: Modulated electro-hyperthermia (mEHT), known as oncothermia, is an anticancer therapy that induces radiofrequency thermal damage to the cancer tissues. This study aimed to evaluate the potential effectiveness of mEHT as a therapeutic tool in ovarian and cervical cancer.</p>
2245<p>Materials and methods: We used both tumor-bearing mice and ovarian and cervical OVCAR-3, SK-OV-3, HeLa and SNU-17 cancer cell lines to investigate the effects of mEHT in vivo and in vitro, respectively, and determine whether it was enhanced by cotreatment with an autophagy inhibitor.</p>
2246<p>Results: We discovered that phosphorylation of p38, a stress-dependent kinase, was induced at the Thr180/Tyr182 residue in cancer cells exposed to mEHT. Apoptotic markers such as cleaved caspase-3 and poly-ADP ribose polymerase (PARP) were increased in OVCAR-3 and SNU-17 cells. Fluorescence-activated cell sorting (FACS) analysis showed a 
2246significant increase in the population of sub-G1 mEHT-exposed cells, which are dying and apoptotic cells. mEHT also reduced both weight and volume of xenograft tumors in mice transplanted with ovarian and cervical cancer cells and patient-derived cancer tissues. We determined that mEHT-induced cellular damage recovery was mediated by autophagy and, therefore, expectedly, cotreatment with mEHT and 3-methyladenine (3-MA), an autophagy inhibitor, more effectively inhibited cancer cell growth than individual treatment did.</p>
2247<p>Conclusions: mEHT treatment alone was sufficient to inhibit cancer growth, while a combined treatment with mEHT and an autophagy inhibitor amplified this inhibition effect.</p>
2248<p>Keywords: Modulated electro-hyperthermia, ovarian cancer, cervical cancer, autophagy inhibitor, anti-cancer effects</p>
2249
2250			<div id="teljes-cikk" class="btn">
2251		<a href="https://doi.org/10.1080/02656736.2018.1528390" target="_blank"> View abstract</a>
2252	</div>
2253	
2254	</div>	<!-- .container -->
2255</div><!-- .entry-content -->
2256
2257
2258
2259</article>
2259<!-- #post-3307 -->
2260
2261			
2262<article id="post-3308" class="post-3308 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
2263	
2264	<header class="pub-entry-header">
2265	<div class="container">
2266		<h2>The effect of modulated electro-hyperthermia on temperature and blood flow in human cervical carcinoma</h2>
2267	</div>
2268	</header><!-- .entry-header -->
2269
2270
2271<div class="entry-content kl-pub-content">
2272	<div class="container">
2273		<div class="acf-fields">
2274	<div class="acf-row"><span class="publ-label">Indication:</span> Temperature <hr/> <span class="publ-label">Evidence:</span>  Phase I</div>
2275	<div class="publ-acf acf-row acf-flex">
2276	<span class="publ-label">Author:&nbsp;</span>
2277	<div class="szerzok">
2278		
2279		 
2280		
2281		<span class="sz-nev">Lee S-Y</span>
2282   
2283		 
2284		
2285		<span class="sz-nev">Kim J-H</span>
2286   
2287		 
2288		
2289		<span class="sz-nev">Han Y-H</span>
2290   
2291		 
2292		
2293		<span class="sz-nev">Cho D-H</span>
2294   
2295				</div>
2296	
2297	</div>
2298	<div class="acf-row"><span class="publ-label">No. of patients:</span> 20 <hr/> <span class="publ-label">Therapy:</span>  mEHT<hr/> <span class="publ-label">Year:</span>  2018</div>
2299	</div><!-- .acf-fields -->
2300	<div>
2301<h2 id="abstract">Abstract</h2>
2302</div>
2303<div>
2304<p>Introduction: Mild hyperthermia has been known to enhance the response of tumours to radiotherapy or chemotherapy by increasing tumour blood flow, thereby increasing tumour oxygenation or drug delivery. The purpose of this study was to assess the changes in temperature and blood flow in human cervical cancer in response to regional heating with modulated electro-hyperthermia (mEHT).</p>
2305<p>Methods: The pelvic area of 20 patients with cervical carcinoma was heated with mEHT. The peri-tumour temperature was measured using an internal organ temperature probe. The tumour blood flow was measured using 3D colour Doppler ultrasound by determining the peak systolic velocity/end-diastolic velocity ratio (S/D ratio) and the resistance index (RI) within blood vessels.</p>
2306<p>Results: The mean peri-tumour temperature was 36.7 ± 0.2 °C before heating and increased to 38.5 ± 0.8 °C at the end of heating for 60 min. The marked declines in RI and S/D values strongly demonstrated that heating significantly increased tumour blood perfusion.</p>
2307<p>Conclusions: Regional heating of the pelvic area with mEHT significantly increased the peri-tumour temperature and improved the blood flow in cervical cancer. This is the first demonstration that the blood flow in cervical cancer is increased by regional hyperthermia. Such increases in temperature and blood flow may account for the clinical observations that hyperthermia improves the response of cervical cancer to radiotherapy or chemotherapy.</p>
2308</div>
2309
2310			<div id="teljes-cikk" class="btn">
2311		<a href="https://www.tandfonline.com/doi/full/10.1080/02656736.2018.1423709" target="_blank"> View abstract</a>
2312	</div>
2313	
2314	</div>	<!-- .container -->
2315</div><!-- .entry-content -->
2316
2317
2318
2319</article>
2319<!-- #post-3308 -->
2320
2321			
2322<article id="post-3309" class="post-3309 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
2323	
2324	<header class="pub-entry-header">
2325	<div class="container">
2326		<h2>The Induction of Immunogenic Cell Death (ICD) During Maintenance Chemotherapy and Subsequent Multimodal Immunotherapy for Glioblastoma (GBM)</h2>
2327	</div>
2328	</header><!-- .entry-header -->
2329
2330
2331<div class="entry-content kl-pub-content">
2332	<div class="container">
2333		<div class="acf-fields">
2334	<div class="acf-row"><span class="publ-label">Indication:</span> Gliomas (advanced) <hr/> <span class="publ-label">Evidence:</span>  Retrospective study</div>
2335	<div class="publ-acf acf-row acf-flex">
2336	<span class="publ-label">Author:&nbsp;</span>
2337	<div class="szerzok">
2338		
2339		 
2340		
2341		<span class="sz-nev">Van Gool SW</span>
2342   
2343		 
2344		
2345		<span class="sz-nev">Makalowski J</span>
2346   
2347		 
2348		
2349		<span class="sz-nev">Feyen O</span>
2350   
2351		 
2352		
2353		<span class="sz-nev">Prix L</span>
2354   
2355		 
2356		
2357		<span class="sz-nev">Schirrmacher V</span>
2358   
2359		 
2360		
2361		<span class="sz-nev">Stuecker W1</span>
2362   
2363				</div>
2364	
2365	</div>
2366	<div class="acf-row"><span class="publ-label">No. of patients:</span> 115 <hr/> <span class="publ-label">Therapy:</span>  IMT+mEHT<hr/> <span class="publ-label">Year:</span>  2018</div>
2367	</div><!-- .acf-fields -->
2368	<p class="text-align-justify"><strong>Abstract</strong></p>
2369<p class="text-align-justify">The prognosis of Glioblastoma multiforme remains poor. Immunotherapy improved survival in a small fraction of patients. We studied the efficiency of multimodal immunotherapy as part of first line treatment for patients with GBM. Immunogenic Cell Death (ICD) was induced with Newcastle Disease Virus (NDV) and Modulated Electrohyperthermia (mEHT), and Dendritic Cell (DC) vaccinations loaded with autologous tumor proteins were performed. In a retrospective analysis of 60 adults, we detected 15 adults in whom NDV/mEHT were added at days 8/9/10 during Temozolomide Maintenance (TMZm) cycles, multimodal immunotherapy with NDV/mEHT/DC vaccinations were administered after TMZm, and further 3-day NDV/mEHT maintenance immunotherapy treatments were given thereafter. Median age was 60 years. Median Karnofsky was 90. There was no added toxicity due to immunotherapy. Median progression-free survival was 13 months (m). With a median follow up of 17m (ranging 4-30m), median overall survival was not reached, and estimated overall survival at 30m was 58% (95%CI: +27, -42). The detection of Apo10 protein epitope (Apo10) and Transketolase-like 1 (TKTL1) in monocytes, the mRNA expression level for PDL1 on circulating tumor cells, and the Th1/Th2 balance in CD4+ T cells showed a dynamic interaction between tumor cells and immune reactivity. The data suggest that the additional induction of ICD via NDV/mEHT during TMZm is beneficial in improving overall survival. While TMZm only targets dividing tumor cells, ICD targets dividing and non-dividing tumor cells. DC vaccination induces an antitumoral and anti-viral immune response which is maintained by the 3-day NDV/mEHT maintenance immunotherapy treatments.</p>
2370<p class="text-align-justify"><strong>Keywords</strong>: Newcastle disease virus; Modulated electrohyperthermia;<br />
2371Glioblastoma; Immunogenic cell death; chemotherapy</p>
2372
2373			<div id="teljes-cikk" class="btn">
2374		<a href="http://www.iozk.de/aktuelles/iozk_glioblastoma_immunotherapy_austin_oncology_report_2018.pdf" target="_blank"> View abstract</a>
2375	</div>
2376	
2377	</div>	<!-- .container -->
2378</div><!-- .entry-content -->
2379
2380
2381
2382</article>
2382<!-- #post-3309 -->
2383
2384			
2385<article id="post-3310" class="post-3310 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
2386	
2387	<header class="pub-entry-header">
2388	<div class="container">
2389		<h2>Modulated Electrohyperthermia in Integrative Cancer Treatment for Relapsed Malignant Glioblastoma and Astrocytoma: Retrospective Multicenter Controlled Study</h2>
2390	</div>
2391	</header><!-- .entry-header -->
2392
2393
2394<div class="entry-content kl-pub-content">
2395	<div class="container">
2396		<div class="acf-fields">
2397	<div class="acf-row"><span class="publ-label">Indication:</span> Gliomas (advanced) <hr/> <span class="publ-label">Evidence:</span>  Retrospective study</div>
2398	<div class="publ-acf acf-row acf-flex">
2399	<span class="publ-label">Author:&nbsp;</span>
2400	<div class="szerzok">
2401		
2402		 
2403		
2404		<span class="sz-nev">Fiorentini G</span>
2405   
2406		 
2407		
2408		<span class="sz-nev">Sarti D</span>
2409   
2410		 
2411		
2412		<span class="sz-nev">Milandri C</span>
2413   
2414		 
2415		
2416		<span class="sz-nev">Dentico P</span>
2417   
2418		 
2419		
2420		<span class="sz-nev">Mambrini A</span>
2421   
2422		 
2423		
2424		<span class="sz-nev">Fiorentini C</span>
2425   
2426		 
2427		
2428		<span class="sz-nev">Mattioli G</span>
2429   
2430		 
2431		
2432		<span class="sz-nev">Casadei</span>
2433   
2434		 
2435		
2436		<span class="sz-nev">Guadagni S</span>
2437   
2438				</div>
2439	
2440	</div>
2441	<div class="acf-row"><span class="publ-label">No. of patients:</span> 149 <hr/> <span class="publ-label">Therapy:</span>  mEHT<hr/> <span class="publ-label">Year:</span>  2018</div>
2442	</div><!-- .acf-fields -->
2443	<h3>Abstract</h3>
2444<h6>BACKGROUND:</h6>
2445<p>There are interesting studies on glioma therapy with modulated electrohyperthermia (mEHT), which combines heat therapy with an electric field. Clinical researchers not only found the mEHT method feasible for palliation but also reported evidence of therapeutic response.</p>
2446<h6>PURPOSE:</h6>
2447<p>To study the efficacy and safety of mEHT for the treatment of relapsed malignant glioma and astrocytoma versus best supportive care (BSC).</p>
2448<h6>METHODS:</h6>
2449<p>We collected data retrospectively on 149 patients affected by malignant glioma and astrocytoma. Inclusion criteria were informed consent signed; &gt;18 years old; histological diagnosis of malignant glioma or astrocytoma; relapsed after surgery, adjuvant temozolomide-based chemotherapy, and radiotherapy; and indication for treatment with mEHT in palliative setting. mEHT was performed with capacitive coupling technique keeping the skin surface at 26°C and the tumor temperature at 40°C to 42.5°C for &gt; 90% of treatment duration (20-60 minutes). The applied power was 40 to 150 W using a step-up heating protocol. Results from patients treated with mEHT were compared with those treated with BSC.</p>
2450<h6>RESULTS:</h6>
2451<p>A total of 149 consecutive patients were enrolled in the study, 111 (74%) had glioblastoma multiforme (GBM), and 38 (26%) had astrocytoma (AST). mEHT was performed for 28 (25%) of GBM and 24 (63%) of AST patients. Tumor response at the 3-month follow-up was observed in 29% and 48% of GBM and AST patients after mEHT, and in 4% and 10% of GBM and AST patients after BSC, respectively. The survival rate at first and second year in the mEHT group was 77.3% and 40.9% for AST, and 61% and 29% for GBM, respectively. The 5-year overall survival of AST was 83% after mEHT versus 25% after BSC and 3.5% after mEHT versus 1.2% after BSC for GBM. The median overall survival of mEHT was 14 months (range 2-108 months) for GBM and 16.5 months (range 3-156 months) for the AST group. We observed 4 long-term survivors in the AST and 2 in the GBM group. Two of the long survivors in AST and 1 in GBM group were treated by mEHT.</p>
2452<h6>CONCLUSIONS:</h6>
2453<p>mEHT in integrative therapy may have a promising role in the treatment and palliation of relapsed GBM and AST.</p>
2454<h6>KEYWORDS:</h6>
2455<p>astrocytoma; modulated electrohyperthermia; relapsed malignant glioma; survival; tumor response</p>
2456
2457			<div id="teljes-cikk" class="btn">
2458		<a href="https://www.ncbi.nlm.nih.gov/pubmed/30580645" target="_blank"> View abstract</a>
2459	</div>
2460	
2461	</div>	<!-- .container -->
2462</div><!-- .entry-content -->
2463
2464
2465
2466</article><!-- #post-3310 -->
2467
2468			
2469<article id="post-3311" class="post-3311 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
2470	
2471	<header class="pub-entry-header">
2472	<div class="container">
2473		<h2>Comparing the Effectiveness of Pain Therapy (PT) and Modulated Electro-Hyperthermia (mEHT) Versus Pain Therapy Alone in Treating Patients W
2473ith Painful Bony Metastases: an observational trial</h2>
2474	</div>
2475	</header><!-- .entry-header -->
2476
2477
2478<div class="entry-content kl-pub-content">
2479	<div class="container">
2480		<div class="acf-fields">
2481	<div class="acf-row"><span class="publ-label">Indication:</span> Non-oncology <hr/> <span class="publ-label">Evidence:</span>  </div>
2482	<div class="publ-acf acf-row acf-flex">
2483	<span class="publ-label">Author:&nbsp;</span>
2484	<div class="szerzok">
2485		
2486		 
2487		
2488		<span class="sz-nev">Virginia Casade</span>
2489   
2490		 
2491		
2492		<span class="sz-nev">Donatella Sarti</span>
2493   
2494		 
2495		
2496		<span class="sz-nev">Carlo Milandri</span>
2497   
2498		 
2499		
2500		<span class="sz-nev">Patrizia Dentico</span>
2501   
2502		 
2503		
2504		<span class="sz-nev">Stefano Guadagni</span>
2505   
2506		 
2507		
2508		<span class="sz-nev">Giammaria Fiorentini</span>
2509   
2510				</div>
2511	
2512	</div>
2513	<div class="acf-row"><span class="publ-label">No. of patients:</span> 19 <hr/> <span class="publ-label">Therapy:</span>  PT + mEHT<hr/> <span class="publ-label">Year:</span>  2018</div>
2514	</div><!-- .acf-fields -->
2515	<p><strong>Overview</strong></p>
2516<p>The aim of the trial is to compare the response, duration of pain relief and time to achieve pain relief after pain therapy (PT) with or without hyperthermia (mEHT) in patients with painful bony metastases. Cancer patients with bony metastases and a VAS score of ≥5 on a 0– 10 scale were treated with fentanyl patches (100 μg every three days) and zoledronic acid (4mg every 28 days) combined with mEHT (PT + mEHT)  versus PT alone. Hyperthermia was performed using the Oncotherm EHY2000 plus device with the maintenance of the target temperature for 60 minutes twice a week for 2 weeks. The primary endpoint was VAS = 0–2 after treatment and an ECOG performance status reduction of at least one point from baseline evaluation.  The study included 19 patients: 10 in the PT + mEHT group and 9 patients in the PT-alone group. The average age of the patients was 57 years (range 40–86). The median VAS for the PT + mEHT group was 8 at baseline and had decreased to 3, 1 and 2 at 1, 3 and 6 months after the start of mEHT respectively. The median VAS for the PT-alone group was 8 at baseline and was unchanged at the subsequent time points. The median ECOG of the PT + mEHT group was 2 at baseline and had decreased to 1, 1 and 0 at 1, 3 and 6 months after the start of mEHT respectively. The median ECOG for the PT-alone group was 2 at baseline and was unchanged at the subsequent time points. The addition of mEHT to PT significantly increases the pain control rate and ECOG compared to RT alone for painful bony metastases.</p>
2517
2518	
2519	</div>	<!-- .container -->
2520</div><!-- .entry-content -->
2521
2522
2523
2524</article><!-- #post-3311 -->
2525
2526			
2527<article id="post-3312" class="post-3312 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
2528	
2529	<header class="pub-entry-header">
2530	<div class="container">
2531		<h2>PD-1, PD-L1 and CTLA-4 in pregnancy-related &#8211; and in early-onset breast cancer: A comparative study</h2>
2532	</div>
2533	</header><!-- .entry-header -->
2534
2535
2536<div class="entry-content kl-pub-content">
2537	<div class="container">
2538		<div class="acf-fields">
2539	<div class="acf-row"><span class="publ-label">Indication:</span>  <hr/> <span class="publ-label">Evidence:</span>  Comparative study</div>
2540	<div class="publ-acf acf-row acf-flex">
2541	<span class="publ-label">Author:&nbsp;</span>
2542	<div class="szerzok">
2543		
2544		 
2545		
2546		<span class="sz-nev">Ács B</span>
2547   
2548		 
2549		
2550		<span class="sz-nev">Madaras L</span>
2551   
2552		 
2553		
2554		<span class="sz-nev">Tőkés AM</span>
2555   
2556		 
2557		
2558		<span class="sz-nev">Kovács AK</span>
2559   
2560		 
2561		
2562		<span class="sz-nev">Kovács E</span>
2563   
2564				</div>
2565	
2566	</div>
2567	<div class="acf-row"><span class="publ-label">No. of patients:</span> 42 <hr/> <span class="publ-label">Therapy:</span>  mEHT<hr/> <span class="publ-label">Year:</span>  2017</div>
2568	</div><!-- .acf-fields -->
2569	<h3>Abstract</h3>
2570<div>
2571<h4>PURPOSE:</h4>
2572<p>We aimed to compare the immunohistochemical expression of PD-1, PD-L1 and CTLA-4 of pregnancy-related breast cancer (PRBC) and early onset non-PRBC (YWBC), and their prognosis prediction potential was correlated to that of conventional clinicopathological factors.</p>
2573<h4>METHODS:</h4>
2574<p>Twenty-one PRBC cases were paired with 21 YWBC in this matched case-control study. Immune-checkpoint markers (ICM) were evaluated with immunohistochemistry (IHC) on whole slides using the following antibodies: PD-1 (NAT-105), PD-L1 (28-8) and CTLA-4 (F-8). IHC score was defined as the percentage of positive cells, assessed separately among tumor cells, intratumoral lymphocytes and peritumoral lymphocytes.</p>
2575<h4>RESULTS:</h4>
2576<p>The optimal threshold of PD-L1 expression of tumor cells occurred at 10% for overall survival (OS, AUC = 0.847, p = 0.009), and at 1% for disease-free survival (DFS, AUC = 0.795, p = 0.010). For PD-L1 expression on intratumoral lymphocytes, the optimal cut-off was 1% (AUC = 0.763, p = 0.048). Considering PD-1, PD-L1 and CTLA-4 expression, no significant difference occurred between PRBC and YWBC (p &gt;
2576 0.05 for all comparisons). PD-1, PD-L1 expressed on peritumoral lymphocytes and CTLA-4 failed, but PD-L1 expressed on tumor cells and on intratumoral lymphocytes was suitable to distinguish patient cohorts with different OS and DFS (p ≤ 0.011 for all comparisons). Higher PD-L1 expression was associated with poor prognosis. PD-L1 expressed on tumor cells represented an independent association with OS (p = 0.023) and DFS (p = 0.032).</p>
2577<h4>CONCLUSIONS:</h4>
2578<p>Our results suggest that PRBC and YWBC do not differ in the expression of PD-1, PD-L1 and CTLA-4. However, our findings emphasize the relevance of PD-L1 expression in early-onset breast cancer, as an independent negative predictor of prognosis.</p>
2579</div>
2580
2581			<div id="teljes-cikk" class="btn">
2582		<a href="https://www.ncbi.nlm.nih.gov/pubmed/28651116" target="_blank"> View abstract</a>
2583	</div>
2584	
2585	</div>	<!-- .container -->
2586</div><!-- .entry-content -->
2587
2588
2589
2590</article><!-- #post-3312 -->
2591
2592			
2593<article id="post-3313" class="post-3313 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
2594	
2595	<header class="pub-entry-header">
2596	<div class="container">
2597		<h2>Oncothermia-Booster (Targeted Radiofrequency) Treatment – in Some Non-Oncological Diseases as Special Physiotherapy</h2>
2598	</div>
2599	</header><!-- .entry-header -->
2600
2601
2602<div class="entry-content kl-pub-content">
2603	<div class="container">
2604		<div class="acf-fields">
2605	<div class="acf-row"><span class="publ-label">Indication:</span> Non-oncology <hr/> <span class="publ-label">Evidence:</span>  Review</div>
2606	<div class="publ-acf acf-row acf-flex">
2607	<span class="publ-label">Author:&nbsp;</span>
2608	<div class="szerzok">
2609		
2610		 
2611		
2612		<span class="sz-nev">Mate M</span>
2613   
2614		 
2615		
2616		<span class="sz-nev">Molnar I</span>
2617   
2618		 
2619		
2620		<span class="sz-nev">Petrovits G et al.</span>
2621   
2622				</div>
2623	
2624	</div>
2625	<div class="acf-row"><span class="publ-label">No. of patients:</span> 155 <hr/> <span class="publ-label">Therapy:</span>  mEHT+TCM<hr/> <span class="publ-label">Year:</span>  2017</div>
2626	</div><!-- .acf-fields -->
2627	<p style="font-weight: 500;"><strong style="font-weight: 800;">Abstract<br />
2628</strong>Introduction: Oncothermia (OTM) is based on electromagnetic interactions with the living organism. Its nano-targeting approach [established a newer paradigm, which could be applied not only in case of malignancies but in any other diseases, when the non-selective conditions are existing. This technique by now is well proven from the simple laboratory level to the several different clinical applications. Oncothermia method ignites the natural processes to rescue them from the system, re-establishing the better communication harmony between the cells of organism. This method will lead us to the treatment of some non-malignant diseases too to try delaying their development or offering earlier recovery. Our aim was to use OTM on the common basis of equilibrium demand; and use the recognition of the deviations from the complex harmony of the organism or its part for selection to act properly.</p>
2629<p style="font-weight: 500;"><strong style="font-weight: 800;">Study</strong><strong style="font-weight: 800;"> protocol and Method</strong>:<br />
2630Oncothermia was successfully applied for non malignant conditions like Lyme disease, for non-specific low-back pain, for Peyronie disease, and for Dupuytren’s contracture, too. We made more extended study, proving in details the applicability of the OTM in these diseases, especially in the situations when traditional Chinese Medicine (TCM) is also applicable (acupuncture, permanent needle techniques). Our special permanent acupuncture method was proven previously and well fits to the complementary applications.Results &amp; Discussion: The synergy of the ancient knowledge &#8211; application of heat energy &#8211; and the high-tech state-of-art of the medical knowledge could be established with our research. Recognition of the distortions in the healthy tissue have some common principles and possibilities in TCM and OTM: the left complexity of the living organization is recognized by both the methods.OTM application is a useful, harmless additional complementary treatment for management of selected diseases. Our topic is giving western trained physicians clinical applications of modern (Oncothermia-Booster) as a physiotherapeutic &#8211; equipment to accommodate accelerating interests in modern complex treatment of chronic low back pain and Dupuytren’s contracture.</p>
2631<p style="font-weight: 500;"><strong style="font-weight: 800;">Conclusion</strong>:<br />
2632In recent study data verified the relevant end-points of the study: the safety, the quality of life (QoL), the shortened rest time, duration of painless state, cost/benefit ratio.</p>
2633<p><strong style="font-weight: 800;">Keywords:</strong> Physiotherapy; Oncothermia; Dupuytran’s contracture; Non-specific low back pain</p>
2634<p><strong style="font-weight: 800;">Abbreviations:</strong> OTH: Oncothermy; LBP: Low Back Pain; TCM: Traditional Chinese Medicine; VAS: Visual Analog Scale; QoL: Quality of Life</p>
2635
2636			<div id="teljes-cikk" class="btn">
2637		<a href="https://juniperpublishers.com/jcmah/pdf/JCMAH.MS.ID.555572.pdf" target="_blank">
2637 View abstract</a>
2638	</div>
2639	
2640	</div>	<!-- .container -->
2641</div><!-- .entry-content -->
2642
2643
2644
2645</article><!-- #post-3313 -->
2646
2647			
2648<article id="post-3314" class="post-3314 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
2649	
2650	<header class="pub-entry-header">
2651	<div class="container">
2652		<h2>Local modulated electro-hyperthermia in combination with traditional Chinese medicine vs. intraperitoneal chemoinfusion for treatment of peritoneal carcinomatosis with malignant ascites: a phase II randomized trial</h2>
2653	</div>
2654	</header><!-- .entry-header -->
2655
2656
2657<div class="entry-content kl-pub-content">
2658	<div class="container">
2659		<div class="acf-fields">
2660	<div class="acf-row"><span class="publ-label">Indication:</span>  <hr/> <span class="publ-label">Evidence:</span>  Phase II</div>
2661	<div class="publ-acf acf-row acf-flex">
2662	<span class="publ-label">Author:&nbsp;</span>
2663	<div class="szerzok">
2664		
2665		 
2666		
2667		<span class="sz-nev">Pang CLK</span>
2668   
2669		 
2670		
2671		<span class="sz-nev">Xinting Z</span>
2672   
2673		 
2674		
2675		<span class="sz-nev">Zhen W</span>
2676   
2677		 
2678		
2679		<span class="sz-nev">Junwen O</span>
2680   
2681		 
2682		
2683		<span class="sz-nev">Yimin L</span>
2684   
2685		 
2686		
2687		<span class="sz-nev">Roussakow R</span>
2688   
2689				</div>
2690	
2691	</div>
2692	<div class="acf-row"><span class="publ-label">No. of patients:</span> 260 <hr/> <span class="publ-label">Therapy:</span>  mEHT<hr/> <span class="publ-label">Year:</span>  2017</div>
2693	</div><!-- .acf-fields -->
2694	<h3>Abstract</h3>
2695<div>
2696<p>The purpose of this study was to develop a safe and non-toxic alternative to the conventional conservative treatment of peritoneal carcinomatosis with malignant ascites (PCMA) by investigating the efficacy and safety of local modulated electro-hyperthermia (mEHT) combined with the traditional Chinese medicine (TCM) &#8216;Shi Pi&#8217; herbal decoction, compared with standard intraperitoneal chemoinfusion (IPCI). A randomized, controlled, single-center, open-label clinical trial (phase II) with two parallel groups (allocation ratio, 1:1) was conducted to investigate the efficacy and safety of mEHT+TCM (study group, SG) vs. standard IPCI (control group, CG) in patients with PCMA by intention-to-treat analysis. A total of 260 patients with PCMA were randomly allocated into the two groups (130/130); mEHT was applied for 60 min per session every second day for 4 weeks, for a total of 14 sessions. The TCM decoction was administered orally, at 400 ml daily. In CG, occlusive IPCI with cisplatin (30-60 mg) and fluorouracil (500-600 mg/m2) was applied twice, biweekly. The objective response rate (ORR), quality of life (QoL) and adverse event rate (AER) in the two groups were evaluated 1 month after treatment, analyzed and compared. The present study is registered on ClinicalTrials.gov (<a title="See in ClinicalTrials.gov" href="http://clinicaltrials.gov/show/NCT02638051" target="_blank" rel="noopener">NCT02638051</a>). No case was lost or excluded (0/260). The ORR in SG was 77.69% (101/130) vs. 63.85% (73/130) in CG (P&lt;0.05). The QoL in SG was 49.23% vs. 32.3% in CG (P&lt;0.05). The AER in SG was 2.3% (3/130) vs. 12.3% (16/130) in CG (P&lt;0.05). All the adverse events were grade I. In conclusion, the combination of mEHT with TCM achieves better control of PCMA compared with standard IPCI, with less toxicity. Both components of the combination are non-toxic treatments easily tolerated by patients. Thus, this combined treatment may be preferred due to the better benefit-harm balance.</p>
2697</div>
2698
2699			<div id="teljes-cikk" class="btn">
2700		<a href="https://www.ncbi.nlm.nih.gov/pubmed/28529748" target="_blank"> View abstract</a>
2701	</div>
2702	
2703	</div>	<!-- .container -->
2704</div><!-- .entry-content -->
2705
2706
2707
2708</article><!-- #post-3314 -->
2709
2710			
2711<article id="post-3315" class="post-3315 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
2712	
2713	<header class="pub-entry-header">
2714	<div class="container">
2715		<h2>Retrospective observational Clinical Study on Relapsed Malignant Gliomas Treated with Electro-Hyperthermia</h2>
2716	</div>
2717	</header><!-- .entry-header -->
2718
2719
2720<div class="entry-content kl-pub-content">
2721	<div class="container">
2722		<div class="acf-fields">
2723	<div class="acf-row"><span class="publ-label">Indication:</span> Gliomas <hr/> <span class="publ-label">Evidence:</span>  </div>
2724	<div class="publ-acf acf-row acf-flex">
2725	<span class="publ-label">Author:&nbsp;</span>
2726	<div class="szerzok">
2727		
2728		 
2729		
2730		<span class="sz-nev">Giammaria Fiorentini</span>
2731   
2732		 
2733		
2734		<span class="sz-nev">Donatella Sarti</span>
2735   
2736		 
2737		
2738		<span class="sz-nev">Carlo Milandr</span>
2739   
2740		 
2741		
2742		<span class="sz-nev">Patrizia Dentico</span>
2743   
2744		 
2745		
2746		<span class="sz-nev">Andrea Mambrini</span>
2747   
2748		 
2749		
2750		<span class="sz-nev">Stefano Guadagni</span>
2751   
2752				</div>
2753	
2754	</div>
2755	<div class="acf-row"><span class="publ-label">No. of patients:</span> 24 <hr/> <span class="publ-label">Therapy:</span>  mEHT<hr/> <span class="publ-label">Year:</span>  2017</div>
2756	</div><!-- .acf-fields -->
2757	<p><strong>ABSTRACT</strong></p>
2758<p>Aim: to evaluate the effi cacy and tolerability of electro-hyperthermia (ET) for the treatment of relapsed malignant glioma. Methods: this was a retrospective observational clinical study. Patients were included in the study if they had &gt;18 years, informed consent signed, histological diagnosis of malignant glioma, failure of previous temozolamide-based chemotherapy and radiotherapy, indication for treatment with ET. Hyperthermia was performed with short radiofrequency waves of 13.56 MHz using a capacitive coupling technique keeping the skin surface at 26 C°. The applied power ranged between 40-150 Watts and the calculated average equivalent temperature in the tumors was above 40 C° for more than 90% of the treatment duration (20-60 minutes gradually). Results: 24 consecutive patients were enrolled in the study, 19 (79%) had glioblastoma multiforme (GBM) 13 were of grade 1-3 and 6 of grade 4, 5 (21%) astrocitoma. Tumor response analysis two months after ET showed 2 (8%) complete remission (astrocytomas) and 5 (21%) partial remission (2 astrocitoma, and 3 glioblastomas), with a response rate of 29%. The median duration of response was 16 months (range 6-120). The median survival of whole study population was 19.5 months (range 2-156), 55% survival rate at 1 year, and 15 % at two years. We observed 3 long survivors at 156, 60, 62 months in atrocitomas. Conclusions: ET appears to have promising effi cacy in adults with relapsed malignant glioma. Keywords: Relapsed Malignant Glioma; Electro-Hyperthermia; Survival; Tumor Response</p>
2759
2760			<div id="teljes-cikk" class="btn">
2761		<a href="https://www.scireslit.com/Neurooncology/IJNBT-ID12.pdf" target="_blank">
2761 View abstract</a>
2762	</div>
2763	
2764	</div>	<!-- .container -->
2765</div><!-- .entry-content -->
2766
2767
2768
2769</article><!-- #post-3315 -->
2770
2771			
2772<article id="post-3316" class="post-3316 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
2773	
2774	<header class="pub-entry-header">
2775	<div class="container">
2776		<h2>Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a 2-centre German cohort trial with systematic comparison</h2>
2777	</div>
2778	</header><!-- .entry-header -->
2779
2780
2781<div class="entry-content kl-pub-content">
2782	<div class="container">
2783		<div class="acf-fields">
2784	<div class="acf-row"><span class="publ-label">Indication:</span> Gliomas (advanced) <hr/> <span class="publ-label">Evidence:</span>  Retrospective study</div>
2785	<div class="publ-acf acf-row acf-flex">
2786	<span class="publ-label">Author:&nbsp;</span>
2787	<div class="szerzok">
2788		
2789		 
2790		
2791		<span class="sz-nev">Roussakow S.</span>
2792   
2793				</div>
2794	
2795	</div>
2796	<div class="acf-row"><span class="publ-label">No. of patients:</span> 168 <hr/> <span class="publ-label">Therapy:</span>  CT+mEHT<hr/> <span class="publ-label">Year:</span>  2017</div>
2797	</div><!-- .acf-fields -->
2798	<p>Abstract</p>
2799<div>
2800<p>OBJECTIVE: To assess the efficacy and cost-effectiveness of modulated electrohyperthermia (mEHT) concurrent to dose-dense temozolomide (ddTMZ) 21/28 days regimen versus ddTMZ 21/28 days alone in patients with recurrent glioblastoma (GBM).</p>
2801<p>DESIGN: A cohort of 54 patients with recurrent GBM treated with ddTMZ+mEHT in 2000-2005 was systematically retrospectively compared with five pooled ddTMZ 21/28 days cohorts (114 patients) enrolled in 2008-2013.</p>
2802<p>RESULTS: The ddTMZ+mEHT cohort had a not significantly improved mean survival time (mST) versus the comparator (p=0.531) after a significantly less mean number of cycles (1.56 vs 3.98, p&lt;0.001). Effect-to-treatment analysis (ETA) suggests that mEHT significantly enhances the efficacy of the ddTMZ 21/28 days regimen (p=0.011), with significantly less toxicity (no grade III-IV toxicity vs 45%-92%, p&lt;0.0001). An estimated maximal attainable median survival time is 10.10 months (9.10-11.10). Cost-effectiveness analysis suggests that, unlike ddTMZ 21/28 days alone, ddTMZ+mEHT is cost-effective versus the applicable cost-effectiveness thresholds €US$25 000-50 000/quality-adjusted life year (QALY). Budget impact analysis suggests a significant saving of €8 577 947/$11 201 761 with 29.1-38.5 QALY gained per 1000 patients per year. Cost-benefit analysis suggests that mEHT is profitable and will generate revenues between €3 124 574 and $6 458 400, with a total economic effect (saving+revenues) of €5 700 034 to $8 237 432 per mEHT device over an 8-year period.</p>
2803<p>CONCLUSIONS: Our ETA suggests that mEHT significantly improves survival of patients receiving the ddTMZ 21/28 days regimen. Economic evaluation suggests that ddTMZ+mEHT is cost-effective, budget-saving and profitable. After confirmation of the results, mEHT could be recommended for the treatment of recurrent GBM as a cost-effective enhancer of ddTMZ regimens, and, probably, of the regular 5/28 days regimen. mEHT is applicable also as a single treatment if chemotherapy is impossible, and as a salvage treatment after the failure of chemotherapy.</p>
2804</div>
2805
2806			<div id="teljes-cikk" class="btn">
2807		<a href="https://www.ncbi.nlm.nih.gov/m/pubmed/29102988/" target="_blank"> View abstract</a>
2808	</div>
2809	
2810	</div>	<!-- .container -->
2811</div><!-- .entry-content -->
2812
2813
2814
2815</article><!-- #post-3316 -->
2816
2817			
2818<article id="post-3317" class="post-3317 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
2819	
2820	<header class="pub-entry-header">
2821	<div class="container">
2822		<h2>Rescue Therapy in Patient with Glioblastoma Multiforme Combining Chemotherapy, Hyperthermia, Phytotherapy</h2>
2823	</div>
2824	</header><!-- .entry-header -->
2825
2826
2827<div class="entry-content kl-pub-content">
2828	<div class="container">
2829		<div class="acf-fields">
2830	<div class="acf-row"><span class="publ-label">Indication:</span> Glioblastoma <hr/> <span class="publ-label">Evidence:</span>  Case report</div>
2831	<div class="publ-acf acf-row acf-flex">
2832	<span class="publ-label">Author:&nbsp;</span>
2833	<div class="szerzok">
2834		
2835		 
2836		
2837		<span class="sz-nev">Carlo Pastore</span>
2838   
2839		 
2840		
2841		<span class="sz-nev">Massimo Fioranelli</span>
2842   
2843		 
2844		
2845		<span class="sz-nev">Maria Grazia Roccia</span>
2846   
2847				</div>
2848	
2849	</div>
2850	<div class="acf-row"><span class="publ-label">No. of patients:</span>  <hr/> <span class="publ-label">Therapy:</span>  Chemotherapy, Hyperthermia, Phytotherapy<hr/> <span class="publ-label">Year:</span>  2017</div>
2851	</div><!-- .acf-fields -->
2852	<p><strong>Abstract</strong><br />
2853Glioblastoma multiforme is a pathology that is poorly treatable and tends towards recurrence. If surg
2853ically unresectable, at least without macroscopically visible residue, the prognosis is severe. Here is the case of a 60-yearold woman suffering from recurrent glioblastoma who comes to my observation with no therapeutic options and treated with a combination of antiangiogenic drug, RF capacitive hyperthermia and herbal medicine, earns an acceptable quality of life and survival prolongation of six months.</p>
2854
2855			<div id="teljes-cikk" class="btn">
2856		<a href="https://www.hilarispublisher.com/open-access/rescue-therapy-in-patient-with-glioblastoma-multiforme-combining-chemotherapy-hyperthermia-phytotherapy-2329-6771-1000199.pdf" target="_blank"> View abstract</a>
2857	</div>
2858	
2859	</div>	<!-- .container -->
2860</div><!-- .entry-content -->
2861
2862
2863
2864</article><!-- #post-3317 -->
2865
2866			
2867<article id="post-3318" class="post-3318 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
2868	
2869	<header class="pub-entry-header">
2870	<div class="container">
2871		<h2>Newer application of oncothermia to non-malignant diseases such as Dupuytren’s contracture of the hand and chronic lower back pain lasting more than 4 weeks</h2>
2872	</div>
2873	</header><!-- .entry-header -->
2874
2875
2876<div class="entry-content kl-pub-content">
2877	<div class="container">
2878		<div class="acf-fields">
2879	<div class="acf-row"><span class="publ-label">Indication:</span> Non-oncology <hr/> <span class="publ-label">Evidence:</span>  </div>
2880	<div class="publ-acf acf-row acf-flex">
2881	<span class="publ-label">Author:&nbsp;</span>
2882	<div class="szerzok">
2883		
2884		 
2885		
2886		<span class="sz-nev">Mate A</span>
2887   
2888		 
2889		
2890		<span class="sz-nev">Molnar I</span>
2891   
2892		 
2893		
2894		<span class="sz-nev">Szoke H</span>
2895   
2896		 
2897		
2898		<span class="sz-nev">Hegyi G.</span>
2899   
2900				</div>
2901	
2902	</div>
2903	<div class="acf-row"><span class="publ-label">No. of patients:</span> 231 <hr/> <span class="publ-label">Therapy:</span>  mEHT<hr/> <span class="publ-label">Year:</span>  2017</div>
2904	</div><!-- .acf-fields -->
2905	<h4><strong>ABSTRACT</strong></h4>
2906<p class="text-align-justify">Oncothermia (OTM) is based on electromagnetic interactions with the living matter. Its nano-targeting approach establishes a new paradigm. OTM could be applied not only to treat malignancies but it is feasible to apply for other diseases too. OTH is well proven method from the laboratory level to the clinical applications, promoting the natural processes, re-establishing of the synchronization between the cells. This approach allows therapy of some non-malignant diseases too. Our objective is to use OTM for the irregularities of tissue-growth and for pain syndromes as well. OTM uses precisely tuned radiofrequency (RF) current flowing through the treated part of the body. We made extensive study, proving in details the applicability of the OTM for Dupuytren&#8217;s contracture and chronic low back pain, in conjunction with permanent acupuncture method, a modified process of traditional Chinese Medicine (TCM). The synergy of the ancient and the state-of-art medical knowledges is the basic method of the present research. Our results with application of OTM for chronic low back pain and Dupuytren&#8217;s contracture shows definite improvements of the patients involved in the study. We measured the success with the Visual Analog Scale (VAS), with anecdotic quality of life (QoL), and the shortening of the of-work period due to the disease. We measured that VAS decreased significantly, the hand contracture became less rigid and less contracted. The QoL of patients improved and their complaints which blocked their regular activity has significantly reduced. OTM method was safe &amp; no adverse effects were observed. Recognition of the distortions in the healthy tissue have some common principles and possibilities in TCM and OTM: both the methods recognize the loss of complexity of the living organization. Data of our recent study verified the relevant end-points of our present study: the safety, the quality of life (QoL), the prolonged painless status of the patient.</p>
2907
2908			<div id="teljes-cikk" class="btn">
2909		<a href="http://www.ingentaconnect.com/content/cog/aetr/2017/00000042/00000002/art00004;jsessionid=1cht8pxx2j3bo.x-ic-live-02" target="_blank"> View abstract</a>
2910	</div>
2911	
2912	</div>	<!-- .container -->
2913</div><!-- .entry-content -->
2914
2915
2916
2917</article><!-- #post-3318 -->
2918
2919			
2920<article id="post-3319" class="post-3319 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
2921	
2922	<header class="pub-entry-header">
2923	<div class="container">
2924		<h2>Bevacizumab-Based Chemotherapy Combined with Regional Deep Capacitive Hyperthermia in Metastatic Cancer Patients: A Pilot Study</h2>
2925	</div>
2926	</header><!-- .entry-header -->
2927
2928
2929<div class="entry-content kl-pub-content">
2930	<div class="container">
2931		<div class="acf-fields">
2932	<div class="acf-row"><span class="publ-label">Indication:</span> Multiple <hr/> <span class="publ-label">Evidence:</span>  </div>
2933	<div class="publ-acf acf-row acf-flex">
2934	<span class="publ-label">Author:&nbsp;</span>
2935	<div class="szerzok">
2936		
2937		 
2938		
2939		<span class="sz-nev">Ranieri G</span>
2940   
2941		 
2942		
2943		<span class="sz-nev">Ferrari C</span>
2944   
2945		 
2946		
2947		<span class="sz-nev">Di Palo A</span>
2948   
2949				</div>
2950	
2951	</div>
2952	<div class="acf-row"><span class="publ-label">No. of patients:</span> 23 <hr/> <span class="publ-label">Therapy:</span>  CT+mEHT<hr/> <span class="publ-label">Year:</span>  2017</div>
2953	</div><!-- .acf-fields -->
2954	<h3>Abstract</h3>
2955<div>
2956<p>As an angiogenesis inhibitor, bevacizumab has been investigated in combination with different chemotherapeutic agents, achieving an established role for metastatic <span class="highlight">cancer</span> treatment. However, potential synergic anti-angiogenic effects of hyperthermia have not tested to date in literature. The aim of our study was to analyze efficacy, safety, and survival of anti-angiogenic-based chemotherapy associated to regional deep capacitive hyperthermia (HT) in metastatic <span class="highlight">cancer</span> patients. Twenty-three patients with metastatic colorectal (<i>n</i> = 16), ovarian (<i>n</i> = 5), and breast (<i>n</i> = 2) <span class="highlight">cancer</span> were treated with HT in addition to a standard bevacizumab-based chemotherapy regimen. Treatment response assessment was performed, according to the modified Response Evaluation Criteria for Solid Tumors (mRECIST), at 80 days (timepoint-1) and at 160 days (timepoint-2) after therapy. Disease Response Rate (DRR), considered as the proportion of patients who had the best response rating (complete response (CR), partial response (PR), or stable disease (SD)), was assessed at timepoint-1 and timepoint-2. Chi-squared for linear trend test was performed to evaluated the association between response groups (R/NR) and the number of previous treatment (none, 1, 2, 3), number of chemotherapy cycles (&lt;6, 6, 12, &gt;12), number of hyperthermia sessions (&lt;12, 12, 24, &gt;24), and lines of chemotherapy (I, II). Survival curves were estimated by Kaplan-Meier method. DRR was 85.7% and 72.2% at timepoint-1 and timepoint-2, respectively. HT was well tolerated without additional adverse effects on chemotherapy-related toxicity. Chi-squared for linear trend test demonstrated that the percentage of responders grew in relation to the number of chemotherapy cycles (<i>p</i> = 0.015) and to number of HT sessions (<i>p</i> &lt; 0.001) performed. Both overall survival (OS) and time to progression (TTP) were influenced by the number of chemotherapy cycles (<i>p</i> &lt; 0.001) and HT sessions (<i>p</i> &lt; 0.001) performed. Our preliminary data, that need to be confirmed in larger studies, suggest that the combined treatment of bevacizumab-based chemotherapy with HT has a favorable tumor response, is feasible and well tolerated, and offers a potentially promising option for metastatic <span class="highlight">cancer</span> patients.</p>
2957</div>
2958
2959			<div id="teljes-cikk" class="btn">
2960		<a href="https://www.ncbi.nlm.nih.gov/pubmed/28684680" target="_blank"> View abstract</a>
2961	</div>
2962	
2963	</div>	<!-- .container -->
2964</div><!-- .entry-content -->
2965
2966
2967
2968</article><!-- #post-3319 -->
2969
2970			
2971<article id="post-3320" class="post-3320 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
2972	
2973	<header class="pub-entry-header">
2974	<div class="container">
2975		<h2>The safety and pharmacokinetics of high dose intravenous ascorbic acid synergy with modulated electrohyperthermia in Chinese patients with stage III-IV non-small cell lung cancer</h2>
2976	</div>
2977	</header><!-- .entry-header -->
2978
2979
2980<div class="entry-content kl-pub-content">
2981	<div class="container">
2982		<div class="acf-fields">
2983	<div class="acf-row"><span class="publ-label">Indication:</span> Lung <hr/> <span class="publ-label">Evidence:</span>  Phase I</div>
2984	<div class="publ-acf acf-row acf-flex">
2985	<span class="publ-label">Author:&nbsp;</span>
2986	<div class="szerzok">
2987		
2988		 
2989		
2990		<span class="sz-nev">Ou J</span>
2991   
2992		 
2993		
2994		<span class="sz-nev">Zhu X</span>
2995   
2996		 
2997		
2998		<span class="sz-nev">Lu Y</span>
2999   
3000		 
3001		
3002		<span class="sz-nev">Zhao C</span>
3003   
3004		 
3005		
3006		<span class="sz-nev">Zhang H</span>
3007   
3008		 
3009		
3010		<span class="sz-nev">Wang X</span>
3011   
3012		 
3013		
3014		<span class="sz-nev">Gui X</span>
3015   
3016		 
3017		
3018		<span class="sz-nev">Wang J</span>
3019   
3020		 
3021		
3022		<span class="sz-nev">Zhang X</span>
3023   
3024		 
3025		
3026		<span class="sz-nev">Zhang T</span>
3027   
3028		 
3029		
3030		<span class="sz-nev">Pang C</span>
3031   
3032				</div>
3033	
3034	</div>
3035	<div class="acf-row"><span class="publ-label">No. of patients:</span> 35 <hr/> <span class="publ-label">Therapy:</span>  mEHT<hr/> <span class="publ-label">Year:</span>  2017</div>
3036	</div><!-- .acf-fields -->
3037	<h2 class="section-title">Abstract</h2>
3038<div id="as0005">
3039<p id="sp0055">Ascorbic acid (AA) infusion and modulated electrohyperthermia (mEHT) are widely used by integrative cancer practitioners for many years. However, there are no safety and <a title="Learn more about Pharmacokinetics" href="http://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/pharmacokinetics" target="_blank" rel="noopener">pharmacokinetics</a> data in Chinese cancer patients. We carried out a clinical trial to evaluate the safety and pharmacokinetics of those methods in patients with stage III-IV non-small cell lung cancer (NSCLC). Blood ascorbic acid in the fasting state was obtained from 35 NSCLC patients; selecting from them 15 patients with stage III-IV entered the phase I study. They were randomized allocated into 3 groups, and received doses 1.0, 1.2, 1.5 g/kg AA infusions. Participants in the first group received <a title="Learn more about Intravenous therapy" href="http://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/intravenous-therapy" target="_blank" rel="noopener">intravenous</a> AA (IVAA) when mEHT was finished, in the second group IVAA was administered simultaneously with mEHT and in the third group IVAA was applied first, and followed with mEHT. Pharmacokinetic profiles were obtained when they received solely IVAA and when IVAA in combination with mEHT. The process was applied 3 times a week (every other day, weekend days off) for 4 weeks. We found that fasting plasma AA levels were significantly correlated with stage of the disease. Peak concentration of AA was significantly higher in the simultaneous treatments than in other combinations with mEHT or in solely IVAA-managed groups. IVAA synergy with simultaneous mEHT is safe and the concomitant application significantly increases the plasma AA level for NSCLC patients.</p>
3040<h2 class="section-title">Graphical abstract</h2>
3041<div id="as0010">
3042<p id="sp0060">Pharmacokinetic plots of each treatment in the six groups by increasing dosage. Junwen Ou, Xinyu Zhu, et al.</p>
3043<p><img fetchpriority="high" decoding="async" class="alignnone size-full wp-image-3144" src="https://oncotherm.com/wp-content/uploads/2023/12/1-s20-S0928098717304554-fx1.jpg" alt="" width="429" height="200" srcset="https://oncotherm.com/wp-content/uploads/2023/12/1-s20-S0928098717304554-fx1.jpg 429w, https://oncotherm.com/wp-content/uploads/2023/12/1-s20-S0928098717304554-fx1-300x140.jpg 300w" sizes="(max-width: 429px) 100vw, 429px" /></p>
3044</div>
3045</div>
3046
3047			<div id="teljes-cikk" class="btn">
3048		<a href="http://www.sciencedirect.com/science/article/pii/S0928098717304554?via%3Dihub=" target="_blank">
3048 View abstract</a>
3049	</div>
3050	
3051	</div>	<!-- .container -->
3052</div><!-- .entry-content -->
3053
3054
3055
3056</article><!-- #post-3320 -->
3057
3058			
3059<article id="post-3321" class="post-3321 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
3060	
3061	<header class="pub-entry-header">
3062	<div class="container">
3063		<h2>Efficacy of metabolically supported chemotherapy combined with ketogenic diet, hyperthermia, and hyperbaric oxygen therapy for stage IV triple-negative breast cancer</h2>
3064	</div>
3065	</header><!-- .entry-header -->
3066
3067
3068<div class="entry-content kl-pub-content">
3069	<div class="container">
3070		<div class="acf-fields">
3071	<div class="acf-row"><span class="publ-label">Indication:</span> Gynecology <hr/> <span class="publ-label">Evidence:</span>  Case report</div>
3072	<div class="publ-acf acf-row acf-flex">
3073	<span class="publ-label">Author:&nbsp;</span>
3074	<div class="szerzok">
3075		
3076		 
3077		
3078		<span class="sz-nev">Iyikesici MS</span>
3079   
3080		 
3081		
3082		<span class="sz-nev">Slocum AK</span>
3083   
3084		 
3085		
3086		<span class="sz-nev">Slocum A</span>
3087   
3088				</div>
3089	
3090	</div>
3091	<div class="acf-row"><span class="publ-label">No. of patients:</span> 1 <hr/> <span class="publ-label">Therapy:</span>  CT+mEHT<hr/> <span class="publ-label">Year:</span>  2017</div>
3092	</div><!-- .acf-fields -->
3093	<h2 id="idm140553567017536title" class="head no_bottom_margin ui-helper-clearfix">Abstract</h2>
3094<div>
3095<p id="__p1" class="p p-first-last">Triple-negative breast cancer (TNBC) is more aggressive and metastatic than other breast cancer types. Cytotoxic chemotherapy is presently the predominant systemic therapy for TNBC patients. This case report highlights the influence of metabolically supported chemotherapy (MSCT), ketogenic diet (KD), hyperthermia (HT), and hyperbaric oxygen therapy (HBOT) in an overweight 29-year-old woman with stage IV (T4N3M1) triple-negative invasive ductal carcinoma of the breast. The patient presented with an observable mass in her left breast detected during a physical examination in December 2015. Magnetic resonance imaging revealed a Breast Imaging Reporting and Data System Category 5 tumor and multiple lymphadenomegaly in the left axilla. A Tru-Cut biopsy led to the diagnosis of a triple-negative nuclear grade 2 invasive ductal carcinoma. The patient was admitted to ChemoThermia Oncology Center, Istanbul, Turkey in October 2016, and a whole body (18F)-fluorodeoxyglucose (FDG)-positron emission tomography-computed tomography (PET-CT) scan revealed a 77 mm x 55 mm primary tumor in her left breast, multiple left pectoral and axillary lymph nodes, multiple widespread liver masses, and an upper left nodular abdominal lesion. The patient received a treatment protocol consisting of MSCT, KD, HT, and HBOT. A follow-up whole body 18F-FDG PET-CT scan in February 2017 showed a complete therapeutic response with no evidence of abnormal FDG uptake. The patient continued to receive this treatment protocol and in April 2017 underwent a mastectomy, which revealed a complete pathological response consistent with the response indicated by her PET-CT imaging. This single case study presents evidence of a complete clinical, radiological, and pathological response following a six-month treatment period using a combination of MSCT and a novel metabolic therapy in a patient with stage IV TNBC.</p>
3096</div>
3097<div class="sec"><strong class="kwd-title">Keywords: </strong><span class="kwd-text">metabolically supported chemotherapy, ketogenic diet, hyperthermia, hyperbaric oxygen therapy, pathological complete response, triple negative breast cancer</span></div>
3098
3099			<div id="teljes-cikk" class="btn">
3100		<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589510/" target="_blank"> View abstract</a>
3101	</div>
3102	
3103	</div>	<!-- .container -->
3104</div><!-- .entry-content -->
3105
3106
3107
3108</article><!-- #post-3321 -->
3109
3110			
3111<article id="post-3322" class="post-3322 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
3112	
3113	<header class="pub-entry-header">
3114	<div class="container">
3115		<h2>A new strategy of cancer immunotherapy combining hyperthermia/oncolytic virus pretreatment with specific autologous anti-tumor vaccination &#8211; a review</h2>
3116	</div>
3117	</header><!-- .entry-header -->
3118
3119
3120<div class="entry-content kl-pub-content">
3121	<div class="container">
3122		<div class="acf-fields">
3123	<div class="acf-row"><span class="publ-label">Indication:</span> Immuno-oncology <hr/> <span class="publ-label">Evidence:</span>  Review</div>
3124	<div class="publ-acf acf-row acf-flex">
3125	<span class="publ-label">Author:&nbsp;</span>
3126	<div class="szerzok">
3127		
3128		 
3129		
3130		<span class="sz-nev">Schirrmacher V</span>
3131   
3132		 
3133		
3134		<span class="sz-nev">Lorenzen D</span>
3135   
3136		 
3137		
3138		<span class="sz-nev">Van Gool SW</span>
3139   
3140		 
3141		
3142		<span class="sz-nev">Stuecker W</span>
3143   
3144				</div>
3145	
3146	</div>
3147	<div class="acf-row"><span class="publ-label">No. of patients:</span> 206 <hr/> <span class="publ-label">Therapy:</span>  IMT+mEHT<hr/> <span class="publ-label">Year:</span>  2017</div>
3148	</div><!-- .acf-fields -->
3149	<h2>Abstract</h2>
3150<p>This review describes and explains a specific immunotherapy strategy that has been developed at the Immunological and Oncological Center Cologne in Germany. The strategy is based on many years of basic and translational research. It is a highly individualized approach to activate and target the patient’s immune system against the patient’s own tumor. In a first step, the patient’s immune system is conditioned by pretreatment with oncolytic virus in combination with hyperthermia. The second step consists of active-specific autologous anti-tumor vaccination. The vaccine, VOL-DC, consists of autologous Dendritic Cells (DCs) which are loaded with Viral Oncolysate (VOL) from the patient’s tumor cells. VOL transfers to the DCs information about tumor-associated antigens from the patient’s tumor and Pathogen-Associated Molecular Patterns (PAMPs, danger signals) from the virus. The product VOL-DC, which involves Newcastle Disease Virus, has been approved in Germany as an Advanced Therapeutic Medicinal Product for individual treatment by the institution which received this permit. This review includes promising results from case-series studies of glioblastoma patients. It also discusses future strategies for treatment of late-stage disease including combination of this immunotherapy with immune checkpoint blocking antibodies and/or with costimulatory bispecific antibodies.</p>
3151
3152			<div id="teljes-cikk" class="btn">
3153		<a href="http://www.iozk.de/aktuelles/iozk_austin_oncology_case_reports_2017.pdf" target="_blank">
3153 View abstract</a>
3154	</div>
3155	
3156	</div>	<!-- .container -->
3157</div><!-- .entry-content -->
3158
3159
3160
3161</article><!-- #post-3322 -->
3162
3163			
3164<article id="post-3323" class="post-3323 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
3165	
3166	<header class="pub-entry-header">
3167	<div class="container">
3168		<h2>Role of HIF-1α in response of tumors to a combination of hyperthermia and radiation in vivo</h2>
3169	</div>
3170	</header><!-- .entry-header -->
3171
3172
3173<div class="entry-content kl-pub-content">
3174	<div class="container">
3175		<div class="acf-fields">
3176	<div class="acf-row"><span class="publ-label">Indication:</span> Immuno-oncology <hr/> <span class="publ-label">Evidence:</span>  Review</div>
3177	<div class="publ-acf acf-row acf-flex">
3178	<span class="publ-label">Author:&nbsp;</span>
3179	<div class="szerzok">
3180		
3181		 
3182		
3183		<span class="sz-nev">Kim W</span>
3184   
3185		 
3186		
3187		<span class="sz-nev">Kim MS</span>
3188   
3189		 
3190		
3191		<span class="sz-nev">Kim HJ</span>
3192   
3193		 
3194		
3195		<span class="sz-nev">Lee E</span>
3196   
3197		 
3198		
3199		<span class="sz-nev">Jeong JH</span>
3200   
3201		 
3202		
3203		<span class="sz-nev">Park I</span>
3204   
3205		 
3206		
3207		<span class="sz-nev">Jeong YK</span>
3208   
3209		 
3210		
3211		<span class="sz-nev">Jang WI</span>
3212   
3213				</div>
3214	
3215	</div>
3216	<div class="acf-row"><span class="publ-label">No. of patients:</span>  <hr/> <span class="publ-label">Therapy:</span>  RT+mEHT<hr/> <span class="publ-label">Year:</span>  2017</div>
3217	</div><!-- .acf-fields -->
3218	<h3>Abstract</h3>
3219<div>
3220<h4>PURPOSE:</h4>
3221<p>Mild temperature hyperthermia (MTH) increases blood flow and oxygenation in tumours. On the other hand, high-dose-per-fraction irradiation damages blood vessels, decreases blood flow and increases hypoxia in tumours. The radiation-induced hypoxia in tumours activates hypoxia-inducible factor-1α (HIF-1α) and its target genes, such as vascular endothelial growth factor (VEGF), promoting revascularization and recurrence. In the present study, we examined the hypothesis that MTH inhibits radiation-induced upregulation of HIF-1α and its target genes by increasing tumour oxygenation.</p>
3222<h4>MATERIALS AND METHODS:</h4>
3223<p>FSaII fibrosarcoma tumours grown subcutaneously in the legs of C3H mice were used. Tumours were irradiated with 15 Gy using a 60Co irradiator or heated at 41 °C for 30 min using an Oncothermia heating unit. Blood perfusion and hypoxia in tumours were assessed with Hoechst 33342 and pimonidazole staining, respectively. Expression levels of HIF-1α and VEGF were determined using immunohistochemical techniques. Apoptosis of tumour cells was quantitated via TUNEL staining and the effects of treatments on tumour growth rate were assessed by measuring tumour diameters.</p>
3224<h4>RESULTS:</h4>
3225<p>Irradiation of FSaII tumours with a single dose of 15 Gy led to significantly decreased blood perfusion, increased hypoxia and upregulation of HIF-1α and VEGF. On the other hand, MTH at 41 °C for 30 min increased blood perfusion and tumour oxygenation, thereby suppressing radiation-induced HIF-1α and VEGF in tumours, leading to enhanced apoptosis of tumour cells and tumour growth delay.</p>
3226<h4>CONCLUSION:</h4>
3227<p>MTH enhances the anti-tumour effect of high-dose irradiation, at least partly by inhibiting radiation-induced upregulation of HIF-1α.</p>
3228</div>
3229
3230			<div id="teljes-cikk" class="btn">
3231		<a href="http://www.ncbi.nlm.nih.gov/pubmed/28659004" target="_blank"> View abstract</a>
3232	</div>
3233	
3234	</div>	<!-- .container -->
3235</div><!-- .entry-content -->
3236
3237
3238
3239</article><!-- #post-3323 -->
3240
3241			
3242<article id="post-3324" class="post-3324 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
3243	
3244	<header class="pub-entry-header">
3245	<div class="container">
3246		<h2>Treatment outcome analysis of chemotherapy combined with modulated electro-hyperthermia compared with chemotherapy alone for recurrent cervical cancer, following irradiation</h2>
3247	</div>
3248	</header><!-- .entry-header -->
3249
3250
3251<div class="entry-content kl-pub-content">
3252	<div class="container">
3253		<div class="acf-fields">
3254	<div class="acf-row"><span class="publ-label">Indication:</span> Gynecology <hr/> <span class="publ-label">Evidence:</span>  </div>
3255	<div class="publ-acf acf-row acf-flex">
3256	<span class="publ-label">Author:&nbsp;</span>
3257	<div class="szerzok">
3258		
3259		 
3260		
3261		<span class="sz-nev">Sun Young Lee</span>
3262   
3263		 
3264		
3265		<span class="sz-nev">Na Ri Lee</span>
3266   
3267		 
3268		
3269		<span class="sz-nev">Dong Hyu Cho</span>
3270   
3271				</div>
3272	
3273	</div>
3274	<div class="acf-row"><span class="publ-label">No. of patients:</span> 20 <hr/> <span class="publ-label">Therapy:</span>  CT+mEHT<hr/> <span class="publ-label">Year:</span>  2017</div>
3275	</div><!-- .acf-fields -->
3276	<p>The survival of patients with recurrent cervical cancer following irradiation remains poor. Chemotherapy combined with hyperthermia has been demonstrated to improve the response rate. The present study was performed to evaluate the effect of modulated electro‑hyperthermia combined with conventional chemotherapy compared with chemotherapy alone on recurrent cervical cancer previously treated with irradiation. A total of 20 patients were treated with chemotherapy alone, and 18 were treated with chemotherapy combined with modulated electro‑hyperthermia. A single patient was treated with chemo‑radiotherapy as primary treatment and then relapsed; the tumor was inoperable and radio‑refractory upon recurrence. Local metastases, including metastasis of the para‑aortic lymph nodes and adjacent pelvic lymph nodes were included, but distant metastases were excluded. Modulated electro‑hyperthermia was performed three times per week beginning at chemotherapy initiation, and patients underwent a total of 36 sessions. The overall response 
3276(complete remission + partial remission + stable disease/progressive disease) to treatment was significantly greater in the group of patients who underwent chemotherapy combined with modulated electro‑hyperthermia (P=0.0461), and at the evaluation conducted at the last follow‑up visit, the response rate was significantly higher (P=0.0218). Additionally, severe complications were not reported. In the present study, of patients with recurrent cervical cancer previously treated with irradiation, the overall response rate for patients treated with chemotherapy combined with modulated electro-hyperthermia was significantly greater than that for those treated with chemotherapy alone.</p>
3277
3278			<div id="teljes-cikk" class="btn">
3279		<a href="https://doi.org/10.3892/ol.2017.6117" target="_blank"> View abstract</a>
3280	</div>
3281	
3282	</div>	<!-- .container -->
3283</div><!-- .entry-content -->
3284
3285
3286
3287</article><!-- #post-3324 -->
3288
3289			
3290<article id="post-3325" class="post-3325 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
3291	
3292	<header class="pub-entry-header">
3293	<div class="container">
3294		<h2>Update on phase III randomized clinical trial investigating the effects of the addition of electro-hyperthermia to chemora-diotherapy for cervical cancer patients in South Africa</h2>
3295	</div>
3296	</header><!-- .entry-header -->
3297
3298
3299<div class="entry-content kl-pub-content">
3300	<div class="container">
3301		<div class="acf-fields">
3302	<div class="acf-row"><span class="publ-label">Indication:</span> Gynecology <hr/> <span class="publ-label">Evidence:</span>  Phase III</div>
3303	<div class="publ-acf acf-row acf-flex">
3304	<span class="publ-label">Author:&nbsp;</span>
3305	<div class="szerzok">
3306		
3307		 
3308		
3309		<span class="sz-nev">C Minnaar</span>
3310   
3311		 
3312		
3313		<span class="sz-nev">A Baeyens</span>
3314   
3315		 
3316		
3317		<span class="sz-nev">J Kotzen</span>
3318   
3319				</div>
3320	
3321	</div>
3322	<div class="acf-row"><span class="publ-label">No. of patients:</span> 100 <hr/> <span class="publ-label">Therapy:</span>  CT+mEHT<hr/> <span class="publ-label">Year:</span>  2016</div>
3323	</div><!-- .acf-fields -->
3324	<div class="c-rich-text">
3325<h3>Introduction</h3>
3326<div id="artTabContent">
3327<div>
3328<div>
3329<section>
3330<div>
3331<p>The Electro-Hyperthermia trial an ongoing phase III randomised clinical trial being conducted at the Charlotte Maxeke Johannesburg Academic Hospital. The general aim is to determine the clinical effects of the addition of modulated electro-hyperthermia (EHT) to the standard treatment protocols for locally advanced cervical cancer patients in state healthcare in South Africa. The objectives are to assess the effects of the addition of EHT on local disease control, quality of life, acute and late toxicity and overall survival.</p>
3332</div>
3333</section>
3334</div>
3335<div>
3336<section>
3337<h3>Materials and methods</h3>
3338<div>
3339<p>The study aims to enrol 236 female participants with FIGO stage IIB distal to IIIB cervical cancer. Participants are being randomised into a “Hyperthermia” group (EHT plus chemoradiation) and a “Control” group (chemoradiation alone), randomisation stratums: HIV status; age; stage of disease. All participants are receiving 50 Gy external beam radiation, 3 doses of high dose rate brachytherapy (8 Gy) and cisplatin. The Hyperthermia group is receiving two 55 minute local EHT treatments per week during radiation therapy. Local disease control is being assessed by Positron Emission Tomography (PET) scans. Adverse events, quality of life and overall survival are being recorded and the data is being analysed.</p>
3340</div>
3341</section>
3342</div>
3343<div>
3344<section>
3345<h3>Results</h3>
3346<div>
3347<p>We report preliminary data of the first 100 participants to reach 6 months post treatment. We see a positive trend in survival and local disease control in the group receiving hyperthermia. There are no significant differences in acute adverse events or quality of life between the groups.</p>
3348</div>
3349</section>
3350</div>
3351<div>
3352<section>
3353<h3>Conclusion</h3>
3354<div>
3355<p>The preliminary results on the addition of EHT are positive with no impact on adverse events, however this must be confirmed with more patients on completion of the study.</p>
3356</div>
3357</section>
3358</div>
3359</div>
3360</div>
3361</div>
3362
3363			<div id="teljes-cikk" class="btn">
3364		<a href="http://www.physicamedica.com/article/S1120-1797(16)30175-2/abstract" target="_blank">
3364 View abstract</a>
3365	</div>
3366	
3367	</div>	<!-- .container -->
3368</div><!-- .entry-content -->
3369
3370
3371
3372</article><!-- #post-3325 -->
3373
3374			
3375<article id="post-3326" class="post-3326 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
3376	
3377	<header class="pub-entry-header">
3378	<div class="container">
3379		<h2>Stage IV Wilms tumor treated by Korean medicine, hyperthermia and thymosin-α1: A case report</h2>
3380	</div>
3381	</header><!-- .entry-header -->
3382
3383
3384<div class="entry-content kl-pub-content">
3385	<div class="container">
3386		<div class="acf-fields">
3387	<div class="acf-row"><span class="publ-label">Indication:</span> Immuno-oncology <hr/> <span class="publ-label">Evidence:</span>  Case report</div>
3388	<div class="publ-acf acf-row acf-flex">
3389	<span class="publ-label">Author:&nbsp;</span>
3390	<div class="szerzok">
3391		
3392		 
3393		
3394		<span class="sz-nev">Donghyun Lee</span>
3395   
3396		 
3397		
3398		<span class="sz-nev">Sung Su Kim</span>
3399   
3400		 
3401		
3402		<span class="sz-nev">Shin Seong</span>
3403   
3404		 
3405		
3406		<span class="sz-nev">Wonjun Cho</span>
3407   
3408		 
3409		
3410		<span class="sz-nev">Hyejin Yu</span>
3411   
3412				</div>
3413	
3414	</div>
3415	<div class="acf-row"><span class="publ-label">No. of patients:</span> 1 <hr/> <span class="publ-label">Therapy:</span>  CT+mEHT<hr/> <span class="publ-label">Year:</span>  2016</div>
3416	</div><!-- .acf-fields -->
3417	<h2 id="__abstractidm139631501530000title">Abstract</h2>
3418<div>
3419<div id="__sec1">
3420<h3>Introduction</h3>
3421<p id="__p1">Wilms tumor is one of general solid cancers that occur in children, which carries a death rate of 7–8 in a million. The cure rate of Wilms tumor in the recent 30 years has dramatically been improved, but a proper remedy is still not prepared enough in terms of application in tumor therapy upon recurrence after radiotherapy, surgery and chemotherapy. We present an integrative medical remedy – hyperthermia and thymosin-α1 treatment focused on herbal remedy – since there have been cases in which this remedy contributed to remission in the liver-transferred part in the 4th phase of Wilms tumor and stable maintenance of metastatic lung lesion.</p>
3422</div>
3423<div id="__sec2">
3424<h3>Case Presentation</h3>
3425<p id="__p2">Our patient, a female Korean mongoloid outpatient, was treated from October 25, 2014, to July 22, 2015. The herbal remedy consisted of 8 ml inhalation of Soram nebulizer solution q.d., Soramdan S 8 g p.o., Hangamdan S 1 g p.o., t.i.d., Cheongjangtang 10–30 ml, and Spiam HC 8 g p.o. The integrative medical therapy was done with hyperthermia therapy (oncothermia) and 1.6 mg of thymosin-α1 treatment (Zadaxin) i.m. According to the CT result on July 15th, 2015, the liver metastasis was not seen anymore, while the lung metastasis was maintained stably without tumor progress.</p>
3426</div>
3427<div id="__sec3">
3428<h3>Conclusions</h3>
3429<p id="__p3">Accompanying integrative medical therapy with herbal remedy in the treatment of Wilms tumor showing progress patterns after surgery and chemotherapy can be meaningful as a new remedy.</p>
3430</div>
3431</div>
3432<div>Key Words: Wilms tumor, Korean medicine therapy, Hangamdan S, Soramdan S, Spiam HC, Hyperthermia, Thymosin-α1</div>
3433
3434			<div id="teljes-cikk" class="btn">
3435		<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4899649/" target="_blank"> View abstract</a>
3436	</div>
3437	
3438	</div>	<!-- .container -->
3439</div><!-- .entry-content -->
3440
3441
3442
3443</article><!-- #post-3326 -->
3444
3445			
3446<article id="post-3327" class="post-3327 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
3447	
3448	<header class="pub-entry-header">
3449	<div class="container">
3450		<h2>Positive response of a primary leiomyosarcoma of the breast following salvage hyperthermia and pazopanib</h2>
3451	</div>
3452	</header><!-- .entry-header -->
3453
3454
3455<div class="entry-content kl-pub-content">
3456	<div class="container">
3457		<div class="acf-fields">
3458	<div class="acf-row"><span class="publ-label">Indication:</span> Gynecology <hr/> <span class="publ-label">Evidence:</span>  Case report</div>
3459	<div class="publ-acf acf-row acf-flex">
3460	<span class="publ-label">Author:&nbsp;</span>
3461	<div class="szerzok">
3462		
3463		 
3464		
3465		<span class="sz-nev">Sun Young Lee</span>
3466   
3467		 
3468		
3469		<span class="sz-nev">
3469Na-Ri Lee</span>
3470   
3471				</div>
3472	
3473	</div>
3474	<div class="acf-row"><span class="publ-label">No. of patients:</span> 1 <hr/> <span class="publ-label">Therapy:</span>  CT+mEHT<hr/> <span class="publ-label">Year:</span>  2016</div>
3475	</div><!-- .acf-fields -->
3476	<p>Primary sarcomas of the breast are rare tumors, accounting for less than 1% of all breast neoplasms. Leiomyosarcoma is an extremely rare subtype of breast sarcoma [1]. Prognoses for primary breast sarcoma are poor and treatment modalities are limited. Pazopanib is an oral, multitargeted tyrosine kinase inhibitor, with activity against vascular endothelial growth factors (VEGFs) 1, 2, and 3, and platelet-derived growth factors (PDGFs) [2]. Pazopanib has been approved for the treatment of advanced renal cell carcinoma and metastatic soft tissue sarcoma (STS) [2]. Hyperthermia inhibits sub-lethal cellular damage repair and improves oxygenation; thus, making it an attractive therapy for combining with radiation and/or chemotherapy to generate a potentially synergistic response. Hyperthermia has a proven benefit for treating STS [3]. Herein, we report a case of primary breast leiomyosarcoma treated with regional hyperthermia and pazopanib.</p>
3477
3478			<div id="teljes-cikk" class="btn">
3479		<a href="https://www.ncbi.nlm.nih.gov/pubmed/27079325" target="_blank"> View abstract</a>
3480	</div>
3481	
3482	</div>	<!-- .container -->
3483</div><!-- .entry-content -->
3484
3485
3486
3487</article><!-- #post-3327 -->
3488
3489			
3490<article id="post-3328" class="post-3328 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
3491	
3492	<header class="pub-entry-header">
3493	<div class="container">
3494		<h2>Complete Response of Locally Advanced (stage III) Rectal Cancer to Metabolically Supported Chemoradiotherapy with Hyperthermia</h2>
3495	</div>
3496	</header><!-- .entry-header -->
3497
3498
3499<div class="entry-content kl-pub-content">
3500	<div class="container">
3501		<div class="acf-fields">
3502	<div class="acf-row"><span class="publ-label">Indication:</span> Rectal Cancer <hr/> <span class="publ-label">Evidence:</span>  </div>
3503	<div class="publ-acf acf-row acf-flex">
3504	<span class="publ-label">Author:&nbsp;</span>
3505	<div class="szerzok">
3506		
3507		 
3508		
3509		<span class="sz-nev">Iyikesici MS.</span>
3510   
3511		 
3512		
3513		<span class="sz-nev">Slocum A.</span>
3514   
3515		 
3516		
3517		<span class="sz-nev">Turkmen E.</span>
3518   
3519		 
3520		
3521		<span class="sz-nev">Akdemir O.</span>
3522   
3523		 
3524		
3525		<span class="sz-nev">Slocum AK.</span>
3526   
3527		 
3528		
3529		<span class="sz-nev">Berkarda FB.</span>
3530   
3531				</div>
3532	
3533	</div>
3534	<div class="acf-row"><span class="publ-label">No. of patients:</span> 1 <hr/> <span class="publ-label">Therapy:</span>  <hr/> <span class="publ-label">Year:</span>  2016</div>
3535	</div><!-- .acf-fields -->
3536	<p><strong>Abstract<br />
3537</strong>Background: Locally advanced rectal cancer is defined as a rectal mass that cannot be resected without a high probability of leaving residual disease at the tumor site. While the standard treatment for locally advanced rectal cancer is chemoradiotherapy followed by surgery, this study reports a locally invasive rectal adenocarcinoma patient who achieved complete pathological and clinical remission after receiving a combination of metabolically supported chemotherapy (MSCT), radiotherapy (RT) and hyperthermia (HT). Case presentation: An 81-year-old female underwent a rectosigmoidoscopy at a referring hospital following a complaint of bloody stools for a period of 20 days. The rectosigmoidoscopy revealed an ulcerated tumor beginning at the level of the anal sphincter. A pathological examination of biopsy material revealed moderately differentiated invasive adenocarcinoma and the patient received a diagnosis of stage III (T3N2M0) lowlying rectal cancer. When further follow-up revealed colonic obstruction, the patient was recommended an abdominoperineal resection (APR) and was referred after refusing surgical treatment. The patient received a metabolically supported combination of oxaliplatin, 5-florouracil (5-FU) and calcium folinate (FOLFOX6) concomitant to RT and local HT and, ultimately, never underwent surgery. 27 months since her disease-free PET-CT scan, the patient remains with 
3537no sign of disease recurrence. Conclusion: According to the findings of the present study, the non-surgical treatment and achievement of complete clinical and pathological remission of locally advanced rectal adenocarcinoma may be possible by means of a combination of MSCT, RT and HT. Keywords: Pathological complete response; Locally advanced rectal cancer; Metabolically supported chemotherapy; Hyperthermia</p>
3538
3539	
3540	</div>	<!-- .container -->
3541</div><!-- .entry-content -->
3542
3543
3544
3545</article><!-- #post-3328 -->
3546
3547			
3548<article id="post-3329" class="post-3329 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
3549	
3550	<header class="pub-entry-header">
3551	<div class="container">
3552		<h2>Effect of modulated electrohyperthermia on the pharmacokinetics of oral transmucosal fentanyl citrate in healthy volunteers</h2>
3553	</div>
3554	</header><!-- .entry-header -->
3555
3556
3557<div class="entry-content kl-pub-content">
3558	<div class="container">
3559		<div class="acf-fields">
3560	<div class="acf-row"><span class="publ-label">Indication:</span> Temperature <hr/> <span class="publ-label">Evidence:</span>  Open-label study</div>
3561	<div class="publ-acf acf-row acf-flex">
3562	<span class="publ-label">Author:&nbsp;</span>
3563	<div class="szerzok">
3564		
3565		 
3566		
3567		<span class="sz-nev">Lee SY</span>
3568   
3569		 
3570		
3571		<span class="sz-nev">Kim M-G</span>
3572   
3573				</div>
3574	
3575	</div>
3576	<div class="acf-row"><span class="publ-label">No. of patients:</span> 12 <hr/> <span class="publ-label">Therapy:</span>  mEHT<hr/> <span class="publ-label">Year:</span>  2016</div>
3577	</div><!-- .acf-fields -->
3578	<h3>Abstract</h3>
3579<div>
3580<h4>PURPOSE:</h4>
3581<p>This study aimed to determine whether changes occur in fentanyl absorption and disposition when administered in conjunction with modulated electrohyperthermia (mEHT) treatment.</p>
3582<h4>METHODS:</h4>
3583<p>A randomized, single-dose, crossover, open-label study was used to investigate the effect of mEHT on the pharmacokinetic properties of fentanyl in 12 healthy volunteers. The 12 healthy volunteers were each administered a single dose of oral transmucosal fentanyl citrate (OTFC) or a single dose of OTFC with mEHT. mEHT was performed on the abdomen for 1 hour. Blood samples were collected for 24 hours after dosing. The temperature of the abdominal skin surface was assessed before dosing and at 10, 20, and 60 minutes after dosing.</p>
3584<h4>FINDINGS:</h4>
3585<p>Geometric mean ratios (ratio of fentanyl with mEHT to fentanyl alone) for the Cmax and AUC0-last were 1.20 (90% CI, 1.09-1.32) and 1.15 (90% CI, 0.99-1.33), respectively. The mean temperature of the abdominal skin surface increased by approximately 4°C.</p>
3586<h4>IMPLICATIONS:</h4>
3587<p>There was an increase in the overall exposure to the drug without implications of any clinical significance. OTFC can be administered without limitations in combination with mEHT, and it is not necessary to modify the dosing regimen. cris.nih.go,kr Identifier: KCT0001286.</p>
3588</div>
3589
3590			<div id="teljes-cikk" class="btn">
3591		<a href="https://www.ncbi.nlm.nih.gov/pubmed/27866658" target="_blank"> View abstract</a>
3592	</div>
3593	
3594	</div>	<!-- .container -->
3595</div><!-- .entry-content -->
3596
3597
3598
3599</article><!-- #post-3329 -->
3600
3601			
3602<article id="post-3330" class="post-3330 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
3603	
3604	<header class="pub-entry-header">
3605	<div class="container">
3606		<h2>Definitive radiotherapy with concurrent oncothermia for stage IIIB non‑small‑cell lung cancer: A case report</h2>
3607	</div>
3608	</header><!-- .entry-header -->
3609
3610
3611<div class="entry-content kl-pub-content">
3612	<div class="container">
3613		<div class="acf-fields">
3614	<div class="acf-row"><span class="publ-label">Indication:</span> Lung <hr/> <span class="publ-label">Evidence:</span>  Case report</div>
3615	<div class="publ-acf acf-row acf-flex">
3616	<span class="publ-label">Author:&nbsp;</span>
3617	<div class="szerzok">
3618		
3619		 
3620		
3621		<span class="sz-nev">Seung-Gu Yeo</span>
3622   
3623				</div>
3624	
3625	</div>
3626	<div class="acf-row"><span class="publ-label">No. of patients:</span> 1 <hr/> <span class="publ-label">Therapy:</span>  RT+mEHT<hr/> <span class="publ-label">Year:</span>  2015</div>
3627	</div><!-- .acf-fields -->
3628	<h2 id="__abstractidm139703974627696title">Abstract</h2>
3629<p>Hyperthermia enhances the susceptibility of tumors to radiotherapy (RT) and chemotherapy. Oncothermia, also known as electro-hyperthermia, is a new treatment modality developed to overcome the problems of traditional hyperthermia by selectively delivering energy to the malignant tissues. The present study reports the outcome of combined oncothermia and RT in a 75-year-old patient with stage IIIB non-small-cell lung cancer (NSCLC). Due to the advanced age and the performance status of the patient, the combination of systemic chemotherapy and RT was deemed infeasible; therefore, the patient instead decided to undergo oncothermia concurrently with definitive RT. The RT was administered at a dose of 64.8 Gy in 36 fractions using a three-dimensional conformal plan technique. Oncothermia was started concomitantly with RT and was performed for 60 min per session, two sessions per week, for a total of 12 sessions. No severe toxicities developed, with the exception of mild odynophagia, which resolved soon after the treatments. Follow-up computed tomography showed complete tumor response, and the patient was alive with no evidence of the disease 18 months after the completion of the treatment. In conclusion, the present case report suggests that oncothermia combined with RT, with the former possessing radiosensitizing potential and n
3629o additional toxicities, may be a promising alternative for advanced-age and/or frail patients with locally advanced NSCLC.</p>
3630
3631			<div id="teljes-cikk" class="btn">
3632		<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4509030/" target="_blank"> View abstract</a>
3633	</div>
3634	
3635	</div>	<!-- .container -->
3636</div><!-- .entry-content -->
3637
3638
3639
3640</article><!-- #post-3330 -->
3641
3642			
3643<article id="post-3331" class="post-3331 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
3644	
3645	<header class="pub-entry-header">
3646	<div class="container">
3647		<h2>The Outcome of the Chemotherapy and Oncothermia for Far Advanced Adenocarcinoma of the Lung: Case reports of four patients</h2>
3648	</div>
3649	</header><!-- .entry-header -->
3650
3651
3652<div class="entry-content kl-pub-content">
3653	<div class="container">
3654		<div class="acf-fields">
3655	<div class="acf-row"><span class="publ-label">Indication:</span> Lung <hr/> <span class="publ-label">Evidence:</span>  Case report</div>
3656	<div class="publ-acf acf-row acf-flex">
3657	<span class="publ-label">Author:&nbsp;</span>
3658	<div class="szerzok">
3659		
3660		 
3661		
3662		<span class="sz-nev">Doo Yun Lee</span>
3663   
3664		 
3665		
3666		<span class="sz-nev">Joon Seok Park</span>
3667   
3668		 
3669		
3670		<span class="sz-nev">Hae Chul Jung</span>
3671   
3672		 
3673		
3674		<span class="sz-nev">Eun Seol Byun</span>
3675   
3676		 
3677		
3678		<span class="sz-nev">Seok Jin Haam</span>
3679   
3680		 
3681		
3682		<span class="sz-nev">Sung Soo Lee</span>
3683   
3684				</div>
3685	
3686	</div>
3687	<div class="acf-row"><span class="publ-label">No. of patients:</span> 4 <hr/> <span class="publ-label">Therapy:</span>  CT+mEHT<hr/> <span class="publ-label">Year:</span>  2015</div>
3688	</div><!-- .acf-fields -->
3689	<p><strong>ABSTRACT</strong></p>
3690<div>
3691<p>Lung cancer is one of the most aggressive and lethal form of cancers. Patients with far advanced lung cancer are treated by chemotherapy with or without radiotherapy. However, median survival of these patients is less than 6 months. To increase survival and quality of life for these patients, various forms of complementary treatments have been tried in clinical practices, and oncothermia is supposed to be one of the promising candidates. From May 2008 to November 2013, 4 patients with far advanced lung adenocarcinoma (stages IIIB and IV) were treated with oncothermia in addition to conventional chemotherapy at Gangnam Severance Hospital and Bundang CHA Hospital. All these patients have survived for more than 2 years.</p>
3692</div>
3693
3694			<div id="teljes-cikk" class="btn">
3695		<a href="http://www.scirp.org/journal/PaperInformation.aspx?PaperID=54620" target="_blank"> View abstract</a>
3696	</div>
3697	
3698	</div>	<!-- .container -->
3699</div><!-- .entry-content -->
3700
3701
3702
3703</article><!-- #post-3331 -->
3704
3705			
3706<article id="post-3332" class="post-3332 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
3707	
3708	<header class="pub-entry-header">
3709	<div class="container">
3710		<h2>Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance</h2>
3711	</div>
3712	</header><!-- .entry-header -->
3713
3714
3715<div class="entry-content kl-pub-content">
3716	<div class="container">
3717		<div class="acf-fields">
3718	<div class="acf-row"><span class="publ-label">Indication:</span> Immuno-oncology <hr/> <span class="publ-label">Evidence:</span>  </div>
3719	<div class="publ-acf acf-row acf-flex">
3720	<span class="publ-label">Author:&nbsp;</span>
3721	<div class="szerzok">
3722		
3723		 
3724		
3725		<span class="sz-nev">Schirrmacher V</span>
3726   
3727				</div>
3728	
3729	</div>
3730	<div class="acf-row"><span class="publ-label">No. of patients:</span>  <hr/> <span class="publ-label">Therapy:</span>  IMT+mEHT<hr/> <span class="publ-label">Year:</span>  2015</div>
3731	</div><!-- .acf-fields -->
3732	<h3>Abstract</h3>
3733<div>
3734<h4>INTRODUCTION:</h4>
3735<p>Oncolytic viruses (OVs) selectively replicate in tumor cells and cause cancer cell death. Most OVs in clinical studies are genetically engineered. In contrast, the avian Newcastle disease virus (NDV) is a naturally oncolytic RNA virus. While anti-viral immunity is considered a major problem in achieving maximal tumor cell killing by OVs, this review discusses the importance of NDV immunogenic cell death (ICD) and how anti-viral immune responses can be integrated to induce maximal post-oncolytic T-cell-mediated anti-tumor immunity. Since replication of NDV is independent of host cell DNA replication (which is the target of many cytostatic drugs and radiotherapy) and because of other findings, oncolytic NDV is a candidate agent to break therapy resistance of tumor cells.</p>
3736<h4>AREAS COVERED:</h4>
3737<p>Properties of this avian paramyxovirus are summarized with special emphasis to its anti-neoplastic and immune-stimulatory properties. The review then discusses prospective anti-cancer therapies, including treatments with NDV alone, and combinations with an autologous NDV-modified tumor cell vaccine or with a viral oncolysate pulsed dendritic cell vaccine. Various combinatorial approaches between these and with other modalities are also reviewed.</p>
3738<h4>EXPERT OPINION:</h4>
3739<p>Post-oncolytic anti-tumor immunity based on ICD is in the expert&#8217;s opinion of greater importance for long-term therapeutic effects than maximal tumor cell killing. Of the various combinatorial approaches discussed, the most promising and feasible for clinical practice appears to be the combination of systemic NDV pre-treatment with anti-tumor vaccination.</p>
3740</div>
3741
3742			<div id="teljes-cikk" class="btn">
3743		<a href="https://www.ncbi.nlm.nih.gov/pubmed/26436571" target="_blank">
3743 View abstract</a>
3744	</div>
3745	
3746	</div>	<!-- .container -->
3747</div><!-- .entry-content -->
3748
3749
3750
3751</article><!-- #post-3332 -->
3752
3753			
3754<article id="post-3333" class="post-3333 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
3755	
3756	<header class="pub-entry-header">
3757	<div class="container">
3758		<h2>Results of Oncothermia Combined with Operation, Chemotherapy and Radiation Therapy for Primary, Recurrent and Metastatic Sarcoma</h2>
3759	</div>
3760	</header><!-- .entry-header -->
3761
3762
3763<div class="entry-content kl-pub-content">
3764	<div class="container">
3765		<div class="acf-fields">
3766	<div class="acf-row"><span class="publ-label">Indication:</span> Sarcoma <hr/> <span class="publ-label">Evidence:</span>  </div>
3767	<div class="publ-acf acf-row acf-flex">
3768	<span class="publ-label">Author:&nbsp;</span>
3769	<div class="szerzok">
3770		
3771		 
3772		
3773		<span class="sz-nev">Tae Sig Jeung</span>
3774   
3775		 
3776		
3777		<span class="sz-nev">Sun Young Ma</span>
3778   
3779		 
3780		
3781		<span class="sz-nev">JiHoon Choi</span>
3782   
3783		 
3784		
3785		<span class="sz-nev">Jeasang Yu</span>
3786   
3787		 
3788		
3789		<span class="sz-nev">Su Yong Lee</span>
3790   
3791		 
3792		
3793		<span class="sz-nev">Sangwook Lim</span>
3794   
3795				</div>
3796	
3797	</div>
3798	<div class="acf-row"><span class="publ-label">No. of patients:</span> 13 <hr/> <span class="publ-label">Therapy:</span>  SRG+CT+mEHT<hr/> <span class="publ-label">Year:</span>  2015</div>
3799	</div><!-- .acf-fields -->
3800	<h4>ABSTRACT</h4>
3801<div>
3802<div>Sarcomas are relatively rare malignancies; however, their huge variety and shortage of the effective therapies make this disease face huge challenge for oncology. It is recently shown that hyperthermia could be successfully applied even in high-risk cases in combination with the available gold-standard regiments. Our aim is to present various advanced cases treated with a new hyperthermia method, oncothermia, showing its advantages and feasibility to successfully treat highly advanced sarcomas with curative intent.</div>
3803</div>
3804
3805			<div id="teljes-cikk" class="btn">
3806		<a href="http://www.scirp.org/journal/PaperInformation.aspx?PaperID=56280" target="_blank"> View abstract</a>
3807	</div>
3808	
3809	</div>	<!-- .container -->
3810</div><!-- .entry-content -->
3811
3812
3813
3814</article><!-- #post-3333 -->
3815
3816			
3817<article id="post-3334" class="post-3334 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
3818	
3819	<header class="pub-entry-header">
3820	<div class="container">
3821		<h2>The effect of modulated electro-hyperthermia on the pharmacokinetic properties of nefopam in healthy volunteers: A randomised, single-dose, crossover open-label study</h2>
3822	</div>
3823	</header><!-- .entry-header -->
3824
3825
3826<div class="entry-content kl-pub-content">
3827	<div class="container">
3828		<div class="acf-fields">
3829	<div class="acf-row"><span class="publ-label">Indication:</span> Temperature <hr/> <span class="publ-label">Evidence:</span>  Open-label study</div>
3830	<div class="publ-acf acf-row acf-flex">
3831	<span class="publ-label">Author:&nbsp;</span>
3832	<div class="szerzok">
3833		
3834		 
3835		
3836		<span class="sz-nev">Lee SY</span>
3837   
3838		 
3839		
3840		<span class="sz-nev">Kim M-G</span>
3841   
3842				</div>
3843	
3844	</div>
3845	<div class="acf-row"><span class="publ-label">No. of patients:</span> 12 <hr/> <span class="publ-label">Therapy:</span>  mEHT<hr/> <span class="publ-label">Year:</span>  2015</div>
3846	</div><!-- .acf-fields -->
3847	<h3>Abstract</h3>
3848<div>
3849<h4>PURPOSE:</h4>
3850<p>Nefopam is a widely available analgesic for the management of pain. The aim of this study was to reveal the effect of regional hyperthermia of the abdominal area on the pharmacokinetics of nefopam.</p>
3851<h4>MATERIALS AND METHODS:</h4>
3852<p>A randomised, single-dose, crossover, open-label study was conducted to reveal the effect of hyperthermia using modulated electro-hyperthermia on the pharmacokinetics of nefopam. The pharmacokinetics of orally administered nefopam without hyperthermia was studied in 12 healthy volunteers and then 7 days later they were treated with nefopam plus modulated electro-hyperthermia to the abdominal area for 1 h. Blood samples were collected up to 24 h after the drug administration. From the blood concentration-time curve, the maxinum plasma concentration (C(max)), time to C(max) (T(max)) and the area under the curve (AUC) were obtained. The safety and tolerability of these treatments were also assessed.</p>
3853<h4>RESULTS:</h4>
3854<p>The geometric mean ratios (GMRs) ((nefopam + modulated electro-hyperthermia)/nefopam) and the associated 90% confidence intervals (CIs) for C(max), AUC(last) and AUC(inf) were 1.2804 (1.1155∼1.4696), 1.0512 (0.9555∼1.1566) and 1.0612 (0.9528∼1.1819), respectively. The increase in C(max) was statistically significant, and T(max) was significantly shortened.</p>
3855<h4>CONCLUSIONS:</h4>
3856<p>The significant increase in C(max) and decrease in T(max) indicated that modulated electro-hyperthermia increased the absorption of the orally administered nefopam, thereby transitionally increasing the blood concentration of the drug. The AUC is an important parameter that c
3856ontributes to the therapeutic effect of drugs. The lack of significant change in AUC suggests that modulated electro-hyperthermia may increases the absorption of orally administered drugs without increasing the systemic adverse effect of the drugs.</p>
3857</div>
3858
3859			<div id="teljes-cikk" class="btn">
3860		<a href="http://www.ncbi.nlm.nih.gov/pubmed/26507458" target="_blank"> View abstract</a>
3861	</div>
3862	
3863	</div>	<!-- .container -->
3864</div><!-- .entry-content -->
3865
3866
3867
3868</article><!-- #post-3334 -->
3869
3870			
3871<article id="post-3335" class="post-3335 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
3872	
3873	<header class="pub-entry-header">
3874	<div class="container">
3875		<h2>Conventional cancer treatment alone or with regional hyperthermia for pain relief in lung cancer: A case–control study</h2>
3876	</div>
3877	</header><!-- .entry-header -->
3878
3879
3880<div class="entry-content kl-pub-content">
3881	<div class="container">
3882		<div class="acf-fields">
3883	<div class="acf-row"><span class="publ-label">Indication:</span> Lung cancer <hr/> <span class="publ-label">Evidence:</span>  Case report</div>
3884	<div class="publ-acf acf-row acf-flex">
3885	<span class="publ-label">Author:&nbsp;</span>
3886	<div class="szerzok">
3887		
3888		 
3889		
3890		<span class="sz-nev">Yeon-PyoKim</span>
3891   
3892		 
3893		
3894		<span class="sz-nev">YuriChoi</span>
3895   
3896		 
3897		
3898		<span class="sz-nev">SunKim</span>
3899   
3900		 
3901		
3902		<span class="sz-nev">Yoon-SungPark</span>
3903   
3904		 
3905		
3906		<span class="sz-nev">In-JaeOh</span>
3907   
3908		 
3909		
3910		<span class="sz-nev">Kyu-SikKim</span>
3911   
3912		 
3913		
3914		<span class="sz-nev">Young-ChulKim</span>
3915   
3916				</div>
3917	
3918	</div>
3919	<div class="acf-row"><span class="publ-label">No. of patients:</span> 115 <hr/> <span class="publ-label">Therapy:</span>  Conventional treatment, Hyperthermia<hr/> <span class="publ-label">Year:</span>  2015</div>
3920	</div><!-- .acf-fields -->
3921	<p>Objective: To investigate the effect of combining conventional treatment with regional hyperthermia on cancer pain in lung cancer patients.<br />
3922Design: Case–control study.<br />
3923Setting: One Korean university hospital and three complementary cancer clinics.<br />
3924Main outcomes and measures: Main outcome was effective analgesic score (EAS, PI[1 + (M/10)], 1: anti-inflammatory drug consumption at a regular dosage, M: weekly dose (mg) of oral morphine equivalent and PI: pain intensity) at four time points (baseline (days −30 to 0), time 1 (days 1–60), time 2 (days 61–120), and time 3 (days 121–180)). Propensity score matching between the hyperthermia and control groups was performed using a 1:5 ratio. A linear mixed effects model was employed to measure EAS changes over time in the two groups.<br />
3925Results: At baseline, there were 83 subjects in the control group and 32 subjects in the hyperthermia group. At time 3, there were 49 subjects in the control group and 16 subjects in the hyperthermia group. Analyses showed rate of change of EAS, treatment × time was significant (<em>p</em> = 0.038). This significant difference was mainly observed for time 1 (mean difference: 101.76 points, 95% confidence interval: 10.20–193.32 points, <em>p</em> = 0.030).<br />
3926Conclusions: Our results indicate an increase in cancer pain in lung cancer patients administered regional hyperthermia, particularly during the early stage of hyperthermia treatment.</p>
3927
3928			<div id="teljes-cikk" class="btn">
3929		<a href="https://doi.org/10.1016/j.ctim.2015.04.004" target="_blank"> View abstract</a>
3930	</div>
3931	
3932	</div>	<!-- .container -->
3933</div><!-- .entry-content -->
3934
3935
3936
3937</article><!-- #post-3335 -->
3938
3939			
3940<article id="post-3336" class="post-3336 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
3941	
3942	<header class="pub-entry-header">
3943	<div class="container">
3944		<h2>Second-line chemotherapy with gemcitabine and oxaliplatin in combination with loco-regional hyperthermia (EHY-2000) in patients with refractory metastatic pancreatic cancer &#8211; preliminary results of a prospective trial</h2>
3945	</div>
3946	</header><!-- .entry-header -->
3947
3948
3949<div class="entry-content kl-pub-content">
3950	<div class="container">
3951		<div class="acf-fields">
3952	<div class="acf-row"><span class="publ-label">Indication:</span> Pancreas <hr/> <span class="publ-label">Evidence:</span>  Clinical study</div>
3953	<div class="publ-acf acf-row acf-flex">
3954	<span class="publ-label">Author:&nbsp;</span>
3955	<div class="szerzok">
3956		
3957		 
3958		
3959		<span class="sz-nev">Volovat C</span>
3960   
3961		 
3962		
3963		<span class="sz-nev">Volovat SR</span>
3964   
3965		 
3966		
3967		<span class="sz-nev">Scripcaru V</span>
3968   
3969		 
3970		
3971		<span class="sz-nev">Miron L</span>
3972   
3973				</div>
3974	
3975	</div>
3976	<div class="acf-row"><span class="publ-label">No. of patients:</span> 26 <hr/> <span class="publ-label">Therapy:</span>  CT+mEHT<hr/> <span class="publ-label">Year:</span>  2014</div>
3977	</div><!-- .acf-fields -->
3978	<div><strong>Abstract</strong></div>
3979<div></div>
3980<div>There is no standard treatment for second-line in patients with metastatic pancreatic cancer. The treatment with local hyperthermia (41–42°C) in order to enhance the activity gemcitabine-oxaliplatin on liver metastasis and primary advanced tumor was added as standard treatment. The primary objective was the response rate while the secondary objective were the safety of chemotherapy associated with hyperthermia and overall survival. There were 26 patients included, diagnosed with metastatic pancreatic cancer with progressive disease after gemcitabine treatment. The patients were enrolled in the peri
3980od January 2005 – May 2011. The patients received gemcitabine 1000 mg/msq IV and oxaliplatin 100 mg/msq IV day 1(GEMOX) combined with locoregional hyperthermia days1, 3 and 5 all repeated at 14 days. From 26 patients included, 19 patients had an evaluable response at the treatment. The toxicity of chemotherapy for these patients was related with chemotherapy (neutropeniagrade III – 24%; anemia grade III – 8%, thrombopenia grade III– 6%; neurologic toxicity grade III – 22%. Toxicity related to hyperthermia was:discomfort because of bolus pressure (2%), pain related with position (12%), power related pain (2%). Rate of response was stable disease 53%, partial response 18% and progression disease 29%. Progression-free-survival was 3.9 months. Overall survival was 8.9 months.</div>
3981
3982			<div id="teljes-cikk" class="btn">
3983		<a href="http://www.rrp.infim.ro/2014_66_1/A18.pdf" target="_blank"> View abstract</a>
3984	</div>
3985	
3986	</div>	<!-- .container -->
3987</div><!-- .entry-content -->
3988
3989
3990
3991</article><!-- #post-3336 -->
3992
3993			
3994<article id="post-3337" class="post-3337 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
3995	
3996	<header class="pub-entry-header">
3997	<div class="container">
3998		<h2>Long‑term remission of prostate cancer with extensive bone metastases upon immuno‑ and virotherapy: A case report</h2>
3999	</div>
4000	</header><!-- .entry-header -->
4001
4002
4003<div class="entry-content kl-pub-content">
4004	<div class="container">
4005		<div class="acf-fields">
4006	<div class="acf-row"><span class="publ-label">Indication:</span> Prostate <hr/> <span class="publ-label">Evidence:</span>  Case report</div>
4007	<div class="publ-acf acf-row acf-flex">
4008	<span class="publ-label">Author:&nbsp;</span>
4009	<div class="szerzok">
4010		
4011		 
4012		
4013		<span class="sz-nev">Volker Schirrmacher</span>
4014   
4015		 
4016		
4017		<span class="sz-nev">Akos-Sigmund Bihari</span>
4018   
4019		 
4020		
4021		<span class="sz-nev">Wilfried Stücker</span>
4022   
4023		 
4024		
4025		<span class="sz-nev">Tobias Sprenger</span>
4026   
4027				</div>
4028	
4029	</div>
4030	<div class="acf-row"><span class="publ-label">No. of patients:</span> 1 <hr/> <span class="publ-label">Therapy:</span>  SRG+CT+mEHT<hr/> <span class="publ-label">Year:</span>  2014</div>
4031	</div><!-- .acf-fields -->
4032	<p><strong>Abstract</strong></p>
4033<p>The present study reports the case of a patient with hormone-refractory metastatic prostate cancer who had failed standard therapy, but then achieved complete remission following combined treatment with local hyperthermia (LHT), Newcastle disease virus and dendritic cell (DC) vaccination, which was an unusual combination. In August 2005, the patient underwent a radical prostatectomy. Despite standard treatment, the patient developed progressive bone metastases and stopped conventional therapy in June 2007. Starting in October 2007, the patient was treated with LHT, oncolytic virotherapy and DC vaccination. Prostate‑specific antigen (PSA)-levels, with the highest level of 233.8 ng/ml in January 2008, decreased to 0.8 ng/ml in late February 2008. In March 2008, a reduction in bone metastases could be detected by positron emission tomography/computed tomography. Since then, the PSA levels have remained low and the patient is doing well. The treatment induced a long-lasting antitumor memory T-cell response. This possibly explains the long-term effectiveness of this novel experimental combined treatment approach.</p>
4034
4035			<div id="teljes-cikk" class="btn">
4036		<a href="https://www.ncbi.nlm.nih.gov/pubmed/25364402" target="_blank"> View abstract</a>
4037	</div>
4038	
4039	</div>	<!-- .container -->
4040</div><!-- .entry-content -->
4041
4042
4043
4044</article><!-- #post-3337 -->
4045
4046			
4047<article id="post-3338" class="post-3338 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
4048	
4049	<header class="pub-entry-header">
4050	<div class="container">
4051		<h2>Synergy between Oncothermia and Traditional Chinese Medicine</h2>
4052	</div>
4053	</header><!-- .entry-header -->
4054
4055
4056<div class="entry-content kl-pub-content">
4057	<div class="container">
4058		<div class="acf-fields">
4059	<div class="acf-row"><span class="publ-label">Indication:</span> Non-oncology <hr/> <span class="publ-label">Evidence:</span>  </div>
4060	<div class="publ-acf acf-row acf-flex">
4061	<span class="publ-label">Author:&nbsp;</span>
4062	<div class="szerzok">
4063		
4064		 
4065		
4066		<span class="sz-nev">Hegyi G</span>
4067   
4068				</div>
4069	
4070	</div>
4071	<div class="acf-row"><span class="publ-label">No. of patients:</span>  <hr/> <span class="publ-label">Therapy:</span>  mEHT+TCM<hr/> <span class="publ-label">Year:</span>  2014</div>
4072	</div><!-- .acf-fields -->
4073	<h4>Abstract</h4>
4074<p>Aim of this article is to show the possibility and great advantage of the synergy of oncothermia with traditional Chinese medicine for treatment of malignant diseases based on the common basis of equilibrium demand. We use the re cognit io n of thedeviat ions fr om the com plex har monyof the org anismor its part for se lectionto actproperly.</p>
4075
4076			<div id="teljes-cikk" class="btn">
4077		<a href="http://www.maot.hu/wp-content/uploads/2014/09/Heft_SPECIAL_eng.pdf" target="_blank">
4077 View abstract</a>
4078	</div>
4079	
4080	</div>	<!-- .container -->
4081</div><!-- .entry-content -->
4082
4083
4084
4085</article><!-- #post-3338 -->
4086
4087			
4088<article id="post-3339" class="post-3339 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
4089	
4090	<header class="pub-entry-header">
4091	<div class="container">
4092		<h2>Current Status of Oncothermia Therapy for Lung Cancer</h2>
4093	</div>
4094	</header><!-- .entry-header -->
4095
4096
4097<div class="entry-content kl-pub-content">
4098	<div class="container">
4099		<div class="acf-fields">
4100	<div class="acf-row"><span class="publ-label">Indication:</span> Lung <hr/> <span class="publ-label">Evidence:</span>  </div>
4101	<div class="publ-acf acf-row acf-flex">
4102	<span class="publ-label">Author:&nbsp;</span>
4103	<div class="szerzok">
4104		
4105		 
4106		
4107		<span class="sz-nev">Andras Szasz</span>
4108   
4109		 
4110		
4111		<span class="sz-nev"> Ph.D</span>
4112   
4113				</div>
4114	
4115	</div>
4116	<div class="acf-row"><span class="publ-label">No. of patients:</span>  <hr/> <span class="publ-label">Therapy:</span>  CT+RT+mEHT<hr/> <span class="publ-label">Year:</span>  2014</div>
4117	</div><!-- .acf-fields -->
4118	<h4 id="__abstractidm140542931376624title">Abstract</h4>
4119<p>Lung cancer is one of the most common malignant tumors, and it has the highest death rate. Oncothermia is a feasible and successful treatment for lung cancer. Results show a remarkable survival benefit for patients, with a good quality of life. The treatment has no, or in some cases mild, side-effects and could decrease the adverse effects of the complementary treatment. Applying oncothermia together with other treatment methods could increase the effects and result in better performance. A comparison of studies demonstrates a good correspondence in the data, which strengthens the reliability of the studies, and clearly shows the feasibility of the application of oncothermia to treating all kinds of pulmonary malignancies including non-small-cell and small-cell primary tumors, and all of the metastatic diseases of the pulmonary system.</p>
4120
4121			<div id="teljes-cikk" class="btn">
4122		<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000888/" target="_blank"> View abstract</a>
4123	</div>
4124	
4125	</div>	<!-- .container -->
4126</div><!-- .entry-content -->
4127
4128
4129
4130</article><!-- #post-3339 -->
4131
4132			
4133<article id="post-3340" class="post-3340 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
4134	
4135	<header class="pub-entry-header">
4136	<div class="container">
4137		<h2>The results of combination of ifosfamid and locoregional hyperthermia (EHY 2000) in patients with advanced abdominal soft-tissue sarcoma after relapse of first line chemotherapy</h2>
4138	</div>
4139	</header><!-- .entry-header -->
4140
4141
4142<div class="entry-content kl-pub-content">
4143	<div class="container">
4144		<div class="acf-fields">
4145	<div class="acf-row"><span class="publ-label">Indication:</span> Sarcoma <hr/> <span class="publ-label">Evidence:</span>  </div>
4146	<div class="publ-acf acf-row acf-flex">
4147	<span class="publ-label">Author:&nbsp;</span>
4148	<div class="szerzok">
4149		
4150		 
4151		
4152		<span class="sz-nev">Volovat C</span>
4153   
4154		 
4155		
4156		<span class="sz-nev">Volovat SR</span>
4157   
4158		 
4159		
4160		<span class="sz-nev">Scripcaru V</span>
4161   
4162		 
4163		
4164		<span class="sz-nev">Miron L</span>
4165   
4166		 
4167		
4168		<span class="sz-nev">Lupascu C</span>
4169   
4170				</div>
4171	
4172	</div>
4173	<div class="acf-row"><span class="publ-label">No. of patients:</span> 24 <hr/> <span class="publ-label">Therapy:</span>  CT+mEHT<hr/> <span class="publ-label">Year:</span>  2014</div>
4174	</div><!-- .acf-fields -->
4175	<h4 class="text-align-justify" data-reactid="166">Abstract</h4>
4176<div class="text-align-justify" data-reactid="168">From 2003 to 2011, 24 patients with advanced soft-tissue sarcoma with high-risk pretreated using first line chemotherapy with doxorubicin and recurrence disease were treated with chemotherapy (ifosfamide 3000mg/sqm, day 1–3) and locoregional hyperthermia (1 hour application with temperature between 41.5°C and 42°C, 3 days/week). The purpose was to evaluate the efficacy and safety of chemotherapy combined with locoregional non-invasive hyperthermia for local tumor control in patients with retroperitoneal or visceral advanced soft tissue sarc
4176omas. From 24 patients, 18 patients have had an evaluable response on CT scan using RECIST 1.0 (stable disease 8 patients for 4 months and 1 patients for 1 month, partial response 8 patients for 4 months, progression disease for 1 patient). The response was mainly on local tumor site. The side effects were correlated only with chemotherapy (neutropenia grade III 40%, grade 4 20%, trombocytopenia 2%, anemia grade III 10%, neurologic toxicity 9%). No toxicity was correlated with hyperthermia treatment.</div>
4177
4178			<div id="teljes-cikk" class="btn">
4179		<a href="https://www.researchgate.net/publication/273968670_The_results_of_combination_of_ifosfamid_and_locoregional_hyperthermia_EHY_2000_in_patients_with_advanced_abdominal_soft-tissue_sarcoma_after_relapse_of_first_line_chemotherapyh" target="_blank"> View abstract</a>
4180	</div>
4181	
4182	</div>	<!-- .container -->
4183</div><!-- .entry-content -->
4184
4185
4186
4187</article><!-- #post-3340 -->
4188
4189			
4190<article id="post-3341" class="post-3341 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
4191	
4192	<header class="pub-entry-header">
4193	<div class="container">
4194		<h2>Sorafenib and locoregional deep electro‑hyperthermia in advanced hepatocellular carcinoma: A phase II study</h2>
4195	</div>
4196	</header><!-- .entry-header -->
4197
4198
4199<div class="entry-content kl-pub-content">
4200	<div class="container">
4201		<div class="acf-fields">
4202	<div class="acf-row"><span class="publ-label">Indication:</span> Gastrointestinal <hr/> <span class="publ-label">Evidence:</span>  Phase II</div>
4203	<div class="publ-acf acf-row acf-flex">
4204	<span class="publ-label">Author:&nbsp;</span>
4205	<div class="szerzok">
4206		
4207		 
4208		
4209		<span class="sz-nev">Gennaro Gadaleta-Caldarola</span>
4210   
4211		 
4212		
4213		<span class="sz-nev">Stefania Infusino</span>
4214   
4215		 
4216		
4217		<span class="sz-nev">Ida Galise</span>
4218   
4219		 
4220		
4221		<span class="sz-nev">Girolamo Ranier</span>
4222   
4223		 
4224		
4225		<span class="sz-nev">Gianluca Vinciarelli</span>
4226   
4227		 
4228		
4229		<span class="sz-nev">Vito Fazio</span>
4230   
4231		 
4232		
4233		<span class="sz-nev">Rosa Divella</span>
4234   
4235		 
4236		
4237		<span class="sz-nev">Antonella Daniele</span>
4238   
4239		 
4240		
4241		<span class="sz-nev">Gianfranco Filippelli</span>
4242   
4243				</div>
4244	
4245	</div>
4246	<div class="acf-row"><span class="publ-label">No. of patients:</span> 21 <hr/> <span class="publ-label">Therapy:</span>  CT+mEHT<hr/> <span class="publ-label">Year:</span>  2014</div>
4247	</div><!-- .acf-fields -->
4248	<p>Abstract.</p>
4249<p>The standard treatment for advanced hepatocellular carcinoma (HCC) is sorafenib, a multikinase inhibitor of tumor cell proliferation and angiogenesis. Hyperthermia inhibits angiogenesis and promotes apoptosis. Potential synergic antiangiogenic and proapoptotic effects represent the rationale for combining sorafenib with electro-hyperthermia (EHY) in HCC. A total of 21 patients (median age, 64 years; range, 55-73 years) with advanced HCC were enrolled in the current study between February 2009 and September 2010. EHY was achieved by arranging capacitive electrodes with a deep hypothermia radiofrequency field of 13.56 Mhz at 80 W for 60 min, three times per week for six weeks, followed by two weeks without treatment, in combination with sorafenib at a dose of 800 mg every other day. According to the modified Response Evaluation Criteria in Solid Tumors criteria, 50% achieved stable disease, 5% achieved partial response and 45% achieved progressive disease. No complete response was observed. The progression-free survival (PFS) rate at six months was 38%, while the median PFS and overall survival times were 5.2 [95% confidence interval (CI), 4.2-6.2) and 10.4 (95% CI, 10-11) months, respectively. The overall incidence of treatment-related adverse events was 80%, predominantly of grade 1 or 2. Grade 3 toxicity included fatigue, diarrhea, hand-foot skin reaction and hypertension. In the present study, the sorafenib plus EHY combination was feasible and well tolerated, and no major complications were observed. The initial findings indicated that this combination offers a promising option for advanced HCC.</p>
4250
4251			<div id="teljes-cikk" class="btn">
4252		<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4156230/" target="_blank">
4252 View abstract</a>
4253	</div>
4254	
4255	</div>	<!-- .container -->
4256</div><!-- .entry-content -->
4257
4258
4259
4260</article><!-- #post-3341 -->
4261
4262			
4263<article id="post-3342" class="post-3342 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
4264	
4265	<header class="pub-entry-header">
4266	<div class="container">
4267		<h2>Long-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report</h2>
4268	</div>
4269	</header><!-- .entry-header -->
4270
4271
4272<div class="entry-content kl-pub-content">
4273	<div class="container">
4274		<div class="acf-fields">
4275	<div class="acf-row"><span class="publ-label">Indication:</span> Prostate <hr/> <span class="publ-label">Evidence:</span>  Case report</div>
4276	<div class="publ-acf acf-row acf-flex">
4277	<span class="publ-label">Author:&nbsp;</span>
4278	<div class="szerzok">
4279		
4280		 
4281		
4282		<span class="sz-nev">Schirrmacher V</span>
4283   
4284		 
4285		
4286		<span class="sz-nev">Bihari A-S</span>
4287   
4288		 
4289		
4290		<span class="sz-nev">Stücker W</span>
4291   
4292				</div>
4293	
4294	</div>
4295	<div class="acf-row"><span class="publ-label">No. of patients:</span> 1 <hr/> <span class="publ-label">Therapy:</span>  mEHT+OV therapy+DC<hr/> <span class="publ-label">Year:</span>  2014</div>
4296	</div><!-- .acf-fields -->
4297	<h3>Abstract</h3>
4298<p>The present study reports the case of a patient with hormone-refractory metastatic prostate cancer who had failed standard therapy, but then achieved complete remission following combined treatment with local hyperthermia (LHT), Newcastle disease virus and dendritic cell (DC) vaccination, which was an unusual combination. In August 2005, the patient underwent a radical prostatectomy. Despite standard treatment, the patient developed progressive bone metastases and stopped conventional therapy in June 2007. Starting in October 2007, the patient was treated with LHT, oncolytic virotherapy and DC vaccination. Prostate-specific antigen (PSA)-levels, with the highest level of 233.8 ng/ml in January 2008, decreased to 0.8 ng/ml in late February 2008. In March 2008, a reduction in bone metastases could be detected by positron emission tomography/computed tomography. Since then, the PSA levels have remained low and the patient is doing well. The treatment induced a long-lasting antitumor memory T-cell response. This possibly explains the long-term effectiveness of this novel experimental combined treatment approach.</p>
4299
4300			<div id="teljes-cikk" class="btn">
4301		<a href="http://www.ncbi.nlm.nih.gov/pubmed/25364402" target="_blank"> View abstract</a>
4302	</div>
4303	
4304	</div>	<!-- .container -->
4305</div><!-- .entry-content -->
4306
4307
4308
4309</article><!-- #post-3342 -->
4310
4311			
4312<article id="post-3343" class="post-3343 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
4313	
4314	<header class="pub-entry-header">
4315	<div class="container">
4316		<h2>Electrochemical Therapy of Tumors</h2>
4317	</div>
4318	</header><!-- .entry-header -->
4319
4320
4321<div class="entry-content kl-pub-content">
4322	<div class="container">
4323		<div class="acf-fields">
4324	<div class="acf-row"><span class="publ-label">Indication:</span> Hemangioma <hr/> <span class="publ-label">Evidence:</span>  </div>
4325	<div class="publ-acf acf-row acf-flex">
4326	<span class="publ-label">Author:&nbsp;</span>
4327	<div class="szerzok">
4328		
4329		 
4330		
4331		<span class="sz-nev">Li Jing-Hong</span>
4332   
4333		 
4334		
4335		<span class="sz-nev">Xin Yu Ling</span>
4336   
4337				</div>
4338	
4339	</div>
4340	<div class="acf-row"><span class="publ-label">No. of patients:</span>  <hr/> <span class="publ-label">Therapy:</span>  ECT<hr/> <span class="publ-label">Year:</span>  2013</div>
4341	</div><!-- .acf-fields -->
4342	<h4>ABSTRACT</h4>
4343<p>Application of electric current for the tumor destruction has a long time history. The theory of the direct galvanic current (galvanotherapy, GT) is worked out by B. Nordenstrom in the frame of biologically closed electric circuits (BCECs). Later, GT was extended by chemical considerations (EChT), and, starting with pioneering work of Professor Xin Yu Ling, a wide, intensive application had been developed in China. My objective is showing the principles and practice of the EChT treatment modality for multiple advanced lesions.<
4343/p>
4344
4345			<div id="teljes-cikk" class="btn">
4346		<a href="http://www.hindawi.com/archive/2013/858319/" target="_blank"> View abstract</a>
4347	</div>
4348	
4349	</div>	<!-- .container -->
4350</div><!-- .entry-content -->
4351
4352
4353
4354</article><!-- #post-3343 -->
4355
4356			
4357<article id="post-3344" class="post-3344 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
4358	
4359	<header class="pub-entry-header">
4360	<div class="container">
4361		<h2>Androtherm application for the Peyronie&#8217;s Disease</h2>
4362	</div>
4363	</header><!-- .entry-header -->
4364
4365
4366<div class="entry-content kl-pub-content">
4367	<div class="container">
4368		<div class="acf-fields">
4369	<div class="acf-row"><span class="publ-label">Indication:</span> Prostate <hr/> <span class="publ-label">Evidence:</span>  </div>
4370	<div class="publ-acf acf-row acf-flex">
4371	<span class="publ-label">Author:&nbsp;</span>
4372	<div class="szerzok">
4373		
4374		 
4375		
4376		<span class="sz-nev">Ballerini M</span>
4377   
4378		 
4379		
4380		<span class="sz-nev">Baronzio G F</span>
4381   
4382		 
4383		
4384		<span class="sz-nev">Capito G</span>
4385   
4386		 
4387		
4388		<span class="sz-nev">Szasz O</span>
4389   
4390		 
4391		
4392		<span class="sz-nev">Cassutti V</span>
4393   
4394				</div>
4395	
4396	</div>
4397	<div class="acf-row"><span class="publ-label">No. of patients:</span> 30 <hr/> <span class="publ-label">Therapy:</span>  mEHT<hr/> <span class="publ-label">Year:</span>  2013</div>
4398	</div><!-- .acf-fields -->
4399	<p><strong>Abstract</strong></p>
4400<p>Peyronie&#8217;s disease is characterized by a scarring fibrosis within the tunica albuginea of the penis that could lead to penile length loss, narrowing, curvature, erectile dysfunction, or pain with erection. This problem has recently no appropriate treatment. Our objective is to treat this kind of disease by a new kind of hyperthermia method.</p>
4401
4402			<div id="teljes-cikk" class="btn">
4403		<a href="http://www.hindawi.com/archive/2013/962349/" target="_blank"> View abstract</a>
4404	</div>
4405	
4406	</div>	<!-- .container -->
4407</div><!-- .entry-content -->
4408
4409
4410
4411</article><!-- #post-3344 -->
4412
4413			
4414<article id="post-3345" class="post-3345 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
4415	
4416	<header class="pub-entry-header">
4417	<div class="container">
4418		<h2>Low back pain – complex approach of treatment by different CAM modalities (Acupuncture and other type of dry-needling, “Targeted RF non invasive physiotherapy” for low back pain).</h2>
4419	</div>
4420	</header><!-- .entry-header -->
4421
4422
4423<div class="entry-content kl-pub-content">
4424	<div class="container">
4425		<div class="acf-fields">
4426	<div class="acf-row"><span class="publ-label">Indication:</span> Non-oncology <hr/> <span class="publ-label">Evidence:</span>  Phase I/II</div>
4427	<div class="publ-acf acf-row acf-flex">
4428	<span class="publ-label">Author:&nbsp;</span>
4429	<div class="szerzok">
4430		
4431		 
4432		
4433		<span class="sz-nev">Hegyi G</span>
4434   
4435		 
4436		
4437		<span class="sz-nev">Jian Li</span>
4438   
4439				</div>
4440	
4441	</div>
4442	<div class="acf-row"><span class="publ-label">No. of patients:</span> 2861 <hr/> <span class="publ-label">Therapy:</span>  mEHT<hr/> <span class="publ-label">Year:</span>  2013</div>
4443	</div><!-- .acf-fields -->
4444	<h3><strong>Abstract</strong></h3>
4445<p>For at least 2,500 years, acupuncture has been an integral part of the traditional Chinese medicine. Recently, more people are diagnosed with chronic disease, and many of them are poorly treated with conventional therapies. Those frequently prefer other forms of complementary medical treatments. Based on the theory of homeostatic equilibrium being the basis of health, acupuncture focuses on restoring the homeostasis by manipulation of the complementary and opposing elements of yin and yang. It is possible that by affecting afferent nerve signaling, acupuncture may influence the release of endogenous opioids to promote pain relief. Our objective is giving western trained physicians clinical applications together with acupuncture and modern physiotherapeutic equipment (booster) to accommodate accelerating interests in acupuncture and related techniques in modern complex treatment of chronic low back pain. In recent prospective phase I/II study, statistical data verified the relevant end points of the study: the safety, the quality of life (QoL), the rest time, duration of painless state, and cost/benefit ratio.</p>
4446
4447			<div id="teljes-cikk" class="btn">
4448		<a href="http://www.hindawi.com/archive/2013/326595/" target="_blank">
4448 View abstract</a>
4449	</div>
4450	
4451	</div>	<!-- .container -->
4452</div><!-- .entry-content -->
4453
4454
4455
4456</article><!-- #post-3345 -->
4457
4458			
4459<article id="post-3346" class="post-3346 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
4460	
4461	<header class="pub-entry-header">
4462	<div class="container">
4463		<h2>Oncothermia with chemotherapy in the patients with Small Cell Lung Cancer</h2>
4464	</div>
4465	</header><!-- .entry-header -->
4466
4467
4468<div class="entry-content kl-pub-content">
4469	<div class="container">
4470		<div class="acf-fields">
4471	<div class="acf-row"><span class="publ-label">Indication:</span> Lung <hr/> <span class="publ-label">Evidence:</span>  Phase I</div>
4472	<div class="publ-acf acf-row acf-flex">
4473	<span class="publ-label">Author:&nbsp;</span>
4474	<div class="szerzok">
4475		
4476		 
4477		
4478		<span class="sz-nev">Doo Yun Lee</span>
4479   
4480		 
4481		
4482		<span class="sz-nev">Seok Jin Haam</span>
4483   
4484		 
4485		
4486		<span class="sz-nev">Tae Hoon Kim</span>
4487   
4488		 
4489		
4490		<span class="sz-nev">Jae Yoon Lim</span>
4491   
4492		 
4493		
4494		<span class="sz-nev">Eun Jung Kim</span>
4495   
4496		 
4497		
4498		<span class="sz-nev">Na Young Kim</span>
4499   
4500				</div>
4501	
4502	</div>
4503	<div class="acf-row"><span class="publ-label">No. of patients:</span> 31 <hr/> <span class="publ-label">Therapy:</span>  CT+mEHT<hr/> <span class="publ-label">Year:</span>  2013</div>
4504	</div><!-- .acf-fields -->
4505	<p><strong>Abstract</strong></p>
4506<p>Small-cell lung cancer (SCLC) is one of the most aggressive and lethal forms of lung cancers. Chemotherapy and radiotherapy would be standard modality for SCLC with median survival being less than 4 months only. Complementary treatment to chemotherapy is desired. Oncothermia will be one of the candidates to this addition. We have made a study of 31 SCLC patients from April 2006 to March 2012. 23 cases were treated with combined chemotherapy and oncothermia, and 8 cases were treated with chemotherapy alone. Three patients from 14 patients (14/31) died in the study period; there were equal numbers in the two arms, including one long survival case of 28 months and one of 26 months, in the combination and chemo-group, respectively .16 patients (16/31) are alive: 4 patients with chemotherapy only, including one long survival case of 28.7 months, and 11 cases with combined therapy including three long survival cases of more than 3 years. We conclude that the combined use of chemotherapy and oncothermia has significantly enhanced the survival rate in comparison with the use of chemotherapy alone (log-rank test: P value &lt; 0.02).</p>
4507
4508			<div id="teljes-cikk" class="btn">
4509		<a href="https://www.hindawi.com/archive/2013/910363/" target="_blank"> View abstract</a>
4510	</div>
4511	
4512	</div>	<!-- .container -->
4513</div><!-- .entry-content -->
4514
4515
4516
4517</article><!-- #post-3346 -->
4518
4519			
4520<article id="post-3347" class="post-3347 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
4521	
4522	<header class="pub-entry-header">
4523	<div class="container">
4524		<h2>Hypoxia Immunity, Metabolism and Hyperthermia</h2>
4525	</div>
4526	</header><!-- .entry-header -->
4527
4528
4529<div class="entry-content kl-pub-content">
4530	<div class="container">
4531		<div class="acf-fields">
4532	<div class="acf-row"><span class="publ-label">Indication:</span> Immuno-oncology <hr/> <span class="publ-label">Evidence:</span>  Review</div>
4533	<div class="publ-acf acf-row acf-flex">
4534	<span class="publ-label">Author:&nbsp;</span>
4535	<div class="szerzok">
4536		
4537		 
4538		
4539		<span class="sz-nev">Baronzio G</span>
4540   
4541		 
4542		
4543		<span class="sz-nev">Kiselevsky M</span>
4544   
4545		 
4546		
4547		<span class="sz-nev">Ballerini M</span>
4548   
4549		 
4550		
4551		<span class="sz-nev">Cassuti V</span>
4552   
4553				</div>
4554	
4555	</div>
4556	<div class="acf-row"><span class="publ-label">No. of patients:</span>  <hr/> <span class="publ-label">Therapy:</span>  mEHT<hr/> <span class="publ-label">Year:</span>  2013</div>
4557	</div><!-- .acf-fields -->
4558	<p><strong>Abstract</strong></p>
4559<p>Hypoxia is common in solid tumors and in many other disease states such as myocardial infarction, stroke, bone fracture, and pneumonitis. Once hypoxia has developed, the undernourished and hypoxic cells trigger signals in order to obtain new blood vessels to satisfy their increasing demands and to resolve hypoxia. The principal signal activated is an ancestral oxygen sensor, the hypoxia inducible factor (HIF). After its nuclear translocation, HIF triggers a series of mediators that recruit, into the hypoxic milieu, several immature myeloid, mesenchymal, and endothelial progenitors cells. Resident and recruited cells participate in the processes of neoangiogenesis, for resolving the hypoxia, while at the same time trigger an inflammatory reaction. The inflammatory reaction has as primary end point, the repair of the damaged area, but if an insufficient production of resolvins is produced, the inflammatory reaction becomes chronic and is unable to repair the damaged t
4559issue. In this brief overview, we will show the differences and the similar events present in cancer, myocardial infarction, and stroke. Furthermore, the metabolic alterations produced in the tumor by hypoxia/HIF axis and the consequences on hyperthermic treatment are also discussed.</p>
4560
4561			<div id="teljes-cikk" class="btn">
4562		<a href="https://www.hindawi.com/archive/2013/528909/" target="_blank"> View abstract</a>
4563	</div>
4564	
4565	</div>	<!-- .container -->
4566</div><!-- .entry-content -->
4567
4568
4569
4570</article><!-- #post-3347 -->
4571
4572			
4573<article id="post-3348" class="post-3348 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
4574	
4575	<header class="pub-entry-header">
4576	<div class="container">
4577		<h2>Lyme Disease and Oncothermia</h2>
4578	</div>
4579	</header><!-- .entry-header -->
4580
4581
4582<div class="entry-content kl-pub-content">
4583	<div class="container">
4584		<div class="acf-fields">
4585	<div class="acf-row"><span class="publ-label">Indication:</span> Lyme-disease <hr/> <span class="publ-label">Evidence:</span>  Phase III</div>
4586	<div class="publ-acf acf-row acf-flex">
4587	<span class="publ-label">Author:&nbsp;</span>
4588	<div class="szerzok">
4589		
4590		 
4591		
4592		<span class="sz-nev">Zais O</span>
4593   
4594				</div>
4595	
4596	</div>
4597	<div class="acf-row"><span class="publ-label">No. of patients:</span> 12 <hr/> <span class="publ-label">Therapy:</span>  mEHT+Vitamins<hr/> <span class="publ-label">Year:</span>  2013</div>
4598	</div><!-- .acf-fields -->
4599	<h4>Abstract</h4>
4600<p>Lyme disease is a tick-borne disease with multiple organ failures, and systemic disorders. Dramatic change becomes apparent in the chronic phase of the disease. Chronic fatigue syndrome, lapse of concentration, depression, joint pain, and muscle pain are a few, but major clinical symptoms characterizing the disease. The human immune system is defenseless. Borrelia uses various mechanisms to escape from immunoattacks or antibiotic therapies. This “stealth phenomenon” needs new therapeutic principles to be interrupted. Our objective in this paper is to study the effect of oncothermia, which is a well-established oncological therapy, on Lyme disease. First, in our present work, we definitely concentrate on the quality of life of the patients.</p>
4601
4602			<div id="teljes-cikk" class="btn">
4603		<a href="http://www.hindawi.com/archive/2013/275013/" target="_blank"> View abstract</a>
4604	</div>
4605	
4606	</div>	<!-- .container -->
4607</div><!-- .entry-content -->
4608
4609
4610
4611</article><!-- #post-3348 -->
4612
4613			
4614<article id="post-3349" class="post-3349 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
4615	
4616	<header class="pub-entry-header">
4617	<div class="container">
4618		<h2>Oncothermia Application for Various Malignant Diseases</h2>
4619	</div>
4620	</header><!-- .entry-header -->
4621
4622
4623<div class="entry-content kl-pub-content">
4624	<div class="container">
4625		<div class="acf-fields">
4626	<div class="acf-row"><span class="publ-label">Indication:</span> Multiple <hr/> <span class="publ-label">Evidence:</span>  Retrospective study</div>
4627	<div class="publ-acf acf-row acf-flex">
4628	<span class="publ-label">Author:&nbsp;</span>
4629	<div class="szerzok">
4630		
4631		 
4632		
4633		<span class="sz-nev">Youngsuk Lee</span>
4634   
4635				</div>
4636	
4637	</div>
4638	<div class="acf-row"><span class="publ-label">No. of patients:</span> 277 <hr/> <span class="publ-label">Therapy:</span>  CT+RT+mEHT<hr/> <span class="publ-label">Year:</span>  2013</div>
4639	</div><!-- .acf-fields -->
4640	<h5>ABSTRACT</h5>
4641<p>Oncothermia was introduced to our hospital in 2010. Our objective is to report results of 277 patients treated by oncothermia during 20 months. We present some characteristic cases and statistical study of the overall results. We concluded by stating the feasibility of oncothermia to treat high variety of malignant diseases also in their very advanced (T4N3M1) stages.</p>
4642
4643			<div id="teljes-cikk" class="btn">
4644		<a href="http://www.hindawi.com/archive/2013/245156/" target="_blank"> View abstract</a>
4645	</div>
4646	
4647	</div>	<!-- .container -->
4648</div><!-- .entry-content -->
4649
4650
4651
4652</article><!-- #post-3349 -->
4653
4654			
4655<article id="post-3350" class="post-3350 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
4656	
4657	<header class="pub-entry-header">
4658	<div class="container">
4659		<h2>Oncothermia in HIV positive and negative locally advanced cervical cancer patients in South Africa</h2>
4660	</div>
4661	</header><!-- .entry-header -->
4662
4663
4664<div class="entry-content kl-pub-content">
4665	<div class="container">
4666		<div class="acf-fields">
4667	<div class="acf-row"><span class="publ-label">Indication:</span> Gynecology <hr/> <span class="publ-label">Evidence:</span>  Phase III</div>
4668	<div class="publ-acf acf-row acf-flex">
4669	<span class="publ-label">Author:&nbsp;</span>
4670	<div class="szerzok">
4671		
4672		 
4673		
4674		<span class="sz-nev">Carrie Strauss</span>
4675   
4676		 
4677		
4678		<span class="sz-nev">Jeffrey Kotzen</span>
4679   
4680		 
4681		
4682		<span class="sz-nev">
4682Ans Baeyens</span>
4683   
4684		 
4685		
4686		<span class="sz-nev">Irma Maré</span>
4687   
4688				</div>
4689	
4690	</div>
4691	<div class="acf-row"><span class="publ-label">No. of patients:</span> 236 <hr/> <span class="publ-label">Therapy:</span>  CT+RT+mEHT<hr/> <span class="publ-label">Year:</span>  2013</div>
4692	</div><!-- .acf-fields -->
4693	<p><strong>Abstract</strong></p>
4694<p>Aim. Investigate the clinical, economic, and cellular effects of the addition of oncothermia to standard treatment for HIV-positive and -negative locally advanced cervical cancer patients in public healthcare in South Africa. Objectives. Evaluate the effect that the addition of oncothermia has on local disease control, progression-free survival, overall survival at 2 years, treatment toxicity, quality of life, economic impact, and HIV status of participants. Radiobiology investigations will evaluate thermoradiosensitivity and the molecular markers for thermoradiosensitivity. Methodology. Phase III randomised clinical trial involving 236 HIV-negative and -positive stage IIb-III locally advanced cervical cancer patients. Treatment includes cisplatin, external beam radiation, and brachytherapy. The study group will receive oncothermia treatments. Participants will be monitored for two years after completion of treatment. Hypothesis. The addition of oncothermia to standard treatment protocols will result in improved clinical response without increasing treatment toxicity in HIV-positive patients or raising healthcare costs.</p>
4695
4696			<div id="teljes-cikk" class="btn">
4697		<a href="https://www.hindawi.com/archive/2013/293968/" target="_blank"> View abstract</a>
4698	</div>
4699	
4700	</div>	<!-- .container -->
4701</div><!-- .entry-content -->
4702
4703
4704
4705</article><!-- #post-3350 -->
4706
4707			
4708<article id="post-3351" class="post-3351 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
4709	
4710	<header class="pub-entry-header">
4711	<div class="container">
4712		<h2>Treatment of advanced cervical cancer with complex chemoradio – hyperthermia</h2>
4713	</div>
4714	</header><!-- .entry-header -->
4715
4716
4717<div class="entry-content kl-pub-content">
4718	<div class="container">
4719		<div class="acf-fields">
4720	<div class="acf-row"><span class="publ-label">Indication:</span> Gynecology <hr/> <span class="publ-label">Evidence:</span>  Retrospective study</div>
4721	<div class="publ-acf acf-row acf-flex">
4722	<span class="publ-label">Author:&nbsp;</span>
4723	<div class="szerzok">
4724		
4725		 
4726		
4727		<span class="sz-nev">Lajos Pesti</span>
4728   
4729		 
4730		
4731		<span class="sz-nev">Zsófia Dankovics</span>
4732   
4733		 
4734		
4735		<span class="sz-nev">Péter Lorencz</span>
4736   
4737		 
4738		
4739		<span class="sz-nev">András Csejtei</span>
4740   
4741				</div>
4742	
4743	</div>
4744	<div class="acf-row"><span class="publ-label">No. of patients:</span> 72 <hr/> <span class="publ-label">Therapy:</span>  CT+mEHT<hr/> <span class="publ-label">Year:</span>  2013</div>
4745	</div><!-- .acf-fields -->
4746	<p><strong>Abstract</strong></p>
4747<p>This single arm, retrospective, single institution study investigated intention to treat patients (n=72) with advanced cancer of cervix of uterus. The study was performed in 2001–2010, providing 331 sessions. All patients had radiotherapies as fractional radiotherapy and intracavital brachytherapy. Some patients (n=34) received chemotherapy (Cisplatin 40 mg/m2/week; concomitantly with tele-radiotherapy) as well. Complementary to the teleradiotherapy, oncothermia was used two times a week, targeting the pelvis. Applied energy dose was 45 W, 60 min. Oncothermia was applied immediately after the infusion, when chemotherapy was also administered. Complete and partial remission were achieved in trimodal therapies for 73.5% of the patients, while we could stabilize the disease for 14.7% of the patients.</p>
4748
4749			<div id="teljes-cikk" class="btn">
4750		<a href="https://www.hindawi.com/archive/2013/192435/" target="_blank"> View abstract</a>
4751	</div>
4752	
4753	</div>	<!-- .container -->
4754</div><!-- .entry-content -->
4755
4756
4757
4758</article><!-- #post-3351 -->
4759
4760			
4761<article id="post-3352" class="post-3352 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
4762	
4763	<header class="pub-entry-header">
4764	<div class="container">
4765		<h2>Successful Treatment of Advanced Ovarian Cancer with Thermochemotherapy and Adjuvant Immune Therapy</h2>
4766	</div>
4767	</header><!-- .entry-header -->
4768
4769
4770<div class="entry-content kl-pub-content">
4771	<div class="container">
4772		<div class="acf-fields">
4773	<div class="acf-row"><span class="publ-label">Indication:</span> Gynecology <hr/> <span class="publ-label">Evidence:</span>  Case report</div>
4774	<div class="publ-acf acf-row acf-flex">
4775	<span class="publ-label">Author:&nbsp;</span>
4776	<div class="szerzok">
4777		
4778		 
4779		
4780		<span class="sz-nev">R. Kleef</span>
4781   
4782		 
4783		
4784		<span class="sz-nev">S. Kekic</span>
4785   
4786		 
4787		
4788		<span class="sz-nev">N. Ludwig</span>
4789   
4790				</div>
4791	
4792	</div>
4793	<div class="acf-row"><span class="publ-label">No. of patients:</span> 1 <hr/> <span class="publ-label">Therapy:</span>  CT+mEHT<hr/> <span class="publ-label">Year:</span>  2012</div>
4794	</div><!-- .acf-fields -->
4795	<p><strong>Abstract</strong><br />
4796We report on a 4-year progression-free survival of a 54-year-old female first diagnosed in December 2007 with advanced bilateral ovarian cancer FIGO IIIc, disseminated peritoneal carcinosis and malignant diaphragm invasion. Treatment started in January 2008 with 6 cycles of Taxol 175 mg/m2/carboplatin AUC 5 in 3-week intervals. Twenty-four hours following each chemotherapy session, fever-range long-duration whole-body hyperthermia (WBH) was performed at the temperature plateau of 40°C body core temperature for 6 h. Three months after completion of chemotherapy, 4 more long-duration WBH procedures were performed in monthly intervals. Importantly, long-duration WBH was paralleled with intradermal vaccination of autologous dendritic cells. No other treatment was given to the patient. Four years following the first diagnosis, the patient is still in complete remission with no evidence of disease.</p>
4797
4798			<div id="teljes-cikk" class="btn">
4799		<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Successful%20Treatment%20of%20Advanced%20Ovarian%20Cancer%20with%20Thermochemotherapy%20and%20Adjuvant%20Immune%20Therapy" target="_blank">
4799 View abstract</a>
4800	</div>
4801	
4802	</div>	<!-- .container -->
4803</div><!-- .entry-content -->
4804
4805
4806
4807</article><!-- #post-3352 -->
4808
4809			
4810<article id="post-3353" class="post-3353 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
4811	
4812	<header class="pub-entry-header">
4813	<div class="container">
4814		<h2>Für und Wider des Prostata-Karzinom-Screenings</h2>
4815	</div>
4816	</header><!-- .entry-header -->
4817
4818
4819<div class="entry-content kl-pub-content">
4820	<div class="container">
4821		<div class="acf-fields">
4822	<div class="acf-row"><span class="publ-label">Indication:</span> Prostate <hr/> <span class="publ-label">Evidence:</span>  </div>
4823	<div class="publ-acf acf-row acf-flex">
4824	<span class="publ-label">Author:&nbsp;</span>
4825	<div class="szerzok">
4826		
4827		 
4828		
4829		<span class="sz-nev">Douwes FR</span>
4830   
4831				</div>
4832	
4833	</div>
4834	<div class="acf-row"><span class="publ-label">No. of patients:</span>  <hr/> <span class="publ-label">Therapy:</span>  <hr/> <span class="publ-label">Year:</span>  2011</div>
4835	</div><!-- .acf-fields -->
4836	
4837	
4838	</div>	<!-- .container -->
4839</div><!-- .entry-content -->
4840
4841
4842
4843</article><!-- #post-3353 -->
4844
4845			
4846<article id="post-3354" class="post-3354 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
4847	
4848	<header class="pub-entry-header">
4849	<div class="container">
4850		<h2>Adjuvante Radiotherapie: Welcher Patient mit Prostatakarzinom profitiert?</h2>
4851	</div>
4852	</header><!-- .entry-header -->
4853
4854
4855<div class="entry-content kl-pub-content">
4856	<div class="container">
4857		<div class="acf-fields">
4858	<div class="acf-row"><span class="publ-label">Indication:</span> Prostate <hr/> <span class="publ-label">Evidence:</span>  </div>
4859	<div class="publ-acf acf-row acf-flex">
4860	<span class="publ-label">Author:&nbsp;</span>
4861	<div class="szerzok">
4862		
4863		 
4864		
4865		<span class="sz-nev">Douwes FR</span>
4866   
4867				</div>
4868	
4869	</div>
4870	<div class="acf-row"><span class="publ-label">No. of patients:</span>  <hr/> <span class="publ-label">Therapy:</span>  <hr/> <span class="publ-label">Year:</span>  2011</div>
4871	</div><!-- .acf-fields -->
4872	
4873	
4874	</div>	<!-- .container -->
4875</div><!-- .entry-content -->
4876
4877
4878
4879</article><!-- #post-3354 -->
4880
4881			
4882<article id="post-3355" class="post-3355 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
4883	
4884	<header class="pub-entry-header">
4885	<div class="container">
4886		<h2>Successful Treatment of Solitary Bone Metastasis of Non-Small Cell Lung Cancer with Bevacizumab and Hyperthermia</h2>
4887	</div>
4888	</header><!-- .entry-header -->
4889
4890
4891<div class="entry-content kl-pub-content">
4892	<div class="container">
4893		<div class="acf-fields">
4894	<div class="acf-row"><span class="publ-label">Indication:</span> Bone <hr/> <span class="publ-label">Evidence:</span>  Case report</div>
4895	<div class="publ-acf acf-row acf-flex">
4896	<span class="publ-label">Author:&nbsp;</span>
4897	<div class="szerzok">
4898		
4899		 
4900		
4901		<span class="sz-nev">Gábor Rubovszky</span>
4902   
4903		 
4904		
4905		<span class="sz-nev">Tünde Nagy</span>
4906   
4907		 
4908		
4909		<span class="sz-nev">Mária Gődény</span>
4910   
4911		 
4912		
4913		<span class="sz-nev">András Szász</span>
4914   
4915		 
4916		
4917		<span class="sz-nev">István Láng</span>
4918   
4919				</div>
4920	
4921	</div>
4922	<div class="acf-row"><span class="publ-label">No. of patients:</span> 1 <hr/> <span class="publ-label">Therapy:</span>  CT+mEHT<hr/> <span class="publ-label">Year:</span>  2011</div>
4923	</div><!-- .acf-fields -->
4924	<p><strong>Abstract</strong></p>
4925<p>Non-small cell lung cancer (NSCLC) represents 85 % of all malignant lung cancers. In metastatic disease the principle goal of palliative therapy is to prolong survival with least toxicity and best patients’ quality of life. Bevacizumab (BEV) has been approved as first line treatment in combination with platinum based chemotherapy and maintenance therapy in NSCLC. BEV can be added safely to several chemotherapeutic agents, however there is no data on coadministration with thermotherapy. Even in localized disease no robust evidence exists about the beneficial effect of loco-regional thermotherapy on overall survival, but it might be used successfully in symptom palliation. In this article a successful co-administration of BEV and hyperthermia is reported in a patient with monolocalized bone metastasis from previously operated NSCLC. This case suggests that electrohyperthermia can probably be incorporated in palliative therapy added not only to radiotherapy or chemotherapy but also to anti-angiogenic BEV treatment.</p>
4926
4927			<div id="teljes-cikk" class="btn">
4928		<a href="https://www.ncbi.nlm.nih.gov/pubmed/22752712" target="_blank">
4928 View abstract</a>
4929	</div>
4930	
4931	</div>	<!-- .container -->
4932</div><!-- .entry-content -->
4933
4934
4935
4936</article><!-- #post-3355 -->
4937
4938			
4939<article id="post-3356" class="post-3356 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
4940	
4941	<header class="pub-entry-header">
4942	<div class="container">
4943		<h2>Neue Studie heizt Diskussion über den Wert von PSA-Tests an</h2>
4944	</div>
4945	</header><!-- .entry-header -->
4946
4947
4948<div class="entry-content kl-pub-content">
4949	<div class="container">
4950		<div class="acf-fields">
4951	<div class="acf-row"><span class="publ-label">Indication:</span> Prostate <hr/> <span class="publ-label">Evidence:</span>  </div>
4952	<div class="publ-acf acf-row acf-flex">
4953	<span class="publ-label">Author:&nbsp;</span>
4954	<div class="szerzok">
4955		
4956		 
4957		
4958		<span class="sz-nev">Douwes FR</span>
4959   
4960				</div>
4961	
4962	</div>
4963	<div class="acf-row"><span class="publ-label">No. of patients:</span>  <hr/> <span class="publ-label">Therapy:</span>  <hr/> <span class="publ-label">Year:</span>  2011</div>
4964	</div><!-- .acf-fields -->
4965	
4966	
4967	</div>	<!-- .container -->
4968</div><!-- .entry-content -->
4969
4970
4971
4972</article><!-- #post-3356 -->
4973
4974			
4975<article id="post-3357" class="post-3357 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
4976	
4977	<header class="pub-entry-header">
4978	<div class="container">
4979		<h2>Oncothermia: Emerging Therapy in Oncology</h2>
4980	</div>
4981	</header><!-- .entry-header -->
4982
4983
4984<div class="entry-content kl-pub-content">
4985	<div class="container">
4986		<div class="acf-fields">
4987	<div class="acf-row"><span class="publ-label">Indication:</span> Multiple <hr/> <span class="publ-label">Evidence:</span>  Review</div>
4988	<div class="publ-acf acf-row acf-flex">
4989	<span class="publ-label">Author:&nbsp;</span>
4990	<div class="szerzok">
4991		
4992		 
4993		
4994		<span class="sz-nev">Marwan Akasheh</span>
4995   
4996				</div>
4997	
4998	</div>
4999	<div class="acf-row"><span class="publ-label">No. of patients:</span>  <hr/> <span class="publ-label">Therapy:</span>  <hr/> <span class="publ-label">Year:</span>  2010</div>
5000	</div><!-- .acf-fields -->
5001	<h4>Abstract</h4>
5002<p class="text-align-justify">The healing effect of heat was already mentioned in the advanced cultures of the old Egypt (2400 B.C.), but only the medical professionals of the Greek Antique used this therapeutic approach consistently, acknowledged it and called it over-warming (in Greek: Hyperthermia). Oncothermia is a new paradigm which entails the generation of temperature gradient by self-selection absorption of electric field energy based on the bio-impedance selection and modulated radiofrequency electric current to produce lethal heat flow between the extra- and intracellular matrix of the tumor cell membrane. It provides synergies with other traditional treatment modalities. The spread of this technology worldwide is a strong evidence to support it, based on palliative pain control and prolongation of survival in many solid tumors e.g. liver, pancreas, brain, prostate and lung when other therapies fail.</p>
5003<p><strong>Keywords:</strong><br />
5004Oncothermia, Cancer, Deep Electro-Hyperthermia, Conductive Hyperthermia, Modulated Radiofrequency Electric Field.</p>
5005
5006			<div id="teljes-cikk" class="btn">
5007		<a href="http://journals.ju.edu.jo/JMJ/article/view/2088" target="_blank"> View abstract</a>
5008	</div>
5009	
5010	</div>	<!-- .container -->
5011</div><!-- .entry-content -->
5012
5013
5014
5015</article><!-- #post-3357 -->
5016
5017			
5018<article id="post-3358" class="post-3358 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
5019	
5020	<header class="pub-entry-header">
5021	<div class="container">
5022		<h2>Transcranial electro-hyperthermia combined with alkylating chemotherapy in patients with relapsed high-grade gliomas: phase I clinical results</h2>
5023	</div>
5024	</header><!-- .entry-header -->
5025
5026
5027<div class="entry-content kl-pub-content">
5028	<div class="container">
5029		<div class="acf-fields">
5030	<div class="acf-row"><span class="publ-label">Indication:</span> Gliomas (advanced) <hr/> <span class="publ-label">Evidence:</span>  Phase I</div>
5031	<div class="publ-acf acf-row acf-flex">
5032	<span class="publ-label">Author:&nbsp;</span>
5033	<div class="szerzok">
5034		
5035		 
5036		
5037		<span class="sz-nev">Wismeth C</span>
5038   
5039		 
5040		
5041		<span class="sz-nev">Dudel C</span>
5042   
5043		 
5044		
5045		<span class="sz-nev">Pascher C</span>
5046   
5047		 
5048		
5049		<span class="sz-nev">
5049Ramm P</span>
5050   
5051		 
5052		
5053		<span class="sz-nev">Pietsch T</span>
5054   
5055		 
5056		
5057		<span class="sz-nev">Hirschmann</span>
5058   
5059		 
5060		
5061		<span class="sz-nev">Reinert C</span>
5062   
5063		 
5064		
5065		<span class="sz-nev">Proescholdt M</span>
5066   
5067		 
5068		
5069		<span class="sz-nev">Rümmele P</span>
5070   
5071		 
5072		
5073		<span class="sz-nev">Schuierer G</span>
5074   
5075		 
5076		
5077		<span class="sz-nev">Bogdahn U</span>
5078   
5079		 
5080		
5081		<span class="sz-nev">Hau P</span>
5082   
5083				</div>
5084	
5085	</div>
5086	<div class="acf-row"><span class="publ-label">No. of patients:</span> 15 <hr/> <span class="publ-label">Therapy:</span>  CT+mEHT<hr/> <span class="publ-label">Year:</span>  2009</div>
5087	</div><!-- .acf-fields -->
5088	<h3>Abstract</h3>
5089<p>Non-invasive loco-regional electro-hyperthermia (EHT) plus alkylating chemotherapy is occasionally used as salvage treatment in the relapse of patients with high-grade gliomas. Experimental data and retrospective studies suggest potential effects. However, no prospective clinical results are available. We performed a single-center prospective non-controlled single-arm Phase I trial. Main inclusion criteria were recurrent high-grade glioma WHO Grade III or IV, age 18-70, and Karnofsky performance score &gt; or = 70. Primary endpoints were dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) with the combined regimen. Groups of 3 or 4 patients were treated 2-5 times a week in a dose-escalation scheme with EHT. Alkylating chemotherapy (ACNU, nimustin) was administered at a dose of 90 mg/m(2) on day 1 of 42 days for up to six cycles or until tumor progression (PD) or DLT occurred. Fifteen patients with high-grade gliomas were included. Relevant toxicities were local pain and increased focal neurological signs or intracranial pressure. No DLT occurred. In some patients, the administration of mannitol during EHT or long-term use of corticosteroids was necessary to resolve symptoms. Although some patients showed responses in their primarily treated sites, the pattern of response was not well defined. EHT plus alkylating chemotherapy is tolerable in patients with relapse of high-grade gliomas. Episodes of intracranial pressure were, at least, possibly attributed to EHT but did not cause DLTs. A Phase II trial targeting treatment effects is warranted on the basis of the results raised in this trial.</p>
5090
5091			<div id="teljes-cikk" class="btn">
5092		<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Transcranial%20electro-hyperthermia%20combined%20with%20alkylating%20chemotherapy%20in%20patients%20with%20relapsed%20high-grade%20gliomas%20%E2%80%93%20Phase%20I%20clinical%20results" target="_blank"> View abstract</a>
5093	</div>
5094	
5095	</div>	<!-- .container -->
5096</div><!-- .entry-content -->
5097
5098
5099
5100</article><!-- #post-3358 -->
5101
5102			
5103<article id="post-3359" class="post-3359 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
5104	
5105	<header class="pub-entry-header">
5106	<div class="container">
5107		<h2>Clinical study for advanced non-small-cell lung-cancer treated by oncothermia</h2>
5108	</div>
5109	</header><!-- .entry-header -->
5110
5111
5112<div class="entry-content kl-pub-content">
5113	<div class="container">
5114		<div class="acf-fields">
5115	<div class="acf-row"><span class="publ-label">Indication:</span> Lung <hr/> <span class="publ-label">Evidence:</span>  Open-label study</div>
5116	<div class="publ-acf acf-row acf-flex">
5117	<span class="publ-label">Author:&nbsp;</span>
5118	<div class="szerzok">
5119		
5120		 
5121		
5122		<span class="sz-nev">Dani A</span>
5123   
5124		 
5125		
5126		<span class="sz-nev">Varkonyi A</span>
5127   
5128		 
5129		
5130		<span class="sz-nev">Magyar T</span>
5131   
5132		 
5133		
5134		<span class="sz-nev">Szasz A</span>
5135   
5136				</div>
5137	
5138	</div>
5139	<div class="acf-row"><span class="publ-label">No. of patients:</span> 258 <hr/> <span class="publ-label">Therapy:</span>  CT+RT+mEHT<hr/> <span class="publ-label">Year:</span>  2009</div>
5140	</div><!-- .acf-fields -->
5141	<p><strong>Abstract</strong></p>
5142<p>The non-small-cell-lung-cancer (NSCLC) is a common malignant tumor, and generally not best candidates for hyperthermia due to the cooling effect of the breathing. We present two retrospective clinical studies for NSCLC done by two medical centers (HTT-MED Day-clinic and Peterfy Hospital) made by special modulated field electro-hyperthermia, called oncothermia. Both of the centers made the treatments by oncothermia in combination with the conventional tumor-therapies. We present the data from both of the centers and make a metaanalysis as well. Results show a remarkable survival benefit for the patients compared to the historical data. The comparison of the studies demonstrates a good correspondence in the data, which strengthens the reliability of the studies, and greatly points out the feasibility of the oncothermia application on the NSCLC.</p>
5143
5144			<div id="teljes-cikk" class="btn">
5145		<a href="http://www.oncotherm.com/sites/oncotherm/files/2017-07/Clinical_study_for_advanced_non-small-cell_lung_cancer_treated.pdf?_gl=1*1ydmeok*_ga*OTcyNjI1MTIwLjE3MDI2MzM4MDM.*_ga_MD8BX5Q6D8*MTcwMjk4NDg5Ny4xLjEuMTcwMjk4NTE1Mi4wLjAuMA.." target="_blank">
5145 View abstract</a>
5146	</div>
5147	
5148	</div>	<!-- .container -->
5149</div><!-- .entry-content -->
5150
5151
5152
5153</article><!-- #post-3359 -->
5154
5155			
5156<article id="post-3360" class="post-3360 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
5157	
5158	<header class="pub-entry-header">
5159	<div class="container">
5160		<h2>Clinical study for advanced pancreas cancer treated by oncothermia</h2>
5161	</div>
5162	</header><!-- .entry-header -->
5163
5164
5165<div class="entry-content kl-pub-content">
5166	<div class="container">
5167		<div class="acf-fields">
5168	<div class="acf-row"><span class="publ-label">Indication:</span> Pancreas <hr/> <span class="publ-label">Evidence:</span>  Clinical study</div>
5169	<div class="publ-acf acf-row acf-flex">
5170	<span class="publ-label">Author:&nbsp;</span>
5171	<div class="szerzok">
5172		
5173		 
5174		
5175		<span class="sz-nev">Dani A</span>
5176   
5177		 
5178		
5179		<span class="sz-nev">Varkonyi A</span>
5180   
5181		 
5182		
5183		<span class="sz-nev">Magyar T</span>
5184   
5185		 
5186		
5187		<span class="sz-nev">Szasz A</span>
5188   
5189				</div>
5190	
5191	</div>
5192	<div class="acf-row"><span class="publ-label">No. of patients:</span> 99 <hr/> <span class="publ-label">Therapy:</span>  CT+RT+mEHT<hr/> <span class="publ-label">Year:</span>  2008</div>
5193	</div><!-- .acf-fields -->
5194	<p><strong>Abstract</strong></p>
5195<p>Pancreas cancer (PCA) is an aggressive, common malignant tumor. We present two retrospective clinical studies of PCA done in two medical centers (HTT-MED Day-clinic and Peterfy Hospital). Both of the centers made the treatments by oncothermia in combination with the conventional tumor-therapies. We present the data from both centers and make a metaanalysis of the data as well. Results show a remarkable survival benefit for the patients compared to the historical data. The comparison of the studies shows a good correspondence in the data, which strengthens the reliability of the studies, and points out the feasibility of the oncothermia application on PCA.</p>
5196
5197			<div id="teljes-cikk" class="btn">
5198		<a href="http://www.pyatthealth.com/wp-content/uploads/2015/03/Hyperthermia-Pancreatic-Cancer.pdf" target="_blank"> View abstract</a>
5199	</div>
5200	
5201	</div>	<!-- .container -->
5202</div><!-- .entry-content -->
5203
5204
5205
5206</article><!-- #post-3360 -->
5207
5208			
5209<article id="post-3361" class="post-3361 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
5210	
5211	<header class="pub-entry-header">
5212	<div class="container">
5213		<h2>Prostatakarzinom: Neue Aspekte für Diagnostik und Therapie</h2>
5214	</div>
5215	</header><!-- .entry-header -->
5216
5217
5218<div class="entry-content kl-pub-content">
5219	<div class="container">
5220		<div class="acf-fields">
5221	<div class="acf-row"><span class="publ-label">Indication:</span> Prostate <hr/> <span class="publ-label">Evidence:</span>  </div>
5222	<div class="publ-acf acf-row acf-flex">
5223	<span class="publ-label">Author:&nbsp;</span>
5224	<div class="szerzok">
5225		
5226		 
5227		
5228		<span class="sz-nev">Douwes FR</span>
5229   
5230				</div>
5231	
5232	</div>
5233	<div class="acf-row"><span class="publ-label">No. of patients:</span>  <hr/> <span class="publ-label">Therapy:</span>  <hr/> <span class="publ-label">Year:</span>  2008</div>
5234	</div><!-- .acf-fields -->
5235	
5236	
5237	</div>	<!-- .container -->
5238</div><!-- .entry-content -->
5239
5240
5241
5242</article><!-- #post-3361 -->
5243
5244			
5245<article id="post-3362" class="post-3362 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
5246	
5247	<header class="pub-entry-header">
5248	<div class="container">
5249		<h2>Prospective phase II trial for recurrent high-grade malignant gliomas with capacitive coupled low radiofrequency (LRF) deep hyperthermia</h2>
5250	</div>
5251	</header><!-- .entry-header -->
5252
5253
5254<div class="entry-content kl-pub-content">
5255	<div class="container">
5256		<div class="acf-fields">
5257	<div class="acf-row"><span class="publ-label">Indication:</span> Gliomas (advanced) <hr/> <span class="publ-label">Evidence:</span>  Phase II</div>
5258	<div class="publ-acf acf-row acf-flex">
5259	<span class="publ-label">Author:&nbsp;</span>
5260	<div class="szerzok">
5261		
5262		 
5263		
5264		<span class="sz-nev">Hager ED</span>
5265   
5266		 
5267		
5268		<span class="sz-nev">Sahinbas H</span>
5269   
5270		 
5271		
5272		<span class="sz-nev">Groenemeyer DH</span>
5273   
5274		 
5275		
5276		<span class="sz-nev">Migeod F</span>
5277   
5278				</div>
5279	
5280	</div>
5281	<div class="acf-row"><span class="publ-label">No. of patients:</span> 179 <hr/> <span class="publ-label">Therapy:</span>  CT+RT+mEHT<hr/> <span class="publ-label">Year:</span>  2008</div>
5282	</div><!-- .acf-fields -->
5283	<p><strong>Abstract</strong></p>
5284<p>Treatment of malignant gliomas is in spite of many new approaches still disappointing. Median survival time (MST) of pts. with glioblastoma multiforme (GM) after diagnosis is 6 to 12 months. Surgery is treatment of first choice, but in most cases healing is not possible. The aims of surgery are tumor debulking or decompression of the brain. Radiation will double MST after surgery but high grade gliomas are not very radiosensitivesurvival. Concomitant radiation with temozollamide 
5284could increase median survival time of pts with GM from 12.1 to 14.6 months.</p>
5285
5286			<div id="teljes-cikk" class="btn">
5287		<a href="http://www.portmoodyhealth.com/resource/prospective-phase-ii-trial-for-recurrent-high-grade-malignant-gliomas-with-capacitive-coupled-low-radiofrequency-lrf-deep-hyperthermia/" target="_blank"> View abstract</a>
5288	</div>
5289	
5290	</div>	<!-- .container -->
5291</div><!-- .entry-content -->
5292
5293
5294
5295</article><!-- #post-3362 -->
5296
5297			
5298<article id="post-3363" class="post-3363 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
5299	
5300	<header class="pub-entry-header">
5301	<div class="container">
5302		<h2>Sanfte Hilfen für die Prostata</h2>
5303	</div>
5304	</header><!-- .entry-header -->
5305
5306
5307<div class="entry-content kl-pub-content">
5308	<div class="container">
5309		<div class="acf-fields">
5310	<div class="acf-row"><span class="publ-label">Indication:</span> Prostate <hr/> <span class="publ-label">Evidence:</span>  </div>
5311	<div class="publ-acf acf-row acf-flex">
5312	<span class="publ-label">Author:&nbsp;</span>
5313	<div class="szerzok">
5314		
5315		 
5316		
5317		<span class="sz-nev">Douwes FR</span>
5318   
5319				</div>
5320	
5321	</div>
5322	<div class="acf-row"><span class="publ-label">No. of patients:</span>  <hr/> <span class="publ-label">Therapy:</span>  <hr/> <span class="publ-label">Year:</span>  2008</div>
5323	</div><!-- .acf-fields -->
5324	
5325	
5326	</div>	<!-- .container -->
5327</div><!-- .entry-content -->
5328
5329
5330
5331</article><!-- #post-3363 -->
5332
5333			
5334<article id="post-3364" class="post-3364 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
5335	
5336	<header class="pub-entry-header">
5337	<div class="container">
5338		<h2>Deep electro-hyperthermia (EHY) with or without thermo-active agents in patients with advanced hepatic cell carcinoma: phase II study</h2>
5339	</div>
5340	</header><!-- .entry-header -->
5341
5342
5343<div class="entry-content kl-pub-content">
5344	<div class="container">
5345		<div class="acf-fields">
5346	<div class="acf-row"><span class="publ-label">Indication:</span> Liver <hr/> <span class="publ-label">Evidence:</span>  Phase II</div>
5347	<div class="publ-acf acf-row acf-flex">
5348	<span class="publ-label">Author:&nbsp;</span>
5349	<div class="szerzok">
5350		
5351		 
5352		
5353		<span class="sz-nev">Ferrari VD</span>
5354   
5355		 
5356		
5357		<span class="sz-nev">De Ponti S</span>
5358   
5359		 
5360		
5361		<span class="sz-nev">Valcamonico F</span>
5362   
5363		 
5364		
5365		<span class="sz-nev">Amoroso V</span>
5366   
5367		 
5368		
5369		<span class="sz-nev">Grisanti S</span>
5370   
5371		 
5372		
5373		<span class="sz-nev">Rangoni G</span>
5374   
5375		 
5376		
5377		<span class="sz-nev">Marpicati P</span>
5378   
5379		 
5380		
5381		<span class="sz-nev">Vassalli L</span>
5382   
5383		 
5384		
5385		<span class="sz-nev">Simoncini E</span>
5386   
5387		 
5388		
5389		<span class="sz-nev">Marini G</span>
5390   
5391				</div>
5392	
5393	</div>
5394	<div class="acf-row"><span class="publ-label">No. of patients:</span> 22 <hr/> <span class="publ-label">Therapy:</span>  SRG+CT+mEHT<hr/> <span class="publ-label">Year:</span>  2007</div>
5395	</div><!-- .acf-fields -->
5396	<p><strong>Background</strong>: Advanced HCC has no standard chemotherapy , all pts would be valuabled in clinical trials. We evaluated effectiveness and toxicity of capacitatively coupled low-frequency 13.56 MHz deep hyperthermia (Oncotherm-EHY 2000) treatment on chemo- refractory malignant primary liver cancer which underwent all other possible treatment. <strong>Methods</strong>: From February 2005 to July 2006, we enrolled 22 pts with advanced HCC. ECOG PS was 1 or O. Viral hepatic infection status was 7 HBV+, 8 HCV+, 1 HCV/HBV+. Median age was 67,5 y (range 63 -78), male/female 20/2 . 15 pts were uneligible for liver surgery, 3 pts received TACE, 1 PEI, 1 a lot of therapy. 7 pts were pre-treated with surgery, 2 also received TACE, 1 PEI and 1 a lot of therapy. 75% of pts were in stage C of BCLC classification. 2 pts had also distant metastases, 70% of pts had portal vein thromboses. 8 pts underwent only to EHY without CT. Schedule: EHY was achieved by arrangements of capacitative electrodes with a radiofrequency field of 13.56 Mhz (RF-DHT) at 80- 130 W equivalent to 41 °- 47° C for 60 minutes, 2 times/w for 5 weeks in combination with thermo-active agents . EHY was applied over 2 time a week over 1 hour as mono &#8211; combined therapy . Concomitant chemotherapy was oxaliplatin 50 mgr at fixed dose on D 1and D 15. One 
5396cycle is 10 treatments of EHY ; 4 pts underwent 2 cycles and 2 pts to 3 cycles and 1 pt to 4 cycles . Median number of cycles was 1,5 (range 1–4), total EHY applications were 365. <strong>Results</strong>: EHY plus thermo-active drug is beneficial on clinical conditions off treated pts with an excellent compliance on out- patients. We observed 1 CR ( pt has only one bone metastases after 6 months without liver relapse), no PR, 25% of SD. Median survival time was 20’5 weeks (5 &#8211; 81+) We noted that 11 pts (50%) presented evidence of increasing well-being. Toxicity : 4 pts had skin reaction after application of EHY. In 3 pts we observed cutaneous hyperemia on the area of treatment and mild burn on the skin ; all symptoms disappeared after local steroid therapy , treatment was interrupted until resolution. <strong>Conclusions</strong>: Low toxicity and clinical benefit will be confirmed in further clinical studies. Capacitively coupled low-frequency 13.56 deep-hyperthermia is feasible for chemo-refractory HCC.</p>
5397
5398			<div id="teljes-cikk" class="btn">
5399		<a href="http://ascopubs.org/doi/abs/10.1200/jco.2007.25.18_suppl.15168" target="_blank"> View abstract</a>
5400	</div>
5401	
5402	</div>	<!-- .container -->
5403</div><!-- .entry-content -->
5404
5405
5406
5407</article><!-- #post-3364 -->
5408
5409			
5410<article id="post-3365" class="post-3365 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
5411	
5412	<header class="pub-entry-header">
5413	<div class="container">
5414		<h2>Retrospective clinical study of adjuvant electro-hyperthermia treatment for advanced brain-gliomas</h2>
5415	</div>
5416	</header><!-- .entry-header -->
5417
5418
5419<div class="entry-content kl-pub-content">
5420	<div class="container">
5421		<div class="acf-fields">
5422	<div class="acf-row"><span class="publ-label">Indication:</span> Gliomas (advanced) <hr/> <span class="publ-label">Evidence:</span>  Retrospective study</div>
5423	<div class="publ-acf acf-row acf-flex">
5424	<span class="publ-label">Author:&nbsp;</span>
5425	<div class="szerzok">
5426		
5427		 
5428		
5429		<span class="sz-nev">Sahinbas H</span>
5430   
5431		 
5432		
5433		<span class="sz-nev">Groenemeyer DHW</span>
5434   
5435		 
5436		
5437		<span class="sz-nev">Boecher E</span>
5438   
5439		 
5440		
5441		<span class="sz-nev">Szasz A</span>
5442   
5443				</div>
5444	
5445	</div>
5446	<div class="acf-row"><span class="publ-label">No. of patients:</span> 140 <hr/> <span class="publ-label">Therapy:</span>  mEHT<hr/> <span class="publ-label">Year:</span>  2007</div>
5447	</div><!-- .acf-fields -->
5448	<h3>Summary</h3>
5449<p>Malignant gliomas represent about 70 % of all brain tumors. Despite advances in standard therapy consisting of surgery, radiation therapy and chemotherapy, gliomas remain an essentially fatal disease, with a median survival time of 10 to 12 months and a 2-year survival rate of 8 % to 12 %. Electro-hyperthermia applied either alone or in combination with chemo- and/or radio-therapy is an advanced hyperthermia technique that has been used as adjuvant treatment for patients with malignant glioma. We present the results of a retrospective study of 140 patients with different stages of malignant glioma, which were treated/followed from January 2000 to February 2005. The endpoint was the overall survival and the survival from the 1st electro-hyperthermia treatment. The overall median survival time for patients with mostly advanced malignant glioma who received adjuvant electro-hyperthermia in this study was 20.4 months. The median survival time from the first electro-hyperthermia treatment was 6.6 months. Electro-hyperthermia was safe and well tolerated. The presented results show the feasibility of the treatment and suggest a benefit of the electro-hyperthermia treatment for patients with advanced malignant glioma.</p>
5450
5451			<div id="teljes-cikk" class="btn">
5452		<a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2007-986020" target="_blank"> View abstract</a>
5453	</div>
5454	
5455	</div>	<!-- .container -->
5456</div><!-- .entry-content -->
5457
5458
5459
5460</article><!-- #post-3365 -->
5461
5462			
5463<article id="post-3366" class="post-3366 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
5464	
5465	<header class="pub-entry-header">
5466	<div class="container">
5467		<h2>A Phase II Clinical Study on Relapsed Malignant Gliomas Treated with Electro-hyperthermia</h2>
5468	</div>
5469	</header><!-- .entry-header -->
5470
5471
5472<div class="entry-content kl-pub-content">
5473	<div class="container">
5474		<div class="acf-fields">
5475	<div class="acf-row"><span class="publ-label">Indication:</span> Gliomas (advanced) <hr/> <span class="publ-label">Evidence:</span>  Phase II</div>
5476	<div class="publ-acf acf-row acf-flex">
5477	<span class="publ-label">Author:&nbsp;</span>
5478	<div class="szerzok">
5479		
5480		 
5481		
5482		<span class="sz-nev">Giammaria Fiorentini</span>
5483   
5484		 
5485		
5486		<span class="sz-nev">Petros Giovanis</span>
5487   
5488		 
5489		
5490		<span class="sz-nev">Susanna Rossi</span>
5491   
5492		 
5493		
5494		<span class="sz-nev">Patrizia Dentico</span>
5495   
5496		 
5497		
5498		<span class="sz-nev">Raffaele Paola</span>
5499   
5500		 
5501		
5502		<span class="sz-nev">Gina Turrisi</span>
5503   
5504		 
5505		
5506		<span class="sz-nev">Paolo Bernardeschi</span>
5507   
5508				</div>
5509	
5510	</div>
5511	<div class="acf-row"><span class="publ-label">No. of patients:</span> 12 <hr/> <span class="publ-label">Therapy:</span>  CT+RT+mEHT<hr/> <span class="publ-label">Year:</span>  2006</div>
5512	</div><!-- .acf-fields -->
5513	<p><strong>Abstract</strong></p>
5514<p>The purpose of this study was to evaluate the activity and toxicity of electro-hyperthermia (ET) on relapsed malignant glioma patients. Twelve patients with histologically diagnosed malignant glioma entered the study. Eight patients had glioblastoma multiforme, two had anaplastic astrocytoma grade III and two had anaplastic oligodendroglioma. All patients were pre-treated with temozolamide-based chemotherapy and radiotherapy. Hyperthermia with short radiofrequency waves of 13.56 MHz was applied using a capacitive coupling technique keeping the skin surface at 20°C. The applied power ranged between 40-150 Watts and the calculated average equivalent temperature in the tumours was above 40°C for more than 90% of the treatment duration. One complete remission and 2 partial remission were achieved, with a response rate of 25%. The median duration of response was 10 months (range 4-32). The median survival of the entire patient population was 9 months, with 25% survival rate at 1 year. ET appears to have some effectiveness in adults with relapsed malignant glioma.</p>
5515
5516			<div id="teljes-cikk" class="btn">
5517		<a href="http://iv.iiarjournals.org/content/20/6A/721.abstract?sid=f49bdb28-d1ae-45fe-ab24-f8344195a4ae" target="_blank">
5517 View abstract</a>
5518	</div>
5519	
5520	</div>	<!-- .container -->
5521</div><!-- .entry-content -->
5522
5523
5524
5525</article><!-- #post-3366 -->
5526
5527			
5528<article id="post-3367" class="post-3367 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
5529	
5530	<header class="pub-entry-header">
5531	<div class="container">
5532		<h2>Glioblastoma multiforme Grad IV: Regionale Tiefenhyperthermie, Antiangiogenese mit Thalidomid, Hochdosis-Ascorbinsäureinfusionen und komplementäre Therapie</h2>
5533	</div>
5534	</header><!-- .entry-header -->
5535
5536
5537<div class="entry-content kl-pub-content">
5538	<div class="container">
5539		<div class="acf-fields">
5540	<div class="acf-row"><span class="publ-label">Indication:</span> Gliomas (advanced) <hr/> <span class="publ-label">Evidence:</span>  </div>
5541	<div class="publ-acf acf-row acf-flex">
5542	<span class="publ-label">Author:&nbsp;</span>
5543	<div class="szerzok">
5544		
5545		 
5546		
5547		<span class="sz-nev">Hager ED</span>
5548   
5549		 
5550		
5551		<span class="sz-nev">Birkenmeier J</span>
5552   
5553				</div>
5554	
5555	</div>
5556	<div class="acf-row"><span class="publ-label">No. of patients:</span>  <hr/> <span class="publ-label">Therapy:</span>  <hr/> <span class="publ-label">Year:</span>  2006</div>
5557	</div><!-- .acf-fields -->
5558	<p><strong>Einleitung</strong></p>
5559<p>Epidemiologisch werden primäre Hirntumoren in Deutschland mit einer Inzidenz von etwa 10/100 000 Einwohner und Jahr beobachtet. Im Erwachsenenalter sind hierbei bis zu 50 % aller Gehirntumoren den Gliomen zuzuordnen mit deutlichem Anstieg ab dem 65. Lebensjahr auf ca. 18/100 000 Einwohner [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-01" target="_blank" rel="noopener">1</a></b>], [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-02" target="_blank" rel="noopener">2</a></b>]. Männer erkranken statistisch gesehen häufiger als Frauen (m/w: 1,2-1,9/1).</p>
5560<p>Die histologische Klassifikation, die nach dem überwiegendem Zelltyp vorgenommen wird, stellt eine wesentliche Grundlage für die Behandlung von malignen Gliomen dar, da die verschiedenen, feingeweblichen Entitäten ein unterschiedliches biologisches Verhalten und somit auch eine unterschiedliche Malignität aufweisen [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-15" target="_blank" rel="noopener">15</a></b>].</p>
5561<p>Nach <em class="ITALIC">Kernohan (1949)</em> und <em class="ITALIC">Russel (1977)</em> werden die einzelnen Tumoren in bis zu 4 Malignitätsgraden, entsprechend dem histologischen Grad der Entdifferenzierung und des Wachstumsverhaltens, unterteilt. Für Grad-I- und -II-Tumoren wird eine mittlere Überlebensdauer von 3 bis 5 Jahren angegeben. Bereits Gehirntumore vom Grad III mit malignem, infiltrativem Tumorwachstum verzeichnen eine Überlebensdauer von 2 bis 3 Jahren, während die Prognose für Patienten mit einem hochmalignem Glioblastoma multiforme Grad IV mit einer mittleren Überlebenszeit von 10 bis 12 Monaten als ganz schlecht anzusehen ist [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-01" target="_blank" rel="noopener">1</a></b>], [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-05" target="_blank" rel="noopener">5</a></b>].</p>
5562<p>Je nach histologischer Klassifikation kommen als leitlinienorientierte Behandlungsmaßnahmen von Hirntumoren die operative Entfernung [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-01" target="_blank" rel="noopener">1</a></b>], [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-02" target="_blank" rel="noopener">2</a></b>], [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-14" target="_blank" rel="noopener">14</a></b>] &#8211; zumindest eines Großteils des Tumors &#8211; und eine postoperative Bestrahlung mit einer empfohlenen Dosis von 60 Gy [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-01" target="_blank" rel="noopener">1</a></b>], [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-02" target="_blank" rel="noopener">2</a></b>
5562], [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-13" target="_blank" rel="noopener">13</a></b>], [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-14" target="_blank" rel="noopener">14</a></b>] sowie ggf. die Chemotherapie (z.B. Temozolomid) in Frage [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-03" target="_blank" rel="noopener">3</a></b>], [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-09" target="_blank" rel="noopener">9</a></b>].</p>
5563<p>Die Radiatio erfuhr in den letzten Jahren einen stärkergradigen positiven Effekt mit Verlängerung der Überlebenszeit um etwa 4 bis 5 Monate, bedingt dadurch, dass eine höhere Strahlendosis hierbei exakter auf den Tumor gerichtet werden kann [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-08" target="_blank" rel="noopener">8</a></b>].</p>
5564<p>Der Nutzen einer Chemotherapie ist allerdings nach wie vor äußerst umstritten und wird unter Experten kontrovers diskutiert, so insbesondere beim Grad-IV-Glioblastom, wo kein wesentlicher Effekt evaluierbar ist [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-01" target="_blank" rel="noopener">1</a></b>]. Nach einer aktuellen randomisierten EORTC-Studie [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-12" target="_blank" rel="noopener">12</a></b>] bei Glioblastomen aus dem Jahr 2005 konnte die mediane Überlebenszeit von Patienten in gutem AZ durch eine Radiochemotherapie mit Temozolomid von 12 auf 15 Monate gesteigert werden, während bei Patienten in schlechtem AZ die adjuvante Chemotherapie nicht sicher wirksam war [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-05" target="_blank" rel="noopener">5</a></b>], [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-13" target="_blank" rel="noopener">13</a></b>]. Literaturangaben zufolge lassen weder eine Polychemotherapie inkl. des PCV-Schemas [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-01" target="_blank" rel="noopener">1</a></b>], [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-02" target="_blank" rel="noopener">2</a></b>], [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-07" target="_blank" rel="noopener">7</a></b>] noch eine Monotherapie mit BCNU oder ACNU nennenswert wirksame und lebensverlängernde Ansprechraten erkennen, wobei die individuelle Lebensqualität der Patienten unter dem Therapieregime entsprechende Berücksichtigung finden sollte [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-05" target="_blank" rel="noopener">5</a></b>], [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-11" target="_blank" rel="noopener">11</a></b>].</p>
5565
5566			<div id="teljes-cikk" class="btn">
5567		<a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050" target="_blank"> View abstract</a>
5568	</div>
5569	
5570	</div>	<!-- .container -->
5571</div><!-- .entry-content -->
5572
5573
5574
5575</article><!-- #post-3367 -->
5576
5577			
5578<article id="post-3368" class="post-3368 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
5579	
5580	<header class="pub-entry-header">
5581	<div class="container">
5582		<h2>Behandlung des fortgeschrittenen Pankreaskarzinoms mit regionaler Hyperthermie und einer Zytostase mit Mitomycin- C und 5-Fluorouracil/ Folinsäure</h2>
5583	</div>
5584	</header><!-- .entry-header -->
5585
5586
5587<div class="entry-content kl-pub-content">
5588	<div class="container">
5589		<div class="acf-fields">
5590	<div class="acf-row"><span class="publ-label">Indication:</span> Pancreas <hr/> <span class="publ-label">Evidence:</span>  </div>
5591	<div class="publ-acf acf-row acf-flex">
5592	<span class="publ-label">Author:&nbsp;</span>
5593	<div class="szerzok">
5594		
5595		 
5596		
5597		<span class="sz-nev">Douwes F</span>
5598   
5599		 
5600		
5601		<span class="sz-nev">Migeod F</span>
5602   
5603		 
5604		
5605		<span class="sz-nev">Grote C</span>
5606   
5607				</div>
5608	
5609	</div>
5610	<div class="acf-row"><span class="publ-label">No. of patients:</span> 30 <hr/> <span class="publ-label">Therapy:</span>  CT+mEHT<hr/> <span class="publ-label">Year:</span>  2006</div>
5611	</div><!-- .acf-fields -->
5612	<p><strong>Zusammenfassung</strong></p>
5613<p><strong>Hintergrund</strong></p>
5614<p>Das Pankreaskarzinom stellt für die onkologische Therapie nach wie vor eine große Herausforderung dar. Bisher lässt sich der fortsc
5614hreitende Verlauf der Erkrankung kaum aufhalten, so dass die 5- Jahres- Überlebensrate unter 1% liegt. Aufgrund der niedrigen Ansprechraten einer zytostatischen Therapie soll die Wirksamkeit einer Chemotherapie mit Mitomycin C/ 5-Fluorouracil/ Folinsäure durch den Einsatz der regionalen Hyperthermie verstärkt werden.</p>
5615<p><strong>Methoden</strong></p>
5616<p>Die Behandlungsergebnisse von 30 Patienten mit einem fortgeschrittenen Pankreaskarzinom wurden ausgewertet. Die Therapie bestand in einer Zytostase mit Mitomycin C (8 mg/m2), Tag 1 sowie 5-Fluorouracil (500 mg/m2) und Folinsäure (200 mg/m2) am Tag 1-5 und einer regionalen kapazitiven Hyperthermie (13,56 MHz), welche am Tag 1, 3, 5 und 10 für jeweils 60 min. angewendet wurde. Während der Hyperthermie wurden dabei im Tumorgewebe Temperaturen von 420C bis 440C erreicht. Der Behandlungszyklus wurde alle 4 Wochen, bis zum Auftreten einer Progression, wiederholt.</p>
5617<p><strong>Ergebnisse</strong></p>
5618<p>Die 30 Patienten erhielten insgesamt 94 Behandlungszyklen. Als Resultat der Kombinationstherapie kam es bei einem Patienten zu einer kompletten Remission, 10 (33,3%) weitere zeigte eine partielle Remission. Bei 12 (40%) konnte eine Stabilisierung der Erkrankung erreicht werden, 7 Patienten (23,3%) sprachen nicht auf die Therapie an. Die mediane Überlebenszeit betrug 8 Monate (2-53), die mediane Zeit bis zur Progression (1-40 Monate). Schluss Die Kombination von regionaler Hyperthermie und Chemotherapie stellt eine sinnvolle Erweiterung in der palliativen Behandlung von Pankreaskarzinomen dar. Die in unserer Klinik gemachten Erfahrungen zeigen eine erhöhte Effektivität der eingesetzten Zytostatika bei guter Verträglichkeit.</p>
5619
5620			<div id="teljes-cikk" class="btn">
5621		<a href="https://www.researchgate.net/publication/237633519_Behandlung_des_fortgeschrittenen_Pankreaskarzinoms_mit_regionaler_Hyperthermie_und_einer_Zytostase_mit_Mitomycin_C_und_5FluorouracilFolinsaure" target="_blank"> View abstract</a>
5622	</div>
5623	
5624	</div>	<!-- .container -->
5625</div><!-- .entry-content -->
5626
5627
5628
5629</article><!-- #post-3368 -->
5630
5631			
5632<article id="post-3369" class="post-3369 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
5633	
5634	<header class="pub-entry-header">
5635	<div class="container">
5636		<h2>Thermo-chemotherapy of the advanced pancreas carcinoma</h2>
5637	</div>
5638	</header><!-- .entry-header -->
5639
5640
5641<div class="entry-content kl-pub-content">
5642	<div class="container">
5643		<div class="acf-fields">
5644	<div class="acf-row"><span class="publ-label">Indication:</span> Pancreas <hr/> <span class="publ-label">Evidence:</span>  </div>
5645	<div class="publ-acf acf-row acf-flex">
5646	<span class="publ-label">Author:&nbsp;</span>
5647	<div class="szerzok">
5648		
5649		 
5650		
5651		<span class="sz-nev">Douwes FR</span>
5652   
5653				</div>
5654	
5655	</div>
5656	<div class="acf-row"><span class="publ-label">No. of patients:</span> 18 <hr/> <span class="publ-label">Therapy:</span>  CT+mEHT<hr/> <span class="publ-label">Year:</span>  2006</div>
5657	</div><!-- .acf-fields -->
5658	<div data-reactid="57"><strong>Abstract</strong></div>
5659<div data-reactid="59">The results of chemotherapy of pancreas carcinoma are still disappointing. In nearly all cases the disease progresses, response rates to cytotoxic therapy are low and the 5-year survival rate amounts to 1%. The purpose of the present study was to evaluate whether response rate, time to progression and survival time can be improved by the combination of cytostatic treatment and loco-regional hyperthermia (thermo-chemotherapy). Results: According to the standard criteria, 1 patient had a complete remission, 10 patients had a partial remission; 7 patients did not respond to the therapy and showed progressive disease. Thermo-chemotherapy as applied in this clinical study shows a remarkable clinical outcome in advanced pancreas cancer and is well tolerated. The results suggest further evaluation in randomized trials.</div>
5660
5661			<div id="teljes-cikk" class="btn">
5662		<a href="https://www.researchgate.net/publication/287861898_Thermo-chemotherapy_of_the_advanced_pancreas_carcinoma" target="_blank"> View abstract</a>
5663	</div>
5664	
5665	</div>	<!-- .container -->
5666</div><!-- .entry-content -->
5667
5668
5669
5670</article><!-- #post-3369 -->
5671
5672			
5673<article id="post-3370" class="post-3370 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
5674	
5675	<header class="pub-entry-header">
5676	<div class="container">
5677		<h2>Malignes Melanom Stadium IV: Anwendung von regionaler Tiefenhyperthermie, Tamoxifen, Interferon-α und komplementären Therapien</h2>
5678	</div>
5679	</header><!-- .entry-header -->
5680
5681
5682<div class="entry-content kl-pub-content">
5683	<div class="container">
5684		<div class="acf-fields">
5685	<div class="acf-row"><span class="publ-label">Indication:</span> Melanoma <hr/> <span class="publ-label">Evidence:</span>  </div>
5686	<div class="publ-acf acf-row acf-flex">
5687	<span class="publ-label">Author:&nbsp;</span>
5688	<div class="szerzok">
5689		
5690		 
5691		
5692		<span class="sz-nev">Hager ED</span>
5693   
5694		 
5695		
5696		<span class="sz-nev">Birkenmeier J</span>
5697   
5698				</div>
5699	
5700	</div>
5701	<div class="acf-row"><span class="publ-label">No. of patients:</span>  <hr/> <span class="publ-label">Therapy:</span>  <hr/> <span class="publ-label">Year:</span>  2006</div>
5702	</div><!-- .acf-fields -->
5703	<article>
5704<div id="sections">
5705<section id="abstract">
5706<h3>Einleitung</h3>
5707<p>Die Prognose von Patienten mit metastasiertem Melanom ist schlecht. Alle bisherigen Behandlungskonzepte sind unbefriedigend. Die mediane Überlebenszeit liegt in den meisten Studien zwischen 6 und 9 Monaten und das 5-Jahresüberleben bei nur 1 bis 2 %.</p>
5708<p>
5708Zytostatika ermöglichen Ansprechraten zwischen 10 und 20 % mit einem Anteil von kompletten Ansprechraten von bis zu 5 %. Am besten sprechen Haut-, Lymphknoten- und Lungenmetastasen an. Obwohl ein Viertel der kompletten Remissionen länger anhalten, überleben weniger als 2 % der Patienten 5-6 Jahre. Dacarbazin ist das einzige für diese Indikation zugelassene Zytostatikum, aber es gibt keine Phase-III-Studien, die einen Überlebensvorteil im Vergleich zu anderen Behandlungen oder selbst Nicht-Behandlungen zeigen. Temozolomid, als aktiver Metabolit von Dacarbazin, kann ebenfalls angewendet werden. Platinderivate weisen eine mäßige Aktivität bei Melanomen auf; ebenso Vinblastin und Taxane. Nach Phase-II-Untersuchungen scheint die Kombination mit Tamoxifen die antineoplastische Wirkung von Zytostatika zu verstärken (von 10 % auf über 40 % mit Œ CR); aber in Phase-III-Studien wurden diese Resultate bisher nicht bestätigt.</p>
5709<p>Obwohl die Immuntherapie nur bei einem kleinen Prozentsatz der Patienten effektiv ist, können die Resultate in Einzelfällen dramatisch sein. Die bisher am meisten untersuchten Substanzen sind Interferon-α (IFN-α) und Interleukin-2 (IL-2), weshalb sie in die Therapie einbezogen werden. Das Tumoransprechen liegt bei 15 %, ist aber meist auf kleinvolumige kutane oder Weichteiltumore beschränkt. Allerdings kann die progressionsfreie Zeit von Patienten mit einer kompletten Remission (ca. 5 %) nach einer Immuntherapie sehr lang sein. Monoklonale Antikörper gegen Ganglioside, meist GD2 und GD3, zeigten antitumorale Aktivitäten in Phase-I/II-Studien. Durch Konjugation mit Antikörpern und Fusion mit Proteinen kann die Wirkung noch gesteigert werden. Die adoptive Immuntherapie mit ‚IL-2-aktivierten peripheren Blut-Lymphozyten’ (LAK-Zellen) führte zu keinem therapeutischen Vorteil. Dagegen konnte mit ‚Tumor-infiltrierenden Lymphozyten’ (TILs) in Phase-I/II-Studien ein Ansprechen in bis zu 34 % erreicht werden. Vakzinationsstrategien mit verschiedenen Melanom-Zellpräparationen erwiesen sich potenziell effektiv, aber die optimalen Bedingungen für diese Therapien müssen noch gefunden werden. Dies gilt auch für die Therapie mit dendritischen Zellen. Das Hauptproblem der Immuntherapie liegt wohl in der Überwindung der tumorassoziierten Immunsuppressionen.</p>
5710</section>
5711</div>
5712</article>
5713
5714			<div id="teljes-cikk" class="btn">
5715		<a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-932313" target="_blank"> View abstract</a>
5716	</div>
5717	
5718	</div>	<!-- .container -->
5719</div><!-- .entry-content -->
5720
5721
5722
5723</article><!-- #post-3370 -->
5724
5725			
5726<article id="post-3371" class="post-3371 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
5727	
5728	<header class="pub-entry-header">
5729	<div class="container">
5730		<h2>Hyperthermia in combination with ACNU chemotherapy in the treatment of recurrent glioblastoma</h2>
5731	</div>
5732	</header><!-- .entry-header -->
5733
5734
5735<div class="entry-content kl-pub-content">
5736	<div class="container">
5737		<div class="acf-fields">
5738	<div class="acf-row"><span class="publ-label">Indication:</span> Gliomas (advanced) <hr/> <span class="publ-label">Evidence:</span>  </div>
5739	<div class="publ-acf acf-row acf-flex">
5740	<span class="publ-label">Author:&nbsp;</span>
5741	<div class="szerzok">
5742		
5743		 
5744		
5745		<span class="sz-nev">Douwes F</span>
5746   
5747		 
5748		
5749		<span class="sz-nev">Douwes O</span>
5750   
5751		 
5752		
5753		<span class="sz-nev">Migeod F</span>
5754   
5755		 
5756		
5757		<span class="sz-nev">Grote C</span>
5758   
5759		 
5760		
5761		<span class="sz-nev">Bogovic J</span>
5762   
5763				</div>
5764	
5765	</div>
5766	<div class="acf-row"><span class="publ-label">No. of patients:</span> 19 <hr/> <span class="publ-label">Therapy:</span>  SRG+CT+RT+mEHT<hr/> <span class="publ-label">Year:</span>  2006</div>
5767	</div><!-- .acf-fields -->
5768	
5769	
5770	</div>	<!-- .container -->
5771</div><!-- .entry-content -->
5772
5773
5774
5775</article><!-- #post-3371 -->
5776
5777			
5778<article id="post-3372" class="post-3372 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
5779	
5780	<header class="pub-entry-header">
5781	<div class="container">
5782		<h2>Bestrahlung der Prostata erhöht Rektum-Ca-Risiko</h2>
5783	</div>
5784	</header><!-- .entry-header -->
5785
5786
5787<div class="entry-content kl-pub-content">
5788	<div class="container">
5789		<div class="acf-fields">
5790	<div class="acf-row"><span class="publ-label">Indication:</span> Prostate <hr/> <span class="publ-label">Evidence:</span>  </div>
5791	<div class="publ-acf acf-row acf-flex">
5792	<span class="publ-label">Author:&nbsp;</span>
5793	<div class="szerzok">
5794		
5795		 
5796		
5797		<span class="sz-nev">Douwes FR</span>
5798   
5799				</div>
5800	
5801	</div>
5802	<div class="acf-row"><span class="publ-label">No. of patients:</span>  <hr/> <span class="publ-label">Therapy:</span>  <hr/> <span class="publ-label">Year:</span>  2005</div>
5803	</div><!-- .acf-fields -->
5804	
5805	
5806	</div>	<!-- .container -->
5807</div><!-- .entry-content -->
5808
5809
5810
5811</article><!-- #post-3372 -->
5812
5813			
5814<article id="post-3373" class="post-3373 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
5815	
5816	<header class="pub-entry-header">
5817	<div class="container">
5818		<h2>Whole body hyperthermia combined with carboplatin/paclitaxel in patients with ovarian carcinoma – Phase-II-study</h2>
5819	</div>
5820	</header><!-- .entry-header -->
5821
5822
5823<div class="entry-content kl-pub-content">
5824	<div class="container">
5825		<div class="acf-fields">
5826	<div class="acf-row"><span class="publ-label">Indication:</span> Gynecology <hr/> <span class="publ-label">Evidence:</span>  Phase II</div>
5827	<div class="publ-acf acf-row acf-flex">
5828	<span class="publ-label">Author:&nbsp;</span>
5829	<div class="szerzok">
5830		
5831		 
5832		
5833		<span class="sz-nev">Strobl B</span>
5834   
5835		 
5836		
5837		<span class="sz-nev">Rjosk D</span>
5838   
5839		 
5840		
5841		<span class="sz-nev">Janni W</span>
5842   
5843		 
5844		
5845		<span class="sz-nev">et al.</span>
5846   
5847				</div>
5848	
5849	</div>
5850	<div class="acf-row"><span class="publ-label">No. of patients:</span> 9 <hr/> <span class="publ-label">Therapy:</span>  CT+WBH<hr/> <span class="publ-label">Year:</span>  2004</div>
5851	</div><!-- .acf-fields -->
5852	
5853			<div id="teljes-cikk" class="btn">
5854		<a href="http://ascopubs.org/doi/abs/10.1200/jco.2004.22.14_suppl.5128" target="_blank">
5854 View abstract</a>
5855	</div>
5856	
5857	</div>	<!-- .container -->
5858</div><!-- .entry-content -->
5859
5860
5861
5862</article><!-- #post-3373 -->
5863
5864			
5865<article id="post-3374" class="post-3374 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
5866	
5867	<header class="pub-entry-header">
5868	<div class="container">
5869		<h2>Rebell gegen den Krebs. Biologische Intersivtherapie – Neue Hoffnung für Patienten?</h2>
5870	</div>
5871	</header><!-- .entry-header -->
5872
5873
5874<div class="entry-content kl-pub-content">
5875	<div class="container">
5876		<div class="acf-fields">
5877	<div class="acf-row"><span class="publ-label">Indication:</span> Prostate <hr/> <span class="publ-label">Evidence:</span>  </div>
5878	<div class="publ-acf acf-row acf-flex">
5879	<span class="publ-label">Author:&nbsp;</span>
5880	<div class="szerzok">
5881		
5882		 
5883		
5884		<span class="sz-nev">Maar K</span>
5885   
5886				</div>
5887	
5888	</div>
5889	<div class="acf-row"><span class="publ-label">No. of patients:</span>  <hr/> <span class="publ-label">Therapy:</span>  <hr/> <span class="publ-label">Year:</span>  2004</div>
5890	</div><!-- .acf-fields -->
5891	
5892	
5893	</div>	<!-- .container -->
5894</div><!-- .entry-content -->
5895
5896
5897
5898</article><!-- #post-3374 -->
5899
5900			
5901<article id="post-3375" class="post-3375 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
5902	
5903	<header class="pub-entry-header">
5904	<div class="container">
5905		<h2>Whole-body hyperthermia in combination with platinum containing drugs in patients with recurrent ovarian cancer</h2>
5906	</div>
5907	</header><!-- .entry-header -->
5908
5909
5910<div class="entry-content kl-pub-content">
5911	<div class="container">
5912		<div class="acf-fields">
5913	<div class="acf-row"><span class="publ-label">Indication:</span> Gynecology <hr/> <span class="publ-label">Evidence:</span>  </div>
5914	<div class="publ-acf acf-row acf-flex">
5915	<span class="publ-label">Author:&nbsp;</span>
5916	<div class="szerzok">
5917		
5918		 
5919		
5920		<span class="sz-nev">Douwes F</span>
5921   
5922		 
5923		
5924		<span class="sz-nev">BogoviC J</span>
5925   
5926		 
5927		
5928		<span class="sz-nev">Douwes O et al.</span>
5929   
5930				</div>
5931	
5932	</div>
5933	<div class="acf-row"><span class="publ-label">No. of patients:</span> 21 <hr/> <span class="publ-label">Therapy:</span>  CT+WBH<hr/> <span class="publ-label">Year:</span>  2004</div>
5934	</div><!-- .acf-fields -->
5935	<h3>Abstract</h3>
5936<div>
5937<h5>BACKGROUND:</h5>
5938<p class="text-align-justify">Patients with advanced ovarian cancer have an enormous risk of relapse after primary therapy, and the prognosis for these patients remains bleak. Primary and acquired resistance of tumor cells to antineoplastic drugs is a major cause of the limited effectiveness of chemotherapy. The effect of whole-body hyperthermia (WBH) combined with platinum-containing chemotherapy in the treatment of recurrent ovarian cancer was examined in this study.</p>
5939</div>
5940
5941			<div id="teljes-cikk" class="btn">
5942		<a href="http://www.ncbi.nlm.nih.gov/pubmed/15108039" target="_blank"> View abstract</a>
5943	</div>
5944	
5945	</div>	<!-- .container -->
5946</div><!-- .entry-content -->
5947
5948
5949
5950</article><!-- #post-3375 -->
5951
5952			
5953<article id="post-3376" class="post-3376 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
5954	
5955	<header class="pub-entry-header">
5956	<div class="container">
5957		<h2>Lebermetastasen bei kolorektalen Karzinomen</h2>
5958	</div>
5959	</header><!-- .entry-header -->
5960
5961
5962<div class="entry-content kl-pub-content">
5963	<div class="container">
5964		<div class="acf-fields">
5965	<div class="acf-row"><span class="publ-label">Indication:</span> Liver <hr/> <span class="publ-label">Evidence:</span>  </div>
5966	<div class="publ-acf acf-row acf-flex">
5967	<span class="publ-label">Author:&nbsp;</span>
5968	<div class="szerzok">
5969		
5970		 
5971		
5972		<span class="sz-nev">Hager ED</span>
5973   
5974				</div>
5975	
5976	</div>
5977	<div class="acf-row"><span class="publ-label">No. of patients:</span>  <hr/> <span class="publ-label">Therapy:</span>  <hr/> <span class="publ-label">Year:</span>  2004</div>
5978	</div><!-- .acf-fields -->
5979	
5980	
5981	</div>	<!-- .container -->
5982</div><!-- .entry-content -->
5983
5984
5985
5986</article><!-- #post-3376 -->
5987
5988			
5989<article id="post-3377" class="post-3377 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
5990	
5991	<header class="pub-entry-header">
5992	<div class="container">
5993		<h2>Thermo-Chemotherapie des fortgeschrittenen Pankreaskarzinoms. Ergebnisseeiner klinischen Anwendungsstudie</h2>
5994	</div>
5995	</header><!-- .entry-header -->
5996
5997
5998<div class="entry-content kl-pub-content">
5999	<div class="container">
6000		<div class="acf-fields">
6001	<div class="acf-row"><span class="publ-label">Indication:</span> Pancreas <hr/> <span class="publ-label">Evidence:</span>  Clinical study</div>
6002	<div class="publ-acf acf-row acf-flex">
6003	<span class="publ-label">Author:&nbsp;</span>
6004	<div class="szerzok">
6005		
6006		 
6007		
6008		<span class="sz-nev">Douwes FR</span>
6009   
6010				</div>
6011	
6012	</div>
6013	<div class="acf-row"><span class="publ-label">No. of patients:</span> 30 <hr/> <span class="publ-label">Therapy:</span>  CT+mEHT<hr/> <span class="publ-label">Year:</span>  2004</div>
6014	</div><!-- .acf-fields -->
6015	<div class="c-rich-text">
6016<p><strong>ABSTRACT</strong>: Oncothermia is a method of hyperthermia in oncology, controlling the locally applied deep heat by selectively targeting the cellular membrane of the malignant cells. The selection of the method is based on various biophysical and biochemical achievements. There are various differences between the malignant and healthy cells, which could be used for their selection by heat targeting. The primary selection factor is a different metabolic activity which creates distinguishable environments of the malignant cells. The other factor is the clear difference of dielectric properties of the membrane and near-membrane extracellular electrolytes, marking off the malignancies. There is also a structural factor, which is clear in the different pathological patterns of the malignancy from their healthy counterparts. This last is described by fractal pattern evaluation technique, in which dynamic time-fractal transformation is used for further discernment of the malignancy. My objective is to show a new heating method, which makes oncological hyperthermia controllable and effective. 1. Introduction Oncological hyperthermia is the overheating of the malignant tissues locally or systemically. The method is deduced from the ancient medical practices, where the heat therapies had a central role in medicine. The local hyperthermia by the radiation of red-hot iron was the first known oncological treatment applied by Hy
6016pocrites, who described the method [1]. The main idea was originated from sacral considerations formulating the overall force of the “fire.” However, physiological consideration was also behind that together with beliefs: the local heat accelerates the metabolic activity without extra supply of this action from the unheated neighboring volumes. This physiological mechanism is accompanied by severe hypoxia, and it finally kills the target by acidosis. The working idea has recently been shown, proving the impoverishment of ATP and enrichment of lactate in the locally heated tumor tissue [2]. Due to the primitive heating techniques, the ancient radiative heat is only rarely applied in real cases. The central point of the locally applied oncological hyperthermia is the selective heat delivery into the deep-seated tumors. The discovery of the electromagnetic heating gave new perspectives for deep heating, and hyperthermia started its first “golden era” in oncology. It was among the first modern curative applications of modern techniques in oncology [3] and was followed by a controlled clinical study involving 100 patients as early as 1912. It showed remarkable.</p>
6017</div>
6018
6019	
6020	</div>	<!-- .container -->
6021</div><!-- .entry-content -->
6022
6023
6024
6025</article><!-- #post-3377 -->
6026
6027			
6028<article id="post-3378" class="post-3378 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
6029	
6030	<header class="pub-entry-header">
6031	<div class="container">
6032		<h2>Malignus és benignus prosztatadaganatok hyperthermiája</h2>
6033	</div>
6034	</header><!-- .entry-header -->
6035
6036
6037<div class="entry-content kl-pub-content">
6038	<div class="container">
6039		<div class="acf-fields">
6040	<div class="acf-row"><span class="publ-label">Indication:</span> Prostate <hr/> <span class="publ-label">Evidence:</span>  </div>
6041	<div class="publ-acf acf-row acf-flex">
6042	<span class="publ-label">Author:&nbsp;</span>
6043	<div class="szerzok">
6044		
6045		 
6046		
6047		<span class="sz-nev">Szasz A</span>
6048   
6049				</div>
6050	
6051	</div>
6052	<div class="acf-row"><span class="publ-label">No. of patients:</span> 252 <hr/> <span class="publ-label">Therapy:</span>  mEHT<hr/> <span class="publ-label">Year:</span>  2003</div>
6053	</div><!-- .acf-fields -->
6054	
6055	
6056	</div>	<!-- .container -->
6057</div><!-- .entry-content -->
6058
6059
6060
6061</article><!-- #post-3378 -->
6062
6063			
6064<article id="post-3379" class="post-3379 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
6065	
6066	<header class="pub-entry-header">
6067	<div class="container">
6068		<h2>The treatment of patients with high-grade malignant gliomas with RF-hyperthermia</h2>
6069	</div>
6070	</header><!-- .entry-header -->
6071
6072
6073<div class="entry-content kl-pub-content">
6074	<div class="container">
6075		<div class="acf-fields">
6076	<div class="acf-row"><span class="publ-label">Indication:</span>  <hr/> <span class="publ-label">Evidence:</span>  </div>
6077	<div class="publ-acf acf-row acf-flex">
6078	<span class="publ-label">Author:&nbsp;</span>
6079	<div class="szerzok">
6080		
6081		 
6082		
6083		<span class="sz-nev">Hager ED</span>
6084   
6085		 
6086		
6087		<span class="sz-nev">Dziambor H</span>
6088   
6089		 
6090		
6091		<span class="sz-nev">App EM</span>
6092   
6093		 
6094		
6095		<span class="sz-nev">Popa C</span>
6096   
6097		 
6098		
6099		<span class="sz-nev">Popa O</span>
6100   
6101		 
6102		
6103		<span class="sz-nev">Hertlein M</span>
6104   
6105				</div>
6106	
6107	</div>
6108	<div class="acf-row"><span class="publ-label">No. of patients:</span> 36 <hr/> <span class="publ-label">Therapy:</span>  CT+RT+mEHT<hr/> <span class="publ-label">Year:</span>  2003</div>
6109	</div><!-- .acf-fields -->
6110	
6111	
6112	</div>	<!-- .container -->
6113</div><!-- .entry-content -->
6114
6115
6116
6117</article><!-- #post-3379 -->
6118
6119			
6120<article id="post-3380" class="post-3380 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
6121	
6122	<header class="pub-entry-header">
6123	<div class="container">
6124		<h2>Tolerability of external electro-hyperthermia in the treatment of solid tumors</h2>
6125	</div>
6126	</header><!-- .entry-header -->
6127
6128
6129<div class="entry-content kl-pub-content">
6130	<div class="container">
6131		<div class="acf-fields">
6132	<div class="acf-row"><span class="publ-label">Indication:</span> Toxicity <hr/> <span class="publ-label">Evidence:</span>  </div>
6133	<div class="publ-acf acf-row acf-flex">
6134	<span class="publ-label">Author:&nbsp;</span>
6135	<div class="szerzok">
6136		
6137		 
6138		
6139		<span class="sz-nev">Cremona F</span>
6140   
6141		 
6142		
6143		<span class="sz-nev">Pignata A</span>
6144   
6145		 
6146		
6147		<span class="sz-nev">Izzo F</span>
6148   
6149		 
6150		
6151		<span class="sz-nev">Ruffolo F</span>
6152   
6153		 
6154		
6155		<span class="sz-nev">Delrio P</span>
6156   
6157				</div>
6158	
6159	</div>
6160	<div class="acf-row"><span class="publ-label">No. of patients:</span>  <hr/> <span class="publ-label">Therapy:</span>  <hr/> <span class="publ-label">Year:</span>  2003</div>
6161	</div><!-- .acf-fields -->
6162	
6163			<div id="teljes-cikk" class="btn">
6164		<a href="http://www.ncbi.nlm.nih.gov/pubmed/12903605" target="_blank">
6164 View abstract</a>
6165	</div>
6166	
6167	</div>	<!-- .container -->
6168</div><!-- .entry-content -->
6169
6170
6171
6172</article><!-- #post-3380 -->
6173
6174			
6175<article id="post-3381" class="post-3381 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
6176	
6177	<header class="pub-entry-header">
6178	<div class="container">
6179		<h2>Whole-body hyperthermia in combination with platinum-containing drugs in patients with recurrent ovarian cancer</h2>
6180	</div>
6181	</header><!-- .entry-header -->
6182
6183
6184<div class="entry-content kl-pub-content">
6185	<div class="container">
6186		<div class="acf-fields">
6187	<div class="acf-row"><span class="publ-label">Indication:</span>  <hr/> <span class="publ-label">Evidence:</span>  </div>
6188	<div class="publ-acf acf-row acf-flex">
6189	<span class="publ-label">Author:&nbsp;</span>
6190	<div class="szerzok">
6191		
6192		 
6193		
6194		<span class="sz-nev">Friedrich Douwes</span>
6195   
6196		 
6197		
6198		<span class="sz-nev">Juri Bogovic</span>
6199   
6200		 
6201		
6202		<span class="sz-nev">Ortrun Douwes</span>
6203   
6204		 
6205		
6206		<span class="sz-nev">Friedrich Migeod</span>
6207   
6208		 
6209		
6210		<span class="sz-nev">Christoph Grote</span>
6211   
6212				</div>
6213	
6214	</div>
6215	<div class="acf-row"><span class="publ-label">No. of patients:</span> 21 <hr/> <span class="publ-label">Therapy:</span>  CT+mEHT<hr/> <span class="publ-label">Year:</span>  2003</div>
6216	</div><!-- .acf-fields -->
6217	<p><strong>Abstract</strong></p>
6218<p>Background. Patients with advanced ovarian cancer have an enormous risk of relapse after primary therapy, and the prognosis for these patients remains bleak. Primary and acquired resistance of tumor cells to antineoplastic drugs is a major cause of the limited effectiveness of chemotherapy. The effect of whole-body hyperthermia (WBH) combined with platinum-containing chemotherapy in the treatment of recurrent ovarian cancer was examined in this study. Methods. Patients studied were those with pathologically verified epithelial ovarian cancer after operation who had had first-line chemotherapy with cisplatin or carboplatin, and relapsed. All 21 patients were treated with WBH and platinum-based chemotherapy. During the WBH, a core temperature of 41.5°C–42°C was attained in the rectum. We combined the WBH with 300–400mg/dl artificial hyperglycemia. The plateau temperature was held over a period of, on average, 90 30min, and the artificial hyperglycemia, on average, 240 30min. WBH was repeated at the beginning of each new chemotherapy cycle. Results. One patient (4.8%) had a complete remission, 7 patients (33.3%) had a partial remission, stable disease was noted in 10 patients (47.6%), and 3 (14.3%) patients did not respond and had progressive disease. Median time to progression was 6.5 months, and median survival time, 16.5 months. Conclusion. Our results validate the efficacy of WBH in the treatment of patients with recurrent platinum-resistant ovarian cancer. The overall tolerance of this treatment was good. The priority for all patients was an improvement in life quality; this was seen 3–4 days after WBH. The encouraging results should be confirmed in randomized studies.</p>
6219
6220			<div id="teljes-cikk" class="btn">
6221		<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Whole-body%20hyperthermia%20in%20combination%20with%20platinum-containing%20drugs%20in%20patients%20with%20recurrent%20ovarian%20cancer" target="_blank"> View abstract</a>
6222	</div>
6223	
6224	</div>	<!-- .container -->
6225</div><!-- .entry-content -->
6226
6227
6228
6229</article><!-- #post-3381 -->
6230
6231			
6232<article id="post-3382" class="post-3382 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
6233	
6234	<header class="pub-entry-header">
6235	<div class="container">
6236		<h2>Radiofrequency Transurethral Hyperthermia and complete Androgen Blockade. A Nonsurgical Approach to Treating Prostate Cancer</h2>
6237	</div>
6238	</header><!-- .entry-header -->
6239
6240
6241<div class="entry-content kl-pub-content">
6242	<div class="container">
6243		<div class="acf-fields">
6244	<div class="acf-row"><span class="publ-label">Indication:</span> Prostate <hr/> <span class="publ-label">Evidence:</span>  </div>
6245	<div class="publ-acf acf-row acf-flex">
6246	<span class="publ-label">Author:&nbsp;</span>
6247	<div class="szerzok">
6248		
6249		 
6250		
6251		<span class="sz-nev">Douwes FR</span>
6252   
6253		 
6254		
6255		<span class="sz-nev">Lieberman S</span>
6256   
6257				</div>
6258	
6259	</div>
6260	<div class="acf-row"><span class="publ-label">No. of patients:</span> 184 <hr/> <span class="publ-label">Therapy:</span>  mEHT<hr/> <span class="publ-label">Year:</span>  2002</div>
6261	</div><!-- .acf-fields -->
6262	
6263			<div id="teljes-cikk" class="btn">
6264		<a href="http://connection.ebscohost.com/c/articles/83564104/radiofrequency-transurethral-hyperthermia-complete-androgen-blockade-nonsurgical-approach-treating-prostate-cancer" target="_blank">
6264 View abstract</a>
6265	</div>
6266	
6267	</div>	<!-- .container -->
6268</div><!-- .entry-content -->
6269
6270
6271
6272</article><!-- #post-3382 -->
6273
6274			
6275<article id="post-3383" class="post-3383 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
6276	
6277	<header class="pub-entry-header">
6278	<div class="container">
6279		<h2>Transurethral hyperthermia in early stage prostate cancer</h2>
6280	</div>
6281	</header><!-- .entry-header -->
6282
6283
6284<div class="entry-content kl-pub-content">
6285	<div class="container">
6286		<div class="acf-fields">
6287	<div class="acf-row"><span class="publ-label">Indication:</span> Prostate <hr/> <span class="publ-label">Evidence:</span>  </div>
6288	<div class="publ-acf acf-row acf-flex">
6289	<span class="publ-label">Author:&nbsp;</span>
6290	<div class="szerzok">
6291		
6292		 
6293		
6294		<span class="sz-nev">Douwes FR</span>
6295   
6296				</div>
6297	
6298	</div>
6299	<div class="acf-row"><span class="publ-label">No. of patients:</span> 34 <hr/> <span class="publ-label">Therapy:</span>  mEHT<hr/> <span class="publ-label">Year:</span>  2001</div>
6300	</div><!-- .acf-fields -->
6301	<p><strong>Objective</strong></p>
6302<p>A treatment only has value if it can be demonstrated to be more effective than doing nothing. The major treatment for early prostate cancer (PC) is surgery or radiation. Unfortunately, none of these has been clearly shown to have a positive effect on long-term survival. In a study published in JAMA in 1997 a prospective, population-based study in Sweden showed that 223 patients that did not have a radical prostatectomy had the same long-term survival rate (81%) as those that did. Several statistics show that prostatectomy in early-stage cancer cannot affect the natural course of the disease. Several investigations have shown the efficiency of hyperthermia in different malignant tumours. We now have more than 10 years of experience with hyperthermia for the treatment of PC and the results are promising. The strategy of modern anticancer therapy is directed towards the control of local tumour growth with the maximum possible elimination of the neoplastic cell load. Hyperthermia offers support for both direct cell killing and sensitising neoplastic cells to hormone-, radio- and chemo-therapy.</p>
6303
6304	
6305	</div>	<!-- .container -->
6306</div><!-- .entry-content -->
6307
6308
6309
6310</article><!-- #post-3383 -->
6311
6312			
6313<article id="post-3384" class="post-3384 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
6314	
6315	<header class="pub-entry-header">
6316	<div class="container">
6317		<h2>Posttreatment Histology and Microcirculation Status of Osteogenic Sarcoma after a Neoadjuvant Chemo- and Radiotherapy in Combination with Local Electromagnetic Hyperthermia</h2>
6318	</div>
6319	</header><!-- .entry-header -->
6320
6321
6322<div class="entry-content kl-pub-content">
6323	<div class="container">
6324		<div class="acf-fields">
6325	<div class="acf-row"><span class="publ-label">Indication:</span> Bone <hr/> <span class="publ-label">Evidence:</span>  Retrospective study</div>
6326	<div class="publ-acf acf-row acf-flex">
6327	<span class="publ-label">Author:&nbsp;</span>
6328	<div class="szerzok">
6329		
6330		 
6331		
6332		<span class="sz-nev">Bogovic J</span>
6333   
6334		 
6335		
6336		<span class="sz-nev">Douwes F</span>
6337   
6338		 
6339		
6340		<span class="sz-nev">Muravjov G</span>
6341   
6342		 
6343		
6344		<span class="sz-nev">Istomin J</span>
6345   
6346				</div>
6347	
6348	</div>
6349	<div class="acf-row"><span class="publ-label">No. of patients:</span> 62 <hr/> <span class="publ-label">Therapy:</span>  CT+RT+mEHT<hr/> <span class="publ-label">Year:</span>  2001</div>
6350	</div><!-- .acf-fields -->
6351	<div class="c-rich-text">
6352<h3>Abstract</h3>
6353<h4>BACKGROUND:</h4>
6354<p>Many biological attributes of tumors (including regional blood flow and microcirculation) can deteriorate the homogeneity of heat distribution and temperature elevation during hyperthermia. We analyzed the connection between the microcirculation status of osteogenic sarcomas and the posttreatment histology after neoadjuvant chemotherapy, irradiation and local hyperthermia.</p>
6355<h4>PATIENTS AND METHODS:</h4>
6356<p>62 patients with histologically verified osteosarcoma (35 men, 27 women, age 9-53, average 21 years) were enrolled in the retrospective pathohistological study. 61 patients were evaluable. In 72.6% of cases the tumor was localized in bones forming knee joints. All patients received neoadjuvant treatment [6 hyperthermias (60 min, 42-45 degrees C), daunorubicin 30-50 mg/m(2), 6 infusions, adriamycin or cisplatin 30 mg/m(2) for 3 days or once 90 mg/m(2) monochemotherapy before the hyperthermic procedure; subsequently gamma-therapy, 20-36 Gy] followed by surgery. From archives, a control group was formed of 20 therapy-naive tumors. Resected tumors were histologically examined for assessment of spontaneous and therapeutically induced alterations. For analysis of the functionality status of microcirculation on histological cuts, 40 tumors (without selection) were investigated: 10 controls and 10 cases each with minimal, subtotal and total posttreatment alterations.</p>
6357<h4>RESULTS:</h4>
6358<p>Chemotherapy and radiotherapy in combination with local hyperthermia induced a distinct damage to osteosarcoma. In 39.3 and 35.7% of cases there was subtotal and total devitalization of tumor parenchyma, respectively. Thrombosis of magistral and middle vessels, stasis in the microcirculation tree (collapse), damage to intimal vessels and endothelial cells, and necrotic alterations of the vessel walls appeared predominantly in central areas of tumors. Tumors with minimal devitalization of the parenchyma had a share of nonfunctional vessels ranging from 10.6 to 61.7%, mean 29.7%. In tumors with subtotal necrosis, between 34.5 and 72.0% (mean 49.46%) of vessels were nonfunctional (stasis, thrombosis). In 10 cases with 100% necrosis of the osteosarcoma parenchyma, a mean of 56.05% of nonfunctional vessels was registered (12.3-83.0%). In the control group, between 2.85 and 73.4% (mean 21.69%) of vessels showed damage to the microcirculation.</p>
6359<h4>CONCLUSION:</h4>
6360<p>There is a direct correlation between deterioration of the microcirculation in osteosarcoma and thermo-radiochemotherapy- induced tissue alteration; the devitalization grade is directly proportional to the number of nonfunctional vessels in the tumor.</p>
6361</div>
6362
6363			<div id="teljes-cikk" class="btn">
6364		<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Posttreatment%20Histology%20and%20Microcirculation%20Status%20of%20Osteogenic%20Sarcoma%20after%20a%20Neoadjuvant%20Chemo-%20and%20Radiotherapy%20in%20Combination%20with%20Local%20Electromagnetic%20Hyperthermia" target="_blank">
6364 View abstract</a>
6365	</div>
6366	
6367	</div>	<!-- .container -->
6368</div><!-- .entry-content -->
6369
6370
6371
6372</article><!-- #post-3384 -->
6373
6374			
6375<article id="post-3385" class="post-3385 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
6376	
6377	<header class="pub-entry-header">
6378	<div class="container">
6379		<h2>Deep hyperthermia with radiofrequencies in patients with liver metastases from colorectal cancer</h2>
6380	</div>
6381	</header><!-- .entry-header -->
6382
6383
6384<div class="entry-content kl-pub-content">
6385	<div class="container">
6386		<div class="acf-fields">
6387	<div class="acf-row"><span class="publ-label">Indication:</span> Gastrointestinal <hr/> <span class="publ-label">Evidence:</span>  Clinical study</div>
6388	<div class="publ-acf acf-row acf-flex">
6389	<span class="publ-label">Author:&nbsp;</span>
6390	<div class="szerzok">
6391		
6392		 
6393		
6394		<span class="sz-nev">Hager ED </span>
6395   
6396		 
6397		
6398		<span class="sz-nev">Dziambor H</span>
6399   
6400		 
6401		
6402		<span class="sz-nev">Höhmann D</span>
6403   
6404		 
6405		
6406		<span class="sz-nev">Gallenbeck D</span>
6407   
6408		 
6409		
6410		<span class="sz-nev">Stephan M</span>
6411   
6412		 
6413		
6414		<span class="sz-nev">Popa C.</span>
6415   
6416				</div>
6417	
6418	</div>
6419	<div class="acf-row"><span class="publ-label">No. of patients:</span> 80 <hr/> <span class="publ-label">Therapy:</span>  CT+mEHT<hr/> <span class="publ-label">Year:</span>  1999</div>
6420	</div><!-- .acf-fields -->
6421	<p><strong>Abstract</strong></p>
6422<p>Patients at advanced stage of colorectal cancer with liver metastases have been treated with deep hyperthermia alone or in combination with chemotherapy (5-FU + FA + MMC). Hyperthermia was achieved by arrangements of capacitive electrodes with a radiofrequency field of 13.56 MHz (RF-DHT). This prospective open single-arm clinical study with 80 patients suffering from liver metastases from colorectal cancer gives some first hints, that deep RF-hyperthermia alone may have a substantial beneficial effect on overall survival time of patients with liver metastases from colorectal cancer. Long lasting no-change, partial and even some complete remissions could be observed. The overall median survival time from progression of metastases or relapse was 24.5 months and survival rates at 1, 2 or 3 years from first diagnosis of metastases or progression were twice as high as expected from patients treated with chemotherapy. The combination of hyperthermia with delayed chemotherapy did not change overall survival time. These encouraging results deserve to be confirmed in randomized clinical studies.</p>
6423
6424			<div id="teljes-cikk" class="btn">
6425		<a href="https://www.ncbi.nlm.nih.gov/pubmed/10629627" target="_blank"> View abstract</a>
6426	</div>
6427	
6428	</div>	<!-- .container -->
6429</div><!-- .entry-content -->
6430
6431
6432
6433</article><!-- #post-3385 -->
6434
6435			
6436<article id="post-3386" class="post-3386 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
6437	
6438	<header class="pub-entry-header">
6439	<div class="container">
6440		<h2>Hoffnung bei Prostata-Beschwerden. Die neue Therapie ohne Messer</h2>
6441	</div>
6442	</header><!-- .entry-header -->
6443
6444
6445<div class="entry-content kl-pub-content">
6446	<div class="container">
6447		<div class="acf-fields">
6448	<div class="acf-row"><span class="publ-label">Indication:</span> Prostate <hr/> <span class="publ-label">Evidence:</span>  </div>
6449	<div class="publ-acf acf-row acf-flex">
6450	<span class="publ-label">Author:&nbsp;</span>
6451	<div class="szerzok">
6452		
6453		 
6454		
6455		<span class="sz-nev">Douwes F</span>
6456   
6457		 
6458		
6459		<span class="sz-nev">Sillner L</span>
6460   
6461		 
6462		
6463		<span class="sz-nev">Köhnlechner M</span>
6464   
6465				</div>
6466	
6467	</div>
6468	<div class="acf-row"><span class="publ-label">No. of patients:</span>  <hr/> <span class="publ-label">Therapy:</span>  <hr/> <span class="publ-label">Year:</span>  1999</div>
6469	</div><!-- .acf-fields -->
6470	
6471			<div id="teljes-cikk" class="btn">
6472		<a href="http://www.zvab.com/9783776620863/Hoffnung-Prostata-Beschwerden-neue-Therapie-Messer-3776620862/plp" target="_blank"> View abstract</a>
6473	</div>
6474	
6475	</div>	<!-- .container -->
6476</div><!-- .entry-content -->
6477
6478
6479
6480</article><!-- #post-3386 -->
6481
6482			
6483<article id="post-3387" class="post-3387 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry">
6484	
6485	<header class="pub-entry-header">
6486	<div class="container">
6487		<h2>Complex therapy of the not in sano respectable carcinoma of the pancreas – a pilot study</h2>
6488	</div>
6489	</header><!-- .entry-header -->
6490
6491
6492<div class="entry-content kl-pub-content">
6493	<div class="container">
6494		<div class="acf-fields">
6495	<div class="acf-row"><span class="publ-label">Indication:</span> Pancreas <hr/> <span class="publ-label">Evidence:</span>  </div>
6496	<div class="publ-acf acf-row acf-flex">
6497	<span class="publ-label">Author:&nbsp;</span>
6498	<div class="szerzok">
6499		
6500		 
6501		
6502		<span class="sz-nev">Hager ED</span>
6503   
6504		 
6505		
6506		<span class="sz-nev">Süsse B</span>
6507   
6508		 
6509		
6510		<span class="sz-nev">Popa C</span>
6511   
6512		 
6513		
6514		<span class="sz-nev">Schritttwieser G</span>
6515   
6516		 
6517		
6518		<span class="sz-nev">Heise A</span>
6519   
6520		 
6521		
6522		<span class="sz-nev">Kleef R</span>
6523   
6524				</div>
6525	
6526	</div>
6527	<div class="acf-row"><span class="publ-label">No. of patients:</span>  <hr/> <span class="publ-label">Therapy:</span>  <hr/> <span class="publ-label">Year:</span>  1994</div>
6528	</div><!-- .acf-fields -->
6529	
6530	
6531	</div>	<!-- .container -->
6532</div><!-- .entry-content -->
6533
6534
6535
6536</article><!-- #post-3387 -->
6537
6538					
6539	</div>
6540	</main><!-- #main -->
6541
6542
6543	<footer id="colophon" class="site-footer">
6544		<div class="container">
6545		
6546				<section id="siteorigin-panels-builder-5" class="widget widget_siteorigin-panels-builder"><div id="pl-w6603f2bb2643b"  class="panel-layout" ><div id="pg-w6603f2bb2643b-0"  class="panel-grid panel-no-style" ><div id="pgc-w6603f2bb2643b-0-0"  class="panel-grid-cell" ><div id="panel-w6603f2bb2643b-0-0-0" class="so-panel widget widget_sow-image panel-first-child panel-last-child" data-index="0" ><div
6547			
6548			class="so-widget-sow-image so-widget-sow-image-default-c67d20f9f743"
6549			
6550		>
6551<div class="sow-image-container">
6552		<img 
6553	src="https://oncotherm.com/wp-content/uploads/2022/11/logo_ar-01.svg" width="220" height="50" alt="" decoding="async" loading="lazy" 		class="so-widget-image"/>
6554	</div>
6555
6556</div></div></div></div><div id="pg-w6603f2bb2643b-1"  class="panel-grid panel-has-style" ><div id="foo-mid" class="panel-row-style panel-row-style-for-w6603f2bb2643b-1" ><div id="pgc-w6603f2bb2643b-1-0"  class="panel-grid-cell" ><div id="panel-w6603f2bb2643b-1-0-0" class="so-panel widget widget_sow-editor panel-first-child panel-last-child" data-index="1" ><div class="footer-text left-foo panel-widget-style panel-widget-style-for-w6603f2bb2643b-1-0-0" ><div
6557			
6558			class="so-widget-sow-editor so-widget-sow-editor-base"
6559			
6560		>
6561<div class="siteorigin-widget-tinymce textwidget">
6562	<p><strong>ONCOTHERM KFT.</strong></p>
6563<p>Gyár u. 2.<br />
65642040 Budaörs, Hungary</p>
6565</div>
6566</div></div></div></div><div id="pgc-w6603f2bb2643b-1-1"  class="panel-grid-cell" ><div id="panel-w6603f2bb2643b-1-1-0" class="so-panel widget widget_sow-editor panel-first-child panel-last-child" data-index="2" ><div class="footer-text panel-widget-style panel-widget-style-for-w6603f2bb2643b-1-1-0" ><div
6567			
6568			class="so-widget-sow-editor so-widget-sow-editor-base"
6569			
6570		>
6571<div class="siteorigin-widget-tinymce textwidget">
6572	<p style="text-align: center;"><a href="tel:+3623555510">+36 23 555 510</a><br />
6573<a href="m&#97;&#x69;&#x6c;t&#111;&#58;&#x69;&#x6e;f&#111;&#x40;&#x6f;n&#99;&#111;&#x74;&#x68;e&#114;&#x6d;&#x2e;o&#114;&#103;">&#x69;&#x6e;&#x66;&#x6f;&#x40;&#x6f;&#x6e;&#x63;&#x6f;&#x74;&#x68;&#x65;&#x72;&#x6d;&#46;&#111;&#114;&#103;</a></p>
6574</div>
6575</div></div></div></div><div id="pgc-w6603f2bb2643b-1-2"  class="panel-grid-cell" ><div id="panel-w6603f2bb2643b-1-2-0" class="so-panel widget widget_sow-editor panel-first-child panel-last-child" data-index="3" ><div class="footer-text panel-widget-style panel-widget-style-for-w6603f2bb2643b-1-2-0" ><div
6576			
6577			class="so-widget-sow-editor so-widget-sow-editor-base"
6578			
6579		>
6580<div class="siteorigin-widget-tinymce textwidget">
6581	<p style="text-align: right;"><a href="https://oncotherm.com/privacy-policy/">Privacy Policy</a><br />
6582<a href="https://oncotherm.com/impressum/">Impressum</a></p>
6583</div>
6584</div></div></div></div></div></div><div id="pg-w6603f2bb2643b-2"  class="panel-grid panel-no-style" ><div id="pgc-w6603f2bb2643b-2-0"  class="panel-grid-cell" ><div id="panel-w6603f2bb2643b-2-0-0" class="so-panel widget widget_sow-social-media-buttons panel-first-child panel-last-child" data-index="4" ><div id="social-footer" class="panel-widget-style panel-widget-style-for-w6603f2bb2643b-2-0-0" ><div
6585			
6586			class="so-widget-sow-social-media-buttons so-widget-sow-social-media-buttons-flat-8f436be6ec16"
6587			
6588		>
6589
6590<div class="social-media-button-container">
6591	
6592		<a 
6593		class="sow-social-media-button-facebook-0 sow-social-media-button" title="Oncotherm Kft. on Facebook" aria-label="Oncotherm Kft. on Facebook" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/oncotherm" 		>
6594			<span>
6595								<span class="sow-icon-fontawesome sow-fab" data-sow-icon="&#xf39e;"
6596		 
6597		aria-hidden="true"></span>							</span>
6598		</a>
6599	
6600		<a 
6601		class="sow-social-media-button-linkedin-0 sow-social-media-button" title="Oncotherm Kft. on Linkedin" aria-label="Oncotherm Kft. on Linkedin" target="_blank" rel="noopener noreferrer" href="https://www.linkedin.com/company/17896963/" 		>
6602			<span>
6603								<span class="sow-icon-fontawesome sow-fab" data-sow-icon="&#xf0e1;"
6604		 
6605		aria-hidden="true"></span>							</span>
6606		</a>
6607	
6608		<a 
6609		class="sow-social-media-button-youtube-0 sow-social-media-button" title="Oncotherm Kft. on Youtube" aria-label="Oncotherm Kft. on Youtube" target="_blank" rel="noopener noreferrer" href="https://www.youtube.com/channel/UCpXgKlXcuZFIsVCOmx85pLg" 		>
6610			<span>
6611								<span class="sow-icon-fontawesome sow-fab" data-sow-icon="&#xf167;"
6612		 
6613		aria-hidden="true"></span>							</span>
6614		</a>
6615	</div>
6616</div></div></div></div></div><div id="pg-w6603f2bb2643b-3"  class="panel-grid panel-has-style" ><div id="bottom-footer" class="panel-row-style panel-row-style-for-w6603f2bb2643b-3" ><div id="pgc-w6603f2bb2643b-3-0"  class="panel-grid-cell" ><div id="panel-w6603f2bb2643b-3-0-0" class="so-panel widget widget_execphp panel-first-child panel-last-child" data-index="5" >			<div class="execphpwidget"><p style="text-align: right;">Copyright © 2026 Oncotherm. All rights reserved.</p></div>
6617		</div></div></div></div></div></section>		</div><!-- .site-info -->
6618	</footer><!-- #colophon -->
6619    <div id="to-top">
6620        <a href="#page" class="totop"><img src="https://oncotherm.com/wp-content/themes/oncotherm/js/rightarrow-01.svg" /></a>
6621    </div>
6622</div><!-- #page -->
6623<script src="https://cdnjs.cloudflare.com/ajax/libs/gsap/3.9.1/gsap.min.js"></script>
vendor: 1 bytes, line 6623
6623
6624<script src="https://cdnjs.cloudflare.com/ajax/libs/gsap/3.9.1/ScrollToPlugin.min.js"></script>
vendor: 1 bytes, line 6624
6624
6625<script src="https://cdnjs.cloudflare.com/ajax/libs/gsap/3.9.1/ScrollTrigger.min.js"></script>
vendor: 1 bytes, line 6625
6625
6626<script>
6627	gsap.registerPlugin(ScrollToPlugin, ScrollTrigger);
6628
6629</script>
vendor: 1 bytes, line 6629
6629
6630<script src="https://cdn.jsdelivr.net/npm/[email protected]/dist/hc-sticky.min.js"></script>
vendor: 1 bytes, line 6630
6630
6631<script type="speculationrules">
6632{"prefetch":[{"source":"document","where":{"and":[{"href_matches":"/*"},{"not":{"href_matches":["/wp-*.php","/wp-admin/*","/wp-content/uploads/*","/wp-content/*","/wp-content/plugins/*","/wp-content/themes/oncotherm/*","/*\\?(.+)"]}},{"not":{"selector_matches":"a[rel~=\"nofollow\"]"}},{"not":{"selector_matches":".no-prefetch, .no-prefetch a"}}]},"eagerness":"conservative"}]}
6633</script>
vendor: 1 bytes, line 6633
6633
6634<script id="lbwps-photoswipe5-js-module" src="https://oncotherm.com/wp-content/plugins/lightbox-photoswipe/assets/ps5/frontend.min.js?ver=5.13.0" type="module"></script>
6634
6635<div class="wpc-filters-overlay"></div>
6636<style media="all" id="siteorigin-panels-layouts-footer">/* Layout w6489d1a75c44d */ #pgc-w6489d1a75c44d-0-0 , #pgc-w6489d1a75c44d-1-0 { width:100%;width:calc(100% - ( 0 * 30px ) ) } #pg-w6489d1a75c44d-0 , #pl-w6489d1a75c44d .so-panel:last-of-type { margin-bottom:0px } #pl-w6489d1a75c44d .so-panel { margin-bottom:30px } #pg-w6489d1a75c44d-0.panel-has-style > .panel-row-style, #pg-w6489d1a75c44d-0.panel-no-style , #pg-w6489d1a75c44d-1.panel-has-style > .panel-row-style, #pg-w6489d1a75c44d-1.panel-no-style { -webkit-align-items:flex-start;align-items:flex-start } @media (max-width:780px){ #pg-w6489d1a75c44d-0.panel-no-style, #pg-w6489d1a75c44d-0.panel-has-style > .panel-row-style, #pg-w6489d1a75c44d-0 , #pg-w6489d1a75c44d-1.panel-no-style, #pg-w6489d1a75c44d-1.panel-has-style > .panel-row-style, #pg-w6489d1a75c44d-1 { -webkit-flex-direction:column;-ms-flex-direction:column;flex-direction:column } #pg-w6489d1a75c44d-0 > .panel-grid-cell , #pg-w6489d1a75c44d-0 > .panel-row-style > .panel-grid-cell , #pg-w6489d1a75c44d-1 > .panel-grid-cell , #pg-w6489d1a75c44d-1 > .panel-row-style > .panel-grid-cell { width:100%;margin-right:0 } #pl-w6489d1a75c44d .panel-grid-cell { padding:0 } #pg-w6489d1a75c44d-0 .panel-grid-cell-empty , #pg-w6489d1a75c44d-1 .panel-grid-cell-empty { display:none } #pl-w6489d1a75c44d .panel-grid .panel-grid-cell-mobile-last { margin-bottom:0px }  } /* Layout w6603f2bb2643b */ #pgc-w6603f2bb2643b-0-0 , #pgc-w6603f2bb2643b-2-0 , #pgc-w6603f2bb2643b-3-0 { width:100%;width:calc(100% - ( 0 * 30px ) ) } #pg-w6603f2bb2643b-0 { margin-bottom:40px } #pgc-w6603f2bb2643b-1-0 , #pgc-w6603f2bb2643b-1-1 , #pgc-w6603f2bb2643b-1-2 { width:33.3333%;width:calc(33.3333% - ( 0.66666666666667 * 30px ) ) } #pg-w6603f2bb2643b-1 { margin-bottom:8px } #pg-w6603f2bb2643b-2 { margin-bottom:20px } #pg-w6603f2bb2643b-3 , #pl-w6603f2bb2643b .so-panel:last-of-type { margin-bottom:0px } #pl-w6603f2bb2643b .so-panel { margin-bottom:30px } #pg-w6603f2bb2643b-0.panel-has-style > .panel-row-style, #pg-w6603f2bb2643b-0.panel-no-style , #pg-w6603f2bb2643b-3.panel-has-style > .panel-row-style, #pg-w6603f2bb2643b-3.panel-no-style { -webkit-align-items:flex-start;align-items:flex-start } #pg-w6603f2bb2643b-1.panel-has-style > .panel-row-style, #pg-w6603f2bb2643b-1.panel-no-style , #pg-w6603f2bb2643b-2.panel-has-style > .panel-row-style, #pg-w6603f2bb2643b-2.panel-no-style { -webkit-align-items:flex-end;align-items:flex-end } @media (max-width:780px){ #pg-w6603f2bb2643b-0.panel-no-style, #pg-w6603f2bb2643b-0.panel-has-style > .panel-row-style, #pg-w6603f2bb2643b-0 , #pg-w6603f2bb2643b-1.panel-no-style, #pg-w6603f2bb2643b-1.panel-has-style > .panel-row-style, #pg-w6603f2bb2643b-1 , #pg-w6603f2bb2643b-3.panel-no-style, #pg-w6603f2bb2643b-3.panel-has-style > .panel-row-style, #pg-w6603f2bb2643b-3 { -webkit-flex-direction:column;-ms-flex-direction:column;flex-direction:column } #pg-w6603f2bb2643b-0 > .panel-grid-cell , #pg-w6603f2bb2643b-0 > .panel-row-style > .panel-grid-cell , #pg-w6603f2bb2643b-1 > .panel-grid-cell , #pg-w6603f2bb2643b-1 > .panel-row-style > .panel-grid-cell , #pg-w6603f2bb2643b-3 > .panel-grid-cell , #pg-w6603f2bb2643b-3 > .panel-row-style > .panel-grid-cell { width:100%;margin-right:0 } #pgc-w6603f2bb2643b-1-0 , #pgc-w6603f2bb2643b-1-1 { margin-bottom:30px } #pl-w6603f2bb2643b .panel-grid-cell { padding:0 } #pg-w6603f2bb2643b-0 .panel-grid-cell-empty , #pg-w6603f2bb2643b-1 .panel-grid-cell-empty , #pg-w6603f2bb2643b-2 .panel-grid-cell-empty , #pg-w6603f2bb2643b-3 .panel-grid-cell-empty { display:none } #pl-w6603f2bb2643b .panel-grid .panel-grid-cell-mobile-last { margin-bottom:0px }  } </style>        
6636<script data-cfasync="false">
6637            window.dFlipLocation = 'https://oncotherm.com/wp-content/plugins/3d-flipbook-dflip-lite/assets/';
6638            window.dFlipWPGlobal = {"text":{"toggleSound":"Turn on\/off Sound","toggleThumbnails":"Toggle Thumbnails","toggleOutline":"Toggle Outline\/Bookmark","previousPage":"Previous Page","nextPage":"Next Page","toggleFullscreen":"Toggle Fullscreen","zoomIn":"Zoom In","zoomOut":"Zoom Out","toggleHelp":"Toggle Help","singlePageMode":"Single Page Mode","doublePageMode":"Double Page Mode","downloadPDFFile":"Download PDF File","gotoFirstPage":"Go to First Page","gotoLastPage":"Go to Last Page","share":"Share","mailSubject":"I wanted you to see this FlipBook","mailBody":"Check out this site {{url}}","loading":"DearFlip: Loading "},"viewerType":"flipbook","moreControls":"download,pageMode,startPage,endPage,sound","hideControls":"","scrollWheel":"false","backgroundColor":"#777","backgroundImage":"","height":"auto","paddingLeft":"20","paddingRight":"20","controlsPosition":"bottom","duration":800,"soundEnable":"true","enableDownload":"true","showSearchControl":"false","showPrintControl":"false","enableAnnotation":false,"enableAnalytics":"false","webgl":"true","hard":"none","maxTextureSize":"1600","rangeChunkSize":"524288","zoomRatio":1.5,"stiffness":3,"pageMode":"0","singlePageMode":"0","pageSize":"0","autoPlay":"false","autoPlayDuration":5000,"autoPlayStart":"false","linkTarget":"2","sharePrefix":"flipbook-"};
6639        </script>
6639
6640      
6640<script id="wp-hooks-js" src="https://oncotherm.com/wp-includes/js/dist/hooks.min.js?ver=f0f188028580e8dc1255"></script>
vendor: 1 bytes, line 6640
6640
6641<script id="wp-i18n-js" src="https://oncotherm.com/wp-includes/js/dist/i18n.min.js?ver=1dfe7db3940c23ea9216"></script>
vendor: 1 bytes, line 6641
6641
6642<script id="wp-i18n-js-after">
6643wp.i18n.setLocaleData( { 'text direction\u0004ltr': [ 'ltr' ] } );
6644//# sourceURL=wp-i18n-js-after
6645</script>
vendor: 1 bytes, line 6645
6645
6646<script id="swv-js" src="https://oncotherm.com/wp-content/plugins/contact-form-7/includes/swv/js/index.js?ver=6.1.7"></script>
vendor: 1 bytes, line 6646
6646
6647<script id="contact-form-7-js-translations">
6648( function( domain, translations ) {
6649	var localeData = translations.locale_data[ domain ] || translations.locale_data.messages;
6650	localeData[""].domain = domain;
6651	wp.i18n.setLocaleData( localeData, domain );
6652} )( "contact-form-7", {"translation-revision-date":"2026-05-05 18:32:38+0000","generator":"GlotPress\/4.0.3","domain":"messages","locale_data":{"messages":{"":{"domain":"messages","plural-forms":"nplurals=2; plural=n != 1;","lang":"en_GB"},"This contact form is placed in the wrong place.":["This contact form is placed in the wrong place."],"Error:":["Error:"]}},"comment":{"reference":"includes\/js\/index.js"}} );
6653//# sourceURL=contact-form-7-js-translations
6654</script>
vendor: 1 bytes, line 6654
6654
6655<script id="contact-form-7-js-before">
6656var wpcf7 = {
6657    "api": {
6658        "root": "https:\/\/oncotherm.com\/wp-json\/",
6659        "namespace": "contact-form-7\/v1"
6660    }
6661};
6662//# sourceURL=contact-form-7-js-before
6663</script>
vendor: 1 bytes, line 6663
6663
6664<script id="contact-form-7-js" src="https://oncotherm.com/wp-content/plugins/contact-form-7/includes/js/index.js?ver=6.1.7"></script>
vendor: 1 bytes, line 6664
6664
6665<script id="cf7apps-honeypot-refill-js-extra">
6666var cf7appsHoneypotRefill = {"forceRefillOnInit":""};
6667//# sourceURL=cf7apps-honeypot-refill-js-extra
6668</script>
vendor: 1 bytes, line 6668
6668
6669<script id="cf7apps-honeypot-refill-js" src="https://oncotherm.com/wp-content/plugins/contact-form-7-honeypot/legacy-honeypot/includes/js/honeypot-refill.js?ver=3.7.1"></script>
vendor: 1 bytes, line 6669
6669
6670<script id="fitvids-js" src="https://oncotherm.com/wp-content/plugins/fitvids-for-wordpress/jquery.fitvids.js?ver=1.1"></script>
vendor: 1 bytes, line 6670
6670
6671<script id="rmp_menu_scripts-js-extra">
6672var rmp_menu = {"ajaxURL":"https://oncotherm.com/wp-admin/admin-ajax.php","wp_nonce":"2534aa4b82","menu":[{"menu_theme":"Default","theme_type":"default","theme_location_menu":"0","submenu_submenu_arrow_width":"40","submenu_submenu_arrow_width_unit":"px","submenu_submenu_arrow_height":"39","submenu_submenu_arrow_height_unit":"px","submenu_arrow_position":"right","submenu_sub_arrow_background_colour":"","submenu_sub_arrow_background_hover_colour":"","submenu_sub_arrow_background_colour_active":"","submenu_sub_arrow_background_hover_colour_active":"","submenu_sub_arrow_border_width":"","submenu_sub_arrow_border_width_unit":"px","submenu_sub_arrow_border_colour":"#1d4354","submenu_sub_arrow_border_hover_colour":"#3f3f3f","submenu_sub_arrow_border_colour_active":"#1d4354","submenu_sub_arrow_border_hover_colour_active":"#3f3f3f","submenu_sub_arrow_shape_colour":"#fff","submenu_sub_arrow_shape_hover_colour":"#fff","submenu_sub_arrow_shape_colour_active":"#fff","submenu_sub_arrow_shape_hover_colour_active":"#fff","use_header_bar":"off","header_bar_items_order":{"logo":"off","title":"on","additional content":"off","menu":"on","search":"off"},"header_bar_title":"Responsive Menu","header_bar_html_content":"","header_bar_logo":"","header_bar_logo_link":"","header_bar_logo_width":"","header_bar_logo_width_unit":"%","header_bar_logo_height":"","header_bar_logo_height_unit":"px","header_bar_height":"80","header_bar_height_unit":"px","header_bar_padding":{"top":"0px","right":"5%","bottom":"0px","left":"5%"},"header_bar_font":"","header_bar_font_size":"14","header_bar_font_size_unit":"px","header_bar_text_color":"#ffffff","header_bar_background_color":"#1d4354","header_bar_breakpoint":"8000","header_bar_position_type":"fixed","header_bar_adjust_page":"on","header_bar_scroll_enable":"off","header_bar_scroll_background_color":"#36bdf6","mobile_breakpoint":"600","tablet_breakpoint":"1024","transition_speed":"0.5","sub_menu_speed":"0.2","show_menu_on_page_load":"off","menu_disable_scrolling":"off","menu_overlay":"off","menu_overlay_colour":"rgba(0,0,0,0.7)","desktop_menu_width":"","desktop_menu_width_unit":"%","desktop_menu_positioning":"absolute","desktop_menu_side":"left","desktop_menu_to_hide":"","use_current_theme_location":"off","mega_menu":{"225":"off","227":"off","229":"off","228":"off","226":"off"},"desktop_submenu_open_animation":"none","desktop_submenu_open_animation_speed":"100ms","desktop_submenu_open_on_click":"off","desktop_menu_hide_and_show":"off","menu_name":"Mobil main menu","menu_to_use":"2","different_menu_for_mobile":"off","menu_to_use_in_mobile":"main-menu","use_mobile_menu":"on","use_tablet_menu":"on","use_desktop_menu":"off","menu_display_on":"all-pages","menu_to_hide":"","submenu_descriptions_on":"off","custom_walker":"","menu_background_colour":"#162c4d","menu_depth":"5","smooth_scroll_on":"off","smooth_scroll_speed":"500","menu_font_icons":{"id":["225"],"icon":[""]},"menu_links_height":"40","menu_links_height_unit":"px","menu_links_line_height":"40","menu_links_line_height_unit":"px","menu_depth_0":"5","menu_depth_0_unit":"%","menu_font_size":"15","menu_font_size_unit":"px","menu_font":"","menu_font_weight":"normal","menu_text_alignment":"left","menu_text_letter_spacing":"","menu_word_wrap":"off","menu_link_colour":"#9e8053","menu_link_hover_colour":"#9e8053","menu_current_link_colour":"#9e8053","menu_current_link_hover_colour":"#9e8053","menu_item_background_colour":"","menu_item_background_hover_colour":"","menu_current_item_background_colour":"","menu_current_item_background_hover_colour":"","menu_border_width":"","menu_border_width_unit":"px","menu_item_border_colour":"#1d4354","menu_item_border_colour_hover":"#1d4354","menu_current_item_border_colour":"#1d4354","menu_current_item_border_hover_colour":"#3f3f3f","submenu_links_height":"40","submenu_links_height_unit":"px","submenu_links_line_height":"40","submenu_links_line_height_unit":"px","menu_depth_side":"left","menu_depth_1":"10","menu_depth_1_unit":"%","menu_depth_2":"15","menu_depth_2_unit":"%","menu_depth_3":"20","menu_depth_3_unit":"%","menu_depth_4":"25","menu_depth_4_unit":"%","submenu_item_background_colour":"","submenu_item_background_hover_colour":"","submenu_current_item_background_colour":"","submenu_current_item_background_hover_colour":"","submenu_border_width":"","submenu_border_width_unit":"px","submenu_item_border_colour":"#1d4354","submenu_item_border_colour_hover":"#1d4354","submenu_current_item_border_colour":"#1d4354","submenu_current_item_border_hover_colour":"#3f3f3f","submenu_font_size":"13","submenu_font_size_unit":"px","submenu_font":"","submenu_font_weight":"normal","submenu_text_letter_spacing":"","submenu_text_alignment":"left","submenu_link_colour":"#9e8053","submenu_link_hover_colour":"#9e8053","submenu_current_link_colour":"#9e8053","submenu_current_link_hover_colour":"#9e8053","inactive_arrow_shape":"+","active_arrow_shape":"-","inactive_arrow_font_icon":"","active_arrow_font_icon":"","
6672inactive_arrow_image":"","active_arrow_image":"","submenu_arrow_width":"40","submenu_arrow_width_unit":"px","submenu_arrow_height":"40","submenu_arrow_height_unit":"px","arrow_position":"right","menu_sub_arrow_shape_colour":"#9e8053","menu_sub_arrow_shape_hover_colour":"#9e8053","menu_sub_arrow_shape_colour_active":"#9e8053","menu_sub_arrow_shape_hover_colour_active":"#9e8053","menu_sub_arrow_border_width":"","menu_sub_arrow_border_width_unit":"px","menu_sub_arrow_border_colour":"#1d4354","menu_sub_arrow_border_hover_colour":"#3f3f3f","menu_sub_arrow_border_colour_active":"#1d4354","menu_sub_arrow_border_hover_colour_active":"#3f3f3f","menu_sub_arrow_background_colour":"","menu_sub_arrow_background_hover_colour":"","menu_sub_arrow_background_colour_active":"rgba(33,33,33,0.01)","menu_sub_arrow_background_hover_colour_active":"","fade_submenus":"off","fade_submenus_side":"left","fade_submenus_delay":"100","fade_submenus_speed":"500","use_slide_effect":"off","slide_effect_back_to_text":"Back","accordion_animation":"on","auto_expand_all_submenus":"off","auto_expand_current_submenus":"off","menu_item_click_to_trigger_submenu":"off","button_width":"55","button_width_unit":"px","button_height":"55","button_height_unit":"px","button_background_colour":"#193156","button_background_colour_hover":"#193156","button_background_colour_active":"#193156","toggle_button_border_radius":"5","button_transparent_background":"on","button_left_or_right":"right","button_position_type":"fixed","button_distance_from_side":"5","button_distance_from_side_unit":"%","button_top":"15","button_top_unit":"px","button_push_with_animation":"off","button_click_animation":"boring","button_line_margin":"9","button_line_margin_unit":"px","button_line_width":"32","button_line_width_unit":"px","button_line_height":"2","button_line_height_unit":"px","button_line_colour":"#9e8053","button_line_colour_hover":"#9e8053","button_line_colour_active":"#9e8053","button_font_icon":"","button_font_icon_when_clicked":"","button_image":"","button_image_when_clicked":"","button_title":"","button_title_open":"","button_title_position":"left","menu_container_columns":"","button_font":"","button_font_size":"14","button_font_size_unit":"px","button_title_line_height":"13","button_title_line_height_unit":"px","button_text_colour":"#fff","button_trigger_type_click":"on","button_trigger_type_hover":"off","button_click_trigger":"","items_order":{"title":"","additional content":"on","menu":"on","search":"on","social-icons":""},"menu_title":"Responsive Menu","menu_title_link":"","menu_title_link_location":"_self","menu_title_image":"","menu_title_font_icon":"","menu_title_section_padding":{"top":"10%","right":"5%","bottom":"0%","left":"5%"},"menu_title_background_colour":"","menu_title_background_hover_colour":"","menu_title_font_size":"25","menu_title_font_size_unit":"px","menu_title_alignment":"center","menu_title_font_weight":"400","menu_title_font_family":"","menu_title_colour":"#ffffff","menu_title_hover_colour":"#fff","menu_title_image_width":"","menu_title_image_width_unit":"%","menu_title_image_height":"","menu_title_image_height_unit":"px","menu_additional_content":"Add more content here...","menu_additional_section_padding":{"top":"0%","right":"5%","bottom":"10%","left":"5%"},"menu_additional_content_font_size":"16","menu_additional_content_font_size_unit":"px","menu_additional_content_alignment":"center","menu_additional_content_colour":"#6fda44","menu_social_icons":[],"menu_social_icons_size":"24","menu_social_icons_size_unit":"px","menu_social_icons_layout":"horizontal","menu_social_icons_alignment":"center","menu_social_icons_gap":"10","menu_social_icons_gap_unit":"px","menu_social_icons_section_padding":{"top":"0%","right":"0%","bottom":"0%","left":"0%"},"menu_search_box_text":"Search","menu_search_box_code":"","menu_search_section_padding":{"top":"5%","right":"5%","bottom":"5%","left":"5%"},"menu_search_box_height":"45","menu_search_box_height_unit":"px","menu_search_box_border_radius":"30","menu_search_box_text_colour":"#14253f","menu_search_box_background_colour":"#ffffff","menu_search_box_placeholder_colour":"#14253f","menu_search_box_border_colour":"","menu_section_padding":{"top":"0px","right":"0px","bottom":"0px","left":"0px"},"menu_width":"75","menu_width_unit":"%","menu_maximum_width":"350","menu_maximum_width_unit":"px","menu_minimum_width":"320","menu_minimum_width_unit":"px","menu_auto_height":"off","menu_container_padding":{"top":"0px","right":"0px","bottom":"0px","left":"0px"},"menu_container_background_colour":"#1d4354","menu_background_image":"","animation_type":"slide","menu_appear_from":"left","animation_speed":"0.5","page_wrapper":"body","menu_close_on_body_click":"off","menu_close_on_scroll":"off","menu_close_on_link_click":"off","enable_touch_gestures":"off","hamburger_position_selector":"","menu_id":2025,"active_toggle_contents":"-","inactive_toggle_contents":"+"}]};
6673//# sourceURL=rmp_menu_scripts-js-extra
6674</script>
vendor: 1 bytes, line 6674
6674
6675<script id="rmp_menu_scripts-js" src="https://oncotherm.com/wp-content/plugins/responsive-menu/v4.0.0/assets/js/rmp-menu.min.js?ver=4.7.3"></script>
vendor: 1 bytes, line 6675
6675
6676<script id="pojo-a11y-js-extra">
6677var PojoA11yOptions = {"focusable":"","remove_link_target":"","add_role_links":"1","enable_save":"1","save_expiration":"6"};
6678//# sourceURL=pojo-a11y-js-extra
6679</script>
vendor: 1 bytes, line 6679
6679
6680<script id="pojo-a11y-js" src="https://oncotherm.com/wp-content/plugins/pojo-accessibility/modules/legacy/assets/js/app.min.js?ver=1.0.0"></script>
vendor: 1 bytes, line 6680
6680
6681<script id="oncotherm-navigation-js" src="https://oncotherm.com/wp-content/themes/oncotherm/js/navigation.js?ver=1.0.0"></script>
vendor: 1 bytes, line 6681
6681
6682<script id="google-api-js" async defer src="https://maps.googleapis.com/maps/api/js?key=AIzaSyB_iiSjX5r5NhuYo76slnO94iS0slyXWL4&#038;callback=initMap&#038;loading=async"></script>
vendor: 1 bytes, line 6682
6682
6683<script id="google-map-js" src="https://oncotherm.com/wp-content/themes/oncotherm/js/gmap.js?ver=1.0.0"></script>
vendor: 1 bytes, line 6683
6683
6684<script id="dflip-script-js" src="https://oncotherm.com/wp-content/plugins/3d-flipbook-dflip-lite/assets/js/dflip.min.js?ver=2.4.37"></script>
vendor: 86 bytes, lines 6684-6685
6684
6685<script id="google-recaptcha-js" src="https://www.google.com/recaptcha/api.js?render=
66856LdoVqYpAAAAAI2la0roHGhvvbDMgeGifOyPAJRr
vendor: 25 bytes, line 6685
6685&#038;ver=3.0"></script>
6686<script id="wp-polyfill-js" src="https://oncotherm.com/wp-includes/js/dist/vendor/wp-polyfill.min.js?ver=3.15.0"></script>
vendor: 1 bytes, line 6686
6686
6687<script id="wpcf7-recaptcha-js-before">
6688var wpcf7_recaptcha = {
6689    "sitekey": "6LdoVqYpAAAAAI2la0roHGhvvbDMgeGifOyPAJRr",
6690    "actions": {
6691        "homepage": "homepage",
6692        "contactform": "contactform"
6693    }
6694};
6695//# sourceURL=wpcf7-recaptcha-js-before
6696</script>
vendor: 1 bytes, line 6696
6696
6697<script id="wpcf7-recaptcha-js" src="https://oncotherm.com/wp-content/plugins/contact-form-7/modules/recaptcha/index.js?ver=6.1.7"></script>
vendor: 1 bytes, line 6697
6697
6698<script id="jquery-ui-core-js-before">
6699jQuery.uiBackCompat = true;
6700//# sourceURL=jquery-ui-core-js-before
6701</script>
vendor: 1 bytes, line 6701
6701
6702<script id="jquery-ui-core-js" src="https://oncotherm.com/wp-includes/js/jquery/ui/core.min.js?ver=1.14.2"></script>
vendor: 1 bytes, line 6702
6702
6703<script id="jquery-ui-mouse-js" src="https://oncotherm.com/wp-includes/js/jquery/ui/mouse.min.js?ver=1.14.2"></script>
vendor: 1 bytes, line 6703
6703
6704<script id="jquery-ui-slider-js" src="https://oncotherm.com/wp-includes/js/jquery/ui/slider.min.js?ver=1.14.2"></script>
vendor: 1 bytes, line 6704
6704
6705<script id="wc-jquery-ui-touchpunch-js" src="https://oncotherm.com/wp-content/plugins/filter-everything/assets/js/jquery-ui-touch-punch/jquery-ui-touch-punch.min.js?ver=1.9.6"></script>
vendor: 1 bytes, line 6705
6705
6706<script id="wpc-filter-everything-js-extra">
6707var wpcFilterFront = {"ajaxUrl":"https://oncotherm.com/wp-admin/admin-ajax.php","wpcAjaxEnabled":"","wpcStatusCookieName":"wpcContainersStatus","wpcMoreLessCookieName":"wpcMoreLessStatus","wpcHierarchyListCookieName":"wpcHierarchyListStatus","wpcWidgetStatusCookieName":"wpcWidgetStatus","wpcMobileWidth":"768","showBottomWidget":"no","_nonce":"9a06b8db7d","wpcPostContainers":{"default":".buttons"},"wpcAutoScroll":"","wpcAutoScrollOffset":"150","wpcWaitCursor":"1","wpcPostsPerPage":{"3389":16},"wpcUseSelect2":"","wpcDateFilters":"","wpcPopupCompatMode":"","wpcApplyButtonSets":[3389],"wpcQueryOnThePageSets":[3389],"wpcNoPostsContainerMsg":"It appears that this page does not contain the container specified in the \u00abResults container\u00bb option. Try to specify the correct one in the Filter Set settings or the common plugin Settings.","wpcIsPro":"","permalinksEnabled":"","wpcMoreLessCount":"5","wpcSearchChipsText":"search: %s","chipsTitle":"Remove %s from results","chipsReset":"Reset all"};
6708//# sourceURL=wpc-filter-everything-js-extra
6709</script>
vendor: 1 bytes, line 6709
6709
6710<script id="wpc-filter-everything-js" src="https://oncotherm.com/wp-content/plugins/filter-everything/assets/js/filter-everything.min.js?ver=1.9.6"></script>
6710
6711		
6711<script type="text/javascript">
6712		jQuery(document).ready(function () {
6713			jQuery('body').fitVids();
6714		});
6715		</script>
6715		<a id="pojo-a11y-skip-content" class="pojo-skip-link pojo-skip-content" tabindex="1" accesskey="s" href="#content">Skip to content</a>
6716				<nav id="pojo-a11y-toolbar" class="pojo-a11y-toolbar-right" aria-label="Accessibility Toolbar">
6717			<div class="pojo-a11y-toolbar-toggle">
6718				<a class="pojo-a11y-toolbar-link pojo-a11y-toolbar-toggle-link" href="javascript:void(0);" title="Accessibility" role="button">
6719					<span class="pojo-sr-only sr-only">Open toolbar</span>
6720					<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" fill="currentColor" width="1em">
6721						<title>Accessibility</title>
6722						<path d="M50 .8c5.7 0 10.4 4.7 10.4 10.4S55.7 21.6 50 21.6s-10.4-4.7-10.4-10.4S44.3.8 50 .8zM92.2 32l-21.9 2.3c-2.6.3-4.6 2.5-4.6 5.2V94c0 2.9-2.3 5.2-5.2 5.2H60c-2.7 0-4.9-2.1-5.2-4.7l-2.2-24.7c-.1-1.5-1.4-2.5-2.8-2.4-1.3.1-2.2 1.1-2.4 2.4l-2.2 24.7c-.2 2.7-2.5 4.7-5.2 4.7h-.5c-2.9 0-5.2-2.3-5.2-5.2V39.4c0-2.7-2-4.9-4.6-5.2L7.8 32c-2.6-.3-4.6-2.5-4.6-5.2v-.5c0-2.6 2.1-4.7 4.7-4.7h.5c19.3 1.8 33.2 2.8 41.7 2.8s22.4-.9 41.7-2.8c2.6-.2 4.9 1.6 5.2 4.3v1c-.1 2.6-2.1 4.8-4.8 5.1z"/>					</svg>
6723				</a>
6724			</div>
6725			<div class="pojo-a11y-toolbar-overlay">
6726				<div class="pojo-a11y-toolbar-inner">
6727					<p class="pojo-a11y-toolbar-title">Accessibility</p>
6728
6729					<ul class="pojo-a11y-toolbar-items pojo-a11y-tools">
6730																			<li class="pojo-a11y-toolbar-item">
6731								<a href="#" class="pojo-a11y-toolbar-link pojo-a11y-btn-resize-font pojo-a11y-btn-resize-plus" data-action="resize-plus" data-action-group="resize" tabindex="-1" role="button">
6732									<span class="pojo-a11y-toolbar-icon"><svg version="1.1" xmlns="http://www.w3.org/2000/svg" width="1em" viewBox="0 0 448 448"><title>Increase font size</title><path fill="currentColor" d="M256 200v16c0 4.25-3.75 8-8 8h-56v56c0 4.25-3.75 8-8 8h-16c-4.25 0-8-3.75-8-8v-56h-56c-4.25 0-8-3.75-8-8v-16c0-4.25 3.75-8 8-8h56v-56c0-4.25 3.75-8 8-8h16c4.25 0 8 3.75 8 8v56h56c4.25 0 8 3.75 8 8zM288 208c0-61.75-50.25-112-112-112s-112 50.25-112 112 50.25 112 112 112 112-50.25 112-112zM416 416c0 17.75-14.25 32-32 32-8.5 0-16.75-3.5-22.5-9.5l-85.75-85.5c-29.25 20.25-64.25 31-99.75 31-97.25 0-176-78.75-176-176s78.75-176 176-176 176 78.75 176 176c0 35.5-10.75 70.5-31 99.75l85.75 85.75c5.75 5.75 9.25 14 9.25 22.5z"></path></svg></span><span class="pojo-a11y-toolbar-text">Increase font size</span>								</a>
6733							</li>
6734
6735							<li class="pojo-a11y-toolbar-item">
6736								<a href="#" class="pojo-a11y-toolbar-link pojo-a11y-btn-resize-font pojo-a11y-btn-resize-minus" data-action="resize-minus" data-action-group="resize" tabindex="-1" role="button">
6737									<span class="pojo-a11y-toolbar-icon"><svg version="1.1" xmlns="http://www.w3.org/2000/svg" width="1em" viewBox="0 0 448 448"><title>Reduce font size</title><path fill="currentColor" d="M256 200v16c0 4.25-3.75 8-8 8h-144c-4.25 0-8-3.75-8-8v-16c0-4.25 3.75-8 8-8h144c4.25 0 8 3.75 8 8zM288 208c0-61.75-50.25-112-112-112s-112 50.25-112 112 50.25 112 112 112 112-50.25 112-112zM416 416c0 17.75-14.25 32-32 32-8.5 0-16.75-3.5-22.5-9.5l-85.75-85.5c-29.25 20.25-64.25 31-99.75 31-97.25 0-176-78.75-176-176s78.75-176 176-176 176 78.75 176 176c0 35.5-10.75 70.5-31 99.75l85.75 85.75c5.75 5.75 9.25 14 9.25 22.5z"></path></svg></span><span class="pojo-a11y-toolbar-text">Reduce font size</span>								</a>
6738							</li>
6739						
6740													<li class="pojo-a11y-toolbar-item">
6741								<a href="#" class="pojo-a11y-toolbar-link pojo-a11y-btn-background-group pojo-a11y-btn-grayscale" data-action="grayscale" data-action-group="schema" tabindex="-1" role="button">
6742									<span class="pojo-a11y-toolbar-icon"><svg version="1.1" xmlns="http://www.w3.org/2000/svg" width="1em" viewBox="0 0 448 448"><title>Greyscale</title><path fill="currentColor" d="M15.75 384h-15.75v-352h15.75v352zM31.5 383.75h-8v-351.75h8v351.75zM55 383.75h-7.75v-351.75h7.75v351.75zM94.25 383.75h-7.75v-351.75h7.75v351.75zM133.5 383.75h-15.5v-351.75h15.5v351.75zM165 383.75h-7.75v-351.75h7.75v351.75zM180.75 383.75h-7.75v-351.75h7.75v351.75zM196.5 383.75h-7.75v-351.75h7.75v351.75zM235.75 383.75h-15.75v-351.75h15.75v351.75zM275 383.75h-15.75v-351.75h15.75v351.75zM306.5 383.75h-15.75v-351.75h15.75v351.75zM338 383.75h-15.75v-351.75h15.75v351.75zM361.5 383.75h-15.75v-351.75h15.75v351.75zM408.75 383.75h-23.5v-351.75h23.5v351.75zM424.5 383.75h-8v-351.75h8v351.75zM448 384h-15.75v-352h15.75v352z"></path></svg></span><span class="pojo-a11y-toolbar-text">Greyscale</span>								</a>
6743							</li>
6744						
6745													<li class="pojo-a11y-toolbar-item">
6746								<a href="#" class="pojo-a11y-toolbar-link pojo-a11y-btn-background-group pojo-a11y-btn-high-contrast" data-action="high-contrast" data-action-group="schema" tabindex="-1" role="button">
6747									<span class="pojo-a11y-toolbar-icon"><svg version="1.1" xmlns="http://www.w3.org/2000/svg" width="1em" viewBox="0 0 448 448"><title>High contrast</title>
6747<path fill="currentColor" d="M192 360v-272c-75 0-136 61-136 136s61 136 136 136zM384 224c0 106-86 192-192 192s-192-86-192-192 86-192 192-192 192 86 192 192z"></path></svg></span><span class="pojo-a11y-toolbar-text">High contrast</span>								</a>
6748							</li>
6749						
6750													<li class="pojo-a11y-toolbar-item">
6751								<a href="#" class="pojo-a11y-toolbar-link pojo-a11y-btn-background-group pojo-a11y-btn-negative-contrast" data-action="negative-contrast" data-action-group="schema" tabindex="-1" role="button">
6752
6753									<span class="pojo-a11y-toolbar-icon"><svg version="1.1" xmlns="http://www.w3.org/2000/svg" width="1em" viewBox="0 0 448 448"><title>Negative contrast</title><path fill="currentColor" d="M416 240c-23.75-36.75-56.25-68.25-95.25-88.25 10 17 15.25 36.5 15.25 56.25 0 61.75-50.25 112-112 112s-112-50.25-112-112c0-19.75 5.25-39.25 15.25-56.25-39 20-71.5 51.5-95.25 88.25 42.75 66 111.75 112 192 112s149.25-46 192-112zM236 144c0-6.5-5.5-12-12-12-41.75 0-76 34.25-76 76 0 6.5 5.5 12 12 12s12-5.5 12-12c0-28.5 23.5-52 52-52 6.5 0 12-5.5 12-12zM448 240c0 6.25-2 12-5 17.25-46 75.75-130.25 126.75-219 126.75s-173-51.25-219-126.75c-3-5.25-5-11-5-17.25s2-12 5-17.25c46-75.5 130.25-126.75 219-126.75s173 51.25 219 126.75c3 5.25 5 11 5 17.25z"></path></svg></span><span class="pojo-a11y-toolbar-text">Negative contrast</span>								</a>
6754							</li>
6755						
6756													<li class="pojo-a11y-toolbar-item">
6757								<a href="#" class="pojo-a11y-toolbar-link pojo-a11y-btn-background-group pojo-a11y-btn-light-background" data-action="light-background" data-action-group="schema" tabindex="-1" role="button">
6758									<span class="pojo-a11y-toolbar-icon"><svg version="1.1" xmlns="http://www.w3.org/2000/svg" width="1em" viewBox="0 0 448 448"><title>Light background</title><path fill="currentColor" d="M184 144c0 4.25-3.75 8-8 8s-8-3.75-8-8c0-17.25-26.75-24-40-24-4.25 0-8-3.75-8-8s3.75-8 8-8c23.25 0 56 12.25 56 40zM224 144c0-50-50.75-80-96-80s-96 30-96 80c0 16 6.5 32.75 17 45 4.75 5.5 10.25 10.75 15.25 16.5 17.75 21.25 32.75 46.25 35.25 74.5h57c2.5-28.25 17.5-53.25 35.25-74.5 5-5.75 10.5-11 15.25-16.5 10.5-12.25 17-29 17-45zM256 144c0 25.75-8.5 48-25.75 67s-40 45.75-42 72.5c7.25 4.25 11.75 12.25 11.75 20.5 0 6-2.25 11.75-6.25 16 4 4.25 6.25 10 6.25 16 0 8.25-4.25 15.75-11.25 20.25 2 3.5 3.25 7.75 3.25 11.75 0 16.25-12.75 24-27.25 24-6.5 14.5-21 24-36.75 24s-30.25-9.5-36.75-24c-14.5 0-27.25-7.75-27.25-24 0-4 1.25-8.25 3.25-11.75-7-4.5-11.25-12-11.25-20.25 0-6 2.25-11.75 6.25-16-4-4.25-6.25-10-6.25-16 0-8.25 4.5-16.25 11.75-20.5-2-26.75-24.75-53.5-42-72.5s-25.75-41.25-25.75-67c0-68 64.75-112 128-112s128 44 128 112z"></path></svg></span><span class="pojo-a11y-toolbar-text">Light background</span>								</a>
6759							</li>
6760						
6761													<li class="pojo-a11y-toolbar-item">
6762								<a href="#" class="pojo-a11y-toolbar-link pojo-a11y-btn-links-underline" data-action="links-underline" data-action-group="toggle" tabindex="-1" role="button">
6763									<span class="pojo-a11y-toolbar-icon"><svg version="1.1" xmlns="http://www.w3.org/2000/svg" width="1em" viewBox="0 0 448 448"><title>Underline links</title><path fill="currentColor" d="M364 304c0-6.5-2.5-12.5-7-17l-52-52c-4.5-4.5-10.75-7-17-7-7.25 0-13 2.75-18 8 8.25 8.25 18 15.25 18 28 0 13.25-10.75 24-24 24-12.75 0-19.75-9.75-28-18-5.25 5-8.25 10.75-8.25 18.25 0 6.25 2.5 12.5 7 17l51.5 51.75c4.5 4.5 10.75 6.75 17 6.75s12.5-2.25 17-6.5l36.75-36.5c4.5-4.5 7-10.5 7-16.75zM188.25 127.75c0-6.25-2.5-12.5-7-17l-51.5-51.75c-4.5-4.5-10.75-7-17-7s-12.5 2.5-17 6.75l-36.75 36.5c-4.5 4.5-7 10.5-7 16.75 0 6.5 2.5 12.5 7 17l52 52c4.5 4.5 10.75 6.75 17 6.75 7.25 0 13-2.5 18-7.75-8.25-8.25-18-15.25-18-28 0-13.25 10.75-24 24-24 12.75 0 19.75 9.75 28 18 5.25-5 8.25-10.75 8.25-18.25zM412 304c0 19-7.75 37.5-21.25 50.75l-36.75 36.5c-13.5 13.5-31.75 20.75-50.75 20.75-19.25 0-37.5-7.5-51-21.25l-51.5-51.75c-13.5-13.5-20.75-31.75-20.75-50.75 0-19.75 8-38.5 22-52.25l-22-22c-13.75 14-32.25 22-52 22-19 0-37.5-7.5-51-21l-52-52c-13.75-13.75-21-31.75-21-51 0-19 7.75-37.5 21.25-50.75l36.75-36.5c13.5-13.5 31.75-20.75 50.75-20.75 19.25 0 37.5 7.5 51 21.25l51.5 51.75c13.5 13.5 20.75 31.75 20.75 50.75 0 19.75-8 38.5-22 52.25l22 22c13.7
67635-14 32.25-22 52-22 19 0 37.5 7.5 51 21l52 52c13.75 13.75 21 31.75 21 51z"></path></svg></span><span class="pojo-a11y-toolbar-text">Underline links</span>								</a>
6764							</li>
6765						
6766													<li class="pojo-a11y-toolbar-item">
6767								<a href="#" class="pojo-a11y-toolbar-link pojo-a11y-btn-readable-font" data-action="readable-font" data-action-group="toggle" tabindex="-1" role="button">
6768									<span class="pojo-a11y-toolbar-icon"><svg version="1.1" xmlns="http://www.w3.org/2000/svg" width="1em" viewBox="0 0 448 448"><title>Readable font</title><path fill="currentColor" d="M181.25 139.75l-42.5 112.5c24.75 0.25 49.5 1 74.25 1 4.75 0 9.5-0.25 14.25-0.5-13-38-28.25-76.75-46-113zM0 416l0.5-19.75c23.5-7.25 49-2.25 59.5-29.25l59.25-154 70-181h32c1 1.75 2 3.5 2.75 5.25l51.25 120c18.75 44.25 36 89 55 133 11.25 26 20 52.75 32.5 78.25 1.75 4 5.25 11.5 8.75 14.25 8.25 6.5 31.25 8 43 12.5 0.75 4.75 1.5 9.5 1.5 14.25 0 2.25-0.25 4.25-0.25 6.5-31.75 0-63.5-4-95.25-4-32.75 0-65.5 2.75-98.25 3.75 0-6.5 0.25-13 1-19.5l32.75-7c6.75-1.5 20-3.25 20-12.5 0-9-32.25-83.25-36.25-93.5l-112.5-0.5c-6.5 14.5-31.75 80-31.75 89.5 0 19.25 36.75 20 51 22 0.25 4.75 0.25 9.5 0.25 14.5 0 2.25-0.25 4.5-0.5 6.75-29 0-58.25-5-87.25-5-3.5 0-8.5 1.5-12 2-15.75 2.75-31.25 3.5-47 3.5z"></path></svg></span><span class="pojo-a11y-toolbar-text">Readable font</span>								</a>
6769							</li>
6770																		<li class="pojo-a11y-toolbar-item">
6771							<a href="#" class="pojo-a11y-toolbar-link pojo-a11y-btn-reset" data-action="reset" tabindex="-1" role="button">
6772								<span class="pojo-a11y-toolbar-icon"><svg version="1.1" xmlns="http://www.w3.org/2000/svg" width="1em" viewBox="0 0 448 448"><title>Reset</title><path fill="currentColor" d="M384 224c0 105.75-86.25 192-192 192-57.25 0-111.25-25.25-147.75-69.25-2.5-3.25-2.25-8 0.5-10.75l34.25-34.5c1.75-1.5 4-2.25 6.25-2.25 2.25 0.25 4.5 1.25 5.75 3 24.5 31.75 61.25 49.75 101 49.75 70.5 0 128-57.5 128-128s-57.5-128-128-128c-32.75 0-63.75 12.5-87 34.25l34.25 34.5c4.75 4.5 6 11.5 3.5 17.25-2.5 6-8.25 10-14.75 10h-112c-8.75 0-16-7.25-16-16v-112c0-6.5 4-12.25 10-14.75 5.75-2.5 12.75-1.25 17.25 3.5l32.5 32.25c35.25-33.25 83-53 132.25-53 105.75 0 192 86.25 192 192z"></path></svg></span>
6773								<span class="pojo-a11y-toolbar-text">Reset</span>
6774							</a>
6775						</li>
6776					</ul>
6777									</div>
6778			</div>
6779		</nav>
6780		
6781		<!-- Cookie Compliance for WordPress (formerly Compliance by Hu-manity.co) plugin v3.1.9 https://cookie-compliance.co/ -->
6782		<div id="cookie-notice" role="dialog" class="cookie-notice-hidden cookie-revoke-hidden cn-position-bottom" aria-label="Cookie Compliance" style="background-color: rgba(20,37,63,1);"><div class="cookie-notice-container" style="color: #9e8053"><span id="cn-notice-text" class="cn-text-container">We use cookies on this site to enhance your user experience. By clicking on the Accept button, you agree to our use of cookies.</span><span id="cn-notice-buttons" class="cn-buttons-container"><button id="cn-accept-cookie" data-cookie-set="accept" class="cn-set-cookie cn-button cn-button-custom btn" aria-label="Accept">Accept</button><button id="cn-refuse-cookie" data-cookie-set="refuse" class="cn-set-cookie cn-button cn-button-custom btn" aria-label="Deny">Deny</button><button data-link-url="https://oncotherm.com/privacy-policy/" data-link-target="_blank" id="cn-more-info" class="cn-more-info cn-button cn-button-custom btn" aria-label="Privacy Policy">Privacy Policy</button></span><button type="button" id="cn-close-notice" data-cookie-set="accept" class="cn-close-icon" aria-label="Deny" tabindex="0"></button></div>
6783			
6784		</div>
6785		<!-- / Cookie Compliance for WordPress plugin -->
6786
6787<script>
6788	//kereso
6789jQuery('#keres-ikon').on('click', function(){
6790    jQuery('#kereso').fadeToggle();
6791    jQuery(this).toggleClass('open');
6792    jQuery(".main-navigation").toggleClass('fade');
6793})
6794
6795//elemek sticky
6796var Sticky = new hcSticky('#sticker', {
6797    top: 0,
6798    bottom:90,
6799    stickTo: '.st-wrap',
6800    wrapperClassName: 'sticker',
6801
6802});
6803
6804
6805//fejlec tapadas
6806let header = jQuery("#masthead,#palyazat");
6807    
6808jQuery(window).scroll(function() {
6809        
6810        var scroll = jQuery(window).scrollTop();
6811        
6812        if (scroll >= 1) {
6813            header.addClass('styk');
6814        } else {
6815            header.removeClass('styk');
6816        }
6817        
6818    });
6819</script>
6819
6820</body>
6821</html>

Line numbers count LF bytes from the start of the resource, as the search results do. Vendor segments are library code the classifier recognised; they are stored but not indexed. Bytes are shown as Latin1 characters, one per byte.